

GenCore version 5.1.6  
Copyright (c) 1993 - 2004 Compugen Ltd.

OM protein - nucleic search, using frame\_plus\_p2n model

Run on: November 6, 2004, 23:33:52 ; Search time 406 seconds  
(without alignments)  
3038.458 Million cell updates/sec

Title: US-09-914-053a-5

Perfect score: 1241

Sequence: 1 MSIWTSGRITSSSYRHDEKRN.....MVKLTQYLSLCCRIQRINR 235

Scoring table:  
BLOSUM62  
Xgapop 10.0 , Xgapext 0.5  
Ygapop 10.0 , Ygapext 0.5  
Fgapop 6.0 , Fgapext 7.0  
Delop 6.0 , Delext 7.0

Searched: 4134886 seqs, 2624710521 residues

Total number of hits satisfying chosen parameters: 8269772

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%  
Listing first 45 summaries

Command line parameters:

-MODE=frame+ p2n.model -DEV=xlp  
-O=/cgn2\_1/USPTO.spool.p/US09914053/runat\_04112004\_183921\_18210/app\_query.fasta\_1.391  
-DB=N\_Geneseq\_23Sep04 -CFMR=fastap -SUFFIX=ring -MINMATCH=0.1 -LCOPCL=0  
-LOPEXT=0 -UNIT=bits -START=1 -END=1 -MATRIX=blosum62 -TRANS=human40.cdi  
-LIST=45 -DOALIGN=200 -THR SCORE=pt -THR MAX=100 -THR MIN=0 -ALIGN=15  
-MODE=LOCAL -OUTFMT=pt -NORM=ext -HEAPSIZE=500 -MINLEN=0 -NAXLEN=2000000000  
-USER=US09914053 @CGN 1.1.708 @runat\_04112004\_183921\_18210 -NCPU=6 -ICPU=3  
-NO MMAP -LARGEQUERY -NEG SCORES=0 -WAIT -DSPBLOCK=100 -LONGLOG  
-DEV TIMEOUT=120 -WARN TIMEOUT=30 -THREADS=1 -XGAPOP=10 -XGAPEXT=0.5 -FGAPOP=6  
-FGAPEXT=7 -YGAPOP=10 -YGAPEXT=0.5 -DELOP=6 -DELEXT=7

Database : N\_Geneseq\_23Sep04:\*  
1: Geneseqn1980s:\*  
2: Geneseqn1990s:\*  
3: Geneseqn2000s:\*  
4: Geneseqn2001as:\*  
5: Geneseqn2001bs:\*  
6: Geneseqn2002as:\*  
7: Geneseqn2002bs:\*  
8: Geneseqn2003as:\*  
9: Geneseqn2003bs:\*  
10: Geneseqn2003cs:\*  
11: Geneseqn2003ds:\*  
12: Geneseqn2004s:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	1235	99.5	1184	AAF27991	Aaf27991 Human cal
2	1228	99.0	1300	AAZ51632	Aaz51632 Human mem
3	1216	98.0	707	AAZ75011	Aaz75011 DNA encod
4	1012	81.5	2098	AAA26355	Aaa26355 Human sec
5	1012	81.5	2098	ADA39669	Ada39669 Human sec
6	1012	81.5	2098	ADA55858	Ada55858 Gene encod

7	1012	81.5	2098	12	ADL71416	Adl71416 Novel hum
8	481.5	38.8	1246	2	AAZ11912	Aaz11912 Human pot
9	481	38.8	558	4	ABA09433	AbA09433 Human K c
10	478.5	38.6	1237	4	AAF27992	Aaf27992 Human cal
11	478	38.5	1111	2	AAZ11913	Aaz11913 Human pot
12	477.5	38.5	1144	4	AAK53128	AaK53128 Human pol
13	477.5	38.5	1251	4	ABA09214	AbA09214 Human Ca-
14	477.5	38.5	1251	4	AAK53112	AaK53112 Human pol
15	474	38.2	1296	4	AAF75009	Aaf75009 DNA encod
16	474	38.2	1296	4	AAF27995	Aaf27995 Human cal
17	474	38.2	1632	4	AAF27993	Aaf27993 Human cal
18	464.5	37.4	1759	4	AAF27994	Aaf27994 Human cal
19	421	33.9	1106	2	AA706477	Aat06477 Human cal
20	421	33.9	1277	6	ABL69681	Ab169681 Prostate
21	421	33.9	1277	10	ADD14749	Ad14749 Human src
22	383	30.9	2238	2	AAT06476	Aat06476 Bovine ca
23	352	28.4	608	4	AA102267	Aa102267 Human rep
24	319	25.7	1228	2	AAK82099	AaK82099 Human cal
25	318	25.6	1501	3	AAK75815	AaK75815 Human ORF
26	318	25.6	1608	3	AAZ22298	AaZ22298 Human pot
27	316	25.5	633	3	AA75010	Aa75010 DNA encod
C 28	207	16.7	11000	12	ADO34927_0	Ado34927 Human vol
C 29	195	15.7	7045	4	ABA07292	AbA07292 Human pan
C 30	195	15.7	7045	4	AAK89937	AaK89937 Human dig
31	195	15.7	7045	4	AA137429	Aa137429 Human mus
32	195	15.7	7045	8	ABX60417	AbX60417 cDNA enco
33	195	15.7	7045	12	ADJ31167	AdJ31167 Human mus
34	177	14.3	394	3	AAK03613	AaK03613 Human sec
35	151.5	12.2	898	6	ABQ25377	AbQ25377 Oligonucl
C 36	151.5	12.2	898	6	ABQ25376	AbQ25376 Oligonucl
37	150	12.1	285	2	AAT2677	Aat2677 Human gen
38	148	11.9	898	6	ABQ25374	AbQ25374 Oligonucl
C 39	148	11.9	898	6	ABQ25375	AbQ25375 Oligonucl
40	138.5	11.2	48000	4	Aaf27996	Aaf27996 Human cal
41	132	10.6	188	3	AAK07442	AaK07442 Human sec
42	125.5	10.1	2787	5	AAK77593	AaK77593 DNA encod
43	125.5	10.1	2787	5	AAK82312	AaK82312 DNA encod
44	125.5	10.1	2787	5	AAK77413	AaK77413 DNA encod
C 45	120.5	9.7	345	12	ADO35048	Ado35048 Human KCh

ALIGNMENTS

RESULT 1  
AAF27991  
ID AAF27991 standard; DNA; 1184 BP.  
XX  
AC AAF27991;  
XX  
DT 08-MAY-2001 (first entry)  
XX  
DE Human calcium sensitive potassium channel beta2 subunit coding sequence.  
XX  
KW Human; calcium sensitive potassium channel; beta2 subunit; asthma;  
KW beta3a subunit; beta3b subunit; beta3c subunit; beta3d subunit; diabetes;  
KW chromosome 3q23-ter; inhibitor; activator; glaucoma; migraine; angina;  
KW irritable bowel syndrome; Alzheimer's disease; ds.  
XX  
OS Homo sapiens.  
XX  
PN WO200105828-A1.  
XX  
PD 25-JAN-2001.  
XX  
PF 18-JUL-2000; 2000WO-US019585.  
XX  
PR 20-JUL-1999; 99US-0144764P.  
XX  
PA (MERI ) MERCK & CO INC.  
XX  
PI Uebele V, Swanson R, Liu Y, Lagrutta A;  
XX  
DR WPI; 2001-159514/16.

DR P-ESDB; AAB35301.

XX Novel human calcium sensitive potassium channel subunits for identifying  
PT inhibitors and agonists of the potassium channel for use in treating  
PT conditions such as asthma, hypertension, memory disorders, depression.

XX Claim 3; Fig 1A; 89pp; English.

XX The present invention provides the protein and coding sequences of the  
CC human calcium sensitive potassium channel beta2, beta3a, beta3b, beta3c  
CC and beta3d subunits. These can be used to identify inhibitors and  
CC activators of the channels, which can be used in the treatment of  
CC conditions including asthma, diabetes, glaucoma, cerebral ischaemia,  
CC Alzheimer's disease, excessive smooth muscle tone, angina, hypertension,  
CC incontinence, migraine and irritable bowel syndrome. The coding sequences  
CC are found at human chromosome 3q23-ter. The present sequence is the beta2  
CC subunit coding sequence

XX Sequence 1184 BP; 356 A; 260 C; 255 G; 313 T; 0 U; 0 Other;

## Alignment Scores:

Pred. No.: 5.92e-134 Length: 1184  
Score: 1235.00 Matches: 234  
Percent Similarity: 99.57% Conservative: 1  
Best Local Similarity: 99.57% Mismatches: 0  
Query Match: 99.52% Indels: 0  
DB: 4 Gaps: 0

US-09-914-053A-5 (1-235) x AAF27991 (1-1184)

QY 1 MetSerIleTprThrSerGlyArgThrSerSerTyrArgHisAspGluLysArgAsn 20  
DB 271 ATGTTTATATGACGACGCGGACCTCTTCATCTTATGACATGATGAAAAAGAAAT 330  
QY 21 IleTyrGlnLysIleArgAspHisAspLeuLeuAspLysArgLysThrValThrAlaLeu 40  
DB 331 ATTTACCAAGAAATCAGGACCATGACCTCTCTGGACAAAAGGAAACAGTCACAGCACTG 390  
QY 41 LysAlaGlyGluAspArgAlaIleLeuGlyLeuAlaMetMetValCysSerIleMet 60  
DB 391 AAGCAGAGAGAGACGACGATTTCTCTGGACTGCTATGATGGTGCTCCATCATG 450  
QY 61 MetTyrPheLeuGlyIleThrLeuLeuArgSerTyrMetGlnSerValTprThrGlu 80  
DB 451 ATGATATTTCTGCGGAATCACACTCTCTGCTCATACATGCAGAGCGTGTGGACCGAA 510  
QY 81 GluSerGlnCysThrLeuLeuAsnAlaSerIleThrGlnThrPheAnCysSerPheSer 100  
DB 511 GAGTCTCAATGACCTTGCTGAATGGCTGCATACGGAACATTTAACTGCTCTCTCAGC 570  
QY 101 CysGlyProAspCysTprLysLeuSerGlnTyrProCysLeuGlnValTyrValAsnLeu 120  
DB 571 TGTGTCAGACTGCGAAACTTCTCAGTACCCCTGCTCCAGGTGTACGTTAACCTG 630  
QY 121 ThrSerSerGlyGluLysLeuLeuLeuTyrHisThrGluGlnThrIleLysIleAsnGln 140  
DB 631 ACTTCTTCCGGGAAAAGCTCTCTCTACACAGAGAGACAAATAAAATCAATCAG 690  
QY 141 LysCysSerTyrIleProLysCysGlyLysAsnPheGluGluSerMetSerLeuValAsn 160  
DB 691 AAGTGCCTCTATATACCTAATATGGGAAAATTTTGAAGATCCATGTCCTCGGTGAAT 750  
QY 161 ValValMetGluAsnPheArgLysTyrGlnHisPheSerCysTyrSerAspProGluGly 180  
DB 751 GTTGTCTAGGAAAATCTCAGGAAGTATCAACACTTCTCGCTATTCGACCCAGAGGA 810  
QY 181 AsnGlnLysSerValIleLeuThrLysLeuTyrSerSerAsnValLeuPheHisSerLeu 200  
DB 811 AACCAAGAGAGTGTATCTTACCAAACTCTACAGTTCACAGTGTCTGTTCCATTCACCTC 870  
QY 201 PheTprProThrCysMetMetAlaGlyGlyValAlaIleValAlaMetValLysLeuThr 220  
DB 871 TTCTGGCCAACTGATGATGGCTGGGGGTGTGGCAATTGTTGCCATGTTGGAACCTTACA 930

QY 221 GlnTyrLeuSerLeuLeuCysGluArgIleGlnArgIleAsnArg 235  
DB 931 CAGTACCTCTCCCTACTATGTGAGAGGATCCACGGATCAATAGA 975

## RESULT 2

AAZ51632

ID AAZ51632 standard; cDNA; 1300 BP.

XX AAZ51632;

XX 21-JUN-2000 (first entry)

DE Human membrane channel protein-16 (MECHP-16) cDNA.

XX Membrane channel protein-16; MECHP-16; diagnosis; treatment; lymphoma;  
KW cell proliferative disorder; bursitis; atherosclerosis; cancer; sarcoma;  
KW inflammatory disorder; AIDS; Addison's disease; cystic fibrosis; asthma;  
KW diabetes mellitus; osmoregulatory disorder; diarrhoea; renal failure;  
KW muscular disorder; myocarditis; Duchenne's muscular dystrophy; nontropic;  
KW cardiovascular disorder; hypertension; bronchitis; vasculitis; cardiac;  
KW neurological disorder; Alzheimer's disease; Parkinson's disease; human;  
KW Huntington's disease; antiarteriosclerotic; hepatotropic; cytostatic;  
KW anti-HIV; antianaemic; neuroprotective; immunomodulator; antidiabetic;  
KW hypertensive; vasotropic; antiasthmatic; antiinflammatory; antidepressant;  
KW anticonvulsant; thrombolytic; antiParkinsonian; immunostimulant; ss.

XX Homo sapiens.

XX Key Location/Qualifiers

CDS 378..1085

/\*tag= a

/product= "MECHP-16"

/note= "Shows homology to human beta subunit of Ca+

FT misc\_binding

activated K+ channel"

381..425

/\*tag= b

/bound\_moiety= "Primer or Probe"

XX WO200012711-A2.

XX 09-MAR-2000.

XX 02-SEP-1999; 99WO-US020468.

XX 02-SEP-1998; 98US-0155226P.

XX 12-NOV-1998; 98US-00191283.

XX 09-DEC-1998; 98US-0155225P.

XX 26-JAN-1999; 99US-0155211P.

XX 10-FEB-1999; 99US-0155263P.

XX (INCY-) INCYTE PHARM INC.

XX Au-Young J, Bandman O, Tang YT, Reddy R, Hillman JL, Yue H;

XX Lal P, Corley NC, Guegler KJ, Gorgone G, Baughn MR, Azimzai Y;

XX WPI; 2000-256643/22.

XX P-PSDB; AAY70466.

XX Novel human membrane channel protein and polynucleotide useful for  
PT diagnosing and treating cell proliferative, inflammatory, secretory,  
PT osmoregulatory, muscular, cardiovascular and neurological disorders.

XX Claim 9; Page 128-129; 140pp; English.

XX The present sequence is a cDNA identified in Incyte clone 2069907 derived  
CC from ISITN01 cDNA library. It encodes human membrane channel protein-16  
CC (MECHP-16), which is expressed in nervous tissues. Anti-MECHP antibodies  
CC can be used as therapeutic antagonists and reagents for diagnosis and  
CC monitoring diseases. MECHP cDNA can be used for diagnosis of MECHP-  
CC related diseases and gene mapping. MECHP can be used for treatment of  
CC cell proliferative disorders such as bursitis and atherosclerosis,  
CC cancers like lymphoma and sarcoma, inflammatory disorders like AIDS and

CC	Addison's disease, transport/secretory disorders like cystic fibrosis and diabetes mellitus, osmoregulatory disorders like diarrhoea and renal failure, muscular disorders like myocardiitis and Duchenne's muscular dystrophy, cardiovascular disorders like hypertension and vasculitis, congenital lung anomalies like bronchitis and asthma and neurological disorders like Alzheimer's disease, Parkinson's disease and Huntington's disease
CC	
XX	
SQL	Sequence 1300 BP; 381 A; 288 C; 279 G; 352 T; 0 U; 0 Other;
Alignment Scores:	
Pred. No.:	4.48e-133 Length: 1300
Score:	1228.00 Matches: 233
Percent Similarity:	99.15% Conservative: 0
Best Local Similarity:	99.15% Mismatches: 2
Query Match:	98.95% Indels: 0
DB:	3 Gaps: 0
US-09-914-053A-5 (1-235) x AAZ51632 (1-1300)	
QY	1 MetSerIleThrThrSerGlyArgThrSerSerSerTyvArgHisAspGluLysArgAsn 20
Db	378 ATGTTTATATGACAGTCAGTGGCGGACCTCTTCATCTTATGACATGATGAAAAAGAAGAAAT 437
QY	21 IletyrGlnLysIleArgAspHisAspLeuLeuAspLysArgLysThrValThrAlaLeu 40
Db	438 ATTTPACCAGAAAAATCAGGACCATGACCTCTCGACAAAAGAAAAACAGTCACAGCAGCTG 497
QY	41 LysnLadylGluAspArgAlaIleLeuLeuLysLeuAlaMetMetValCysSerIleMet 60
Db	498 AAGCAGGAGAGAGACCGAGCTATTCTCTGGGACTGGCTATGATGGTGTGCTCCATCATG 557
QY	61 MetTyrPheLeuLeuGluGlyIleThrLeuLeuArgSerTyvMetGlnSerValTyrThrGlu 80
Db	558 ATGTATTTTCTGCTGGGAATCACACTCTCTGGCTCATACATGACAGGGTGTGGACCGAA 617
QY	81 GluSerGlnCysThrLeuLeuAsnAlaSerIleThrGluThrPheAsnCysSerPheSer 100
Db	618 GAGTCTCAATGACACTTGCTGAATCGCTCCATCATCAGGAAAAATTTAACTGCTCTCCTCAGC 677
QY	101 CysGlyProAspCysTyrLysLeuSerGlnTyrProCysLeuGlnValTyrValAsnLeu 120
Db	678 TGTGCTCAGACTGCTGAAACTTTCAGTACCCTCCCTCCAGGGTGTAGCTTAACCTG 737
QY	121 ThrSerSerGlyGluLysLeuLeuLeuTyrHisThrGluGluThrIleLysIleAsnGln 140
Db	738 ACTTCTTCCGGGAAAAAGCTCTCTCTACACACAGAGAGACAAATAAAATCAATCAG 797
QY	141 LysCysSerTyrrIleProLysCysGlyLysAsnPheGluGluSerMetSerLeuValAsn 160
Db	798 AAGTGCTCCTATATACCTAAATATGSAAAAAATTTGAAGAAATCCATGTCCTCGTGAAT 857
QY	161 ValValMetGluAsnPheArgLysTyrrGlnHisPheSerCysTyvSerAspProGluGly 180
Db	858 GTTGTCATGGAACCTTCAGGAAGTATCAACACTTCTCTCTGCTATCTGACCCAGAGGA 917
QY	181 AsnGlnLysSerValIleLeuThrLysLeuTyrSerSerAsnValLeuPheHisSerLeu 200
Db	918 AACACAGAAGAGTGTATCTCTAACCAAACTCTACAGTTCCAACGTCGTGTTCCTCATTCATC 977
QY	201 PheTyrProThrCysMetMetAlaGlyClyValAlaIleValAlaMetValLysLeuThr 220
Db	978 TTCCTGGCAACCTGTATGATGGCTGGGGGTGGCAATTGTGCCATGTGGTGAACCTTACA 1037
QY	221 GlnTyrLeuSerLeuLeuCysGluArgIleGlnArgIleAsnArg 235
Db	1038 CAGTACCTCTCCTACTATGTGAGAGGATCCAAACGGATCAATAGA 1082
RESULT 3	
AAAY75011	
ID	AAAY75011 standard; DNA; 707 BP.
XX	
AC	AAAY75011;

Db 1 ATGTCGATATGACACGACGCGGACCTCTTCATCTTATAGACATGATGATGAAAAAGAAAT 60  
 Qy 21 IletyGlnLysIleAsgAHisAspLeuLeuAspLysArgLysThrValThrAlaLeu 40  
 Db 61 ATTTACCAAGAAATCAGGACCATGCTCTCTGACAAAGGAAACAGTCACAGCACTG 120  
 Qy 41 LysAlaGlyGluAspArgAlaIleLeuLeuGlyLeuAlaMetMetValCysSerIleMet 60  
 Db 121 AAGCAGGAGAGACCGAGCTATCTCTGGGACTGGCTATGATGGTGTCTCCATCATG 180  
 Qy 61 MetTyrPheLeuLeuGlyIleThrLeuLeuArgSerTyrMetGlnSerValTyrThrGlu 80  
 Db 181 ATGTATTTCTGCTGGGAATCACACTCTCTGGCTCATACATGACAGCGTGTGGACCGAA 240  
 Qy 81 GluSerGlnCysThrLeuLeuAsnAlaSerIleThrGluThrPheAsnCysSerPheSer 100  
 Db 241 GAGTCTCAATGCACTGCTGCTGAATGCGTCCATCAGGAAACATTTAAATGCTCTCTCAGC 300  
 Qy 101 CysGlyProAspCysTyrPheLeuSerGlnTyrProCysLeuGlnValTyrValAsnLeu 120  
 Db 301 TGTGTCACAGACTGCTGAAACTTCTCAGTACCCCTGCTCCAGGCTGACGTTAACCTG 360  
 Qy 121 ThrSerSerGlyGluLysLeuLeuTyrHisThrGluThrIleLysIleAsnGln 140  
 Db 361 ACTTCTCTCCGGGAAAAGCTCTCTCTACACAGAGAGACAATAAAAATCAATCAG 420  
 Qy 141 LysCysSerTyrIleProLysCysGlyLysAsnPheGluGluSerMetSerLeuValAsn 160  
 Db 421 AAGTCTCTCTATATACCTAATATGGAATAATTTGAGAAATCCATGCTCTCTGGTGAAT 480  
 Qy 161 ValValMetGluAsnPheArgLysTyrGlnHisPheSerCysTyrSerAspProGluGly 180  
 Db 481 GTTGTCTGGAATACTTTCAGGAAGTATCAACACTTCTCTGCTATTTGACCCAGAGGA 540  
 Qy 181 AsnGlnLysSerValIleLeuThrLysLeuTyrSerSerAsnValLeuPheHisSerLeu 200  
 Db 541 AACAGAGAGAGTGTATCTTACCAAACTCTACAGTTCCACGCTGCTGTTCCATTCTCTC 600  
 Qy 201 PheTyrProThrCysMetMetAlaGlyGlyValAlaIleValAlaMetValLysLeuThr 220  
 Db 601 TTTGCGCCACCTGTATGATGGCTGGGGTGTGGCAATTGTCATGTTGGAATACATA 660  
 Qy 221 GlnTyrLeuSerLeuLeuCysGluArgIleGlnArgIleAsnArg 235  
 Db 661 CAGTACTCTCTCTACTATGTGAGAGATCCA-CGGATCAATAGA 704

RESULT 4  
 ID AAA26355 standard; cDNA; 2098 BP.  
 XX AAA26355;  
 AC AAA26355;  
 DT 29-JUN-2000 (first entry)  
 DE Human secreted protein gene 10 SEQ ID NO:20.  
 DE Human; secreted protein; diagnosis; cytostatic; immunosuppressive;  
 KW antiHIV; antineoplastic; neurotrophic; neuroprotective; antiallergic;  
 KW osteopathic; antidiabetic; antibacterial; antidiabetic; antidiabetic;  
 KW antipsoriasis; cardiant; gene therapy; cancer; neurological disorder;  
 KW immune disease; inflammation; blood disorder; tumour; ss.  
 XX Homo sapiens.  
 XX WO200006698-A1.  
 FN 10-FEB-2000.  
 PD 10-FEB-2000.  
 XX 29-JUL-1999; 99WO-US017130.  
 XX 30-JUL-1998; 98US-0094657P.  
 PR 05-AUG-1998; 98US-0095486P.  
 PR 06-AUG-1998; 98US-0095454P.

PR 06-AUG-1998; 98US-0095455P.  
 PR 12-AUG-1998; 98US-0096319P.  
 PA (HUMA-) HUMAN GENOME SCI INC.  
 XX Komatsoulis GA, Rosen CA, Ruben SM, Duan R, Moore PA, Shi Y;  
 PI Lafleur D, Wei Y, Ni J, Florence KA, Young PE, Brewer LA;  
 PI Soppet DR, Endress GA, Ebner R, Olsen HS, Mucenski M;  
 XX WPI; 2000-195282/17.  
 DR P-PSDB; AAY91460.  
 XX New isolated human genes and the secreted polypeptides they encode,  
 PT useful for diagnosis and treatment of e.g. cancers, neurological  
 PT disorders, immune diseases, inflammation or blood disorders.  
 XX Claim 1; Page 378-379; 634pp; English.  
 XX The polynucleotide sequences given in AAA26346 to AAA26458 encode the  
 CC human secreted proteins given in AAY91451 to AAY91691. The human secreted  
 CC proteins can have activities based on the tissues and cells they are  
 CC expressed in. Examples of the activities are: cytostatic;  
 CC immunosuppressive; antiHIV; antiinflammatory; neurotrophic; neuroprotective;  
 CC antiallergic; osteopathic; antidiabetic; antibacterial; antidiabetic;  
 CC antiasthma; antipsoriasis; and cardiant. The polynucleotides and their  
 CC corresponding secreted proteins are useful for preventing, treating or  
 CC ameliorating medical conditions, e.g. by protein or gene therapy. Also  
 CC pathological conditions can be diagnosed by determining the amount of the  
 CC proteins in a sample or by determining the presence of mutations in the  
 CC polynucleotides. Specific uses are described for each of the  
 CC polynucleotides, based on which tissues they are most highly expressed  
 CC in, and include developing products for the diagnosis or treatment of  
 CC cancer, tumours, neurodegenerative disorders, developmental abnormalities  
 CC and foetal deficiencies, blood disorders, diseases of the immune system,  
 CC autoimmune diseases, hepatic and renal disease, inflammation, allergies,  
 CC Alzheimer's and behavioural disorders, schizophrenia, osteoporosis,  
 CC arthritis, infections, AIDS, spinal cord injuries, transplant rejection,  
 CC diabetes, asthma, sepsis, acne, psoriasis, cardiovascular disorders,  
 CC reproductive disorders, gastrointestinal disorders, respiratory disorders  
 CC and metabolic disorders. The proteins or polynucleotides can also be used  
 CC as food additives or preservatives. The proteins are also useful for  
 CC identifying their binding partners. AAA26337 to AAA26345 and AAY91450 are  
 CC sequences used in the exemplification of the present invention  
 XX Sequence 2098 BP; 645 A; 366 C; 368 G; 719 T; 0 U; 0 Other;

Alignment Scores:  
 Pred. No.: 1.6e-107 Length: 2098  
 Score: 1012.00 Matches: 191  
 Percent Similarity: 100.00% Conservative: 0  
 Best Local Similarity: 100.00% Mismatches: 0  
 Query Match: 81.55% Indels: 0  
 DB: 3 Gaps: 0  
 US-09-914-053A-5 (1-235) x AAA26355 (1-2098)  
 Qy 45 AspArgAlaIleLeuLeuGlyLeuAlaMetValCysSerIleMetMetTyrPheLeu 64  
 Db 10 GACGAGCTATTTCTCTGGGACTGGCTATGATGGTGTCTCCATCATGATGATTTCTG 69  
 Qy 65 LeuGlyIleThrLeuLeuArgSerTyrMetGlnSerValTyrThrGluLysGlnCys 84  
 Db 70 CTGGGAATCACACTCTCTGGCTCATACATGACAGCGTGTGGACCGAAGAGTCTCAATGC 129  
 Qy 85 ThrLeuLeuAsnAlaSerIleThrGluThrPheAsnCysSerPheSerCysGlyProAsp 104  
 Db 130 ACCTTGTGAATGCGTCCATCAGGAAACATTTAATGCTCTCTCAGCTGTGGTCCAGAC 189  
 Qy 105 CysTyrLysLeuSerGlnTyrProCysLeuGlnValTyrValAsnLeuThrSerSerGly 124  
 Db 190 TGTGGAAACTTTCTCAGTACCTGCTCCAGGCTGCTGCTGCTGCTGCTGCTGCTGCTG 249  
 Qy 125 GluLysLeuLeuLeuTyrHisThrGluThrIleLysIleAsnGlnLysCysSerTyr 144



Db 250 GAAGAGCTCTCTCTACACAGAGACAAATAAATCAATCAGAGTCTCTCTAT 309  
 Qy 145 IleProLysCysGlyLysAsnPhelGluSerMetSerLeuValAsnValMetGlu 164  
 Db 310 ATACCTAAATGTGAAAAATTTTGAAGATCCATGCTCCCTGGTGAATGTGTGATGGAA 369  
 Qy 165 AsnPhelArgLysTyrGlnHisPheSerCysTyrSerAspProGluGlyAsnGlnLysSer 184  
 Db 370 AACTTTCAGGAGATCAACACTTCTCTGCTATCTTGACCCAGAGAAACCAAGAGAT 429  
 Qy 185 ValIleLeuThrLysLeuTyrSerSerAsnValLeuPheHisSerLeuPheTyrProThr 204  
 Db 430 GTTATCTCAACAAACTCTACAGTCCACGTCGTGTCCATTCCTCTTCGCGCAACC 489  
 Qy 205 CysMetMetAlaGlyGlyValAlaIleValAlaValMetValLysLeuThrGlnTyrLeuSer 224  
 Db 490 TGTATGATGCTGGGGGTGGCAATTTGGCCATGTTGAACCTTACACAGTACCTCTCC 549  
 Qy 225 LeuLeuCysGluArgIleGlnArgIleAsnArg 235  
 Db 550 CTACTATGTGAGAGATCCACCGATCAATAGA 582

## RESULT 5

ADA39669  
 ID ADA39669 standard; cDNA; 2098 BP.

AC ADA39669;

XX 20-NOV-2003 (first entry)

DE Human secreted protein encoding cDNA.

XX Human; secreted protein; cancer; hyperproliferative disorder;  
 KW rheumatoid arthritis; autoimmune disorder; haematopoietic disorder;  
 KW anaemia; allergic reaction; asthma; cardiovascular disorder;  
 KW wound healing; cytostatic; immunosuppressive; neutropenic; neuroprotective;  
 KW antiviral; antiallergic; hepatotropic; antidiabetic; antiinflammatory;  
 KW vulnerable; cardiac; gene therapy; ss.

XX Homo sapiens.

XX WO2002102993-A2.

XX 27-DEC-2002.

XX 19-MAR-2002; 2002WO-US008123.

XX 21-MAR-2001; 2001US-0277340P.

XX 19-JUL-2001; 2001US-0306171P.

XX 13-NOV-2001; 2001US-0331287P.

XX (HUMA-) HUMAN GENOME SCI INC.

XX Rosen CA, Ruben SM;

XX WPI; 2003-175238/17.

XX New human secreted proteins and nucleic acid molecules, useful for  
 PT preparing a diagnostic or pharmaceutical composition for diagnosing,  
 PT preventing or treating cancer or other hyperproliferative disorder,  
 PT asthma, allergies or AIDS.

XX Claim 9; SEQ ID NO 51; 3205pp; English.

XX The invention relates to novel genes ADA39629-ADA40565 and proteins  
 CC ADA40566-ADA41501 for human secreted proteins, useful for preventing,  
 CC treating or ameliorating medical conditions e.g. by protein or gene  
 CC therapy. The polypeptides, nucleic acid molecules, antibodies or their  
 CC fragments, and agonists or antagonists that bind to the polypeptide are  
 CC useful for preparing a diagnostic or pharmaceutical composition for  
 CC diagnosing or treating cancer or other hyperproliferative disorder. The  
 CC polypeptides and nucleic acid molecules are also useful for detecting,

CC preventing, diagnosing, prognosticating, treating or ameliorating cancer  
 CC or other hyperproliferative disorders including neoplasms, autoimmune  
 CC disorders (e.g. diabetes, rheumatoid arthritis, systemic lupus  
 CC erythematosus, multiple sclerosis, autoimmune thyroiditis or haemolytic  
 CC anaemia), haematopoietic or haematological disorders (e.g. anaemia,  
 CC thrombocytopenia), allergic reactions including asthma or eczema,  
 CC inflammatory disorders (e.g. ischaemia-reperfusion injury, inflammatory  
 CC bowel disease or Crohn's disease), neurodegenerative disorders (e.g.  
 CC Alzheimer's disease or Parkinson's disease), cardiovascular disorders  
 CC (e.g. atherosclerosis, myocarditis), infectious diseases (bacterial,  
 CC fungal or viral infections including HIV/AIDS), or wound healing and  
 CC disorders of epithelial cell proliferation. The nucleic acids are also  
 CC useful for chromosome identification, radiation hybrid mapping or long-  
 CC range restriction mapping, as molecular weight markers, or as  
 CC hybridization or diagnostic probes. The polypeptides and antibodies are  
 CC useful for providing immunological probes for differential identification  
 CC of the tissues immunohistochemistry assays. Note: The sequence data for  
 CC this patent did not form part of the printed specification, but was  
 CC obtained in electronic format directly from WIPO at  
 CC ftp.wipo.int/pub/published\_pct\_sequences.

XX SQ Sequence 2098 BP; 645 A; 366 C; 368 G; 719 T; 0 U; 0 Other;

## Alignment Scores:

Pred. No.: 1.6e-107 Length: 2098  
 Score: 1012.00 Matches: 191  
 Percent Similarity: 100.00% Conservative: 0  
 Best Local Similarity: 100.00% Mismatches: 0  
 Query Match: 81.55% Indels: 0  
 DB: 8 Gaps: 0

US-09-914-053A-5 (1-235) x ADA39669 (1-2098)

Qy 45 AspArgAlaIleLeuLeuGlyLeuAlaMetMetValCysSerIleMetMetTyrPheLeu 64  
 Db 10 GACCGAGCTATCTCTCTGGACTGCTATGATGGTGTCTCCATCATCATGATATTTCTG 69  
 Qy 65 LeuGlyIleThrLeuLeuArgSerTyrMetGlnSerValThrThrGluGluSerGlnCys 84  
 Db 70 CTGGGAATCACACTCTCTCGCTCATACATGACAGACGCTGGACCAAGAGTCTCAATGC 129  
 Qy 85 ThrLeuLeuAsnAlaSerIleThrGluThrPheAsnCysSerPheSerCysGlyProAsp 104  
 Db 130 ACCTTGCTGAATGCTGCTCATACGGAACATTAATTCCTCTTCAGTGTGGTCCAGAC 189  
 Qy 105 CysTrpLysLeuSerGlnTyrProCysLeuGlnValTyrValAsnLeuThrSerSerGly 124  
 Db 190 TGCTGAAACTTCTCAGTACCCCTGCTCCAGGTGTACGTAACTGACATCTCTTCGGG 249  
 Qy 125 GluLysLeuLeuLeuTyrHisThrGluThrIleLysIleAsnGlnLysCysSerTyr 144  
 Db 250 GAAAGAGTCTCTCTACACACAGAGACAAATAAAATCAATCAGAAGTGTCTCTAT 309  
 Qy 145 IleProLysCysGlyLysAsnPhelGluSerMetSerLeuValAsnValValMetGlu 164  
 Db 310 ATACCTAAATGTGAAAAATTTTGAAGAATCCATGTCCTGGTGAATGTTGTATGAA 369  
 Qy 165 AsnPhelArgLysTyrGlnHisPheSerCysTyrSerAspProGluGlyAsnGlnLysSer 184  
 Db 370 AACTTCAGAGAGTATCAACACTTCTCTGCTATTCGACCCAGAGAGAAACAGAGAGT 429  
 Qy 185 ValIleLeuThrLysLeuTyrSerSerAsnValLeuPheHisSerLeuPheTyrProThr 204  
 Db 430 GTTATCTCAACAAACTCTACAGTTCACACGCTGCTTCCATTCACCTCTCTTCGCGCAACC 489  
 Qy 205 CysMetMetAlaGlyGlyValAlaIleValAlaMetValLysLeuThrGlnTyrLeuSer 224  
 Db 490 TGTATGATGCTGGGGGTGTGGCAATTTGTGCATGTGGTGAACCTTACACAGTACCTCTCC 549  
 Qy 225 LeuLeuCysGluArgIleGlnArgIleAsnArg 235  
 Db 550 CTACTATGTGAGAGATCCACCGATCAATAGA 582

## RESULT 6

AD55858  
ID ADA55858 standard; DNA; 2098 BP.  
XX  
AC ADA55858;  
XX  
DT 20-NOV-2003 (first entry)  
XX  
DE Gene encoding human secreted protein #37.  
XX  
KW immunosuppressive; antiinflammatory; antiasthmatic; antiallergic;  
KW cytostatic; cerebroprotective; neuroprotective; nootropic;  
KW cardiovascular; antiarteriosclerotic; gene therapy;  
KW human secreted protein; immune disorder; inflammation;  
KW respiratory disorder; cancer; CNS disorder; neurodegenerative disorders;  
KW inflammatory bowel disease; nephritis; Crohn's disease; asthma; allergy;  
KW multiple sclerosis; ischaemic brain injury; Parkinson's disease;  
KW Alzheimer's disease; atherosclerosis; myocarditis; chromosome mapping;  
KW triple helix formation; antisense gene therapy; forensic biology; ds;  
KW gene.  
XX  
OS Homo sapiens.  
XX  
PN WO2002102994-A2.  
XX  
PD 27-DEC-2002.  
XX  
PF 19-MAR-2002; 2002WO-US008278.  
XX  
PR 21-MAR-2001; 2001US-0277340P.  
PR 19-JUL-2001; 2001US-0306171P.  
PR 13-NOV-2001; 2001US-0331287P.  
XX  
PA (HUMA-) HUMAN GENOME SCI INC.  
XX  
PI Rosen CA, Ruben SM;  
XX  
XX WPI; 2003-167512/16.  
DR P-PSDB; ADA56755.  
XX  
XX New human secreted polypeptides and polynucleotides, useful for  
PT diagnosing, treating or preventing e.g. immune disorders, inflammatory  
PT conditions, respiratory disorders, cancers, CNS disorders, or  
PT neurodegenerative disorders.  
XX  
PS Claim 21; SEQ ID NO 47; 1754pp; English.  
XX  
XX The invention relates to 592 new human secreted polypeptides useful for  
CC diagnosing, treating or preventing e.g. immune disorders, inflammatory  
CC conditions, respiratory disorders, cancers, CNS disorders, or  
CC neurodegenerative disorders, or polypeptides comprising an amino acid  
CC sequence at least 95% identical to the new sequences. The polypeptides,  
CC antibodies or antibody fragments that bind to the polypeptides, nucleic  
CC acids encoding the polypeptides, agonists or antagonists that binds to  
CC the polypeptide, are useful in preparing diagnostic or pharmaceutical  
CC compositions for diagnosing, treating or preventing an e.g. immune  
CC disorders, inflammatory conditions (e.g. inflammatory bowel disease,  
CC nephritis or Crohn's disease), respiratory disorders (e.g. asthma and  
CC allergy), cancers (e.g. gastric, ovarian or lung cancer), CNS disorders  
CC (e.g. multiple sclerosis or ischaemic brain injury), neurodegenerative  
CC disorders (e.g. Parkinson's disease or Alzheimer's disease), and  
CC cardiovascular disorders (e.g. atherosclerosis or myocarditis). The  
CC polynucleotides are useful for chromosome identification, chromosome  
CC mapping, for controlling gene expression through triple helix formation  
CC or antisense DNA or RNA, in gene therapy, for identifying individuals  
CC from minute biological samples, in forensic biology, and as hybridization  
CC probes. The polypeptides are useful for as molecular weight markers on  
CC sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE)  
CC gels, to raise antibodies, for testing biological activities, and for  
CC treating or preventing neural disorders, immune system disorders,  
CC muscular, reproductive, gastrointestinal, pulmonary, cardiovascular,  
CC renal, proliferative and/or cancerous diseases. This sequence corresponds  
CC to a gene encoding one of the polypeptide of the invention. Note: The

CC sequence data for this patent did form part of the printed specification,  
CC but was obtained in electronic format directly from WIPO at  
CC ftp.wipo.int/pub/published\_pct\_sequences.

XX  
SQ Sequence 2098 BP; 645 A; 366 C; 368 G; 719 T; 0 U; 0 Other;

## Alignment Scores:

Pred. No.: 1.6e-107 Length: 2098  
Score: 1012.00 Matches: 191  
Percent Similarity: 100.00% Conservative: 0  
Best Local Similarity: 100.00% Mismatches: 0  
Query Match: 81.55% Indels: 0  
DB: 10 Gaps: 0

US-09-914-053A-5 (1-235) x ADA55858 (1-2098)

QY 45 AspArgAlaileLeuLeuGlyLeuAlaMetMetValCysSerIleMetMetTyrPheLeu 64  
Db 10 GACCGAGCTATTCTCTGGGACTGCTATGATGGTGTGCTCCATCATGATGATTTCTG 69  
QY 65 LeuGlyIleThrLeuLeuArgSerTyrMetGlnSerValTTrpThrGluGlnSerGlnCys 84  
Db 70 CTGGGAATCACACTCTCGCTCATACATGACAGCGGTGGACCGAAGAGTCTCAATGC 129  
QY 85 ThrLeuLeuAsnAlaSerIleThrGluThrPheAsnCysSerPheSerCysGlyProAsp 104  
Db 130 ACCTTGCTGATGCTCCATCAGGAAACATTTAATTGCTCTTCAGCTGTGGTCCAGAC 189  
QY 105 CysTrpLysLeuSerGlnTyrProCysLeuGlnValTyrValAsnLeuThrSerSerGly 124  
Db 190 TGTGGAACATTTCTCAGTACCCCTCCCTCAGGTGACGTAACTGACTTCTTCCGGG 249  
QY 125 GluLysLeuLeuLeuTyrHisThrGluGluThrIleLysIleAsnGlnLysCysSerTyr 144  
Db 250 GAAAGCTCTCTCTACACACACAGAGACAAATAAATCAATCAGAGTGTCTCTAT 309  
QY 145 IleProLysCysGlyLysAsnPheGluGluSerMetSerLeuValAsnValValMetGlu 164  
Db 310 ATACCTTAATGTGGAATAATTTGAAGAATCCATGTCCTGGTGAATGTTGTCAAGAA 369  
QY 165 AsnPheArgLysTyrGlnHisPheSerCysTyrSerAspProGluGlyAsnGlnLysSer 184  
Db 370 ACCTTCAGAGAGTATCAACACTTCTCTGCTATCTGACCCAGAGAAACAGAGAGT 429  
QY 185 ValIleLeuThrLysLeuTyrSerSerAsnValLeuPheHisSerLeuPheTrpProThr 204  
Db 430 GTTATCTTAACAAAACCTTACAGTTCACAGTGTGTTCCATTCCTCTTCTGGCAACC 489  
QY 205 CysMetMetAlaGlyGlyValAlaIleValAlaMetValLysLeuThrGlnTyrLeuSer 224  
Db 490 TGTAATGATGGCTGGGGGTGGCAATTTGTCATGGTGAAGAACTTACAGTACCTCTCC 549  
QY 225 LeuLeuLysGluArgIleGlnArgIleAsnArg 235  
Db 550 CTATATGTGAGAGGATCCACCGATCAATAGTA 582

## RESULT 7

ADL71416  
ID ADL71416 standard; cDNA; 2098 BP.  
XX  
XX ADL71416;  
XX  
XX 20-MAY-2004 (first entry)  
XX  
XX Novel human secreted protein cDNA seqid 20.

XX  
XX antinflammatory; neuroprotective; nootropic; antiparkinsonian;  
KW anticonvulsant; antihypertensive; CNS; gynaecological; antiarthritic;  
KW antiasthmatic; anti-HIV; virucide; endocrine; cytostatic;  
KW immunosuppressive; antiallergic; cardiovascular; respiratory;  
KW dermatological; antimicrobial; gastrointestinal; gene therapy;  
KW neurodegenerative disease; behavioral disorder; inflammatory condition;  
KW hyperproliferative disorder; Alzheimer's disease; Parkinson's disease;

KW Huntington's disease; metabolic disorder; Tay-Sach's disease;  
KW Leash-Nyhan syndrome; reproductive disorder; immunological disorder;  
KW arthritis; asthma; AIDS; endocrine disorder; immune disorder;  
KW Hodgkin's lymphoma; haematopoietic disorder; muscular disorder;  
KW leukaemia; autoimmune disorder; allergy; cancer; cardiovascular disorder;  
KW respiratory disorder; pulmonary disorder; connective tissue disorder;  
KW skin disorder; CNS disorder; congenital disorder; infectious disorder;  
KW gastrointestinal disorder; human; secreted protein; gene; ss.  
XX Homo sapiens.  
OS  
XX  
XX US2004034196-A1.  
XX  
XX 19-FEB-2004.  
XX  
XX 27-JAN-2003; 2003US-00351334.  
XX  
XX 30-JUL-1998; 98US-0094557P.  
PR 03-AUG-1998; 98US-0095486P.  
PR 06-AUG-1998; 98US-0095454P.  
PR 08-AUG-1998; 98US-0095455P.  
PR 12-AUG-1998; 98US-0096319P.  
PR 29-JUL-1999; 99WO-US017130.  
PR 24-JAN-2000; 2000US-00489847.  
PR 25-JAN-2002; 2002US-0350898P.  
XX  
XX (KOMA/) KOMATSOULIS G A.  
PA (ROSE/) ROSEN C A.  
PA (RUBE/) RUBEN S M.  
PA (DUAN/) DUAN D R.  
PA (MOOR/) MOORE P A.  
PA (SHIY/) SHI Y.  
PA (LAFLE/) LAFLEUR D W.  
PA (WEIY/) WEI Y.  
XX  
XX Komatsoulis GA, Rosen CA, Ruben SM, Duan DR, Moore PA, Shi Y;  
PI Lafleur DW, Wei Y;  
PI  
XX  
XX WFI; 2004-180094/17.  
DR P-PSDB; ADL71532.  
XX  
XX New human secreted nucleic acid, useful for diagnosing and treating  
PT neurodegenerative, inflammatory, hyperproliferative, metabolic,  
PT reproductive, cardiovascular, respiratory or immunological disorders or  
PT diseases.  
XX  
XX Claim 1; SEQ ID NO 20; 234pp; English.  
PS  
XX The invention describes an isolated human nucleic acid molecule (I)  
CC comprising a polynucleotide having a nucleotide sequence at least 95%  
CC identical to a sequence polynucleotide fragment of SEQ ID NO: X or of  
CC the cDNA sequence included in ATCC Deposit No: Z, which is hybridisable  
CC to SEQ ID NO: X; or a sequence encoding a polypeptide fragment, domain or  
CC epitope of SEQ ID NO: Y or a polypeptide sequence encoded by the cDNA  
CC sequence included in ATCC Deposit No: Z, which is hybridisable to SEQ ID  
CC NO: X, having a biological activity. The nucleic acids and polypeptides,  
CC pharmaceutical formulations and kits are useful in diagnosing and  
CC treating neurodegenerative diseases states, behavioral disorders,  
CC inflammatory conditions, hyperproliferative disorders (e.g. Alzheimer's  
CC disease, Parkinson's disease or Huntington's disease), metabolic  
CC disorders (e.g. Tay-Sach's disease or Leash-Nyhan syndrome), reproductive  
CC disorders, immunological disorders (e.g. arthritis, asthma or AIDS),  
CC endocrine and immune disorders (e.g. Hodgkin's lymphoma), haematopoietic  
CC or muscular disorders (e.g. leukaemia), autoimmune disorders, allergy,  
CC cancer, cardiovascular, respiratory or pulmonary disorders, disorders or  
CC conditions afflicting connective tissue, skin disorders, CNS disorders,  
CC congenital disorders, infectious disorders and gastrointestinal  
CC disorders. This sequence encodes a novel human secreted protein of the  
CC invention. Note: This sequence does not appear in the printed  
CC specification but is available in electronic format from the US patent  
CC office at ftp.seqdata.uspto.gov/seqdata.html?DocID=20040034196.  
XX  
XX Sequence 2098 BP; 545 A; 366 C; 368 G; 719 T; 0 U; 0 Other;

## Alignment Scores:

Pred. No.:	1.6e-107	Length:	2098
Score:	1012.00	Matches:	191
Percent Similarity:	100.00%	Conservative:	0
Best Local Similarity:	100.00%	Mismatches:	0
Query Match:	81.55%	Indels:	0
DB:	12	Gaps:	0

US-09-914-053A-5 (1-235) x ADL71416 (1-2098)

QY	45	AspArgAlaIleLeuLeuGlyLeuAlaMetMetValCysSerIleMetMetTyrPheLeu	64
DB	10	GACCGAGCTATTCTCTGGGACTGGCTATGATGGTGTCTCCATCATGATGATTTCTG	69
QY	65	LeuGlyIleThrLeuLeuArgSerTyrMetGlnSerValTrpThrGluGluSerGlnCys	84
DB	70	CTGGGANTCACACTCTCTGGCTCATACATGACAGCGGTGGACCGAAGAGTCTCAATGC	129
QY	85	ThrLeuLeuAsnAlaSerIleThrGluThrPheAsnCysSerPheSerCysGlyProAsp	104
DB	130	ACCTTGCTGGAATGGCTCCATCACGAAACATTTAATTGCTCTCTCAGCTGGTCCAGAC	189
QY	105	CysTyrLysLeuSerGlnTyrProCysLeuGlnValTyrValAsnLeuThrSerSerGly	124
DB	190	TGCTGGAACCTTCTCAGTACCCCTGCTCCAGGTAGCTTACCTGACTTCTTCGGG	249
QY	125	GluLysLeuLeuLeuTyrHisThrGluThrIleLysIleAsnGlnLysCysSerTyr	144
DB	250	GAAGAAGCTCTCTCTACACACAGAGAGACAATAAAATCAATCAGAGAGTGTCTCTAT	309
QY	145	IleProLysCysGlyLysAsnPheGluGluSerMetSerLeuValAsnValMetGlu	164
DB	310	ATACCTAAATGTGGAAAAAATTTGAAGATCCATGTCCTGGTGAATGTTGTATGAA	369
QY	165	AsnPheArgLysTyrGlnHisPheSerCysTyrSerAspProGluGlyAsnGlnLysSer	184
DB	370	AACCTTCAGGAAGTATCAACACTTCTCTGCTGCTATCTGACCCAGAGGAACACAGAAGAGT	429
QY	185	VallIleLeuThrLysLeuTyrSerSerAsnValLeuPheHisSerLeuPheTrpProThr	204
DB	430	GTAATCTTCAACAAACTCTCAGATTCACACGCTGTTTCCATTCACTTCTTGGCCAAAC	489
QY	205	CysMetMetAlaGlyGlyValAlaIleValAlaMetValLysLeuThrGlnTyrLeuSer	224
DB	490	TGTATGATGGCTGGGGGTGTGGCAATTGTCCTGCTGGTGAACATTACACAGTACCTCTCC	549
QY	225	LeuLeuCysGluArgIleGlnArgIleAsnArg	235
DB	550	CTACTATGTGAGAGATCCAAACGGATCAATAGA	582

## RESULT 8

AAZ11912  
ID AAZ11912 standard; cDNA; 1246 BP.

XX AAZ11912;

XX 30-NOV-1999 (first entry)

XX Human potassium channel K-Hnov44 cDNA (splice variant 1).

XX Potassium channel; ataxia; arrhythmia; epilepsy; Bartter's syndrome;

XX cardiovascular disorder; CNS disorder; renal disorder; ds.

XX Homo sapiens.

XX Key Location/Qualifiers

XX CDS 432..1094

XX /\*tag= a

XX /product= "Human K-Hnov44 potassium channel"

XX W09943696-A1.

XX



XX WPI; 2001-457740/49.  
DR P-PSDB; ABB12189.  
XX Human proteins and DNA encoding sequences useful for preventing, treating  
PT or ameliorating a medical condition in a mammalian subject e.g. arthritis  
PT and cancer.  
XX  
PS Claim 1; Page 945; 1963pp; English.  
XX  
CC Sequences ABB10981-ABB12330 represent 1350 novel human polypeptides, and  
CC sequences ABA08225-ABA09574 represent nucleic acids encoding them. The  
CC invention also relates to vectors and recombinant host cells comprising a  
CC nucleotide of the invention, methods of producing the novel polypeptides,  
CC antibodies against the polypeptides, methods of detecting the nucleotides  
CC or polypeptides in a sample, and methods of identifying compounds which  
CC bind to polypeptides of the invention. Although novel, many of the  
CC polypeptides of the invention have homology to known proteins, thereby  
CC giving an insight into their probable biological activities, and hence  
CC potential therapeutic applications. The polypeptides of the invention may  
CC have various activities, including cytokine, cell proliferation or cell  
CC differentiation activities; stem cell growth factor activity;  
CC haematopoiesis regulatory activity; tissue growth activity;  
CC immunomodulatory activity; activin- or inhibin-related activities;  
CC chemotactic or chemokinetic activities; haemostatic, thrombotic or  
CC thrombolytic activities; receptor or ligand activities; or may be  
CC involved in oncogenesis, cancer cell proliferation and metastasis.  
CC Depending on their biological activities, polypeptides and nucleotides of  
CC the invention are useful for preventing, treating or ameliorating medical  
CC conditions, e.g., by protein or gene therapy. Such conditions include  
CC cancers, haematopoietic disorders (e.g., myeloid or lymphoid cell  
CC disorders), chronic inflammatory conditions (e.g., asthma or arthritis),  
CC proliferative retinopathy, atherosclerosis, coronary heart disease,  
CC arterial ischaemia, bone disorders (e.g., osteoporosis), and abnormal  
CC vascular growth. Polypeptides involved with tissue regeneration and  
CC repair (or nucleic acids encoding them) may be used to promote wound  
CC healing (e.g., of burns, incisions and ulcers), while those with  
CC immunomodulatory activities may be used in the treatment of viral,  
CC bacterial and fungal infections in addition to immune disorders.  
CC Polypeptides with growth factor activity may be used in cell cultures to  
CC promote cell growth. For example, such polypeptides may be used to  
CC manipulate stem cells in culture to give rise to neuroepithelial cells  
CC that can be used to augment or replace cells damaged by illness,  
CC autoimmune disease or accidental damage. The polypeptides and nucleotides  
CC may also be used in the diagnosis of the above conditions, and in drug  
CC screening techniques. The present sequence represents a cDNA encoding a  
CC novel human polypeptide of the invention  
XX  
SQ Sequence 558 BP; 165 A; 128 C; 144 G; 121 T; 0 U; 0 Other;

Alignment Scores:  
Pred. No.: 2,46e-46 Length: 558  
Score: 481.00 Matches: 94  
Percent Similarity: 97.94% Conservative: 1  
Best Local Similarity: 96.91% Mismatches: 2  
Query Match: 38.76% Indels: 0  
DB: 4 Gaps: 0

US-09-914-053A-5 (1-235) x ABA09433 (1-558)

Qy 1 MetSerIleThrSerGlyArgThrSerSerSerTyrArgHisAspGluLysArgAsn 20  
Db 268 ATGTCGATATGGACAGTGGCGGACCTCTTCATCTTATAGCATGATGAAAGAGAAAT 327  
Qy 21 IleTyrGlnLysIleArgAspHisAspLeuLeuAspLysArgLysThrValThrAlaLeu 40  
Db 328 ATTTACAGAGAAATCAGGACCATGACCTCTGAGCAAAAGAAACAGTCACAGCACTG 387  
Qy 41 LysAlaGlyGluAspArgAlaIleLeuLeuGlyLeuAlaMetMetValCysSerIleMet 60  
Db 388 AAGCAGGAGAGGACCGAGCTATTCTACTGGAGCTGCTATGATGATGCTGCTCCATCATG 447  
Qy 61 MetTyrPheLeuLeuGlyIleThrLeuLeuArgSerTyrMetGlnSerValThrGlu 80

Db 448 ATGTAATTTCTGCTGGGAATCACACTCTCTGGCTCATACATGCAGAGCTGTGACCCGA 507  
Qy 81 GluSerGlnCysThrLeuLeuAsnAlaSerIleThrGluThrPheAsnCys 97  
Db 508 GAGTCTCATGCACTTGCTGTAATGGCTCCATCATCGGAACATTAATCTGTC 558  
RESULT 10  
AAF27992  
ID AAF27992 standard; DNA; 1237 BP.  
XX  
AC AAF27992;  
XX  
XX 08-MAY-2001 (first entry)  
DT Human calcium sensitive potassium channel beta3a subunit coding sequence.  
DE  
XX Human; calcium sensitive potassium channel; beta2 subunit; asthma;  
KW beta3a subunit; beta3b subunit; beta3c subunit; diabetes;  
KW chromosome 3q23-ter; inhibitor; activator; glaucoma; migraine; angina;  
KW irritable bowel syndrome; Alzheimer's disease; ds.  
XX  
OS Homo sapiens.  
XX  
XX WO200105828-A1.  
PN  
XX 25-JAN-2001.  
PD  
XX 18-JUL-2000; 2000WO-US019585.  
PF  
XX 20-JUL-1999; 99US-0144764P.  
PR  
XX (MERI ) MERCK & CO INC.  
XX  
XX Debele V, Swanson R, Liu Y, Lagrutta A;  
PI  
XX WPI; 2001-159514/16.  
DR  
XX P-PSDB; AAB35302.  
DR  
XX Novel human calcium sensitive potassium channel subunits for identifying  
PT inhibitors and agonists of the potassium channel for use in treating  
PT conditions such as asthma, hypertension, memory disorders, depression.  
XX  
XX Claim 3; Fig 2A; 89pp; English.  
XX  
CC The present invention provides the protein and coding sequences of the  
CC human calcium sensitive potassium channel beta2, beta3a, beta3b, beta3c  
CC and beta3d subunits. These can be used to identify inhibitors and  
CC activators of the channels, which can be used in the treatment of  
CC conditions including asthma, diabetes, glaucoma, cerebral ischaemia,  
CC Alzheimer's disease, excessive smooth muscle tone, angina, hypertension,  
CC incontinence, migraine and irritable bowel syndrome. The coding sequences  
CC are found at human chromosome 3q23-ter. The present sequence is the  
CC beta3a subunit coding sequence  
XX  
SQ Sequence 1237 BP; 314 A; 312 C; 324 G; 287 T; 0 U; 0 Other;

Alignment Scores:  
Pred. No.: 1.6e-45 Length: 1237  
Score: 478.50 Matches: 97  
Percent Similarity: 60.00% Conservative: 44  
Best Local Similarity: 41.28% Mismatches: 81  
Query Match: 38.56% Indels: 13  
DB: 4 Gaps: 5

US-09-914-053A-5 (1-235) x AAF27992 (1-1237)

Qy 7 GlyArgThrSerSerSerTyrArgHisAspGluLysArgAsnIleTyrGlnLysIleArg 26  
Db 398 GGGAGGACAGCCCTTCTCTCCCTCAGGAGAGAGAGAGACAGACTACAGT----- 448  
Qy 27 AspHisAspLeuLeuAspLysArgLysThrValThrAlaLeuLysAlaGlyGluAspArg 46

Db 449 GATGAGACCCACTAGATGTGTGCACAAAGAGGTGCCATCC---AGTACTGGAGAGGACCGA 505  
QY 47 AlalileuLeuGlyLeuAlaMetMetValCysSerIleMetTyrPheLeuLeuGly 66  
Db 506 GCCGTGATGCTGGGTTTGCATGATGGCTTCTCAGTCCCTAAATGTTCTTCTCTCGGA 565  
QY 67 IletHrLeuLeuArgSerTyrMetGlnSerValThrTrpThrGluGluSerGlnCysThrLeu 86  
Db 566 ACAACCACTTCTAAAGCCTTTATGCTCAGCATTCAGAGAGAAGAAATCGACCTGCACCTGCC 625  
QY 87 LeuAsnAlaSerIleThrGluThrPhe---AsnCysSerPheSerCysGlyProAspCys 105  
Db 626 ATCCACACAGATATCATGAGCACTGGCTGAGCTGCTTCCACTGTGGTGCACCTGC 685  
QY 106 TrpLysLeuSerGlnTyrProCysLeuGlnValTyrValAsnLeuThrSerSerGlyGlu 125  
Db 686 CACGGTCAGGGAGTAGTACCGGTGCTTCCAGGTGTTGTGAACCTCAGCCATCCAGGTGAG 745  
QY 126 LysLeuLeuLeuTyrHisThrGluGluThrIleLysLeuGlnCysSerTyrIle 145  
Db 746 AARGCTCTCTACATTATATCAAGAGGCTGTCCAGATAAATCCCAAGTGTCTTTACACA 805  
QY 146 ProLysCysGlyLysAsnPheGluGluSerMetSerLeuValAsnValMetGluAsn 165  
Db 806 CCTAAGTGC-----CACCAAGATAGAAGTATTTGCTCAACAGCTCTCGACATA 856  
QY 166 PheArgLysTyrGlnHis-----PheSerCysTyrSerAspProGluGly 180  
Db 857 AAAGAAATCTTCGATCAAAAATGGAACCCCTTTTCATGCTTCTACAGTCCAGCCAGC 916  
QY 181 AsnGlnLysSerValIleLeuThrLysLeuTyrSerSerAsnValLeuPheHisSerLeu 200  
Db 917 CAATCTGAGATGATCTTATATAAAGATGATGACCAATGGCTATCTTCCACTGTTTA 976  
QY 201 PheTrpProThrCysMetMetAlaGlyGlyValAlaIleValAlaMetValLysLeuThr 220  
Db 977 TTTTGGCCTTCAGTGACTCTCTAGGTGGTGGCCCTGATTTGTGCGATGGTGAGATTAA 1036  
QY 221 GlnTyrLeuSerLeuLeuCysGluArgIleGlnArgIleAsnArg 235  
Db 1037 CAACACTGTCTTACTGTGTGAAAAATATAGCACTGTAGTCAGA 1081

RESULT 11

AAZ11913

ID AAZ11913 standard; cDNA; 1111 BP.

AC AAZ11913;

DT 30-NOV-1999 (first entry)

XX Human potassium channel K-Hnov44 cDNA (splice variant 2).

XX Potassium channel; ataxia; arrhythmia; epilepsy; Bartter's syndrome;

XX cardiovascular disorder; CNS disorder; renal disorder; ds.

XX Homo sapiens.

XX Key Location/Qualifiers

XX CDS 297..959

XX /\*tag=a

XX /product= "Human K-Hnov44 potassium channel"

XX WO9943696-A1.

XX 02-SEP-1999.

XX 22-FEB-1999; 99WO-US0003826.

XX 25-FEB-1998; 98US-0076687P.

XX 07-AUG-1998; 98US-0095836P.

XX 19-JAN-1999; 99US-0116448P.

XX (AXIS-) AXIS PHARM INC.

XX Miller AP, Curran ME, Hu P, Rutter M, Wang J;  
PI WPI; 1999-527591/44.  
DR P-PSDB; AAY34131.  
XX New nucleic acids encoding mammalian K-Hnov potassium channel proteins,  
PT useful for the diagnosis and treatment of episodic ataxia with myokymia,  
PT cardiac arrhythmia, epilepsy and Bartter's syndrome.  
XX Claim 4; Page 90-91; 112pp; English.  
XX This sequence represents splice variant 2 of a human potassium channel  
CC K-Hnov44 cDNA. Alternative splicing does not affect the amino acid  
CC sequence of the protein. K-Hnov proteins have a high degree of homology  
CC to known potassium channels and may be alpha subunits, which form the  
CC functional channel, or accessory subunits that act to modulate the  
CC channel activity. K-Hnov44 is a potassium channel beta subunit. The  
CC gene's chromosomal location is 22p13, determined via PCR chromosomal  
CC localisation using primers AAZ11934 and AAZ11936. K-Hnov cDNAs were  
CC isolated by extension of expressed sequence tags (ESTs) which were  
CC related but not identical to known human potassium channels. Potential  
CC polymorphisms detected as sequence variants between multiple independent  
CC clones. Potassium channels have critical roles in various cell types and  
CC biochemical pathways. Defective potassium channels are known to cause  
CC four human diseases: episodic ataxia with myokymia; cardiac arrhythmia  
CC (long QT syndrome); epilepsy; and Bartter's syndrome. As potassium  
CC channels are critical components of virtually all cells, it is likely  
CC that abnormal potassium channels are also implicated in certain renal,  
CC cardiovascular and central nervous system (CNS) disorders. Nucleotides  
CC encoding K-Hnov proteins may be used for identifying homologous or  
CC related proteins and the DNA sequences encoding them. They may be used to  
CC produce compositions that modulate the expression and function of the  
CC K-Hnov protein and in studying the biochemical pathways associated with  
CC it. They may also be used for the recombinant production of K-Hnov  
CC protein in fermentation cultures. Additionally, such nucleotides may be  
CC used in gene therapy protocols for the treatment of diseases associated  
CC with abnormal potassium channels  
XX

SQ Sequence 1111 BP; 347 A; 237 C; 263 G; 264 T; 0 U; 0 Other;

Alignment Scores:

Pred. No.:	1,55e-45	Length:	1111
Score:	478.00	Matches:	94
Percent Similarity:	62.73%	Conservative:	41
Best Local Similarity:	43.72%	Mismatches:	70
Query Match:	38.52%	Indels:	10
DB:	2	Gaps:	4

US-09-914-053A-5 (1-235) x AAZ11913 (1-1111)

QY 27 AspHisAspLeuLeuAspLysArgLysThrValThrAlaLeuLysAlaGlyGluAspArg 46

Db 234 GATGAGACCCACTAGATGTGCACAAAGAGGCTGCATCC---AGTGTGGAGAGGACCGA 290

QY 47 AlalileuLeuGlyLeuAlaMetMetValCysSerIleMetTyrPheLeuLeuGly 66

Db 291 GCCGTGATGCTGGGTTTGCATGATGGCTTCTCAGTCCCTAAATGTTCTTCTCTCGGA 350

QY 67 IletHrLeuLeuArgSerTyrMetGlnSerValThrTrpThrGluGluSerGlnCysThrLeu 86

Db 351 ACAACCACTTCTAAAGCCTTTTATGCTCAGCATTCAGAGAGAAGAAATCGACCTGCACCTGCC 410

QY 87 LeuAsnAlaSerIleThrGluThrPhe---AsnCysSerPheSerCysGlyProAspCys 105

Db 411 ATCCACACAGATATCATGAGCACTGGCTGAGCTGTGCCTTCCACTGTGGTGTGCATGC 470

QY 106 TrpLysLeuSerGlnTyrProCysLeuGlnValTyrValAsnLeuThrSerSerGlyGlu 125

Db 471 CACGGTCAGGGGAAGTAGTACCGGTGCTTCTCAGGTGTTTGTGAACCTCAGCCATCCAGGTGAG 530

QY 126 LysLeuLeuLeuTyrHisThrGluGluThrIleLysIleAsnGlnLysCysSerTyrIle 145

531 AAGAGCTCTCCATATATGAAGAGCTGTCCAGATAAATCCCAAGTCTTTTACACA 590  
146 ProLysCysGlyLysAsnPheGluGluSerMetSerLeuValValMetGluAsn 165  
591 CCTAAGTGC-----CACCAGATAGAAATGTTTCTCAACAGTCTCTGGACATA 641  
166 PheArgLysTyrGlnHis-----PheSerCysTyrSerAspProGluGly 180  
642 AAGAATCTTCGATCACAATAAATGGAATCCCTTTTCATGCTTCTACAGTCCAGCCAGC 701  
181 AsnGlnLysSerValLeuThrLysLeuTyrSerSerAsnValLeuPheHisSerLeu 200  
702 CAATCTGAAGATGTCATCTTAATAAAAGATGACCAAAATGGCTATCTTCCACTGTTTA 761  
201 PheTyrProThrCysMetMetAlaGlyGlyValAlaLeuValAlaMetValLysLeuThr 220  
762 TTTTGGCTTCACAGCTCTGCTAGGTGGTGGCTGATTGTTGGCATGGTGAGATTAAACA 821  
221 GlnTyrLeuSerLeuLysCysGluArgGlyGlnArgIleAsnArg 235  
822 CAACACGTGCTTACTGTGTGTAATAATATAGCACTGTAGTCAGA 866

RESULT 12

AAK52128  
ID AAK52128 standard; cDNA; 1144 BP.

AC AAK52128;

XX 06-NOV-2001 (first entry)

DT Human polynucleotide SEQ ID NO 673.

DE Human; cytokine; cell proliferation; cell differentiation; gene therapy;  
KW vaccine; peptide therapy; stem cell growth factor; haematopoiesis;  
KW tissue growth factor; immunomodulatory; cancer; leukaemia;  
KW nervous system disorder; arthritis; inflammation; ss.

XX Homo sapiens.

OS WO200157190-A2.

FN 09-AUG-2001.

PD 05-FEB-2001; 2001WO-US004098.

PF 03-FEB-2000; 2000US-00496914.

XX 27-APR-2000; 2000US-00360875.

PR 20-JUN-2000; 2000US-00598075.

PR 19-JUL-2000; 2000US-00620325.

PR 01-SEP-2000; 2000US-00654936.

PR 15-SEP-2000; 2000US-00663561.

PR 20-OCT-2000; 2000US-00893325.

PR 30-NOV-2000; 2000US-00728422.

XX (HYSE-) HYSEQ INC.

PA Tang YT, Liu C, Drwanac RT, Asundi V, Zhou P, Xu C, Cao Y;

XX Ma Y, Zhao QA, Wang D, Wang J, Zhang J, Ren F, Chen R, Wang ZW;

PI Xue AJ, Yang Y, Wehrman T, Goodrich R;

XX WPI; 2001-476283/51.

DR P-PSDB; AAM78995.

XX Nucleic acids encoding polypeptides with cytokine-like activities, useful  
in diagnosis and gene therapy.

XX Claim 1; Page 2356-2357; 6221pp; English.

XX The invention relates to polynucleotides (AAK51456-AAK53435) and the  
CC encoded polypeptides (AAM78323-AAM80302) that exhibit activity relating to  
CC cytokine, cell proliferation or cell differentiation or which may induce  
CC production of other cytokines in other cell populations. The  
CC polynucleotides and polypeptides are useful in gene therapy, vaccines or

CC peptide therapy. The polypeptides have various cytokine-like activities,  
CC e.g. stem cell growth factor activity, haematopoiesis regulating  
CC activity, tissue growth factor activity, immunomodulatory activity and  
CC activin/inhibin activity and may be useful in the diagnosis and/or  
CC treatment of cancer, leukaemia, nervous system disorders, arthritis and  
CC inflammation. Note: Records for SEQ ID NO 2110 (AAK52581), 2111  
CC (AAK52582) and 3666 (AAM80020) are omitted as the relevant pages from the  
CC sequence listing were missing at the time of publication  
XX  
SQ Sequence 1144 BP; 289 A; 296 C; 291 G; 268 T; 0 U; 0 Other;

Alignment Scores:  
Pred. No.: 1,86e-45 Length: 1144  
Score: 477.50 Matches: 97  
Percent Similarity: 60.00% Conservative: 44  
Best Local Similarity: 41.28% Mismatches: 81  
Query Match: 38.48% Indels: 13  
DB: 4 Gaps: 5

US-09-914-053A-5 (1-235) x AAK52128 (1-1144)

QY 7 GlyArgThrSerSerTyrArgHisAspGluLysArgAsnIleTyrGlnLysIleArg 26  
DB 371 GGGAGGACAGCCCTTCTCCCTCAGGGAAGAGAGAGACAGACTACAGT----- 421  
QY 27 AspHisAspLeuLeuAspLysArgLysThrValThrAlaLeuLysAlaGlyGluAspArg 46  
DB 422 GATGAGACCCACTAGATGTGCACAGAGGCTGCCATCC---AGTACTGGAGAGACCGA 478  
QY 47 AlaIleLeuLeuGlyLeuAlaMetMetValCysSerIleMetMetTyrPheLeuLeuGly 66  
DB 479 GCGGTGATCTGGGTTTGCCATGATGGCTTCTCAGTCTTAATGTTCTTGTGTCGA 538  
QY 67 IleThrLeuLeuArgSerTyrMetGlnSerValTyrThrGluGluSerGlnCysThrLeu 86  
DB 539 ACAACATCTTAAGCCCTTTATGTCACATTCAGAGAGAGATCGACCTGCACGTGCC 598  
QY 87 LeuAsnAlaSerIleThrGluThrPhe---AsnCysSerPheSerCysGlyProAspCys 105  
DB 599 ATCCACACAGATATCATGGACACTGGCTGGTGGCTTGCCTTCCCTGTGTGCTGCACTGC 658  
QY 106 TrpLysLeuSerGlnTyrProCysLeuGlnValTyrValAsnLeuThrSerSerGlyGlu 125  
DB 659 CACGGTCAGGGAAGTACCCTGCTTTCAGGTGTTGTGAACCTCAGCCATCCAGTCTCAG 718  
QY 126 LysLeuLeuLeuTyrHisThrGluGluThrIleLysIleAsnGlnLysCysSerTyrIle 145  
DB 719 AAGCTCTCTACATTATATGAGAGAGGCTGCCAGATAAATCCCAAGTCTTTACACA 778  
QY 146 ProLysCysGlyLysAsnPheGluGluSerMetSerLeuValValMetGluAsn 165  
DB 779 CCTAAGTGC-----CACCAAGATAGAAATGATTTCCTCAACAGTCTCTGGACATA 829  
QY 166 PheArgLysTyrGlnHis-----PheSerCysTyrSerAspProGluGly 180  
DB 830 AAGAATCTTCGATCACAATAAATGGAATCCCTTTTCATGCTTCTACAGTCCAGCCAGC 889  
QY 181 AsnGlnLysSerValIleLeuThrLysLeuTyrSerSerAsnValLeuPheHisSerLeu 200  
DB 890 CAATCTGAAGATGCTCATCTTATAAAAAAGATGACCAAAATGGCTATCTTCCACTGTTTA 949  
QY 201 PheTyrProThrCysMetMetAlaGlyGlyValAlaIleValAlaMetValLysLeuThr 220  
DB 950 TTTTGGCTTCACAGTCTCTGCTAGGTGGTGGCTGATGTTGTCGATGTTGGATGATTAAACA 1009  
QY 221 GlnTyrLeuSerLeuLysCysGluArgIleGlnArgIleAsnArg 235  
DB 1010 CAACACCTGCTTACTGTGTGTAATAATATAGCACTGTAGTCAGA 1054

RESULT 13

ABA09214  
ID ABA09214 standard; cDNA; 1251 BP.

XX







(ICAG-) ICAGEN INC.

Jegla TJ, Wickenden A, Liu Y;  
WPI; 2000-533179/48.  
P-PSDB; AAB08818.

Isolated beta subunit polynucleotides and polypeptides of slo potassium channels are used to determine the effects of compounds on ion flux through a potassium channel and in computer modelling systems.

Claim 7; Page 79; 84pp; English.

The present sequence encodes a human BK beta-2 polypeptide. The polypeptide is a beta subunit of a slo potassium channel. The specification also describes BK beta-3 and BK beta-4 polypeptides. BK beta subunits are auxiliary subunits or monomers of slo potassium channels. The polypeptides when expressed in cells and cell membranes, are used to determine the effects of compounds on ion flux through a potassium channel. The compounds identified may be useful as therapeutic agents e.g. modulators that target specific slo channels are useful for treating migraines, hearing and vision problems, seizures, stroke, asthma, cell proliferation and hormone secretion. The computer generated 3-dimensional structures of BK beta 2, BK beta 3 or BK beta 4 are used to identify ligands that bind to the beta subunit. The characterized BK beta subunits are used to determine how slo potassium channels function in different environments and how they respond to different activation mechanisms. The polynucleotides are used to transfect cells in vivo and in vitro to mitigate effects of absent, partial inactivation or abnormal expression of the BK beta subunit gene e.g. to correct genetic defects, cancer and viral infection

Sequence 774 BP; 223 A; 177 C; 179 G; 195 T; 0 U; 0 Other;

Qy	166	PheArgLysTyrGlnHis-----PheSerCysTyrSerAspProGluGly	180
		:::::	
Db	457	AAAGAATCTTCGATCAAAAATAAGGAACCCCTTTTCATGCTTCACAGTCACGCAGC	516
Qy	181	AsnGlnLysSerValIleLeuThrLysLeuTyrSerSerAsnValLeuPheHisSerLeu	200
		:::::	
Db	517	CAATCTGAAGATGTCATTCTTATAAAAAAGTAIGACCAAATGGCTATCTTCACACTGT	576
Qy	201	PheTrrProThrCysMetAlaGlyGlyValAlaIleValAlaMetValLysLeuThr	220
		:::::	
Db	577	TTTTGGCCTTCACACTCTCGTAGGTGGTCCCTGATTTGGCATGGTGAGATTACA	636
Qy	221	GlnTyrLeuSerLeuLeuCysGluArgIleGlnArgIleAsnArg	235
		:::::	
Db	637	CAACACCTGTCCTTACTGTGTGAAAAATATAGCACCTGTAGTCAGAC	681

Search completed: November 7, 2004, 01:38:40  
Job time : 412 secs

GenCore version 5.1.6  
Copyright (c) 1993 - 2004 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: November 6, 2004, 23:31:06 ; Search time 3203 Seconds  
(without alignments)  
10438.282 Million cell updates/sec

Title: US-09-914-053A-6  
Perfect score: 707  
Sequence: 1 atctgatattggaccagtgg.....atccacggatcaatagataa 707

Scoring table: IDENTITY NUC

Gapop 10.0 , Gapext 1.0

Searched: 4526729 seqs, 23644849745 residues

Total number of hits satisfying chosen parameters: 9053458

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%  
Listing first 45 summaries

Database :

GenEmbl.\*

1: gb.ba.\*  
2: gb.rtg.\*  
3: gb.in.\*  
4: gb.om.\*  
5: gb.ov.\*  
6: gb.pat.\*  
7: gb.ph.\*  
8: gb.pl.\*  
9: gb.pr.\*  
10: gb.ro.\*  
11: gb.sts.\*  
12: gb.sy.\*  
13: gb.un.\*  
14: gb\_vi.\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

#### SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	692	97.9	1075	9 AF099137	AF099137 Homo sapi
2	692	97.9	1285	9 BC017825	BC017825 Homo sapi
3	692	97.9	2574	9 AF209747	AF209747 Homo sapi
4	666	94.2	1062	6 CQ714334	CQ714334 Sequence
5	567.2	80.2	708	10 AV062429	AV062429 Mus muscu
6	567.2	80.2	2947	10 BC046227	BC046227 Mus muscu
7	567.2	80.2	2947	10 BC058957	BC058957 Mus muscu
8	564.2	79.8	2098	6 B0223084	B0223084 98 human
9	564.2	79.8	2098	6 AR243782	AR243782 Sequence
10	562.4	79.5	708	10 AY191836	AY191836 Rattus no
11	438.4	62.0	1546	5 BX950825	BX950825 Gallus ga
12	438.4	62.0	1546	5 BX950833	BX950833 Gallus ga
13	384.4	54.4	487	10 BX0517198	AX517198 Rattus no
14	274.8	38.9	204899	9 AC117457	AC117457 Homo sapi
15	229.8	32.5	191186	2 AC115077	AC115077 Mus muscu
16	225	31.8	227094	2 AC126508	AC126508 Rattus no
17	225	31.8	297398	2 AC097578	AC097578 Rattus no
18	193.6	27.4	815	5 CU067865	U67865 Coturnix co
19	193.6	27.4	826	5 AF077369	AF077369 Gallus ga

20	193.6	27.4	1290	5 AF420468	AF420468 Gallus ga
C 21	151.2	21.4	270878	2 AC114433	AC114433 Rattus no
C 22	145.8	20.6	191186	2 AC115077	AC115077 Mus muscu
23	140.6	19.9	622	11 G97798	G97798 S209P6139FA
24	135.4	19.2	1022	6 CQ715541	CQ715541 Sequence
25	135.4	19.2	1111	6 AR212368	AR212368 Sequence
26	135.4	19.2	1246	6 AR212367	AR212367 Sequence
27	134.4	19.0	952	9 AF214561	AF214561 Homo sapi
28	134.4	19.0	1022	9 AF139471	AF139471 Homo sapi
29	134.4	19.0	1160	9 AF210916	AF210916 Homo sapi
30	134.4	19.0	1225	9 AF204159	AF204159 Homo sapi
31	134.4	19.0	1311	9 AR204162	AR204162 Homo sapi
32	134.4	19.0	1488	9 AF160968	AF160968 Homo sapi
33	134.4	19.0	1620	9 AF204160	AF204160 Homo sapi
34	134.4	19.0	1747	9 AF204161	AF204161 Homo sapi
35	134	19.0	576	9 AF026002	AF026002 Homo sapi
36	134	19.0	576	9 HSU38907	U38907 Human beta-
37	134	19.0	715	9 AY044441	AY044441 Homo sapi
38	134	19.0	835	9 AY515264	AY515264 Homo sapi
39	134	19.0	1041	9 HSU42600	U42600 Human calci
40	134	19.0	1092	9 HSU61536	U61536 Human potas
41	134	19.0	1106	6 AR016453	AR016453 Sequence
42	134	19.0	1106	6 I45572	I45572 Sequence 3
43	134	19.0	1276	6 CQ726048	CQ726048 Sequence
44	134	19.0	1277	6 AX337509	AX337509 Sequence
45	134	19.0	1277	9 HSU25138	U25138 Human Maxik

#### ALIGNMENTS

RESULT 1  
LOCUS AF099137  
DEFINITION Homo sapiens Maxik channel beta 2 subunit (KCNMB2) mRNA, complete cds.  
ACCESSION AF099137  
VERSION AF099137.1 GI:4566496  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
REFERENCE 1 (bases 1 to 1075)  
AUTHORS Wallner M., Meera P. and Toro L.  
TITLE Molecular basis of fast inactivation in voltage and Ca2+-activated K+ channels: a transmembrane beta-subunit homolog  
JOURNAL Proc. Natl. Acad. Sci. U.S.A. 96 (7), 4137-4142 (1999)  
MEDLINE 99199323  
REFERENCE 2 (bases 1 to 1075)  
AUTHORS Wallner M.  
TITLE Direct Submission  
JOURNAL Submitted (16-OCT-1998) Dept. of Anesthesiology, UCLA, BH-612, CHS Box 951778, Los Angeles, CA 90095-1778, USA  
FEATURES  
source  
Location/Qualifiers  
1..1075  
/organism="Homo sapiens"  
/mol\_type="mRNA"  
/db\_xref="taxon:9606"  
/clone="IMAGE Consortium ID 1417217"  
/tissue\_type="neuroendocrine lung carcinoid"  
1..1075  
/gene="KCNMB2"  
146..853  
/gene="KCNMB2"  
/function="coexpression with the pore forming Maxik channel alpha subunit leads to fast inactivating currents and to an increase in apparent Ca2+ sensitivity"  
/notes="modulatory subunit of the voltage and Ca2+-activated K+ (Maxik) channel"  
/codon\_start=1  
/product="Maxik channel beta 2 subunit"

```

/protein_id="AAD23380.1"
/db_xref="GI:4566497"
/translation="MFPTSGTSSYRHDEKRNLYQKIRHDLLDKRKTVALKAGE
DRAILLGLAMVYQVNTLILSRYSQVWTEESQCTLLNASTETFCFSFG
PDKWLQVPCVQVNTLILSRYSQVWTEESQCTLLNASTETFCFSFG
VYVNFPRKYHFCSCYSDPEGNQSVILTKLYSSNVLFSLFWPTCMAGGVAIVAMVK
LTOYLSLLCERIQIRNR"
misc_feature
146..202
/gene="KCNMB2"
/notes="intracellular inactivating 'ball' domain;
unclassified site"
misc_feature
287..355
/gene="KCNMB2"
/notes="transmembrane-region site"
misc_feature
728..796
/gene="KCNMB2"
/notes="transmembrane-region site"
ORIGIN
Query Match          97.9%; Score 692; DB 9; Length 1075;
Best Local Similarity 99.3%; Pred. No. 2, 3e-194;
Matches 703; Conservative 2; Mismatches 2; Indels 1; Gaps 1;
QY 1 ATGTGATATGACAGAGCGGACCTCTTCATCTTATGACATGATGAAAAAGAAAT 60
Db 1 ATGTGATATGACAGAGCGGACCTCTTCATCTTATGACATGATGAAAAAGAAAT 60
QY 146 ATGTTTATATGACAGAGCGGACCTCTTCATCTTATGACATGATGAAAAAGAAAT 205
Db 146 ATGTTTATATGACAGAGCGGACCTCTTCATCTTATGACATGATGAAAAAGAAAT 205
QY 61 ATTTACGAAAAATCAGGACCATCACTCTCTGGACAAAAGAAACAGTCACAGCACTG 120
Db 61 ATTTACGAAAAATCAGGACCATCACTCTCTGGACAAAAGAAACAGTCACAGCACTG 120
QY 206 ATTTACGAAAAATCAGGACCATCACTCTCTGGACAAAAGAAACAGTCACAGCACTG 265
Db 206 ATTTACGAAAAATCAGGACCATCACTCTCTGGACAAAAGAAACAGTCACAGCACTG 265
QY 121 AAGCAGGAGAGAGCGAGCTATTCCTGGAGATGCTATGATGCTGCTCCATCATG 180
Db 121 AAGCAGGAGAGAGCGAGCTATTCCTGGAGATGCTATGATGCTGCTCCATCATG 180
QY 266 AAGGAGGAGAGAGCGAGCTATTCCTGGAGATGCTATGATGCTGCTCCATCATG 325
Db 266 AAGGAGGAGAGAGCGAGCTATTCCTGGAGATGCTATGATGCTGCTCCATCATG 325
QY 181 ATGTATTTCTCTGGAAATCACTCTCTGGAGATGCTATGATGCTGCTCCATCATG 400
Db 181 ATGTATTTCTCTGGAAATCACTCTCTGGAGATGCTATGATGCTGCTCCATCATG 400
QY 326 ATGTATTTCTCTGGAAATCACTCTCTGGAGATGCTATGATGCTGCTCCATCATG 385
Db 326 ATGTATTTCTCTGGAAATCACTCTCTGGAGATGCTATGATGCTGCTCCATCATG 385
QY 241 GAGTCTCAATGACACTTCTGTAATCGCTCCATCAAGGAAACATTTAATGCTCTTCA 300
Db 241 GAGTCTCAATGACACTTCTGTAATCGCTCCATCAAGGAAACATTTAATGCTCTTCA 300
QY 386 GAGTCTCAATGACACTTCTGTAATCGCTCCATCAAGGAAACATTTAATGCTCTTCA 445
Db 386 GAGTCTCAATGACACTTCTGTAATCGCTCCATCAAGGAAACATTTAATGCTCTTCA 445
QY 301 TGTGTCAGAGCTGCGAAACTTCTCAGTACCCCTGCTCCAGGAGTGTAGTTAACTG 360
Db 301 TGTGTCAGAGCTGCGAAACTTCTCAGTACCCCTGCTCCAGGAGTGTAGTTAACTG 360
QY 446 TGTGTCAGAGCTGCGAAACTTCTCAGTACCCCTGCTCCAGGAGTGTAGTTAACTG 505
Db 446 TGTGTCAGAGCTGCGAAACTTCTCAGTACCCCTGCTCCAGGAGTGTAGTTAACTG 505
QY 361 ACTTCTCCGGGAAAAAGCTCTCTCTTACACAGAGAGACAAATAAATCAATCAG 420
Db 361 ACTTCTCCGGGAAAAAGCTCTCTCTTACACAGAGAGACAAATAAATCAATCAG 420
QY 506 ACTTCTCCGGGAAAAAGCTCTCTCTTACACAGAGAGACAAATAAATCAATCAG 565
Db 506 ACTTCTCCGGGAAAAAGCTCTCTCTTACACAGAGAGACAAATAAATCAATCAG 565
QY 421 AAGTCTCTTATATACCTTAATGTGGAATAAATTTGAAGAAATCCATGTCCTGGTGA 480
Db 421 AAGTCTCTTATATACCTTAATGTGGAATAAATTTGAAGAAATCCATGTCCTGGTGA 480
QY 566 AAGTCTCTTATATACCTTAATGTGGAATAAATTTGAAGAAATCCATGTCCTGGTGA 625
Db 566 AAGTCTCTTATATACCTTAATGTGGAATAAATTTGAAGAAATCCATGTCCTGGTGA 625
QY 481 GTTGTGATGGAAGAACTTCAGGAAGTATCAACACTTCTCTGCTATCTGACCCAGAGGA 540
Db 481 GTTGTGATGGAAGAACTTCAGGAAGTATCAACACTTCTCTGCTATCTGACCCAGAGGA 540
QY 626 GTTGTGATGGAAGAACTTCAGGAAGTATCAACACTTCTCTGCTATCTGACCCAGAGGA 685
Db 626 GTTGTGATGGAAGAACTTCAGGAAGTATCAACACTTCTCTGCTATCTGACCCAGAGGA 685
QY 541 AACCAAGAGAGTGTATCTTAACAAACTCTACAGTTCACAGTGTGTTCCATTCATC 600
Db 541 AACCAAGAGAGTGTATCTTAACAAACTCTACAGTTCACAGTGTGTTCCATTCATC 600
QY 686 AACCAAGAGAGTGTATCTTAACAAACTCTACAGTTCACAGTGTGTTCCATTCATC 745
Db 686 AACCAAGAGAGTGTATCTTAACAAACTCTACAGTTCACAGTGTGTTCCATTCATC 745
QY 601 TTCTGGCCAACTGATGATGCTGGGGGTGGAATTTGTCATGCTGGTGAACCTTACA 660
Db 601 TTCTGGCCAACTGATGATGCTGGGGGTGGAATTTGTCATGCTGGTGAACCTTACA 660
QY 746 TTCTGGCCAACTGATGATGCTGGGGGTGGAATTTGTCATGCTGGTGAACCTTACA 805
Db 746 TTCTGGCCAACTGATGATGCTGGGGGTGGAATTTGTCATGCTGGTGAACCTTACA 805
QY 661 CAGTACCTCTCCCTACTATGTGAGAGGATCC-ACGGATCAATAGATAA 707
Db 661 CAGTACCTCTCCCTACTATGTGAGAGGATCC-ACGGATCAATAGATAA 707
QY 806 CAGTACCTCTCCCTACTATGTGAGAGGATCC-ACGGATCAATAGATAA 853
Db 806 CAGTACCTCTCCCTACTATGTGAGAGGATCC-ACGGATCAATAGATAA 853

```

```

BC017825
LOCUS
DEFINITION
Homo sapiens potassium large conductance calcium-activated channel,
subfamily M, beta member 2, transcript variant 1, mRNA (cDNA clone
MGC:22431 IMAGE:4657825), complete cds.
ACCESSION
BC017825
VERSION
BC017825.1 GI:17389593
KEYWORDS
MGC.
SOURCE
Homo sapiens (human)
ORGANISM
Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
1 (bases 1 to 1285)
Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
Klausner R.D., Collins F.S., Wagner J., Shenmen C.M., Schuler G.D.,
Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Hsieh F.,
Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
Stapleton M., Soares M.B., Bonaldo M.P., Casavant T.L.,
Schaefer T.E., Brownstein M.J., Udwin T.B., Tchuyuk S.,
Carninci P., Prange C., Raha S.S., Loquellano N.A., Peters G.J.,
Abramson R.D., Mullany S.J., Bosak S.A., McEwan P.J.,
McKernan K.J., Malek J.A., Gunaratne P.H., Richards S.W.,
Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
Villalón D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
Fahey J., Helton E., Kettelman M., Madan A., Rodriguez S.,
Sanchez A., Whiting M., Madan A., Young A.C., Shevchenko Y.,
Bouffard G.G., Blakeley R.W., Touchman J.W., Green E.D.,
Dickson M.C., Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
Butterfield Y.S., Krzywinski M.I., Skalska U., Small D.E.,
Schnerch A., Schein J.E., Jones S.J. and Marra M.A.
Generation and initial analysis of more than 15,000 full-length
human and mouse cDNA sequences
Proc. Natl. Acad. Sci. U.S.A. 99 (26), 15899-15903 (2002)
12477932
PUBMED
2 (bases 1 to 1285)
Strausberg R.
Direct Submission
Submitted (03-DEC-2001) National Institutes of Health, Mammalian
Gene Collection (MGC), Cancer Genomics Office, National Cancer
Institute, 31 Center Drive, Room 11A03, Bethesda, MD 20892-2590,
USA
NIH-MGC Project URL: http://mgc.nci.nih.gov
Contact: MGC help desk
Email: cgabbs@mail.nih.gov
Tissue Procurement: ATCC
cDNA Library Preparation: CLONTECH Laboratories, Inc.
cDNA Library Arrayed by: The I.M.A.G.E. Consortium (LNL)
DNA Sequencing by: Sequencing Group at the Stanford Human Genome
Center, Stanford University School of Medicine, Stanford, CA 94305
Web site: http://www.shgc.stanford.edu
Contact: (Dickson, Mark) mcd@paxil.stanford.edu
Dickson, M., Schmutz, J., Grimwood, J., Rodriguez, A., and Myers,
R. M.

```

Clone distribution: MGC clone distribution information can be found through the I.M.A.G.E. Consortium/LLNL at: <http://image.llnl.gov>  
 Series: IRAL Place: 36 Row: 1 Column: 8  
 This clone was selected for full length sequencing because it passed the following selection criteria: matched mRNA gi: 19923319.

```

FEATURES
Location/Qualifiers
1..1285
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
/clone="MGC:22431 IMAGE:4657825"
/tissue_type="Testis, embryonal carcinoma"
/clone_lib="NIH MGC 61"
/lab_host="DH10B"
/notes="Vector: pDNR-LIB"
1..1285
/gene="KCNMB2"
/notes="synonym: MGC22431"

```

LOCUS DEFINITION ACCESSION VERSION KEYWORDS SOURCE ORGANISM REFERENCE AUTHORS TITLE JOURNAL MEDLINE PUBMED REFERENCE AUTHORS TITLE JOURNAL FEATURES source	/db_xref="LocusID:10242" /db_xref="MIM:605214" 344..1051 /gene="KCNMB2" /codon_start=1 /product="calcium-activated potassium channel beta 2 subunit" /protein_id="AAH:7825.1" /db_xref="GI:17389594" /db_xref="LocusID:10242" /db_xref="MIM:605214"		2574 bp mRNA linear PRI 29-FEB-2000 Homo sapiens large conductance calcium-activated potassium channel beta2 subunit (KCNMB2) mRNA, complete cds.	
	DRAILGLAMVCSIMYFLLGITLLRSYVQSWTFESQCTLLNASITETFNCSFSCG PDCWKLSQYPCLOVYNLTSSGKLLYHTETIKINQKSYIPKCKNFEESMLVN VVMENFRKYQHPSCYSDPEGNQKSVILTKLYSSNVLFHFWPTCMAGGVAIVAMVK LTQYLSLLCERIQIRNR"		Brenner R., Jegla T.J., Wickenden A., Liu Y. and Aldrich R.W. Cloning and functional characterization of novel large conductance calcium-activated potassium channel beta subunits, hKCNMB3 and hKCNMB4	
	J. Biol. Chem. 275 (9), 6453-6461 (2000)		J. Biol. Chem. 275 (9), 6453-6461 (2000)	
	20158960 10692449		2 (bases 1 to 2574)	
	Brenner R., Jegla T.J., Wickenden A., Liu Y. and Aldrich R.W. Direct Submission		Submitted (30-NOV-1999) Molecular and Cell Physiology, Howard Hughes Medical Institute, Stanford School of Medicine, Beckman B173, Stanford, CA 94305, USA	
	Location/Qualifiers		Location/Qualifiers	
	1..2574		/organism="Homo sapiens" /mol_type="mRNA" /db_xref="taxon:9606" /tissue_type="ovary" 1..2574 /gene="KCNMB2" 353..1060 /gene="KCNMB2" /note="KCNMB2; large conductance (BK) potassium channel beta2 subunit" /codon_start=1 /product="large conductance calcium-activated potassium channel beta2 subunit" /protein_id="AAF3562.1" /db_xref="GI:7108973" /translation="MFMTSGRTSSSYRHDEKRNLYQKIRHDLDDKRTVTALKAGE DRAILLGLAMVCSIMYFLLGITLLRSYVQSWTFESQCTLLNASITETFNCSFSCG PDCWKLSQYPCLOVYNLTSSGKLLYHTETIKINQKSYIPKCKNFEESMLVN VVMENFRKYQHPSCYSDPEGNQKSVILTKLYSSNVLFHFWPTCMAGGVAIVAMVK LTQYLSLLCERIQIRNR"	
	CDS		CDS	
	gene		gene	
	ORIGIN		ORIGIN	
Query Match Best Local Similarity Matches 703; Conservative 2; Mismatches 2; Indels 1; Gaps 1;	97.9%; Score 692; DB 9; Length 1285; 99.3%; Pred. No. 2.3e-194;		97.9%; Score 692; DB 9; Length 2574; 99.3%; Pred. No. 2.4e-194;	
	1 ATGTCGATATGACAGTGGCGGACCTCTTCATCTTATAGACATGATGAAAAAGAAAT 60		1 ATGTCGATATGACAGTGGCGGACCTCTTCATCTTATAGACATGATGAAAAAGAAAT 60	
	353 ATGTTTATATGACAGTGGCGGACCTCTTCATCTTATAGACATGATGAAAAAGAAAT 412		353 ATGTTTATATGACAGTGGCGGACCTCTTCATCTTATAGACATGATGAAAAAGAAAT 412	
	61 ATTTACAGAAAAATCAGGACCATGACCTCTCTGGACAAAAGAAAAACAGTCACAGCACTG 120		61 ATTTACAGAAAAATCAGGACCATGACCTCTCTGGACAAAAGAAAAACAGTCACAGCACTG 120	
	413 ATTTACAGAAAAATCAGGACCATGACCTCTCTGGACAAAAGAAAAACAGTCACAGCACTG 472		413 ATTTACAGAAAAATCAGGACCATGACCTCTCTGGACAAAAGAAAAACAGTCACAGCACTG 472	
	121 AAGGACGAGAGACCGAGCTATTCTCTGGACATGGCTATGATGCTGTGCTCCATCATG 180		121 AAGGACGAGAGACCGAGCTATTCTCTGGACATGGCTATGATGCTGTGCTCCATCATG 180	
	473 AAGGACGAGAGACCGAGCTATTCTCTGGACATGGCTATGATGCTGTGCTCCATCATG 532		473 AAGGACGAGAGACCGAGCTATTCTCTGGACATGGCTATGATGCTGTGCTCCATCATG 532	
	181 ATGATTTTCTCTGGGAATACACTCTCTGGCTCATATCATGACAGAGCGTGTGGACCGAA 240		181 ATGATTTTCTCTGGGAATACACTCTCTGGCTCATATCATGACAGAGCGTGTGGACCGAA 240	
	533 ATGATTTTCTCTGGGAATACACTCTCTGGCTCATATCATGACAGAGCGTGTGGACCGAA 592		533 ATGATTTTCTCTGGGAATACACTCTCTGGCTCATATCATGACAGAGCGTGTGGACCGAA 592	
	241 GAGTCTCAATGACCTTGTGTAATCGTCCATCAGGAAACATTTAAATGCTCTCTCAGC 300		241 GAGTCTCAATGACCTTGTGTAATCGTCCATCAGGAAACATTTAAATGCTCTCTCAGC 300	
RESULT 3 AF209747	593 GAGTCTCAATGACCTTGTGTAATCGTCCATCAGGAAACATTTAAATGCTCTCTCAGC 652		593 GAGTCTCAATGACCTTGTGTAATCGTCCATCAGGAAACATTTAAATGCTCTCTCAGC 652	
	301 TGTGTCGACAGTGTCTGGAACACTTTCTCAGTACCCCTGCTCCAGGTGTACGTTAACTG 360		301 TGTGTCGACAGTGTCTGGAACACTTTCTCAGTACCCCTGCTCCAGGTGTACGTTAACTG 360	
	420		420	
	763		763	
	480		480	
	823		823	
	540		540	
	883		883	
	600		600	
	943		943	
Query Match Best Local Similarity Matches 703; Conservative 2; Mismatches 2; Indels 1; Gaps 1;	97.9%; Score 692; DB 9; Length 1285; 99.3%; Pred. No. 2.3e-194;		97.9%; Score 692; DB 9; Length 2574; 99.3%; Pred. No. 2.4e-194;	
	1 ATGTCGATATGACAGTGGCGGACCTCTTCATCTTATAGACATGATGAAAAAGAAAT 60		1 ATGTCGATATGACAGTGGCGGACCTCTTCATCTTATAGACATGATGAAAAAGAAAT 60	
	344 ATGTTTATATGACAGTGGCGGACCTCTTCATCTTATAGACATGATGAAAAAGAAAT 403		344 ATGTTTATATGACAGTGGCGGACCTCTTCATCTTATAGACATGATGAAAAAGAAAT 403	
	61 ATTTACAGAAAAATCAGGACCATGACCTCTCTGGACAAAAGAAAAACAGTCACAGCACTG 120		61 ATTTACAGAAAAATCAGGACCATGACCTCTCTGGACAAAAGAAAAACAGTCACAGCACTG 120	
	404 ATTTACAGAAAAATCAGGACCATGACCTCTCTGGACAAAAGAAAAACAGTCACAGCACTG 463		404 ATTTACAGAAAAATCAGGACCATGACCTCTCTGGACAAAAGAAAAACAGTCACAGCACTG 463	
	121 AAGGACGAGAGACCGAGCTATTCTCTGGACATGGCTATGATGCTGTGCTCCATCATG 180		121 AAGGACGAGAGACCGAGCTATTCTCTGGACATGGCTATGATGCTGTGCTCCATCATG 180	
	464 AAGGACGAGAGACCGAGCTATTCTCTGGACATGGCTATGATGCTGTGCTCCATCATG 523		464 AAGGACGAGAGACCGAGCTATTCTCTGGACATGGCTATGATGCTGTGCTCCATCATG 523	
	181 ATGATTTTCTCTGGGAATACACTCTCTGGCTCATATCATGACAGAGCGTGTGGACCGAA 240		181 ATGATTTTCTCTGGGAATACACTCTCTGGCTCATATCATGACAGAGCGTGTGGACCGAA 240	
	524 ATGATTTTCTCTGGGAATACACTCTCTGGCTCATATCATGACAGAGCGTGTGGACCGAA 583		524 ATGATTTTCTCTGGGAATACACTCTCTGGCTCATATCATGACAGAGCGTGTGGACCGAA 583	
	241 GAGTCTCAATGACCTTGTGTAATCGTCCATCAGGAAACATTTAAATGCTCTCTCAGC 300		241 GAGTCTCAATGACCTTGTGTAATCGTCCATCAGGAAACATTTAAATGCTCTCTCAGC 300	
Query Match Best Local Similarity Matches 703; Conservative 2; Mismatches 2; Indels 1; Gaps 1;	97.9%; Score 692; DB 9; Length 1285; 99.3%; Pred. No. 2.3e-194;		97.9%; Score 692; DB 9; Length 2574; 99.3%; Pred. No. 2.4e-194;	
	594 GAGTCTCAATGACCTTGTGTAATCGTCCATCAGGAAACATTTAAATGCTCTCTCAGC 643		594 GAGTCTCAATGACCTTGTGTAATCGTCCATCAGGAAACATTTAAATGCTCTCTCAGC 643	
	301 TGTGTCGACAGTGTCTGGAACACTTTCTCAGTACCCCTGCTCCAGGTGTACGTTAACTG 360		301 TGTGTCGACAGTGTCTGGAACACTTTCTCAGTACCCCTGCTCCAGGTGTACGTTAACTG 360	
	644 TGTGTCGACAGTGTCTGGAACACTTTCTCAGTACCCCTGCTCCAGGTGTACGTTAACTG 703		644 TGTGTCGACAGTGTCTGGAACACTTTCTCAGTACCCCTGCTCCAGGTGTACGTTAACTG 703	
	361 ACTTCTTCGCGGAAAAAGCTCTCTCTTACCACAGAGAGACATAAATAAATCAATCAG 420		361 ACTTCTTCGCGGAAAAAGCTCTCTCTTACCACAGAGAGACATAAATAAATCAATCAG 420	
	704 ACTTCTTCGCGGAAAAAGCTCTCTCTTACCACAGAGAGACATAAATAAATCAATCAG 763		704 ACTTCTTCGCGGAAAAAGCTCTCTCTTACCACAGAGAGACATAAATAAATCAATCAG 763	
	421 AAGTGTCTCTATATACCTAAATGTGGAAAAATTTTGAAGAATCCATGTCCCTGGTGAAT 480		421 AAGTGTCTCTATATACCTAAATGTGGAAAAATTTTGAAGAATCCATGTCCCTGGTGAAT 480	
	764 AAGTGTCTCTATATACCTAAATGTGGAAAAATTTTGAAGAATCCATGTCCCTGGTGAAT 823		764 AAGTGTCTCTATATACCTAAATGTGGAAAAATTTTGAAGAATCCATGTCCCTGGTGAAT 823	
	481 GTTGTCTGGAAGAACTTCAGAGATATCAACATCTCTCTGCTATTCTGACCCAGAGGA 540		481 GTTGTCTGGAAGAACTTCAGAGATATCAACATCTCTCTGCTATTCTGACCCAGAGGA 540	
	824 GTTGTCTGGAAGAACTTCAGAGATATCAACATCTCTCTGCTATTCTGACCCAGAGGA 883		824 GTTGTCTGGAAGAACTTCAGAGATATCAACATCTCTCTGCTATTCTGACCCAGAGGA 883	
Query Match Best Local Similarity Matches 703; Conservative 2; Mismatches 2; Indels 1; Gaps 1;	97.9%; Score 692; DB 9; Length 1285; 99.3%; Pred. No. 2.3e-194;		97.9%; Score 692; DB 9; Length 2574; 99.3%; Pred. No. 2.4e-194;	
	541 AACCAGAGAGTGTATCTTAAACMAAACTCTACAGTTCACAGTGTGCTGTTCCTTCACTC 600		541 AACCAGAGAGTGTATCTTAAACMAAACTCTACAGTTCACAGTGTGCTGTTCCTTCACTC 600	
	884 AACCAGAGAGTGTATCTTAAACMAAACTCTACAGTTCACAGTGTGCTGTTCCTTCACTC 943		884 AACCAGAGAGTGTATCTTAAACMAAACTCTACAGTTCACAGTGTGCTGTTCCTTCACTC 943	
	601 TTCTGGCCAACTGTATGATGGCTGGGGGTGTGGCAATTTGTCATGGTGAACATTACA 660		601 TTCTGGCCAACTGTATGATGGCTGGGGGTGTGGCAATTTGTCATGGTGAACATTACA 660	
	944 TTCTGGCCAACTGTATGATGGCTGGGGGTGTGGCAATTTGTCATGGTGAACATTACA 1003		944 TTCTGGCCAACTGTATGATGGCTGGGGGTGTGGCAATTTGTCATGGTGAACATTACA 1003	
	661 CAGTACCTCTCCCTACTATGTGAGAGGATCC-ACGGATCAATAGATAA 707		661 CAGTACCTCTCCCTACTATGTGAGAGGATCC-ACGGATCAATAGATAA 707	
	1004 CAGTACCTCTCCCTACTATGTGAGAGGATCC-ACGGATCAATAGATAA 1051		1004 CAGTACCTCTCCCTACTATGTGAGAGGATCC-ACGGATCAATAGATAA 1051	
	ORIGIN		ORIGIN	
	Query Match		Query Match	
	Best Local Similarity		Best Local Similarity	
	Matches 703; Conservative 2; Mismatches 2; Indels 1; Gaps 1;		Matches 703; Conservative 2; Mismatches 2; Indels 1; Gaps 1;	



VWENFRHOFPCYSDPEGNQKSVILTKLYSSNVLFHSLFWFTCMAGGVAIVAMVK  
LTYQLSLLCERIORINR

## ORIGIN

Query Match 80.2%; Score 567.2; DB 10; Length 708;  
Best Local Similarity 88.3%; Pred. No. 2.9e-157;  
Matches 625; Conservative 2; Mismatches 80; Indels 1; Gaps 1;

Qy	1	ATGTCGATATGACATGCGCGGACCTCTTCATCTTATAGACATGATGAAAAAGAAAT	60
Db	1	ATGTTTATATGACATGCGCGGACCTCTTCATCTTACAGACAGGAGAAAGAAAT	60
Qy	61	ATTTACAGAAAAATCAGGACCATGACCTCTGTCGACAAAAGGAAACAGTCACGACCTG	120
Db	61	ATCTACAGAAAAATCAGGACCATGACCTCTGTCGACAAAAGGAAACATGTGACGCTCTG	120
Qy	121	AAGCGAGGAGGAGGACCGAGCTATTTCTCTGGGACTGGCTATGATGGTCTCCATCATG	180
Db	121	AAGCGTGGGAGGAGGACCGGACCATCTGCTGGCTGGCCATGATGGTCTCCATCATG	180
Qy	181	ATGTATTTCTGCTGGGAATCACACTCTGGCTCTACATGTCAGAGCGTGTGGACCGAA	240
Db	181	ATGTACTTCTGCTGGGAATCACACTCTGGCTCTACATGTCAGAGCGTGTGGACGAA	240
Qy	241	GAGTCTCAATGCACCTTGTGTAATGCGTCCATCACGGAACATTTAAATGCTCTCTCAGC	300
Db	241	GAAGCCAGTGTGCGCTGCTGAATGTGTCATCACAGAACGTTTAACTGTCTCTCAGC	300
Qy	301	TGTGGTCAGACTCTGGAAATCTTCTCAGTACCCCTGCTCAGAGTGTAGCTTAACCTG	360
Db	301	TGTGGCCCGACTTGTGAAGCTCTCTCAGTACCCCTTGGCTGCAAGGTGTAGCTGAACCTG	360
Qy	361	ACTTCTTCGGGGAAAGCTCTCTCTTACCACAGACAGACAAATAAAATCAATCAG	420
Db	361	ACATCTTCGGGGAGAGCTCTCTCTTACCACAGGAGACCATGAGATCAATCAA	420
Qy	421	AAGTGCTCTATATACCTAATATGGAATAATTTGAAGATCCATGTCCCTGGTGAAT	480
Db	421	AAGTGCTCTATATTCCTAAGTGTGGAACAACTTTGAGGAGTCCATGTCTCTCGTGAGT	480
Qy	481	GTTCTCATGGAACACTTCAGGAAGTATCAACATCTCTGCTATCTGACCCAGGAGGA	540
Db	481	GTGCTCATGGAACACTTCAGGAGACACAACTTCCCTGCTATCTGACCCAGGAGGA	540
Qy	541	AACGAGAGAGTGTATCTCAACMAAACTCTACAGTTCACAGTGTCTTCCATTCACCTC	600
Db	541	AACGAGAGAGTGTATCTCAACAACTCTACAGTTCACAGTGTCTTCCATTCCTC	600
Qy	601	TTCTGGCAACCTGTATGATGGCTGGGGGTGTGCAATTTGTCCATGGTGAACCTTACA	660
Db	601	TTCTGGCAACTTGTATGATGGCTGGGGGTGTGCAATCTGTGTATGGTGAACCTTAACT	660
Qy	661	CAGTACCTCTCCCTACTATGTGAGGAGTCC-ACGGATCAATAGATAA	707
Db	661	CAGTACCTCTCCCTGCTTTGTGAGAGGATCCACCGATCAACAGATAA	708

## RESULT 6

BC046227 2947 bp mRNA linear ROD 30-JUN-2004  
LOCUS Mus musculus potassium large conductance calcium-activated  
DEFINITION subfamily M, beta member 2, mRNA (cDNA clone MGC:57945  
IMAGE:5703879), complete cds.

## ACCESSION

BC046227

## VERSION

BC046227.1 GI:28279339

## KEYWORDS

MGC.

## SOURCE

Mus musculus (house mouse)

## ORGANISM

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.

## REFERENCE

1 (bases 1 to 2947)

## AUTHORS

Strausberg, R.L., Feingold, E.A., Grouse, L.H., Derge, J.G.,  
Klausner, R.D., Collins, F.S., Wagner, L., Shenmen, C.M., Schuler, G.D.,

Altschul, S.F., Zeeberg, B., Buetow, K.H., Schaefer, C.F., Bhat, N.K.,  
Hopkins, R.F., Jordan, H., Moore, T., Max, S.I., Wang, J., Hsieh, F.,  
Diatchenko, L., Marusina, K., Farmer, A.A., Rubin, G.M., Hong, L.,  
Stapleton, M., Soares, M.B., Bonaldo, M.F., Casavant, T.L.,  
Scheetz, T.E., Brownstein, M.J., Usdin, T.B., Toshiyuki, S.,  
Carninci, P., Prange, C., Raha, S.S., Loquellano, N.A., Peters, G.J.,  
Abramson, R.D., Mullahy, S.J., Bosak, S.A., McEwan, P.J.,  
McKernan, K.J., Malek, J.A., Gunaratne, P.H., Richards, S.,  
Worley, K.C., Hale, S., Garcia, A.M., Gay, L.J., Hulyk, S.W.,  
Villalón, D.C., Muzny, D.M., Sodergren, E.J., Lu, X., Gibbs, R.A.,  
Fahy, J., Hellon, E., Kettman, M., Madan, A., Rodriguez, S.,  
Sanchez, A., Whitting, M., Madan, A., Young, A.C., Shevchenko, Y.,  
Bouffard, G.G., Blakesley, R.W., Touchman, J.W., Green, E.D.,  
Dickson, M.C., Rodriguez, A.C., Grimwood, J., Schmutz, J., Wyers, R.M.,  
Butterfield, Y.S., Krzywinski, M.I., Skalska, U., Smalios, D.E.,  
Schnerch, A., Schein, J.E., Jones, S.J., and Marra, M.A.  
Generation and initial analysis of more than 15,000 full-length  
human and mouse cDNA sequences  
Proc. Natl. Acad. Sci. U.S.A. 99 (26), 16899-16903 (2002)  
12477932  
2 (bases 1 to 2947)  
Strausberg, R.  
Direct Submission  
Submitted (31-JAN-2003) National Institutes of Health, Mammalian  
Gene Collection (MGC), Cancer Genomics Office, National Cancer  
Institute, 31 Center Drive, Room 11A03, Bethesda, MD 20892-2590,  
USA  
NIH-MGC Project URL: <http://mgc.nci.nih.gov>  
Contact: MGC help desk  
Email: [cgpbbs@mail.nih.gov](mailto:cgpbbs@mail.nih.gov)  
Tissue Procurement: Dr. Jim Lin, University of Iowa  
cDNA Library Preparation: M. Bento Soares, University of Iowa  
cDNA Library Arrayed by: The I.M.A.G.E. Consortium (LLNL)  
DNA Sequencing by: University of Iowa, Dr. M. Bento Soares and Dr.  
Thomas L. Casavant.  
Web site: <http://genome.uiowa.edu>  
Contact: [bento-soares@uiowa.edu](mailto:bento-soares@uiowa.edu); [tom-casavant@uiowa.edu](mailto:tom-casavant@uiowa.edu)  
Bonaldo, M.F., Akabogu, I., Bair, T., Bair, J., Crouch, K., Davis, A.,  
Fisher, K., Keppel, C., Kucaba, T., Lebeck, M., Melo, A., Schaefer, K.,  
Scheetz, T., Smith, C., Snir, E., Tack, D., Trout, K., Walters, J.,  
Casavant, T., Soares, M.B.

Clone distribution: MGC clone distribution information can be found  
through the I.M.A.G.E. Consortium/LLNL at: <http://image.llnl.gov>  
Series: Plate: Row: Column: 0  
This clone was selected for full length sequencing because it  
passed the following selection criteria: matched mRNA gi: 21312299.

## FEATURES

## source

1..2947  
/organism="Mus musculus"  
/mol\_type="mRNA"  
/strain="C57BL/6"  
/db\_xref="taxon:10090"  
/clone="MGC:57945 IMAGE:5703879"  
/tissue\_type="Brain, mouse 15.5 dpc"  
/clone\_lib="NIH BMAP\_EW0"  
/lab\_host="DH103"  
/note="Vector: pYX-ASC"  
1..2947  
/gene="Kcnmb2"  
/note="synonym: MGC57945"  
/db\_xref="LocusID:72413"  
/db\_xref="MGI:1919663"  
391..1098  
/gene="Kcnmb2"  
/codon\_start=1  
/product="potassium large conductance calcium-activated  
channel, subfamily M, beta member 2"  
/protein\_id="AAH46227.1"  
/db\_xref="GI:28279340"  
/db\_xref="LocusID:72413"  
/db\_xref="MGI:1919663"  
/translation="VFIIWTSGRSSSRQDEKRNYYQKIRDHLLDKRVTALKAGE

## gene

## CDS





```
/protein_id="AAH58957.1"
/db_xref="GI:37589335"
/db_xref="LocusID:72413"
/db_xref="MGI:1919663"
/translation="MFTWTSGRTSSSYRQDEKNIYKIRHDLDRKTVTAKAGE
DRLLLGLAMVQVIMVYLLGLITLLRSYQSVYVTEAOCALLNISTTFNCSFGSG
PDCKWLSQVPLQVYVNLTSGBRELLIYHTEETMKINOKCSYIPKGNPFBSMSLVS
VYVNEFRHGHFPCYSPEGNQKSVILTKLYSSNLFHSLFWFTCMWAGGVAIVAVK
LTQVLSLLECIQRIQR"

ORIGIN
Query Match      80.2%; Score 567.2; DB 10; Length 2947;
Best Local Similarity 88.3%; Pred. No. 3.3e-157;
Matches 625; Conservative 2; Mismatches 80; Indels 1; Gaps 1;

QY 1 ATGTCGATATGACACAGTGGCGGACCTCTTCATCTTATAGACATGATGAAAAAGAAAT 60
DB 391 ATGTTTATGACACAGTGGCGGACCTCTTCATCTTACAGACAGGACGAAAAAGAAAT 450
QY 61 ATTTACAGAAAAATCAGGACCATGACCTCTGACAAAAAGAAAAAGTACAGCACTG 120
DB 451 ATCTACAGAAAAATCAGGACCATGACCTCTGACAAAAAGAAAAAGTACAGCACTG 510
QY 121 AAGCAGAGAGAGACCGAGTATTTCTCTGGGACTGCGTATGATGGTGTCTCATCATG 180
DB 511 AAGCTGGGAGGACCGGGCCATCTGCTGGCCCTGCGCATGATGGTGTCTCATCATG 570
QY 181 ATGTATTTCTGCTGGGATCACACTCTGCGCTCATACATGACAGAGCGGTGGACCGAA 240
DB 571 ATGTACTTCTGCTGGGATCACACTGCTGGCTCTTACATGACAGCGGTGGACAGAA 630
QY 241 GAGTCTCAATGACCTTCTGTAATCGGTCCATCACGGAACATTTAAATGCTCTTCAGC 300
DB 631 GAAGCCAGTGTGCCCTGCTGAATGTGCAATCACAGAAAGCTTTAACTGTTCCTTCAGC 690
QY 301 TGTGTCACAGACTGTGGAACATTTCTCAGTACCCCTGCGCTCAGGTGTAGTTAACTG 360
DB 691 TGTGGCCCGACTGTGGAAGCTCTCTCAGTACCCCTGCGCTCAGGTGTAGTTAACTG 750
QY 361 ACTTCTCCGGGAAAAAGCTCTCTCTTACACACAGAGACAAATAAAATCAATCAG 420
DB 751 ACATCTCCGGGAGAGGCTCTCTCTTACACACAGGAGACCATGATCAATCAA 810
QY 421 AAGTGTCTCTATATACCTAAATGTGGAAAAATTTGAAGATCATGTCCTCGTGAAT 480
DB 811 AAGTGTCTCTATATCTTAAAGTGTGGAACAACTTTGAGGAGTCCATGTCTCTCGTGA 870
QY 481 GTTGTCATGGAACCTTCCAGGAAGTATCAACACTTCTCTCTATTTCTGACCCAGAGGA 540
DB 871 GTGTCATGGAACCTTCCAGGAGACCAACACTTCCCTCTATTTCTGACCCAGAGGA 930
QY 541 AACCAAGAGAGTGTATCTTAAACAACTTACAGTTCACAGTCCAACTGCTTCCATCTC 600
DB 931 AACCAAGAGAGTGTATCTTCAACAACTTACAGTTCACAGTCCAACTGCTTCCATCTC 990
QY 601 TTCTGGCAACCTGTATGATGGCTGGGGGTGGCAATTTGTCATGGTGAATTTACA 660
DB 991 TTCTGGCAACCTGTATGATGGCTGGGGGTGGCAATTTGTCATGGTGAATTTACT 1050
QY 661 CAGTACCTCTCCCTACTATGTGAGAGGATCC-ACGGATCAATAGATAA 707
DB 1051 CAGTACCTCTCCCTCTTTGTGAGAGGATCCACCGATCAACAGATAA 1098

RESULT 8
BD223084
LOCUS      98 human secretory proteins.
DEFINITION
ACCESSION  BD223084
VERSION    BD223084.1 GI:33032854
KEYWORDS  JP 2002521055-A/19.
SOURCE     Homo sapiens (human)
ORGANISM  Homo sapiens
```

```
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1 (bases 1 to 2098)
Komatsoulis,G.A., Rosen,C.A., Ruben,S.M., Duan,R., Moore,P.A.,
Shi,Y., Lafleur,D., Wei,Y.F., Ni,Y., Florence,K.A., Young,P.B.,
Brewer,L.A., Soppet,D.R., Endress,G.A., Ebner,R., Olsen,H.S. and
Mucenski,M.
98 human secretory proteins
Patent: JP 2002521055-A 19 16-JUL-2002;
HUMAN GENOME SCIENCES INC
OS Homo sapiens (human)
PN JP 2002521055-A/19
PD 16-JUL-2002
PP 29-JUL-1999 JP 2000562480
PR 30-JUL-1998 US 60/094657,05-AUG-1998 US 60/095486 PR
06-AUG-1998 US 60/095455,06-AUG-1998 US 60/095454 PR
12-AUG-1998 US 60/096319
PI GEORGE A KOMATSOULIS, CRAIG A ROSEN, STEVEN
M RUBEN, ROXANNE DUAN,
PI PAUL A MOORE, YANGGU SHI, DAVID LAFLEUR, YING FEI WEI, JIAN NI, PI
KIMBERLY A FLORENCE, PAUL E YOUNG, LAURIE A BREWER, DANIEL R PI
SOPPET.
PI GREGORY A ENDRESS, REINHARD EBNER, HENRIK S OLSEN, MICHAEL PI
MUCENSKI
PC C12N15/09, A61K31/713, A61K38/00, A61K48/00, C07K14/47, C07K16/18,
PC C12N1/15,
PC C12N1/19, C12N1/21, C12N5/10, C12P21/02, C12P21/08, C12Q1/68, G01N33/ PC
15,
PC G01N33/50, G01N33/53//A61P1/18, A61P5/02, A61P5/06, A61P5/14, A61P9/ PC
10,
PC A61P11/06, A61P17/06, A61P19/02, A61P25/02, A61P25/14, A61P25/16,
A61P25/24,
PC A61P25/28, A61P27/02, A61P29/00, A61P31/18, A61P35/02, C12N15/00,
PC C12N5/00,
PC A61K37/02
CC 98 human secretory proteins
FH Key Location/Qualifiers
FT source 1..2098
FT /organism='Homo sapiens (human)'
FT Location/Qualifiers
1..2098
/organism='Homo sapiens'
/mol_type='genomic DNA'
/db_xref='taxon:9606'

ORIGIN
Query Match      79.8%; Score 564.2; DB 6; Length 2098;
Best Local Similarity 99.5%; Pred. No. 2.5e-156;
Matches 574; Conservative 2; Mismatches 0; Indels 1; Gaps 1;

QY 132 GGACCGAGCTATTTCTCTGGGACTGGCTATGATGGTGTCTCCATCATGATGATTTTCT 191
DB 9 GGACCGAGCTATTTCTCTGGGACTGGCTATGATGGTGTCTCCATCATGATGATTTTCT 68
QY 192 GCTGGGAATCACACTCTCGGCTCATACATGACAGCGGTGGACCAAGAGTCTCAATG 251
DB 69 GCTGGGAATCACACTCTCGGCTCATACATGACAGCGGTGGACCAAGAGTCTCAATG 128
QY 252 CACCTTGTGTAATGCGTCCATCACGGAACATTTAAATGCTCTTCCAGTGTGTCAG 311
DB 129 CACCTTGTGTAATGCGTCCATCACGGAACATTTAAATGCTCTTCCAGTGTGTCAG 188
QY 312 CTGCTGGAACTTTCTCAGTACCCCTGCGCTCAGGTGTACGTTAACTGCTTCTCCGG 371
DB 189 CTGCTGGAACTTTCTCAGTACCCCTGCGCTCAGGTGTACGTTAACTGCTTCTCCGG 248
QY 372 GGAAAAAGCTCTCTCTTACACACAGAGACAAATAAAAAATCAATCAGAAGTCTCTTA 431
DB 249 GGAAAAAGCTCTCTCTTACACACAGAGACAAATAAAAAATCAATCAGAAGTCTCTTA 308
QY 432 TATACCTAAATGTGGAAAAAATTTTGAAGATCCATGTCCTCGTGGTGAATGTCATGGA 491
```



Qy	1	ATGTCGATATGGACAGTGGCGGACCTCTTTCATCTTTATAGACATGATGAAAAAGAAAT	60
Db	1	ATGTTTATATGGACAGTGGCGGACCTCTTTCATCTTTACAGACAGGAGAAAGAAAT	60
Qy	61	ATTTCACAGAAATACAGGACCATGACCTCTGGCAAAAGGAAACAGTCACAGACTG	120
Db	61	ATCTACAGAAATACAGGACCATGACCTCTGGCAAAAGGAAACAGTCGACGCTCTG	120
Qy	121	AAGCAGAGAGGACCGAGCTATCTCTGGGACTGGCTATGATGGTGTCTCCATCATG	180
Db	121	AAGCCTGGAGGACCGGACCTCTCTGGGACTGGCTATGATGGTGTCTCCATCATG	180
Qy	181	ATGTAATTTCTGGGAATACACTCTCTGGGCTATACATGTCAGAGCGTGTGACCGAA	240
Db	181	ATGTAATTTCTGGGAATACACTCTCTGGGCTATACATGTCAGAGCGTGTGACAGAA	240
Qy	241	GAGTCTCAATGCACCTTCTGTAATGCTGCATCAGGAAACATTTAAATGCTCTCTCAGC	300
Db	241	GAACCCAGCGTGGCTCTGTAATGCTGCATCAGGAAACATTTAAATGCTCTCTCAGC	300
Qy	301	TGTGGTCCAGACTCTGGAACTTTCTCAGTACCCCTCCCTCCAGGTTGAGTTAACCTG	360
Db	301	TGTGGGCTGACTCTGGAAGCTCTCTCAGTACCCCTCCCTCCAGGTTATAGTGAACCTG	360
Qy	361	ACTTCTCCGGGAAAGCTCTCTTACACACAGAGACAATAAAATCAATCAG	420
Db	361	ACATCTCTGGGAGAGCTCTCTTACACACAGAGACAATAAAATCAATCAA	420
Qy	421	AAGTGCCTCTATATACCTAAATGTGAAAAAATTTTGAAGAATCCATGCTCCCTGGTGAAT	480
Db	421	AAGTGCCTCTATATCTAAATGTGAAAAAATTTTGAAGATCCATGCTCCCTGTGAGT	480
Qy	481	GTTCATGAGAACTTCAGGAATATCAACATCTCTCCCTGCTATTTCTGACCCAGAGGA	540
Db	481	GTCTCATGAAAACTTCAGGAGACCAACATCTCCCTGCTATTTCTGACCCAGAGGG	540
Qy	541	AACAGAGAGTGTATCTTAAACAACTCTACAGTTCCCAAGCTGCTTCCATTCACCTC	600
Db	541	AACCAAGAGCTATCTTGAACAACTCTATAGCTCCATGCTGCTTCCATTCCTCTC	600
Qy	601	TTCTGGCAACCTGTATGATGGCTGGGGTGTGGCAATTTGTGCCATGTTGAACTTACA	660
Db	601	TTCTGGCAACCTGTATGATGGCTGGGGTGTGGCAATCGTTGTATGGTGAACCTAACT	660
Qy	661	CAGTACCTCTCCCTACTATGTGAGAGATCC-ACGGATCAATAGATAA	707
Db	661	CAGTACCTCTCCCTGTTGTGAGAGATCCACCGATCAACAGATAA	708
RESULT 11			
BX950825			
LOCUS			
Gallus gallus finished cdna, clone ChEST48b4.			
BX950825			
VERSION			
BX950825.1			
KEYWORDS			
Gallus gallus (chicken)			
ORGANISM			
Eukaryota; Metazoa; Craniata; Vertebrata; Euteleostomi;			
Archosauria; Aves; Neognathae; Galliformes; Phasianidae;			
Phasianinae; Gallus.			
1 (bases 1 to 1546)			
Boardman, P.E., Bonfield, J.K., Brown, W.R.A., Carder, C., Chalk, S.E.,			
Croning, M.D.R., Davies, R.M., Francis, M.D., Grafham, D.V.,			
Hubbard, S.J., Humphray, S.J., Hunt, P.J., Maddison, M., McLaren, S.R.,			
Nilett, D., Overton, I.M., Rogers, J., Scott, C.E., Taylor, R.G.,			
Tickle, C. and Wilson, S.A.			
Direct Submission			
TITLE			
SUBMITTED (16-FEB-2004) Sanger Institute, Hinxton, Cambridgeshire,			
JOURNAL			
CB10 ISA, UK. E-mail enquiries: chickst@bms.unist.ac.uk			
COMMENT			
BBSRC/Dundee/Nottingham/Sanger/Sheffield/UMIST Gallus gallus cdna			
sequencing project.			
This sequence is from the			

BBSRC/Dundee/Nottingham/Sanger/Sheffield/UMIST cdna collection,			
from a library constructed by Elizabeth Bosch. cdna was prepared			
from RNA extracted from whole embryo, normalised, and poly			
A-trimmed. EcoRI-NotI cut cdna was then ligated into the vector.			
Vector: pBluescript II KS(+); Site_1: EcoRI; Site_2: NotI Host:			
Escherichia coli DH10B.			
FEATURES			
Location/Qualifiers			
1..1546			
/organism="Gallus gallus"			
/mol_type="mRNA"			
/strain="White Leghorn, Hisex"			
/db_xref="taxon:9031"			
/clone="ChEST48b4"			
/clone_lib="CSEQCHN04"			
/dev_stage="stage 10"			
ORIGIN			
Query Match			
Best Local Similarity 62.0%; Score 438.4; DB 5; Length 1546;			
Matches 556; Conservative 2; Mismatches 128; Indels 22; Gaps 2;			
Qy	1	ATGTCGATATGACAGTGGCGGACCTCTTTCATCTTTATAGACATGATGAAAAAGAAAT	60
Db	144	ATGTTTATTTGACAGTGGCGGAGCTCTACATCTTACAGACAGCATGAGAAA-----	197
Qy	61	ATTACCAGAAATCAGGGACCATGACCTCTCGGACAAAAGGAAACAGTCACAGACTG	120
Db	198	-----AGGATCAGCATCTACTGGAACAAAGGAAACAGTCACAGCCCTA	242
Qy	121	AAGCAGAGAGAGACCGAGCTATTTCTCGGACATGGCTATGATGGTGTCTCCATCATG	180
Db	243	AAAGCTGGAGAGACCGGGCCATCTCTCGGGCTGGCCATGATGGTGTCTCTATCATG	302
Qy	181	ATGTAATTTCTCTGGGAATCACTCTCTGGGCTATGATGGTGTCTCCATCATG	240
Db	303	ATGTAATTTCTCTGGGAATCACTCTCTGGGCTATGATGGTGTCTCCATCATG	362
Qy	241	GAGTCTCAATGCACCTTCTGTAATGCTGCATCAGGAAACATTTAAATGCTCTCTCAGC	300
Db	363	GAGGCTCAGTGTCTGCTTCTCAAGCATCCATCAGGAAACCTTCACTGCTCGTTAGC	422
Qy	301	TGTGTCAGACTGTGGAAACTTTCTCAGTACCCCTCCCTCCAGGTTGAGTTAACCTG	360
Db	423	TGCGGCCAGACTGTGGAAATCTCTCAGTACCCCTCCCTCCAGGTTGAGTTAACCTC	482
Qy	361	ACTTCTCCGGGAAAGCTCTCTCTACACAGAGAGACAATAAAATCAATCAG	420
Db	483	ACTTCTTCTGGCCAGAGCTTCTGCTTACACAGAGAGACAATAAAATTAATTTCT	542
Qy	421	AAGTGTCTCTATATACCTAAATGTGAAAAAATTTTGAAGAATCCATGCTCCCTGTAAT	480
Db	543	GAGTGTCTCATATACCCAAAGTGTGCAAGAAATACAGAGAAATCCATGTCATGTTGAAC	602
Qy	481	GTTGTCATGGAACCTTCAGGAAGTATCAACTTCTCTCTCTCTCTCTCTCTCTCTCTCT	540
Db	603	GTTGTGATGGAACCTTCGGAAGTATCAACGCTTCTCTCTCTCTCTCTCTCTCTCTCT	662
Qy	541	AACCAAGAGTGTATCTCTTAAACAACTCTACAGTTCCCAAGCTGCTTCCATTCACCTC	600
Db	663	ACTCAGAGACGTGATATTGACCAAACTGTACAGCTCCCAAGCTGCTGTTCCACTGCTC	722
Qy	601	TTCTGGCAACCTGTATGATGGCTGGGGTGTGGCAATTTGTGCCATGTTGAACTTACA	660
Db	723	TTCTGGCCCACTGTCATGATGATGCGGGCGGTGTGCAATTTGTTCGATGTTAAAGTACT	782
Qy	661	CAGTACCTCTCCCTACTATGTGAGAGATCC-ACGGATCAATAGATAA	707
Db	783	CAATACCTTCTCTCTCTCTGCGAGAGATCCAAAGGATCAACAGATAA	830
RESULT 12			
BX950833			
LOCUS			
BX950833			
1546 bp			
mRNA			
linear			
VRT 30-MAR-2004			

```
DEFINITION Gallus gallus finished cDNA, clone CHEST43b24.
ACCESSION BX950833
VERSION BX950833.2 GI:46019324
KEYWORDS Gallus gallus (chicken)
SOURCE Gallus gallus
ORGANISM Gallus gallus
REFERENCE 1 (bases 1 to 1546)
AUTHORS Boardman,P.E., Bonfield,J.K., Brown,W.R.A., Carder,C., Chalk,S.E.,
Croning,M.D.R., Davies,R.M., Francis,M.D., Graham,D.V.,
Hubbard,S.J., Humphray,S.J., Hunt,P.J., Maddison,M., McLaren,S.R.,
Niblett,D., Overton,I.M., Rogers,J., Scott,C.E., Taylor,R.G.,
Tickle,C. and Wilson,S.A.
TITLE Direct Submission
JOURNAL Submitted (29-MAR-2004) Sanger Institute, Hinxton, Cambridgeshire,
CB10 1SA, UK. E-mail enquiries: chickest@hms.unist.ac.uk
COMMENT On Apr 1, 2004 this sequence version replaced gi:42600518.
BBSRC/Dundee/Nottingham/Sanger/Sheffield/UMIST Gallus gallus cDNA
sequencing project.
This sequence is from the
BBSRC/Dundee/Nottingham/Sanger/Sheffield/UMIST cDNA collection,
from a library constructed by Elizabeth Bosch. cDNA was prepared
from RNA extracted from whole embryo, normalised, and poly
A-trimmed. EcoRI-NotI cut cDNA was then ligated into the vector.
Vector: pBluescript II KS(+); Site_1: EcoRI; Site_2: NotI Host:
Escherichia coli DH10B.
FEATURES
    source
        1..1546
            /organism="Gallus gallus"
            /mol_type="mRNA"
            /strain="White Leghorn, HiseX"
            /db_xref="taxon:9031"
            /clone="CHEST43b24"
            /clone_lib="CSEQCHN04"
            /dev_stage="stage 10"
ORIGIN
Query Match 62.0%; Score 438.4; DB 5; Length 1546;
Best Local Similarity 78.5%; Pred. No. 6.5e-119;
Matches 556; Conservative 2; Mismatches 128; Indels 22; Gaps 2;
QY 1 ATGTGATATGACAGGCGGCGGAGCTTCTTCACTTATACACATGATGAAAGAAAT 60
DB 144 ATGTTATTGGACAGTGGCGGAGCTTCTTCACTTATACACATGATGAAAGAAAT 197
QY 61 ATTTACGAAATACAGGACCATGACCTCTCTGGACAAAGGAAACAGTCACGACTG 120
DB 198 -----ACGGATCAGCATCTACTGGACAAAGGAAACAGTCACGACCTA 242
QY 121 AAGCAGGAGGAGCGGAGCTTCTCTCTGGAGTGGCTATGATGGTCTCTCATCATG 180
DB 243 AAAGCTGAGAGAGCGGGGCATCTCTCTGGGTCGATGGTGGTCTCTCATCATG 302
QY 181 ATGATTTTCTGCTGGGAATCACACTCTCTGGCTCATACATGACAGCGTGTGGACGAA 240
DB 303 ATGACTTTCTCTGGGAATCACCTCTCTGGCTCTACATGACAGCGTGTGGACGAA 362
QY 241 GAGTCTCAATGACCTTCTCTGAATGCGTCCATCAGGAACATTTAATGCTCTTCAGC 300
DB 363 GAGGCTAGTCTGCTCTCTCAACGATCCATCATCCGAAACCTTCAACTGCTGTTAGC 422
QY 301 TGTGCTCAGACTGCTGGAATCTTCTCAGTACCCCTCGCTCCAGGCTGACGTTAAGCTG 360
DB 423 TGGGCCCCAGACTGCTGGAATCTCTCAGTACCCCTGCTGAGGTGACGTCATCTC 482
QY 361 ACTTCTCCGGGGAAGCTCTCTCTTACACAGAGACAAATAAATAATCATCATG 420
DB 483 ACTTCTCTGCGGAGAGCTTCTCTCTTACACACCGAAGAAACAAATGAAATAATCT 542
QY 421 AAGTGCTCTATATACCTAAATGTTGGAATAATTTGAAGAATCCATGTCCTCGTGAAT 480
543 GAGTGTTCGTACATACCCAAAGTGTGGCAAGAAATTACGAGGAATCCATGTCAATGGTGAAC 602
481 GTTGTGATGGAAGAACTTCAGGAAGATATCAACACTTCTCTCTCTCTCTCTCTCTCTCT 540
603 GTTGTGATGGAAGAACTTCGGAAGATATCAACAGCTTCTCTCTCTCTCTCTCTCTCTCT 662
541 AACCAAGAAGAGTGTATCTCTAAACAACTCTACAGTTCCAAAGCTGTGTTCCTCATTCAC 600
663 ACTCAGAAGAACGTGATATTGACCAAACTGTACAGCTCCCAACGCTGTGTTCCTCATCTG 722
601 TTCTGCGCAACCTGTATGATGGCTGGGGGTGTGGCAATTTGTCCTCATGTTGAACCTTACA 660
723 TTCTGCGCCACGCTGATGATGATCGCGCGCTGTGCAATTTGTCCTCATGTTGAAGCTGACT 782
661 CAGTACTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT 707
783 CAATACCTTTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT 830
RN0517198 487 bp mRNA linear ROD 15-DEC-2002
Rattus norvegicus partial mRNA for calcium-activated potassium
channel beta 2 subunit (Kcmb2 gene).
ACCESSION AJ517198
VERSION AJ517198.1 GI:26801163
KEYWORDS calcium-activated potassium channel beta 2 subunit; Kcmb2 gene.
SOURCE Rattus norvegicus (Norway rat)
ORGANISM Rattus norvegicus
    location/Qualifiers
        1..487
            /organism="Rattus norvegicus"
            /mol_type="mRNA"
            /strain="Wistar"
            /db_xref="taxon:10116"
            /tissue_type="brain"
            /gene="Kcmb2"
            /gene="Kcmb2"
            /function="ion channel"
            /codon_start=2
            /product="calcium-activated potassium channel beta 2
            subunit"
            /protein_id="CAD56888.1"
            /db_xref="GI:26801164"
            /db_xref="GOA:Q8CF83"
            /db_xref="TREMBL:Q8CF83"
            /translation="LKAGEDRAILGLAMVCSIMVFLGLITLLRSVMQSVWTEBAQ
            CALLNVSTFETNCSFGCPDWKLSOYPCLOVYVNLTSCEKLLVHTETMKINOK
            CSYIPKCGNPFESMSLSVVMENFRHQHPCYSIDPEGNOKSVILTKLYSSNVLFHS
            LF"
REFERENCE 1
AUTHORS Langer,P., Grunder,S. and Rusch,A.
TITLE Expression of Ca2+-activated BK channel mRNA and its splice
variants in the rat cochlea
JOURNAL J. Comp. Neurol. 455 (2), 198-209 (2003)
MEDLINE 22342043
PUBMED 12454985
REFERENCE 2 (bases 1 to 487)
AUTHORS Langer,P.
TITLE Direct Submission
JOURNAL Submitted (16-NOV-2002) Langer P., Institute of Physiology II,
University of Tuebingen, Gmelinstr. 5, Tuebingen, D-72076, GERMANY
FEATURES
    source
        1..487
            /organism="Rattus norvegicus"
            /mol_type="mRNA"
            /strain="Wistar"
            /db_xref="taxon:10116"
            /tissue_type="brain"
            /gene="Kcmb2"
            /gene="Kcmb2"
            /function="ion channel"
            /codon_start=2
            /product="calcium-activated potassium channel beta 2
            subunit"
            /protein_id="CAD56888.1"
            /db_xref="GI:26801164"
            /db_xref="GOA:Q8CF83"
            /db_xref="TREMBL:Q8CF83"
            /translation="LKAGEDRAILGLAMVCSIMVFLGLITLLRSVMQSVWTEBAQ
            CALLNVSTFETNCSFGCPDWKLSOYPCLOVYVNLTSCEKLLVHTETMKINOK
            CSYIPKCGNPFESMSLSVVMENFRHQHPCYSIDPEGNOKSVILTKLYSSNVLFHS
            LF"
ORIGIN
Query Match 54.4%; Score 384.4; DB 10; Length 487;
Best Local Similarity 86.6%; Pred. No. 6.8e-103;
Matches 421; Conservative 2; Mismatches 63; Indels 0; Gaps 0;
```



at URL:  
http://www.hgsc.bcm.tmc.edu:8088/quality.info/genbank.annotation.ht

## FEATURES

## Source

## Location/Qualifiers

1..204899  
/organism="Homo sapiens"  
/mol\_type="genomic DNA"  
/db\_xref="taxon:9606"  
/chromosome="3"  
/clone="RP11-385J1"  
complement(1..2000)  
/note="overlaps bases 1..2000 of clone AC139661"  
/function="clone overlap"  
complement(501..659)  
/rpt\_family="L2"  
complement(1481..1546)  
/rpt\_family="L2"  
1611..1689  
/rpt\_family="MLT1B"  
1694..1879  
/rpt\_family="MER2"  
1893..1922  
/rpt\_family="AT\_rich"  
1964..2082  
/rpt\_family="MLT1B"  
2083..2421  
/rpt\_family="MLT1A1"  
2422..2587  
/rpt\_family="MLT1B"  
complement(2948..3005)  
/rpt\_family="L2"  
complement(4400..4536)  
/rpt\_family="L2"  
complement(5059..5175)  
/rpt\_family="MER20"  
complement(5428..5572)  
/rpt\_family="MIR"  
complement(5578..5707)  
/rpt\_family="MIR"  
complement(7006..7250)  
/rpt\_family="MIR"  
7575..9962  
/rpt\_family="L2"  
complement(10792..10921)  
/rpt\_family="MIR"  
complement(11688..11850)  
/rpt\_family="MIR"  
complement(12469..13201)  
/rpt\_family="MER49"  
13643..13814  
/rpt\_family="L2"  
13815..13840  
/rpt\_family="(TTG)n"  
13841..13878  
/rpt\_family="L2"  
complement(13891..13953)  
/rpt\_family="L1PA2"  
complement(14053..14222)  
/rpt\_family="PRAX"  
15888..15985  
/rpt\_family="MER5B"  
15990..16149  
/rpt\_family="MIR"  
complement(16360..16474)  
/rpt\_family="MIR"  
16570..16676  
/rpt\_family="L2"  
16945..17166  
/rpt\_family="MIR"  
complement(17322..17473)  
/rpt\_family="MER33"  
17474..18315  
/rpt\_family="L1PA16"

## repeat\_region

complement(18329..18510)  
/rpt\_family="MER33"  
18610..19373  
/rpt\_family="L1MA8"  
19374..19673  
/rpt\_family="AluSp"  
19674..19760  
/rpt\_family="L1MA8"  
20088..20127  
/rpt\_family="MER5B"  
20874..20893  
/rpt\_family="(GA)n"  
complement(21009..21423)  
/rpt\_family="MER39"  
22482..22503  
/rpt\_family="AT\_rich"  
24182..24476  
/rpt\_family="AluY"  
24861..24881  
/rpt\_family="AT\_rich"

Query Match 38.9%; Score 274.8; DB 9; Length 204899;

Best Local Similarity 98.3%; Pred. No. 4.6e-70;

Matches 287; Conservative 1; Mismatches 3; Indels 1; Gaps 1;

QY 417 TCAGAGTCTCTATATACCTAAATGTGGAAAAAATTTTGAAGATCCATGCTCCTGGT 476  
Db 177474 TCACAGTCTCTATATACCTAAATGTGGAAAAAATTTTGAAGATCCATGCTCCTGGT 177533  
QY 477 GAATGTTGTCAATGGAACCTTCAGGAAGTATCAACACTTCTCTGCTATTCGACCCAGA 536  
Db 177534 GAATGTTGTCAATGGAACCTTCAGGAAGTATCAACACTTCTCTGCTATTCGACCCAGA 177593  
QY 537 AGAAACAGAGAGTGTATCTCTAACMAAATCTACAGTTCCAAAGTCTGTTCCATTC 596  
Db 177594 AGAAACAGAGAGTGTATCTCTAACMAAATCTACAGTTCCAAAGTCTGTTCCATTC 177653  
QY 597 ACTCTTCTGCGCAACTGTATGATGCTGGGGGTGGCAATGTTGCCATGTTGAACT 656  
Db 177654 ACTCTTCTGCGCAACTGTATGATGCTGGGGGTGGCAATGTTGCCATGTTGAACT 177713  
QY 657 TACACAGTACCTCTCCTACTATGTCAGAGGATCC-ACGGATCAATAGATAA 707  
Db 177714 TACACAGTACCTCTCCTACTATGTCAGAGGATCCACGGATCAATAGATAA 177765

## RESULT 15

## AC115077

## LOCUS

## DEFINITION

## AC115077

## VERSION

## KEYWORDS

## SOURCE

## ORGANISM

## REFERENCE

## AUTHORS

## TITLE

## JOURNAL

## AUTHORS

## REFERENCE

## AUTHORS

## TITLE

## JOURNAL

## AUTHORS

## REFERENCE

## AUTHORS

## TITLE

## JOURNAL

## AUTHORS

## REFERENCE

## AUTHORS

## TITLE

## JOURNAL

## AUTHORS

## REFERENCE

## AUTHORS

## TITLE

## JOURNAL

## AUTHORS

Maclean, C., Macdonald, P., Major, J., Marquis, N., Matthews, C., McCarthy, M., McEwan, P., McKernan, K., Meldrum, J., Meneus, L., Mihova, T., Mienga, V., Murphy, T., Naylor, J., Nguyen, C., Nicol, R., Norbu, C., Norman, C.H., O'Connor, T., O'Donnell, P., O'Neil, D., Oliver, J., Peterson, K., Phunkhang, P., Pierre, N., Pollara, V., Raymond, C., Retta, R., Rieback, M., Riley, R., Rise, C., Rogov, P., Roman, J., Rosetti, M., Roy, A., Santos, R., Schauer, S., Schupback, R., Seaman, S., Severy, P., Spencer, B., Stange-Thomann, N., Stojanovic, N., Straus, N., Subramanian, A., Talamas, J., Teefaye, S., Theodore, J., Toham, K., Travers, M., Travis, N., Trigilio, J., Vassiliev, H., Viel, R., Vo, A., Wilson, B., Wu, X., Wyman, D., Ye, W.J., Young, G., Zainoun, J., Zembek, L., Zimmer, A. and Zody, M.

**TITLE**  
**JOURNAL**  
**REFERENCE**  
**AUTHORS**

Submitted (14-MAR-2002) Whitehead Institute/MIT Center for Genome Research, 320 Charles Street, Cambridge, MA 02141, USA  
 3 (bases 1 to 191186)  
 Biren, B., Linton, L., Nussbaum, C., Lander, E., Ali, A., Allen, N., Anderson, S., Barna, N., Bastien, V., Bloom, T., Boguslavsky, L., Boukhgalter, B., Brown, A., Camarata, J., Campopiano, A., Chang, J., Chazaro, B., Chospel, Y., Colangelo, M., Collins, S., Collymore, A., Cook, A., Cooke, P., DeArelano, K., Dewar, K., Diaz, J.S., Dodge, S., Faro, S., Ferreira, P., FitzGerald, M., FitzHugh, W., Gage, D., Galagan, J., Gardyna, S., Ginde, S., Gord, S., Goyette, M., Graham, L., Grand-Pierre, N., Hagos, B., Horton, L., Hulme, W., Iliev, I., Johnson, R., Jones, C., Kamat, A., Karatas, A., Keils, C., LaRoque, K., Lamazares, R., Landers, T., Lehoczy, J., Levine, R., Lindblad-Toh, K., Liu, G., Maclean, C., Macdonald, P., Major, J., Marquis, N., Matthews, C., McCarthy, M., McEwan, P., McKernan, K., Meldrum, J., Meneus, L., Mihova, T., Mienga, V., Murphy, T., Naylor, J., Nguyen, C., Nicol, R., Norbu, C., Norman, C.H., O'Connor, T., O'Donnell, P., O'Neil, D., Oliver, J., Peterson, K., Phunkhang, P., Pierre, N., Pollara, V., Raymond, C., Retta, R., Rieback, M., Riley, R., Rise, C., Rogov, P., Roman, J., Rosetti, M., Roy, A., Santos, R., Schauer, S., Schupback, R., Seaman, S., Severy, P., Spencer, B., Stange-Thomann, N., Stojanovic, N., Strauss, N., Subramanian, A., Talamas, J., Teefaye, S., Theodore, J., Toham, K., Travers, M., Travis, N., Trigilio, J., Vassiliev, H., Viel, R., Vo, A., Wilson, B., Wu, X., Wyman, D., Ye, W.J., Young, G., Zainoun, J., Zembek, L., Zimmer, A. and Zody, M.

**TITLE**  
**JOURNAL**  
**COMMENT**

Submitted (10-JUN-2002) Whitehead Institute/MIT Center for Genome Research, 320 Charles Street, Cambridge, MA 02141, USA  
 On Jun 10, 2002 this sequence version replaced gi:19424573.  
 All repeats were identified using RepeatMasker:  
 Smit, A.F.A. & Green, P. (1996-1997)  
<http://ftp.genome.washington.edu/RM/RepeatMasker.html>

Center: Whitehead Institute/ MIT Center for Genome Research

Center code: WIBR

Web site: <http://www-seq.wi.mit.edu>

Contact: [sequence.submissions@genome.wi.mit.edu](mailto:sequence.submissions@genome.wi.mit.edu)

----- Project Information

Center project name: L24846

Center clone name: 455\_M\_3

----- Summary Statistics

Sequencing vector: Plasmid; n/a; 100% of reads

Chemistry: Dye-terminator Big Dye; 100% of reads

Assembly program: Phrap; version 0.960731

Consensus quality: 184146 bases at least Q40

Consensus quality: 187658 bases at least Q30

Insert size: 183000; agarose-fp

Quality coverage: 6.1 in Q20 bases; agarose-fp

Quality coverage: 5.9 in Q20 bases; sum-of-contigs

----- NOTE: This is a 'working draft' sequence. It currently consists of 20 contigs. Gaps between the contigs are represented as runs of N. The order of the pieces is believed to be correct as given, however the sizes of the gaps between them are based on estimates that have been provided by the submitter.  
 \* This sequence will be replaced  
 \* by the finished sequence as soon as it is available and

\* the accession number will be preserved.

1	733:	contig of 733 bp in length
734	833:	gap of 100 bp
834	1739:	contig of 906 bp in length
1740	1839:	gap of 100 bp
1840	3336:	contig of 1697 bp in length
3637	3636:	gap of 100 bp
3637	5172:	contig of 1536 bp in length
5173	5272:	gap of 100 bp
5273	7064:	contig of 1792 bp in length
7065	7164:	gap of 100 bp
7165	9538:	contig of 2374 bp in length
9539	11944:	contig of 2206 bp in length
11945	11944:	gap of 100 bp
11945	13280:	contig of 1336 bp in length
13281	13280:	gap of 100 bp
13281	16275:	contig of 2835 bp in length
16276	16375:	gap of 100 bp
16376	18266:	contig of 2251 bp in length
18267	18726:	gap of 100 bp
18727	23667:	contig of 4941 bp in length
23668	23767:	gap of 100 bp
23768	31948:	contig of 8181 bp in length
31949	32048:	gap of 100 bp
32049	39436:	gap of 100 bp
39437	49369:	contig of 9933 bp in length
49370	49469:	gap of 100 bp
49470	61362:	contig of 11893 bp in length
61363	61462:	gap of 100 bp
61463	77912:	contig of 16450 bp in length
77913	78012:	gap of 100 bp
78013	92810:	contig of 14798 bp in length
92811	92810:	gap of 100 bp
92911	113012:	contig of 20102 bp in length
113013	113112:	gap of 100 bp
113113	137314:	contig of 24202 bp in length
137315	137414:	gap of 100 bp
137415	191186:	contig of 53772 bp in length.

**FEATURES**  
 source  
 1..191186  
 /organism="Mus musculus"  
 /mol\_type="genomic DNA"  
 /db\_xref="taxon:10090"  
 /clone\_lib="RP24-455M3"  
 /clone\_lib="RPC1-24 Male Mouse BAC"  
 1..733  
 /note="assembly\_fragment"  
 834..1739  
 /note="assembly\_fragment"  
 1840..3536  
 /note="assembly\_fragment"  
 3637..5172  
 /note="assembly\_fragment"  
 5273..7064  
 /note="assembly\_fragment"  
 7165..9538  
 /note="assembly\_fragment"  
 9539..11844  
 /note="assembly\_fragment"  
 11945..13280  
 /note="assembly\_fragment"  
 13381..16275  
 /note="assembly\_fragment"  
 16376..18626  
 /note="assembly\_fragment"  
 18727..23667  
 /note="assembly\_fragment"  
 23768..31948  
 /note="assembly\_fragment"  
 32049..39336  
 /note="assembly\_fragment"

**misc\_feature**  
 1..733  
 /note="assembly\_fragment"  
 834..1739  
 /note="assembly\_fragment"  
 1840..3536  
 /note="assembly\_fragment"  
 3637..5172  
 /note="assembly\_fragment"  
 5273..7064  
 /note="assembly\_fragment"  
 7165..9538  
 /note="assembly\_fragment"  
 9539..11844  
 /note="assembly\_fragment"  
 11945..13280  
 /note="assembly\_fragment"  
 13381..16275  
 /note="assembly\_fragment"  
 16376..18626  
 /note="assembly\_fragment"  
 18727..23667  
 /note="assembly\_fragment"  
 23768..31948  
 /note="assembly\_fragment"  
 32049..39336  
 /note="assembly\_fragment"

```
misc_feature 39437..49369
              /note="assembly_fragment"
misc_feature 49470..61362
              /note="assembly_fragment"
misc_feature 61463..77912
              /note="assembly_fragment"
misc_feature 78013..92810
              /note="assembly_fragment"
misc_feature 92911..113012
              /note="assembly_fragment"
misc_feature 113113..137314
              /note="assembly_fragment"
misc_feature 137415..191186
              /note="assembly_fragment"

ORIGIN
Query Match      32.5%; Score 229.8; DB 2; Length 191186;
Best Local Similarity 89.5%; Fred.No.1.1e-56;
Matches 257; Conservative 1; Mismatches 28; Indels 1; Gaps 1;

QY 422 AGTGCTCTATATACCTAAATGTGAAAAAATTTTGAAAGATCCATGTCCTGTGAATG 481
    |||||
Db 154789 AGTGCTCTATATATCTTAAGTGTGAAACAACTTIGAGAGTCCATGTCTCTGTGAGTG 154848

QY 482 TTGTCATGGAACACTTCAGGAAGTATCAACACTTCTCTCTGCTATCTGACCCAGAGGAA 541
    |||||
Db 154849 TCGTCATGGAACACTTCAGGAGACACCAACACTTCCCTGTCTATTTGACCCAGAGGAA 154908

QY 542 ACCAGAAGAGTGTTATCCTAACMAAATCTACAGTTCACAGTCTGCTGTTCATTCACTCT 601
    |||||
Db 154909 ACCAGAAGAGTGTCATCTGACCAACTCTACAGCTCCAATGTGCTGTTCATTCTCT 154968

QY 602 TCTGCCCAACCTGTATGATGCTGGGGGTGTGGCAATTTGTTGCCATGGTGAACCTTACAC 661
    |||||
Db 154969 TCTGCCCAACTTGTATGATGCTGGGGGTGTGGCAATCGTTGCTATGTTGGAACCTAAC 155028

QY 662 AGTACCTCTCCCTACTATGTGAGAGGATCC-ACGATCAATAGATAA 707
    |||||
Db 155029 AGTACCTCTCCCTGCTTTGTGAGAGGATCCACCGATCAACAGATAA 155075
```

Search completed: November 7, 2004, 00:34:42  
Job time : 3210 secs



GenCore version 5.1.6  
Copyright (c) 1993 - 2004 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: November 6, 2004, 23:29:46 ; Search time 425 Seconds  
(without alignments)  
8732.566 Million cell updates/sec

Title: US-09-914-053a-6  
Perfect score: 707  
Sequence: 1 atctcgatattggaccagtgg.....atccacggatcaatagataa 707

Scoring table: IDENTITY NUC  
Gapop 10.0 , Gapext 1.0

Searched: 4134886 seqs, 2624710521 residues

Total number of hits satisfying chosen parameters: 8269772

Minimum DB seq length: 0  
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 45 summaries

Database : N Geneseq\_23Sep04:.\*  
1: Geneseq11980s:.\*  
2: Geneseq11980s:.\*  
3: Geneseq11980s:.\*  
4: Geneseq12000s:.\*  
5: Geneseq12000s:.\*  
6: Geneseq12000s:.\*  
7: Geneseq12000s:.\*  
8: Geneseq12000s:.\*  
9: Geneseq12000s:.\*  
10: Geneseq12000s:.\*  
11: Geneseq12000s:.\*  
12: Geneseq12000s:.\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	706.2	99.9	707	3	AA75011 DNA encod
2	692	97.9	1184	4	AA75011 Human cal
3	690.4	97.7	1300	3	AA251632 Human mem
4	564.2	79.8	2098	3	AA26355 Human sec
5	564.2	79.8	2098	8	ADA39669 Human sec
6	564.2	79.8	2098	10	ADA55858 Gene enco
7	564.2	79.8	2098	12	ADL71416 Novel hum
8	281	39.7	558	4	ABA09433 Human k c
9	135.4	19.2	1111	2	AZ11913 Human pot
10	135.4	19.2	1246	2	AZ11912 Human pot
11	134.4	19.0	774	3	AA75009 DNA encod
12	134.4	19.0	1144	4	AAK52128 Human pol
13	134.4	19.0	1251	4	ABA09214 Human Ca-
14	134.4	19.0	1251	4	AAK53112 Human pol
15	134.4	19.0	1296	4	AA75095 Human cal
16	134.4	19.0	1632	4	AA75093 Human cal
17	134	19.0	1106	2	AA75047 Human cal
18	134	19.0	1277	6	ABL69681 Prostata
19	134	19.0	1277	10	ADD14749 Human src
20	132.8	18.8	1237	4	AA75092 Human cal
21	131.2	18.6	1759	4	AA75094 Human cal

22	114.2	16.2	2238	2	AAT06476	Aat06476 Bovine ca
23	102.2	14.5	608	4	AA102267	Aa102267 Human rep
24	80	11.3	110000	12	ADO34927_0	Ado34927 Human vol
25	75.8	10.7	1228	3	AAx82099	Aax82099 Human cal
26	74.8	10.6	188	3	AAc07442	Aac07442 Human sec
27	74.2	10.5	533	3	AA75010	Aa75010 DNA encod
28	74.2	10.5	1501	3	AA75815	Aa75815 Human ORF
29	74.2	10.5	1608	3	AA22298	Aa22298 Human pot
30	67	9.5	394	3	AAc03613	Aac03613 Human sec
31	60	8.5	60	6	ABN38341	Abn38341 Human spl
32	51.4	7.3	7045	4	ABA07292	Aba07292 Human pan
33	51.4	7.3	7045	4	AAK89937	Aak89937 Human dig
34	51.4	7.3	7045	4	AA137429	Aa137429 Human mus
35	51.4	7.3	7045	8	ABX60417	Abx60417 CDNA enco
36	51.4	7.3	7045	12	ADJ31167	Adj31167 Human mus
37	49.2	7.0	413	12	ADO35047	Ado35047 Human KCh
38	47.2	6.7	285	2	AAT22677	Aat22677 Human gen
39	45.4	6.4	48000	4	AA727996	Aaf727996 Human cal
40	44.8	6.3	2787	5	AA577593	Aas77593 DNA encod
41	44.8	6.3	2787	5	AA822312	Aas822312 DNA encod
42	44.8	6.3	2787	5	AA577413	Aas77413 DNA encod
43	44.4	6.3	483	12	ADO35049	Ado35049 Human KCh
44	44.2	6.3	2000	8	ADA71938	Ada71938 Rice gene
45	43.2	6.1	898	6	ABQ25377	Abq25377 Oligonuel

ALIGNMENTS

RESULT 1  
AAA75011  
ID AAA75011 standard; DNA; 707 BP.  
AC AAA75011;  
XX  
XX 02-JAN-2001 (first entry)  
XX  
DE DNA encoding a human BK beta-4 polypeptide.

XX Human; BK beta-2; beta subunit; Slo potassium channel; BK beta-3;  
XX BK beta-4; ion flux; migraine; hearing; vision problem; seizure; stroke;  
XX asthma; cell proliferation; hormone secretion; cancer; viral infection;  
XX ss.  
XX Homo sapiens.  
XX  
XX  
XX Key Location/Qualifiers  
XX CDS 1..707  
FT /\*tag= a  
FT /product= "BK beta-4"  
FT /transl\_except= (pos: 691..692, aa: Gln)  
XX

PN WO200050444-A1.  
XX  
XX 31-AUG-2000.  
XX  
XX 22-FEB-2000; 2000WO-US004441.  
XX  
XX 23-FEB-1999; 99US-0121224P.  
XX 03-NOV-1999; 99US-0163367P.  
XX (ICAG-) ICAGEN INC.  
XX Jegla TJ, Wickenden A, Liu Y;  
XX WPI; 2000-533179/48.  
XX P-PSDB; AAB08820.  
XX  
XX Isolated beta subunit polynucleotides and polypeptides of Slo potassium  
XX channels are used to determine the effects of compounds on ion flux  
XX through a potassium channel and in computer modelling systems.  
XX Claim 7; Page 79-80; 84pp; English.  
PS

The present sequence encodes a human BK beta-4 polypeptide. The polypeptide is a beta subunit of a slo potassium channel. The specification also describes BK beta-3 and BK beta-3 polypeptides. BK beta subunits are auxiliary subunits or monomers of slo potassium channels. The polypeptides, when expressed in cells and cell membranes, are used to determine the effects of compounds on ion flux through a potassium channel. The compounds identified may be useful as therapeutic agents e.g. modulators that target specific slo channels are useful for treating migraines, hearing and vision problems, seizures, stroke, asthma, cell proliferation and hormone secretion. The computer generated 3-dimensional structures of BK beta 2, BK beta 3 or BK beta 4 are used to identify ligands that bind to the beta subunit. The characterized BK beta subunits are used to determine how slo potassium channels function in different environments and how they respond to different activation mechanisms. The polynucleotides are used to transfect cells in vivo and in vitro to mitigate effects of absent, partial inactivation or abnormal expression of the BK beta subunit gene e.g. to correct genetic defects, cancer and viral infection

SQ Sequence 707 BP; 205 A; 170 C; 153 G; 177 T; 0 U; 2 Other;  
Query Match 99.9%; Score 706.2; DB 3; Length 707;

QY	1	ATGTGATATGGACGAGTGGCGGACCTCTTTCATCTTATAGACATGATGAAAAAGAAAT	60
Db	1		60
QY	61	ATTTACCAGAAAATCAGGAGCCATGACCTCTGCAAAAAGGAAAAACAGTCACACACTG	120
Db	61		120
QY	121	AAGGAGGAGGAGCCGAGCTATTCTCTGGGACTGGCTATGATGGTGTGCTCCATCATG	180
Db	121		180
QY	181	ATGTATTCTCTGCTGGGAATCACACTCTCGCTCTATACATGCAGAGCGTGTGGACCCAA	240
Db	181		240
QY	241	GAGTCTCTCAATGCACCTTGCTGTAATCGGTCCATCACGAAACATTTAAATGCTCTTCAGC	300
Db	241		300
QY	301	TGTGCTCAGACTGCTGGAACCTTTCTCAGTACCCCTGCTCCAGTGTACGTTAACTCG	360
Db	301		360
QY	361	ACTTCTTCGCGGAAAAAGCTCCTCCTCTACACACAGAGAGACAATAAAAAATCAATCAG	420
Db	361		420
QY	421	AGTGCCTCTATATACCTAAATGTGAAAAAAATTTTGAAGATCCATGTCCTCGTGAAT	480
Db	421		480
QY	481	GTTGTTCATGGAAAACTTCAGGAAGTATCAACACTTCTCTGCTATTCTGACCACGAAGA	540
Db	481		540
QY	541	AACCAAGAGAGTGTATCTCTAAACAACTCTACAGTTCGAAAGTGCTGTTCAATTCATC	600
Db	541		600
QY	601	TTCTGGCCAACTGTATGATGGCTGGGGGTGTGGCAATTGTTGCCATGGTGAACCTTACA	660
Db	601		660
QY	661	CAGTACCTCTCCCTACTATGTGAGAGGATCCACGGATCAATAGATAA	707
Db	661		707

Db 511 GAGTCTCAATGCACCTTGTGTAATGCGTCCATCAGCAAAATTTAACTGCTCTTCAGC 570  
Qy 301 TGTGGTCCAGACTGCTGGAACATTTCTCAGTACCCCTGCTCCAGGTGACGTAACTTG 360  
Db 571 TGTGGTCCAGACTGCTGGAACATTTCTCAGTACCCCTGCTCCAGGTGACGTAACTTG 630  
Qy 361 ACTTCTTCGCGGGAAGCTCTCTCTTACACAGAGAGACAATAAAAAATCAATCAG 420  
Db 631 ACTTCTTCGCGGGAAGCTCTCTCTTACACAGAGAGACAATAAAAAATCAATCAG 690  
Qy 421 AAGTGTCTCTATATACCTAATGTGGAATAATTTTGAAGATCCATGCTCCCTGGTGAAT 480  
Db 691 AAGTGTCTCTATATACCTAATGTGGAATAATTTTGAAGATCCATGCTCCCTGGTGAAT 750  
Qy 481 GTTGTCTATGAGAAACTTTCAGGAAGTATCAACACTTCTCTCTGATTTGACCCAGAGGA 540  
Db 751 GTTGTCTATGAGAAACTTTCAGGAAGTATCAACACTTCTCTCTGATTTGACCCAGAGGA 810  
Qy 541 AACGAGAGAGTGTATCTTAAACAACTCTACAGTTCCAACTGCTGTTCCATTCACCTC 600  
Db 811 AACGAGAGAGTGTATCTTAAACAACTCTACAGTTCCAACTGCTGTTCCATTCACCTC 870  
Qy 601 TTCTGGCCAACTGTATGAGTGGCTGGGGGTGGCAATTTGTCATGGTGAACCTTACA 660  
Db 871 TTCTGGCCAACTGTATGAGTGGCTGGGGGTGGCAATTTGTCATGGTGAACCTTACA 930  
Qy 661 CAGTACCTCTCTCTACTATGTGAGAGGATCC-ACGGATCAATAGATAA 707  
Db 931 CAGTACCTCTCTCTACTATGTGAGAGGATCC-ACGGATCAATAGATAA 978

RESULT 3

AAZ51632  
ID AAZ51632 standard; cDNA; 1300 BP.  
XX  
AC AAZ51632;  
XX  
DT 21-JUN-2000 (first entry)  
XX  
DE Human membrane channel protein-16 (MECHP-16) cDNA.  
XX

Membrane channel protein-16; MECHP-16; diagnosis; treatment; lymphoma;  
cell proliferative disorder; bursitis; atherosclerosis; cancer; sarcoma;  
inflammatory disorder; AIDS; Addison's disease; cystic fibrosis; asthma;  
diabetes mellitus; osmoregulatory disorder; diarrhoea; renal failure;  
muscular disorder; myocarditis; Duchenne's muscular dystrophy; noctropic;  
cardiovascular disorder; hypertension; bronchitis; vasculitis; cardiac;  
neurological disorder; Alzheimer's disease; Parkinson's disease; human;  
Huntington's disease; antiarteriosclerotic; hepatotropic; cytostatic;  
anti-HIV; antianaemic; neuroprotective; immunomodulator; antidiabetic;  
hypotensive; vasotropic; antiasthmatic; antiinflammatory; antidepressant;  
anticonvulsant; thrombolytic; antiParkinsonian; immunostimulant; ss.

OS Homo sapiens.

XX Key Location/Qualifiers  
XX CDS 378..1085  
XX /tag= a  
XX /product= "MECHP-16"  
XX /note= "Shows homology to human beta subunit of Ca+  
activated K+ channel"  
XX misc\_binding 381..425  
XX /tag= b  
XX /bound\_moiety= "Primer or Probe"

XX WO200012711-A2.

XX PD 09-MAR-2000.

XX PF 02-SEP-1999; 99WO-US020468.

XX PP 02-SEP-1998; 98US-0155226P.

PR 12-NOV-1998; 98US-00191283.  
PR 09-DEC-1998; 98US-0155225P.  
PR 26-JAN-1999; 98US-0155211P.  
PR 10-FEB-1999; 98US-0155263P.  
XX  
PA (INCY-) INCYTE PHARM INC.  
XX  
PI Au-Young J, Bandman O, Tang YT, Reddy R, Hillman JL, Yue H;  
PI Lal P, Corley NC, Guegler KJ, Gorgone G, Baughn MR, Azimzai Y;  
XX  
DR WPI: 2000-256643/22.  
DR P-FSDB; AAY70466.  
XX  
PT Novel human membrane channel protein and polynucleotide useful for  
PT diagnosing and treating cell proliferative, inflammatory, secretory,  
PT osmoregulatory, muscular, cardiovascular and neurological disorders.  
XX  
PS Claim 9; Page 128-129; 140pp; English.

CC The present sequence is a cDNA identified in Incyte clone 2069907 derived  
CC from ISLNOT01 cDNA library. It encodes human membrane channel protein-16  
CC (MECHP-16), which is expressed in nervous tissues. Anti-MECHP antibodies  
CC can be used as therapeutic antagonists and reagents for diagnosis and  
CC monitoring diseases. MECHP cDNA can be used for diagnosis of MECHP-  
CC related diseases and gene mapping. MECHP can be used for treatment of  
CC cell proliferative disorders such as bursitis and atherosclerosis,  
CC cancers like lymphoma and sarcoma, inflammatory disorders like AIDS and  
CC Addison's disease, transport/secretory disorders like cystic fibrosis and  
CC diabetes mellitus, osmoregulatory disorders like diarrhoea and renal  
CC failure, muscular disorders like myocarditis and Duchenne's muscular  
CC dystrophy, cardiovascular disorders like hypertension and vasculitis,  
CC congenital lung anomalies like bronchitis and asthma and neurological  
CC disorders like Alzheimer's disease, Parkinson's disease and Huntington's  
CC disease

XX SQ Sequence 1300 BP; 381 A; 288 C; 279 G; 352 T; 0 U; 0 Other;

Query Match 97.7%; Score 690.4; DB 3; Length 1300;

Best Local Similarity 99.2%; Pred. No. 6.5e-206;

Matches 702; Conservative 2; Mismatches 3; Indels 1; Gaps 1;

QY 1 ATGTCGATATGACAGGACCGGACCTCTTTCATCTTATAGACATGATGAAAAAGAAAT 60  
DB 378 ATGTTATATGACAGGACCGGACCTCTTTCATCTTATAGACATGATGAAAAAGAAAT 437  
QY 61 ATTTACCAAGAAATCAGGACCATGACCTCTTGGACAAAAGAAACAGTCACACACTG 120  
DB 438 ATTTACCAAGAAATCAGGACCATGACCTCTTGGACAAAAGAAACAGTCACACACTG 497  
QY 121 AAGGACGAGAGACCGGACCTATTTCTCTGGGACCTGGCTATGATGCTGCTCCATCATG 180  
DB 498 AAGGACGAGAGACCGGACCTATTTCTCTGGGACCTGGCTATGATGCTGCTCCATCATG 557  
QY 181 ATGTAATTTTCTCTGGGAATCACACTCTCTGGCTCATATGCTGAGAGGTGTGGACCGAA 240  
DB 558 ATGTAATTTTCTCTGGGAATCACACTCTCTGGCTCATATGCTGAGAGGTGTGGACCGAA 617  
QY 241 GAGTCTCAATGACACCTTGTCTGAATCGCTCCATCAGGAAACATTTAAATGCTCTTCAGC 300  
DB 618 GAGTCTCAATGACACCTTGTCTGAATCGCTCCATCAGGAAACATTTAAATGCTCTTCAGC 677  
QY 301 TGTGTCTCAGACTGCTGGAAACTTTTCTCAGTACCCCTCCAGGTGTAGCTTAACCTG 360  
DB 678 TGTGTCTCAGACTGCTGGAAACTTTTCTCAGTACCCCTCCAGGTGTAGCTTAACCTG 737  
QY 361 ACTTCTTCGCGGGAAGCTCTCTCTTACACAGAGAGACATATAAAATCAATCAG 420  
DB 738 ACTTCTTCGCGGGAAGCTCTCTCTTACACAGAGAGACATATAAAATCAATCAG 797  
QY 421 AAGTGTCTCTATATACCTAATGTGGAATAATTTTGAAGATCCATGCTCCCTGGTGAAT 480  
DB 798 AAGTGTCTCTATATACCTAATGTGGAATAATTTTGAAGATCCATGCTCCCTGGTGAAT 857

QY 481 GTTGTGATGGAAGAACTTCAGGAAGTATCAACACTTCTCTGCTATTTCTGACCCAGGAAGGA 540  
DB 858 GTTGTGATGGAAGAACTTCAGGAAGTATCAACACTTCTCTGCTATTTCTGACCCAGGAAGGA 917  
QY 541 AACCAAGAGAGTGTATCTCTAACMAAACTCTACAGTTCACACGTCGTGTTCCATTCACCTC 600  
DB 918 AACCAAGAGAGTGTATCTCTAACMAAACTCTACAGTTCACACGTCGTGTTCCATTCACCTC 977  
QY 601 TTTGCGCAACTGTATGATGCTGGGGGTGCGCAATTGTCGTCAGTGTGAACCTTACA 660  
DB 978 TTTGCGCAACTGTATGATGCTGGGGGTGCGCAATTGTCGTCAGTGTGAACCTTACA 1037  
QY 661 CAGTACCTCTCCCTACTATGTCAGAGATCC-ACGGATCAATAGATAA 707  
DB 1038 CAGTACCTCTCCCTACTATGTCAGAGATCCACACGGATCAATAGATAA 1085

RESULT 4  
ID AAA26355 standard; cDNA; 2098 BP.  
XX AAA26355;  
XX 29-JUN-2000 (first entry)  
XX Human secreted protein gene 10 SEQ ID NO:20.  
DE Human; secreted protein; diagnosis; cytostatic; immunosuppressive;  
KW antiHIV; antiinflammatory; nootropic; neuroprotective; antiallergic;  
KW osteopathic; antiarthritic; antibacterial; antidiabetic; antiasthma;  
KW antipsoriatic; cardiant; gene therapy; cancer; neurological disorder;  
KW immune disease; inflammation; blood disorder; tumour; ss.  
XX Homo sapiens.  
OS WO200006698-A1.  
XX 10-FEB-2000.  
XX 29-JUL-1999; 99WO-US017130.  
XX 30-JUL-1998; 98US-0094657P.  
PR 05-AUG-1998; 98US-0095486P.  
PR 06-AUG-1998; 98US-0095454P.  
PR 06-AUG-1998; 98US-0095455P.  
PR 12-AUG-1998; 98US-0096319P.  
XX (HUMA-) HUMAN GENOME SCI INC.  
XX Konatsoulis GA, Rosen CA, Ruben SM, Duan R, Moore PA, Shi Y;  
PI Lafleur D, Wei Y, Ni J, Florence KA, Young PE, Brewer LA;  
PI Soppet DR, Endress GA, Ebner R, Olsen HS, Mucenski M;  
XX WPI; 2000-195282/17.  
DR P-PSDB; AAY91460.  
XX New isolated human genes and the secreted polypeptides they encode,  
PT useful for diagnosis and treatment of e.g. cancers, neurological  
PT disorders, immune diseases, inflammation or blood disorders.  
XX Claim 1; Page 378-379; 634pp; English.

CC The polynucleotide sequences given in AAA26346 to AAA26458 encode the  
CC human secreted proteins given in AAY91451 to AAY91691. The human secreted  
CC proteins can have activities based on the tissues and cells they are  
CC expressed in. Examples of the activities are: cytostatic;  
CC immunosuppressive; antiHIV; antiinflammatory; nootropic; neuroprotective;  
CC antiallergic; osteopathic; antiarthritic; antibacterial; antidiabetic;  
CC antiasthma; antipsoriatic; and cardiant. The polynucleotides and their  
CC corresponding secreted proteins are useful for preventing, treating or  
CC ameliorating medical conditions, e.g. by protein or gene therapy. Also  
CC pathological conditions can be diagnosed by determining the amount of the  
CC proteins in a sample or by determining the presence of mutations in the

CC polynucleotides. Specific uses are described for each of the  
CC polynucleotides, based on which tissues they are most highly expressed  
CC in, and include developing products for the diagnosis or treatment of  
CC cancer, tumors, neurodegenerative disorders, developmental abnormalities  
CC and foetal deficiencies, blood disorders, diseases of the immune system,  
CC autoimmune diseases, hepatic and renal disease, inflammation, allergies,  
CC Alzheimer's and behavioural disorders, schizophrenia, osteoporosis,  
CC arthritis, infections, AIDS, spinal cord injuries, transplant rejection,  
CC diabetes, asthma, sepsis, acne, psoriasis, cardiovascular disorders,  
CC reproductive disorders, gastrointestinal disorders, respiratory disorders  
CC and metabolic disorders. The proteins or polynucleotides can also be used  
CC as food additives or preservatives. The proteins are also useful for  
CC identifying their binding partners. AAA26337 to AAA26345 and AAY91450 are  
CC sequences used in the exemplification of the present invention  
XX Sequence 2098 BP; 645 A; 366 C; 368 G; 719 T; 0 U; 0 Other;  
SQ

Query Match 79.8%; Score 564.2; DB 3; Length 2098;  
Best Local Similarity 99.5%; Pred. No. 3.9e-166;  
Matches 574; Conservative 2; Mismatches 0; Indels 1; Gaps 1;  
QY 132 GGACCGAGCTATTCTCTGGGACTGGCTATGATGCTGCTCCATCATGATGATTTCT 191  
DB 9 GGACCGAGCTATTCTCTGGGACTGGCTATGATGCTGCTCCATCATGATGATTTCT 68  
QY 192 GCTGGGAATCACACTCTCTGGCTCATATGATGAGCGGTGGACCGAGAGTCTCAATG 251  
DB 69 GCTGGGAATCACACTCTCTGGCTCATATGATGAGCGGTGGACCGAGAGTCTCAATG 128  
QY 252 CACCTTGTCTGAATGCTGCATCACGGAAACATTTAATGCTCTCTTCACTGCTGTCAGAG 311  
DB 129 CACCTTGTCTGAATGCTGCATCACGGAAACATTTAATGCTCTCTTCACTGCTGTCAGAG 188  
QY 312 CTGCTGGAAACTTTCTCAGTAGCCCTGCTCCAGGTGACGTTAACCTGACTTCTTCGG 371  
DB 189 CTGCTGGAAACTTTCTCAGTAGCCCTGCTCCAGGTGACGTTAACCTGACTTCTTCGG 248  
QY 372 GGAAAGCTCTCTCTACACACAGAGAGACAATAAATCAATCAGAGTGTCTCTA 431  
DB 249 GGAAAGCTCTCTCTACACACAGAGAGACAATAAATCAATCAGAGTGTCTCTA 308  
QY 432 TATACCTAAATGTGGAAGAAATTTTGAAGAAATCCATGTCCTTGGTGAATGTTGTCATGA 491  
DB 309 TATACCTAAATGTGGAAGAAATTTTGAAGAAATCCATGTCCTTGGTGAATGTTGTCATGA 368  
QY 492 AAACCTCAGAGATATCAACACTTCTCTGCTATTCAGCCAGAGAGAAACCAAGAG 551  
DB 369 AAACCTCAGAGATATCAACACTTCTCTGCTATTCGACCCAGAGAGAAACCAAGAG 428  
QY 552 TGTATCTCTAAACMAAACTCTACAGATTCACAACTGCTGTTTCCATTCACTCTTTCGCCAAC 611  
DB 429 TGTATCTCTAAACMAAACTCTACAGATTCACAACTGCTGTTTCCATTCACTCTTTCGCCAAC 488  
QY 612 CTGTATGATGCTGGGGGTGTCGCAATTTGTCCTGCTATTCGCAACTTACACAGTACTCTC 671  
DB 489 CTGTATGATGCTGGGGGTGTCGCAATTTGTCCTGCTATTCGCAACTTACACAGTACTCTC 548  
QY 672 CCTACTATGTGAGAGATCC-ACGGATCAATAGATAA 707  
DB 549 CCTACTATGTGAGAGATCCACCGATCAATAGATAA 585

RESULT 5  
ADA39669  
ID ADA39669 standard; cDNA; 2098 BP.  
XX ADA39669;  
XX 20-NOV-2003 (first entry)  
XX Human secreted protein encoding cDNA.  
DE Human; secreted protein; cancer; hyperproliferative disorder;  
KW

KW rheumatoid arthritis; autoimmune disorder; haematopoietic disorder;  
 KW anaemia; allergic reaction; asthma; cardiovascular disorder;  
 KW wound healing; cytostatic; immunosuppressive; neuroprotective;  
 KW antiviral; anti-allergic; hepatotropic; antidiabetic; anti-inflammatory;  
 KW vulnerary; cardiant; gene therapy; ss.  
 XX Homo sapiens.  
 OS  
 XX  
 FN WO2002102993-A2.  
 XX  
 XX 27-DEC-2002.  
 XX  
 XX 19-MAR-2002; 2002WO-US008123.  
 XX  
 XX 21-MAR-2001; 2001US-0277340P.  
 PR 19-JUL-2001; 2001US-0306171P.  
 PR 13-NOV-2001; 2001US-0331287P.  
 XX  
 XX (HUMA-) HUMAN GENOME SCI INC.  
 PA  
 XX Rosen CA, Ruben SM;  
 FI WPI; 2003-175236/17.  
 XX  
 XX New human secreted proteins and nucleic acid molecules, useful for  
 PT preparing a diagnostic or pharmaceutical composition for diagnosing,  
 PT preventing or treating cancer or other hyperproliferative disorder,  
 PT asthma, allergies or AIDS.  
 XX  
 XX Claim 9; SEQ ID NO 51; 3205pp; English.  
 PS  
 XX  
 CC The invention relates to novel genes ADA39629-ADA40565 and proteins  
 CC ADA40566-ADA41501 for human secreted proteins, useful for preventing,  
 CC treating or ameliorating medical conditions e.g. by protein or gene  
 CC therapy. The polypeptides, nucleic acid molecules, antibodies or their  
 CC fragments, and agonists or antagonists that bind to the polypeptide are  
 CC useful for preparing a diagnostic or pharmaceutical composition for  
 CC diagnosing or treating cancer or other hyperproliferative disorder. The  
 CC polypeptides and nucleic acid molecules are also useful for detecting,  
 CC preventing, diagnosing, prognosticating, treating or ameliorating cancer  
 CC or other hyperproliferative disorders including neoplasms, autoimmune  
 CC disorders (e.g. diabetes, rheumatoid arthritis, systemic lupus  
 CC erythematosus, multiple sclerosis, autoimmune thyroiditis or haemolytic  
 CC anaemia), haematopoietic or haematological disorders (e.g. anaemia,  
 CC thrombocytopenia), allergic reactions including asthma or eczema,  
 CC inflammatory disorders (e.g. ischaemia-reperfusion injury, inflammatory  
 CC bowel disease or Crohn's disease), neurodegenerative disorders (e.g.  
 CC Alzheimer's disease or Parkinson's disease), cardiovascular disorders  
 CC (e.g. atherosclerosis, myocarditis), infectious diseases (bacterial,  
 CC fungal or viral infections including HIV/AIDS), or wound healing and  
 CC disorders of epithelial cell proliferation. The nucleic acids are also  
 CC useful for chromosome identification, radiation hybrid mapping or long-  
 CC range restriction mapping, as molecular weight markers, or as  
 CC hybridization or diagnostic probes. The polypeptides and antibodies are  
 CC useful for providing immunological probes for differential identification  
 CC of the tissues immunohistochemistry assays. Note: The sequence data for  
 CC this patent did not form part of the printed specification, but was  
 CC obtained in electronic format directly from WIPO at  
 CC ftp.wipo.int/pub/published\_pt\_sequences.  
 XX  
 XX Sequence 2098 BP; 645 A; 366 C; 368 G; 719 T; 0 U; 0 Other;  
 SQ  
 Query Match 79.8%; Score 564.2; DB 8; Length 2098;  
 Best Local Similarity 99.5%; Pred. No. 3.9e-166;  
 Matches 574; Conservative 2; Mismatches 0; Indels 1; Gaps 1;  
 132 GGACCGAGCTATTCTCTGGGACTGGCTATGATGGTGTCTCCATCATGATGATTTTCT 191  
 9 GGACCGAGCTATTCTCTGGGACTGGCTATGATGGTGTCTCCATCATGATGATTTTCT 68  
 192 GCTGGGAATCACACTCTCTGGCTCATATGAGCGGTGTGACGAGAGTCTCAATG 251  
 69 GCTGGGAATCACACTCTCTGGCTCATATGAGCGGTGTGACGAGAGTCTCAATG 128

QY 252 CACCTTGCTGATGCGTCCATCCGGAACATTTTAATGCTCCTTCAGCTGGTCCAGA 311  
 DB 129 CACCTTGCTGATGCGTCCATCCGGAACATTTTAATGCTCCTTCAGCTGGTCCAGA 188  
 QY 312 CTGCTGGAAACTTTTCTCAGTACCCCTGCTCAGGTGACGTTAACTGACTTCTCCGG 371  
 DB 189 CTGCTGGAAACTTTTCTCAGTACCCCTGCTCAGGTGACGTTAACTGACTTCTCCGG 248  
 QY 372 GGAAGAAGCTCCTCTTACCACAGAGAGACATTAATAATCAATCAGAAGTCTCCTA 431  
 DB 249 GGAAGAAGCTCCTCTTACCACAGAGAGACATTAATAATCAATCAGAAGTCTCCTA 308  
 QY 432 TATACCTAAATGTGGAAAAAATTTTGAAGAATCCATGTCCTCTGGTGAATGTTGTCATGA 491  
 DB 309 TATACCTAAATGTGGAAAAAATTTTGAAGAATCCATGTCCTCTGGTGAATGTTGTCATGA 368  
 QY 492 AAACCTTCAGGAAGTATCAACACTTCTCTGCTGCTATTTCTGACCCAGAGAGAACCAAGAG 551  
 DB 369 AAACCTTCAGGAAGTATCAACACTTCTCTGCTGCTATTTCTGACCCAGAGAGAACCAAGAG 428  
 QY 552 TGTATATCTTAACMAAACTCTACAGTTCCAAACGCTGTTCCATTCACCTCTTCTGGCCCAAC 611  
 DB 429 TGTATATCTTAACMAAACTCTACAGTTCCAAACGCTGTTCCATTCACCTCTTCTGGCCCAAC 488  
 QY 612 CTGTATGATGGCTGGGGGTGTGGCAATTTGTTCCCATGTTGAAACTTACACAGTACTCTC 671  
 DB 489 CTGTATGATGGCTGGGGGTGTGGCAATTTGTTCCCATGTTGAAACTTACACAGTACTCTC 548  
 QY 672 CCTACTATGTGAGAGATCC-ACGGATCAATAGATAA 707  
 DB 549 CCTACTATGTGAGAGATCCACGATCAATAGATAA 585  
 RESULT 6  
 ADA55858  
 ID ADA55858 standard; DNA; 2098 BP.  
 XX  
 AC ADA55858;  
 XX  
 DT 20-NOV-2003 (first entry)  
 XX  
 DE Gene encoding human secreted protein #37.  
 XX  
 XX immunosuppressive; antiinflammatory; antiasthmatic; antiallergic;  
 KW cytostatic; cerebroprotective; neuroprotective; neurotropic;  
 KW cardiovascular; antiarteriosclerotic; gene therapy;  
 KW human secreted protein; immune disorder; inflammation;  
 KW respiratory disorder; cancer; CNS disorder; neurodegenerative disorders;  
 KW inflammatory bowel disease; nephritis; Crohn's disease; asthma; allergy;  
 KW multiple sclerosis; ischaemic brain injury; Parkinson's disease;  
 KW Alzheimer's disease; atherosclerosis; myocardiitis; chromosome mapping;  
 KW triple helix formation; antisense gene therapy; forensic biology; ds;  
 KW gene.  
 XX  
 OS Homo sapiens.  
 XX  
 PN WO2002102994-A2.  
 XX  
 XX 27-DEC-2002.  
 XX  
 XX 19-MAR-2002; 2002WO-US008278.  
 XX  
 XX 21-MAR-2001; 2001US-0277340P.  
 PR 19-JUL-2001; 2001US-0306171P.  
 PR 13-NOV-2001; 2001US-0331287P.  
 XX  
 XX (HUMA-) HUMAN GENOME SCI INC.  
 PA  
 XX Rosen CA, Ruben SM;  
 PI WPI; 2003-167512/16.  
 DR P-PsDB; ADA56755.

XX New human secreted polypeptides and polynucleotides, useful for  
 PT diagnosing, treating or preventing e.g. immune disorders, inflammatory  
 PT conditions, respiratory disorders, cancers, CNS disorders, or  
 XX neurodegenerative disorders.

PS Claim 21; SEQ ID NO 47; 1754pp; English.

XX The invention relates to 592 new human secreted polypeptides useful for  
 CC diagnosing, treating or preventing e.g. immune disorders, inflammatory  
 CC conditions, respiratory disorders, cancers, CNS disorders, or  
 CC neurodegenerative disorders, or polypeptides comprising an amino acid  
 CC sequence at least 9% identical to the new sequences. The polypeptides,  
 CC antibodies or antibody fragments that bind to the polypeptides, nucleic  
 CC acids encoding the polypeptides, agonists or antagonists that binds to  
 CC the polypeptide, are useful in preparing diagnostic or pharmaceutical  
 CC compositions for diagnosing, treating or preventing an e.g. immune  
 CC disorders, inflammatory conditions (e.g. inflammatory bowel disease,  
 CC nephritis or Crohn's disease), respiratory disorders (e.g. asthma and  
 CC allergy), cancers (e.g. gastric, ovarian or lung cancer), CNS disorders  
 CC (e.g. multiple sclerosis or ischaemic brain injury), neurodegenerative  
 CC disorders (e.g. Parkinson's disease or Alzheimer's disease), and  
 CC cardiovascular disorders (e.g. atherosclerosis or myocarditis). The  
 CC polynucleotides are useful for chromosome identification, chromosome  
 CC mapping, for controlling gene expression through triple helix formation  
 CC or antisense DNA or RNA, in gene therapy, for identifying individuals  
 CC from minute biological samples, in forensic biology, and as hybridization  
 CC probes. The polypeptides are useful for as molecular weight markers on  
 CC sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE)  
 CC gels, to raise antibodies, for testing biological activities, and for  
 CC treating or preventing neural disorders, immune system disorders,  
 CC muscular, reproductive, gastrointestinal, pulmonary, cardiovascular,  
 CC renal, proliferative and/or cancerous diseases. This sequence corresponds  
 CC to a gene encoding one of the polypeptide of the invention. Note: The  
 CC sequence data for this patent did form part of the printed specification,  
 CC but was obtained in electronic format directly from WIPO at  
 CC ftp.wipo.int/pub/published\_pct\_sequences.

XX Sequence 2098 BP; 645 A; 366 C; 368 G; 719 T; 0 U; 0 Other;

Query Match 79.8%; Score 564.2; DB 10; Length 2098;  
 Best Local Similarity 99.5%; Pred. No. 3.9e-166;  
 Matches 574; Conservative 2; Mismatches 0; Indels 1; Gaps 1;

QY 132 GGACCGAGCTATTCCTCGGACGTGGCTATGATGCTGCTCCATCATGATGATGATTTCT 191  
 DB 9 GGACCGAGCTATTCCTCGGACGTGGCTATGATGCTGCTCCATCATGATGATTTCT 68

QY 192 GCTGGGAATCACACTCTCTGCGCTCATACATGACAGAGCGTGTGGACCGAAGTCTCAATG 251  
 DB 69 GCTGGGAATCACACTCTCTGCGCTCATACATGACAGAGCGTGTGGACCGAAGTCTCAATG 128

QY 252 CACCTTGCTGAATGGTCCATCAGGAAACATTTAAATGCTCCTTACGCTGTGCTCAGA 311  
 DB 129 CACCTTGCTGAATGGTCCATCAGGAAACATTTAAATGCTCCTTACGCTGTGCTCAGA 188

QY 312 CTGCTGGAAATTTTCTCAGTACCCCTGCTCCAGGTGTACGTTAACTGACTTCTCCGG 371  
 DB 189 CTGCTGGAAATTTTCTCAGTACCCCTGCTCCAGGTGTACGTTAACTGACTTCTCCGG 248

QY 372 GGAAAGCTCTCTCTACCCACAGAGAGACAAATAAATCAATCAGAAAGTCTCCTTA 431  
 DB 249 GGAAAGCTCTCTCTACCCACAGAGAGACAAATAAATCAATCAGAAAGTCTCCTTA 308

QY 432 TATACCTAAATGTGAAAAATTTTGAAGATCCATGTCCTGCTGAATGTTGTCATGGA 491  
 DB 309 TATACCTAAATGTGAAAAATTTTGAAGATCCATGTCCTGCTGAATGTTGTCATGGA 368

QY 492 AAACCTCAGGAAGTATCAACTCTCTGCTGATTTCTGACCCAGAGAAACAGAGAG 551  
 DB 369 AAACCTCAGGAAGTATCAACTCTCTGCTGATTTCTGACCCAGAGAAACAGAGAG 428

QY 552 TGTATCTCTACMAACTCTACAGTTCACAGTCTCCAGCTGCTGTTCAATTCACCTCTCTGGCCAAC 611

DB 429 TGTATCTCTACMAAACTCTACAGTTCACAGTTCACAGTGTGTTCCATTCCTCTCTGGCCAAC 488  
 QY 612 CTGTATGATGGCTGGGGTGTGGCAATTTGTTGCCATGTTGAACCTTACACAGTACCTCTC 671  
 DB 489 CTGTATGATGGCTGGGGTGTGGCAATTTGTTGCCATGTTGAACCTTACACAGTACCTCTC 548

QY 672 CCTACTATGTGAGAGATCC-ACGGATCAATAGATAA 707  
 DB 549 CCTACTATGTGAGAGATCCACGATCAATAGATAA 585

RESULT 7  
 ID ADL71416  
 ID ADL71416 standard; cDNA; 2098 BP.  
 XX  
 AC ADL71416;  
 XX  
 DT 20-MAY-2004 (first entry)  
 XX  
 DE Novel human secreted protein cDNA seqid 20.  
 XX  
 KW antiinflammatory; neuroprotective; neurotropic; antiparkinsonian;  
 KW anticonvulsant; antilipemic; CNS; gynaecological; antiarthritic;  
 KW antiasthmatic; anti-HIV; virucide; endocrine; cytostatic;  
 KW immunosuppressive; antiallergic; cardiovascular; respiratory;  
 KW dermatological; antimicrobial; gastrointestinal; gene therapy;  
 KW neurodegenerative disease; behavioral disorder; inflammatory condition;  
 KW hyperproliferative disorder; Alzheimer's disease; Parkinson's disease;  
 KW Huntington's disease; metabolic disorder; Tay-Sach's disease;  
 KW Leash-Nyhan syndrome; reproductive disorder; immunological disorder;  
 KW arthritis; asthma; AIDS; endocrine disorder; immune disorder;  
 KW Hodgkin's lymphoma; haematopoietic disorder; muscular disorder;  
 KW leukaemia; autoimmune disorder; allergy; cancer; cardiovascular disorder;  
 KW respiratory disorder; pulmonary disorder; connective tissue disorder;  
 KW skin disorder; CNS disorder; congenital disorder; infectious disorder;  
 KW gastrointestinal disorder; human; secreted protein; gene; ss.  
 XX  
 OS Homo sapiens.  
 XX  
 PN US2004034196-A1.  
 XX  
 PD 19-FEB-2004.  
 XX  
 XX 27-JAN-2003; 2003US-00351334.  
 PF  
 XX 30-JUL-1998; 98US-0094657P.  
 PR 05-AUG-1998; 98US-0095486P.  
 PR 06-AUG-1998; 98US-0095454P.  
 PR 06-AUG-1998; 98US-0095455P.  
 PR 12-AUG-1998; 98US-0096319P.  
 PR 29-JUL-1999; 99WO-US017130.  
 PR 24-JAN-2000; 2000US-00489847.  
 PR 25-JAN-2002; 2002US-0350898P.  
 XX  
 PA (KOMA/) KOMATSOUKIS G A.  
 PA (ROSE/) ROSEN C A.  
 PA (RUBE/) RUBEN S M.  
 PA (DUAN/) DUAN D R.  
 PA (MOOR/) MOORE P A.  
 PA (SHIY/) SHI Y.  
 PA (LAFLE/) LAFLEUR D W.  
 PA (WEIY/) WEI Y.  
 XX  
 PI Komatsoulis GA, Rosen CA, Ruben SM, Duan DR, Moore PA, Shi Y;  
 PI Lafleur DW, Wei Y;  
 XX  
 XX WPI; 2004-180094/17.  
 DR P-PSDB; ADL71532.  
 XX  
 PT New human secreted nucleic acid, useful for diagnosing and treating  
 PT neurodegenerative, inflammatory, hyperproliferative, metabolic,  
 PT reproductive, cardiovascular, respiratory or immunological disorders or

PT diseases.

XX Claim 1; SEQ ID NO 20; 234pp; English.

XX The invention describes an isolated human nucleic acid molecule (I) comprising a polynucleotide having a nucleotide sequence at least 95% identical to a sequence polynucleotide fragment of SEQ ID NO: X or of the cDNA sequence included in ATCC Deposit No: Z, which is hybridisable to SEQ ID NO: X; or a sequence encoding a polypeptide fragment, domain or epitope of SEQ ID NO: Y or a polypeptide sequence encoded by the cDNA sequence included in ATCC Deposit No: Z, which is hybridisable to SEQ ID NO: X, having a biological activity. The nucleic acids and polypeptides, pharmaceutical formulations and kits are useful in diagnosing and treating neurodegenerative diseases states, behavioral disorders, inflammatory conditions, hyperproliferative disorders (e.g. Alzheimer's disease, Parkinson's disease or Huntington's disease), metabolic disorders (e.g. Tay-Sachs' disease or Leish-Nyhan syndrome), reproductive disorders, immunological disorders (e.g. arthritis, asthma or AIDS), endocrine and immune disorders (e.g. Hodgkin's lymphoma), haematopoietic or muscular disorders (e.g. leukaemia), autoimmune disorders, allergy, cancer, cardiovascular, respiratory or pulmonary disorders, disorders, or conditions afflicting connective tissue, skin disorders, CNS disorders, congenital disorders, infectious disorders and gastrointestinal disorders. This sequence encodes a novel human secreted protein of the invention. Note: This sequence does not appear in the printed specification but is available in electronic format from the US patent office at [ftp.seqdata.uspro.gov/seqdata.html?DocID=20040034196](http://ftp.seqdata.uspro.gov/seqdata.html?DocID=20040034196).

XX Sequence 2098 BP; 645 C; 368 G; 719 T; 0 U; 0 Other;

Query Match 79.8%; Score 564.2; DB 12; Length 2098;  
Best Local Similarity 99.5%; Pred. No. 3.9e-166;  
Matches 574; Conservative 2; Mismatches 0; Indels 1; Gaps 1;

Qy	132	GGACCGAGCTATCTCTCGGAGCTGGCTATGATGGTGTGCTCCATCATGATGATTTTCT	191
Db	9	GGACCGAGCTATCTCTCGGAGCTGGCTATGATGGTGTGCTCCATCATGATGATTTTCT	68
Qy	192	GCTGGGAATCACACTCTCGGCTCATACATGACGAGCGTGTGACCGAAGAGTCTCAATG	251
Db	69	GCTGGGAATCACACTCTCGGCTCATACATGACGAGCGTGTGACCGAAGAGTCTCAATG	128
Qy	252	CACCTTCTGAATGCTCCATCAGGAAACATTTAATGCTCTTTCAGCTGTGGTCGAGA	311
Db	129	CACCTTCTGAATGCTCCATCAGGAAACATTTAATGCTCTTTCAGCTGTGGTCGAGA	188
Qy	312	CTGCTGGAATCTTCTCAGTACCCCTCCCTCCAGGTGATGTTAACTGACTTCTTCCGG	371
Db	189	CTGCTGGAATCTTCTCAGTACCCCTCCCTCCAGGTGATGTTAACTGACTTCTTCCGG	248
Qy	372	GGAAAGCTCTCTCTTACCACACAGAGAGACAATAAAATCAATCAGAAGTGTCTCTA	431
Db	249	GGAAAGCTCTCTCTTACCACACAGAGAGACAATAAAATCAATCAGAAGTGTCTCTA	308
Qy	432	TATACCTTAATGTGGAATAATTTTGAAGATCCATGCTCCCTGGTGAATGTTCTATGA	491
Db	309	TATACCTTAATGTGGAATAATTTTGAAGATCCATGCTCCCTGGTGAATGTTCTATGA	368
Qy	492	AAACTTCAGGAAGTATCAACACTTCTCTGCTATTTCTGACCCAGAGAAACAGGAAGAG	551
Db	369	AAACTTCAGGAAGTATCAACACTTCTCTGCTATTTCTGACCCAGAGAAACAGGAAGAG	428
Qy	552	TGTTATCTCAACMAACTTACAGTTCACAGTGTCTTTCATCTCTTCTGGCCAC	611
Db	429	TGTTATCTCAACMAACTTACAGTTCACAGTGTCTTTCATCTCTTCTGGCCAC	488
Qy	612	CTGTATGATGGCTGGGGTGTGCAATTTGTCATGCTGTAACACTTACACAGTACCTCTC	671
Db	489	CTGTATGATGGCTGGGGTGTGCAATTTGTCATGCTGTAACACTTACACAGTACCTCTC	548
Qy	672	CTTACTATGTGAGAGGATCC-ACGATCAATAGATAA	707
Db	549	CTTACTATGTGAGAGGATCCACGATCAATAGATAA	585

RESULT 8  
ABA09433

ID ABA09433 standard; cDNA; 558 BP.

XX AC ABA09433;

DT 11-JAN-2002 (first entry)

XX Human K channel subunit homologue-encoding cDNA, SEQ ID NO:1209.

XX Human; cytokine; cell proliferation; cell differentiation; growth factor;  
XX haematopoiesis regulation; tissue growth; immunomodulator; activin;  
XX inhibin; chemotaxis; chemokinesis; thrombolysis; oncogenesis;  
XX proliferation; metastasis; cancer; tumour; haematopoietic disorder;  
XX myeloid cell disorder; lymphoid cell disorder; asthma; arthritis;  
XX chronic inflammatory condition; proliferative retinopathy;  
XX atherosclerosis; coronary heart disease; arterial ischaemia;  
XX bone disorder; osteoporosis; vascular growth disorder;  
XX tissue regeneration; wound healing; infection; immune disorder;  
XX cell culture; drug screening; gene therapy; antiinflammatory;  
XX antialsthmatic; antiarthritic; haemostatic; antiarteriosclerotic;  
XX cystostatic; osteopathic; vasotropic; cardiant; virucide; antibacterial;  
XX antifungal; vulnery; antiulcer; ss.

OS Homo sapiens.

XX WO200157188-A2.

XX 09-AUG-2001.

XX 05-FEB-2001; 2001WO-US003800.

XX 03-FEB-2000; 2000US-00496914.

XX 27-APR-2000; 2000US-00560875.

XX (HYSE-) HYSEQ INC.

XX Tang YT, Liu C, Drmanac RT;

XX WPI: 2001-457740/49.

XX P-PSDB; ABB12189.

XX Human proteins and DNA encoding sequences useful for preventing, treating  
or ameliorating a medical condition in a mammalian subject e.g. arthritis  
and cancer.

XX Claim 1; Page 945; 1963pp; English.

XX Sequences ABB10981-ABB12330 represent 1350 novel human polypeptides, and  
sequences ABA08225-ABA09574 represent nucleic acids encoding them. The  
invention also relates to vectors and recombinant host cells comprising a  
nucleotide of the invention, methods of producing the novel polypeptides,  
antibodies against the polypeptides, methods of detecting the nucleotides  
or polypeptides in a sample, and methods of identifying compounds which  
bind to polypeptides of the invention. Although novel, many of the  
polypeptides of the invention have homology to known proteins, thereby  
giving an insight into their probable biological activities, and hence  
potential therapeutic applications. The polypeptides of the invention may  
have various activities, including cytokine, cell proliferation or cell  
differentiation activities; stem cell growth factor activity;  
haematopoiesis regulatory activity; tissue growth activity;  
immunomodulatory activity; activin- or inhibin-related activities;  
chemotactic or chemokinetic activities; haemostatic, thrombotic or  
thrombolytic activities; receptor or ligand activities; or may be  
involved in oncogenesis, cancer cell proliferation or metastasis.  
Depending on their biological activities, polypeptides and nucleotides of  
the invention are useful for preventing, treating or ameliorating medical  
conditions, e.g., by protein or gene therapy. Such conditions include  
cancers, haematopoietic disorders (e.g. myeloid or lymphoid cell  
disorders), chronic inflammatory conditions (e.g. asthma or arthritis),  
proliferative retinopathy, atherosclerosis, coronary heart disease,

CC arterial ischaemia, bone disorders (e.g., osteoporosis), and abnormal  
CC vascular growth. Polypeptides involved with tissue regeneration and  
CC repair (or nucleic acids encoding them) may be used to promote wound  
CC healing (e.g., of burns, incisions and ulcers), while those with  
CC immunomodulatory activities may be used in the treatment of viral,  
CC bacterial and fungal infections in addition to immune disorders.  
CC Polypeptides with growth factor activity may be used in cell cultures to  
CC promote cell growth. For example, such polypeptides may be used to  
CC manipulate stem cells in culture to give rise to neuroepithelial cells  
CC that can be used to augment or replace cells damaged by illness,  
CC autoimmune disease or accidental damage. The polypeptides and nucleotides  
CC may also be used in the diagnosis of the above conditions, and in drug  
CC screening techniques. The present sequence represents a cDNA encoding a  
CC novel human polypeptide of the invention

XX Sequence 558 BP; 165 A; 128 C; 144 G; 121 T; 0 U; 0 Other;  
SQ  
Query Match 39.7%; Score 281; DB 4; Length 558;  
Best Local Similarity 97.6%; Pred. No. 2e-77;  
Matches 284; Conservative 1; Mismatches 6; Indels 0; Gaps 0;  
QY 1 ATGTCGATATGACACAGTGGCGGACCTTCTCATCTTATAGACATGATGAAGAAAT 60  
DB 268 ATGTCGATATGACACAGTGGCGGACCTTCTCATCTTATAGACATGATGAAGAAAT 327  
QY 61 ATTACCAAGAAATCAGGGACCATGACCTCTCTGACAAAAGGAAAACAGTCACAGCACTG 120  
DB 328 ATTACCAAGAAATCAGGGACCATGACCTCTCTGACAAAAGGAAAACAGTCACAGCACTG 387  
QY 121 AAGCAGAGAGACCGAGCTATTCTCTCTGGACTGGCTATGATGGTGTGCTCCATCATG 180  
DB 388 AAGCAGAGAGACCGAGCTATTCTCTCTGGACTGGCTATGATGGTGTGCTCCATCATG 447  
QY 181 ATGATTTTCTGCTGGGAATCACACTCTCTGGCTCATACATGACAGCGTGTGGACCGAA 240  
DB 448 ATGATTTTCTGCTGGGAATCACACTCTCTGGCTCATACATGACAGCGTGTGGACCGAA 507  
QY 241 GAGTCTCAATGACCTTGTGAAATGCGTCCATCATCGGAAACATTTAAATGTC 291  
DB 508 GAGTCTCAATGACCTTGTGAAATGCGTCCATCATCGGAAACATTTAACTGC 558

RESULT 9  
ID AA211913 standard; cDNA; 1111 BP.  
AC AA211913;  
DT 30-NOV-1999 (first entry)  
XX Human potassium channel K-Hnov44 cDNA (splice variant 2).  
DE Potassium channel; ataxia; arrhythmia; epilepsy; Bartter's syndrome;  
KW cardiovascular disorder; CNS disorder; renal disorder; ds.  
XX Homo sapiens.  
XX Key Location/Qualifiers  
FH 297..959  
FT CDS /\*tag= a  
FT /product= "Human K-Hnov44 potassium channel"

XX WO9943696-A1.  
XX 02-SEP-1999.  
XX 22-FEB-1999;  
XX 99WO-US0003826.  
XX 25-FEB-1998; 98US-0076687P.  
XX 07-AUG-1998; 98US-0095836P.  
XX 19-JAN-1999; 99US-0116448P.  
XX (AXYS-) AXYS PHARM INC.

XX Miller AP, Curran ME, Hu P, Rutter M, Wang J;  
PI WFI; 1999-527591/44.  
XX P-PSDB; AAY34131.

XX New nucleic acids encoding mammalian K-Hnov potassium channel proteins,  
PT useful for the diagnosis and treatment of episodic ataxia with myokymia,  
PT cardiac arrhythmia, epilepsy and Bartter's syndrome.  
XX Claim 4; Page 90-91; 112pp; English.

XX This sequence represents splice variant 2 of a human potassium channel  
CC K-Hnov44 cDNA. Alternative splicing does not affect the amino acid  
CC sequence of the protein. K-Hnov proteins have a high degree of homology  
CC to known potassium channels and may be alpha subunits, which form the  
CC functional channel, or accessory subunits that act to modulate the  
CC gene's chromosomal location is 2p13, determined via PCR chromosomal  
CC localisation using primers AA211934 and AA211936. K-Hnov cDNAs were  
CC isolated by extension of expressed sequence tags (ESTs) which were  
CC related but not identical to known human potassium channels. Potential  
CC polymorphisms detected as sequence variants between multiple independent  
CC clones. Potassium channels have critical roles in various cell types and  
CC biochemical pathways. Defective potassium channels are known to cause  
CC four human diseases: episodic ataxia with myokymia; cardiac arrhythmia  
CC (long QT syndrome); epilepsy; and Bartter's syndrome. As potassium  
CC channels are critical components of virtually all cells, it is likely  
CC that abnormal potassium channels are also implicated in certain renal,  
CC cardiovascular and central nervous system (CNS) disorders. Nucleotides  
CC encoding K-Hnov proteins may be used for identifying homologous or  
CC related proteins and the DNA sequences encoding them. They may be used to  
CC produce compositions that modulate the expression and function of the  
CC K-Hnov protein and in studying the biochemical pathways associated with  
CC it. They may also be used for the recombinant production of K-Hnov  
CC protein in fermentation cultures. Additionally, such nucleotides may be  
CC used in gene therapy protocols for the treatment of diseases associated  
CC with abnormal potassium channels

XX Sequence 1111 BP; 347 A; 237 C; 263 G; 264 T; 0 U; 0 Other;  
SQ  
Query Match 19.2%; Score 135.4; DB 2; Length 1111;  
Best Local Similarity 54.6%; Pred. No. 1.7e-31;  
Matches 312; Conservative 2; Mismatches 248; Indels 9; Gaps 2;  
QY 124 GCAGGAGGACCGAGCTATTCTCTGGACTGGCTATGATGGTGTGCTCCATCATGATG 183  
DB 276 GCTGAGAGGACCGAGCGCTGATGCTGGGTTTGCATGATGGGCTTCTCAGTCTTAATG 335  
QY 184 TATTTCTGCTGGGAATCACACTCTCTGGCTCATACATGACAGCGTGTGGACGAGAG 243  
DB 336 TTCTTTCTGCTGGGAACCAACCTTCTAAAGCCTTTTATGCTCAGCATTCAGAGAGAGAA 395  
QY 244 TCTCAATGACACTTCTGTAATGCGTCCATCACGAAACAT---TTAATGCTCTCTCAGC 300  
DB 396 TCGACCTGCACTGCCATCCACACAGATATCATGACGACTGGCTGGCTTCCACC 455  
QY 301 TGTGTCAGACTGCTGGAACCTTCTCAGTACCCCTCCCTCCAGGTGAGTAACTG 360  
DB 456 TGTGTTGCTGCACTGCCACGGTTCAGGGGAAGTACCGTGTCTCTCAGGTTTGTGAACCTC 515  
QY 361 ACTTCTTCCGGGAAAAGCTCTCTCTCTACACACAGAGAGACAATAAATCAATCAG 420  
DB 516 AGCCATCCAGGTCAGAAAGCTCTCTCATATTATGAGAGGCTGTCAGATATAATCCC 575  
QY 421 AAGTCTCTCTATATACCTTAATGTGGAAAAAATTTTGAAGATCCATGCTCCCTGGTGAAT 480  
DB 576 AAGTCTCTTTTACACACCTTAAGTGGCCACCAAGATAGAAATGATTTTCTCAACAGTCTG 635  
QY 481 GTTGTGATGGAAACCTT-----CAGGAAGTATCAACACTTCTCTGCTATCTGACCCA 534  
DB 636 GACATAAAGAAATTTCTTCATCAAAAATGGAATCCCTTTTCATGCTTCTACAGTCCA 695





```
XX Key Location/Qualifiers
FH 1..774
FT CDS
FT /*tag= a
FT /product= "BK beta-2"
XX
PN WO200050444-A1.
XX
PD 31-AUG-2000.
XX
XX 22-FEB-2000; 2000WO-US004441.
XX
PR 23-FEB-1999; 99US-0121224P.
PR 03-NOV-1999; 99US-0163367P.
XX
PA (ICAG-) ICAGEN INC.
XX
XX Jegla TJ, Wickenden A, Liu Y;
XX WPI: 2000-533179/48.
DR P-PSDB; AAB08918.
XX
XX Isolated beta subunit polynucleotides and polypeptides of slo potassium
PT channels are used to determine the effects of compounds on ion flux
PT through a potassium channel and in computer modelling systems.
XX
PS Claim 7; Page 79; 84pp; English.
XX
CC The present sequence encodes a human BK beta-2 polypeptide. The
CC polypeptide is a beta subunit of a slo potassium channel. The
CC specification also describes BK beta-3 and BK beta-4 polypeptides. BK
CC beta subunits are auxiliary subunits or monomers of slo potassium
CC channels. The polypeptides, when expressed in cells and cell membranes,
CC are used to determine the effects of compounds on ion flux through a
CC potassium channel. The compounds identified may be useful as therapeutic
CC agents e.g. modulators that target specific slo channels are useful for
CC treating migraines, hearing and vision problems, seizures, stroke,
CC asthma, cell proliferation and hormone secretion. The computer generated
CC 3-dimensional structures of BK beta 2, BK beta 3 or BK beta 4 are used to
CC identify ligands that bind to the beta subunit. The characterized BK beta
CC subunits are used to determine how slo potassium channels function in
CC different environments and how they respond to different activation
CC mechanisms. The polynucleotides are used to transfect cells in vivo and
CC in vitro to mitigate effects of absent, partial inactivation or abnormal
CC expression of the BK beta subunit gene e.g. to correct genetic defects,
CC cancer and viral infection
XX
SQ Sequence 774 BP; 223 A; 177 C; 179 G; 195 T; 0 U; 0 Other;

Query Match 19.0%; Score 134.4; DB 3; Length 774;
Best Local Similarity 54.6%; Pred. No. 2.8e-31;
Matches 311; Conservative 2; Mismatches 248; Indels 9; Gaps 2;

QY 125 CAGGAGGACCGAGCTATTCTCTGGGACTGGCTATGATGGTGTGCTCCATCATGATGT 184
D5 92 CTGAGAGAGACCGAGCGGTGATGGGGTTTGGCATGATGGGTTCTCAGTCTCTAATGT 151
QY 185 ATTTTCTCTGGGAATCACACTCTCTGGCTCATACATGCAGAGCGTGTGGACGGAAGT 244
D5 152 TCTTCTTCTCGGAACACCACTTCTAAGCCCTTTTATGCTCAGCATTCAGAGAGAAGAT 211
QY 245 CTCATGACACTTGTGTAATCGTCCATCAGGAAACAT---TTAATGCTCTCTAGCT 301
D5 212 CGACTGCACTGCCATCCACAGATATCATGAGGAGCTGCTGAGCTGCTCTACCT 271
QY 302 GTGTGTCAGACTGTGGGAAACCTTCTCAGTACCCCTCCAGTGTAGCTTAACCTGA 361
D5 272 GTGTGTGCACTGCCACCGTTCAGGGGAGTACCGGTCTCTCAGTGTGTGTAACCTCA 331
QY 362 CTTCTTCCGGGAAAGCTCTCTCTTACCAACAGAGAGACAAATAAATCAATCAGA 421
D5 332 GCCATCCAGGTTCAGAAAGCTCTCTTACATATATATGAAGAGGCTGTCCAGATAATCCCA 391
```

```
QY 422 AGTGCTCTTATATACCTAAATGTGAAATAATTTTGAAGATCCATGCTCCCTGGTGAATG 481
D5 392 AGTGCTTTTACACACCTAAGTCCCAAGATAGAAATGATTGTCTCAACAGTGTCTGG 451
QY 482 TTGTCATGGAARACTT-----CAGGAAGTATCAACACATTCCTCTGCTATTCTGACCCAG 535
D5 452 ACATTAAGAAATCTTCGATCAAAAATGGAACCCCTTTTCATGCTCTACAGTCCAG 511
QY 536 AAGGAAACCAAGAGAGTGTATCTTAACVAAACTCTACAGTTCACAGTGTCTTCCATT 595
D5 512 CCAGCCATCTGAAGATGCAATCTTATATAAAAAGTATGACCAATGGTATCTTCCACT 571
QY 596 CACTCTTCTGGCAACCTGTATGATGGCTGGGGTGTGCAATTTGCCATGGTGAAC 655
D5 572 GTTTATTTTGGCCTTCACTGACTCTGCTAGGTGGTGCCTGATTGTGGCATGGTGAGAT 631
QY 656 TTACACAGTACCTCTCCCTACTATGTGAGA 685
D5 632 TAACACACACCTGCTCTTACTGTGTGAAA 661

RESULT 12
AAK52128
ID AAK52128 standard; cDNA; 1144 BP.
XX
AC AAK52128;
XX
DT 06-NOV-2001 (first entry)
XX
DE Human polynucleotide SEQ ID NO 673.
XX
KW Human; cytokine; cell proliferation; cell differentiation; gene therapy;
KW vaccine; peptide therapy; stem cell growth factor; haematopoiesis;
KW tissue growth factor; immunomodulatory; cancer; leukaemia;
KW nervous system disorder; arthritis; inflammation; ss.
XX
OS Homo sapiens.
XX
PN WO200157190-A2.
XX
PD 09-AUG-2001.
XX
PF 05-FEB-2001; 2001WO-US004098.
XX
PR 03-FEB-2000; 2000US-00496914.
PR 27-APR-2000; 2000US-00560875.
PR 20-JUN-2000; 2000US-00598075.
PR 19-JUL-2000; 2000US-00620325.
PR 01-SEP-2000; 2000US-00654936.
PR 15-SEP-2000; 2000US-00666361.
PR 20-OCT-2000; 2000US-00693325.
PR 30-NOV-2000; 2000US-00728422.
XX
(HYSE-) HYSEQ INC.
XX
Tang YT, Liu C, Drmanac RT, Asundi V, Zhou P, Xu C, Cao Y;
Ma Y, Zhao Q, Wang D, Wang J, Zhang J, Ren F, Chen R, Wang ZW;
Xue AJ, Yang Y, Wejhrman T, Goodrich R;
WPI: 2001-476283/51.
P-PSDB; AAM78995.
XX
Nucleic acids encoding polypeptides with cytokine-like activities, useful
in diagnosis and gene therapy.
XX
Claim 1; Page 2356-2357; 6221pp; English.
XX
The invention relates to polynucleotides (AAK51456-AAK53435) and the
encoded polypeptides (AAM78323-AAM80302) that exhibit activity elating to
cytokine, cell proliferation or cell differentiation or which may induce
production of other cytokines in other cell populations. The
polynucleotides and polypeptides are useful in gene therapy, vaccines or
peptide therapy. The polypeptides have various cytokine-like activities,
```

CC e.g. stem cell growth factor activity, haematopoiesis regulating  
CC activity, tissue growth factor activity, immunomodulatory activity and  
CC activin/inhibin activity and may be useful in the diagnosis and/or  
CC treatment of cancer, leukaemia, nervous system disorders, arthritis and  
CC inflammation. Note: Records for SEQ ID NO.2110 (AAK52581), 2111  
CC (AAK52582) and 3666 (AAM80020) are omitted as the relevant pages from the  
CC sequence listing were missing at the time of publication  
XX  
SQ  
Sequence 1144 BP; 289 A; 296 C; 291 G; 268 T; 0 U; 0 Other;  
Query Match 19.0%; Score 134.4; DB 4; Length 1144;  
Best Local Similarity 54.6%; Pred. No. 3 5e-31;  
Matches 311; Conservative 2; Mismatches 248; Indels 9; Gaps 2;  
Qy 125 CAGGAGAGCCGAGCTATTCTCTGGGACTGGCTATGATGTTGCTCCATCATGATGT 184  
Db |||||  
465 CTGGAGAGGACCGAGCGTGATGCTGGGGTTTGGCATGATGGGCTTCTCAGTCTTAATGT 524  
Qy 185 ATTTCTCTGGGATCACACTCTCTCGCTCATACATGCAGAGCGTGTGCACCGAGAGT 244  
Db |||||  
525 TCCTCTCTGGGAAACACANTCTAAAGCCTTTATGCTCAGCATTCAGAGAGAGAT 584  
Qy 245 CTCAATGCACCTTCTCTGAATGCTCCATCAGCGAAACAT---TTAAVTGCTCTTCAGCT 301  
Db |||||  
585 CGACCTGCACTGCCATCCACACAGATATCATGGACGACTGGCTGCACTGTGCCTTCACCT 644  
Qy 302 GTGCTCAGACTCTGGAAACTTCTCAGTACCCCTGCCCTCCAGGTGCTGTTAACTGA 361  
Db |||||  
645 GTGGTGTGCACTGCCACGGTCAGGGAAGTACCACCTGCTTCAGGTGTTTGTGAACCTCA 704  
Qy 362 CTTCTTCGGGAAAGCTCTCTCTTACCACAGAGACAAATAAATAATCAATCAGA 421  
Db |||||  
705 GCCATCAGGTCAGAAAGCTCTCTCATATATATGAGAGGCTGTCAGATAATCCCA 764  
Qy 422 AGTGCTCTATATACCTAAATGTGGAAATAATTTTGAAGATCCATGCTCCGTGGTAATG 481  
Db |||||  
765 AGTGCTTTTACACACCTAAAGTGCACCAAGATAGAAATGATTTTCTCAACAGTGTCTGG 824  
Qy 482 TTGTCATGGAAACTT-----CAGGAAGTATCAACTTCTCTGCTATTCTGACCCAG 535  
Db |||||  
825 ACATAAAGAATTTCTGATCACAATAATGGAATCCCTTTTCAAGTCTTACAGTCCAG 884  
Qy 536 AAGGAACCCAGAGAGTGTATCTCTAACMAAATCTACAGTCCAACTGCTGTTCATT 595  
Db |||||  
895 CCAGCAATCTGAAGATGCTATTCTTATAAAGATATGACCAATGGCTATCTTCCACT 944  
Qy 596 CACTCTTCTGCCACCTGTATGATGCTGGGGTGGCAATGTTGCCATGCTGTAAC 655  
Db |||||  
945 GTTTATTTGGCTTCACTGACTCTGCTAGGTGGTGGCTGATTTGGCATGTGAGAT 1004  
Qy 656 TTACACAGTACTCTCTCCCTACTATGTGAGA 685  
Db |||||  
1005 TAACACACACTGTCCTTACTGTGTGAA 1034  
RESULT 13  
ABA09214  
ID ABA09214 standard; cDNA; 1251 BP.  
XX  
AC ABA09214;  
XX  
DT 11-JAN-2002 (first entry)  
XX  
DE Human Ca-activated K channel homologue-encoding cDNA, SEQ ID NO:990.  
XX  
KW Human; cytokine; cell proliferation; cell differentiation; growth factor;  
KW haematopoiesis regulation; tissue growth; immunomodulator; activin;  
KW inhibin; chemotaxis; chemokinesis; thrombolysis; oncogenesis;  
KW proliferation; metastasis; cancer; tumour; haematopoietic disorder;  
KW myeloid cell disorder; lymphoid cell disorder; asthma; arthritis;  
KW chronic inflammatory condition; proliferative retinopathy;  
KW atherosclerosis; coronary heart disease; arterial ischaemia;  
KW bone disorder; osteoporosis; vascular growth disorder;

XX tissue regeneration; wound healing; infection; immune disorder;  
KW cell culture; drug screening; gene therapy; antiinflammatory;  
KW antiashtatic; antiarthritic; haemostatic; antiarteriosclerotic;  
KW cytostatic; osteopathic; vasotropic; cardiant; virucide; antibacterial;  
XX antifungal; vulnery; antiulcer; ss.  
OS Homo sapiens.  
XX WO200157188-A2.  
PN 09-AUG-2001.  
XX 05-FEB-2001; 2001WO-US003800.  
XX 03-FEB-2000; 2000US-00496914.  
PR 27-APR-2000; 2000US-00560875.  
XX (HYSE-) HYSEQ INC.  
XX Tang YT, Liu C, Drmanac RT;  
PI WPI; 2001-457740/49.  
XX P-PSDB; ABB11970.  
DR Human proteins and DNA encoding sequences useful for preventing, treating  
PT or ameliorating a medical condition in a mammalian subject e.g. arthritis  
PT and cancer.  
XX Claim 1; Page 843-844; 1963pp; English.  
XX Sequences ABB10981-ABB12330 represent 1350 novel human polypeptides, and  
CC sequences ABA08225-ABA09574 represent nucleic acids encoding them. The  
CC invention also relates to vectors and recombinant host cells comprising a  
CC nucleotide of the invention, methods of producing the novel polypeptides,  
CC antibodies against the polypeptides, methods of detecting the nucleotides  
CC or polypeptides in a sample, and methods of identifying compounds which  
CC bind to polypeptides of the invention. Although novel, many of the  
CC polypeptides of the invention have homology to known proteins, and hence  
CC giving an insight into their probable biological activities, and hence  
CC potential therapeutic applications. The polypeptides of the invention may  
CC have various activities, including cytokine, cell proliferation or cell  
CC differentiation activities; stem cell growth factor activity;  
CC haematopoiesis regulatory activity; tissue growth activity;  
CC immunomodulatory activity; activin- or inhibin-related activities;  
CC chemotactic or chemokinetic activities; haemostatic, thrombotic or  
CC thrombolytic activities; receptor or ligand activities; or may be  
CC involved in oncogenesis, cancer cell proliferation or metastasis.  
CC Depending on their biological activities, polypeptides and nucleotides of  
CC the invention are useful for preventing, treating or ameliorating medical  
CC conditions, e.g., by protein or gene therapy. Such conditions include  
CC cancers, haematopoietic disorders (e.g., myeloid or lymphoid cell  
CC disorders), chronic inflammatory conditions (e.g., asthma or arthritis),  
CC proliferative retinopathy, atherosclerosis, coronary heart disease,  
CC arterial ischaemia, bone disorders (e.g., osteoporosis), and abnormal  
CC vascular growth. Polypeptides involved with tissue regeneration and  
CC repair (or nucleic acids encoding them) may be used to promote wound  
CC healing (e.g., of burns, incisions and ulcers), while those with  
CC immunomodulatory activities may be used in the treatment of viral,  
CC bacterial and fungal infections in addition to immune disorders.  
CC Polypeptides with growth factor activity may be used in cell cultures to  
CC promote cell growth. For example, such polypeptides may be used to  
CC manipulate stem cells in culture to give rise to neuroepithelial cells  
CC that can be used to augment or replace cells damaged by illness,  
CC autoimmune disease or accidental damage. The polypeptides and nucleotides  
CC may also be used in the diagnosis of the above conditions, and in drug  
CC screening techniques. The present sequence represents a cDNA encoding a  
CC novel human polypeptide of the invention  
XX  
SQ Sequence 1251 BP; 331 A; 304 C; 310 G; 306 T; 0 U; 0 Other;

Query Match 19.0%; Score 134.4; DB 4; Length 1251;  
Best Local Similarity 54.6%; Pred. No. 3 7e-31;  
Matches 311; Conservative 2; Mismatches 248; Indels 9; Gaps 2;

QY 125 CAGGAGGACGAGCTATTCTCTGGAGCTGGCTATGATGGTGGCTCCATCATGATGT 184  
Db |||||  
QY 433 CTGAGAGGACGAGCGGTGATGCTGGGTTGGCCATGATGGCTTCTCAGTCCCTAATGT 492  
Db |||||  
QY 185 ATTTCTGTGGGAATCACACTCTCTGGCTCATATGACAGAGCGTGTGGACCGAAGAGT 244  
Db |||||  
QY 493 TCTTCTGTGGGAACCACTTCTAAAGCCTTTTATGCTCAGCATTCAGAGAGAAT 552  
QY 245 CTCATGACACTTGTGATGGTCCATCAGGAACAT---TTAATGCTCTTCACT 301  
Db |||||  
QY 553 CGACCTGACCTGCCATCCACAGATATCATGGACGACTGGTGGCTTCACT 612  
QY 302 GTGGTCCAGACTGCTGGAAACTTTCTCAGTACCCCTGCTCCAGGTGTACGTTAACTGA 361  
Db |||||  
QY 613 GTGGTGTGCACTGCCAGGTGAGGGAGTACCCGTGCTTCAGTGTTTGTGAACCTCA 672  
QY 362 CTTCTTCGGGGAAGCTCTCTCTACACAGAGAGACAAATAAAATCAATCAGA 421  
Db |||||  
QY 673 GGCATCCAGGTGAGAAAGCTCTCTACATTAATGAAGAGGCTGTCCAGATAAATCCA 732  
QY 422 AGTGCTCTATATACCTAAATGTGGAAAAATTTTGAAGATCCATGTCCTGGTGAATG 481  
Db |||||  
QY 733 AGTGCTTTTACACCTTAAGTGGCCACCAAGATAGATTTGCTCAACAGTGTCTGG 792  
QY 482 TTGTCATGGAACCTT-----CAGGAAGTATCAACACTTCTCTGCTATTCTGACCCAG 535  
Db |||||  
QY 793 ACATAAAAGAAATCTTCGATCACAATAATGGAACCCCTTTTCATGCTTCTACAGTCCAG 852  
QY 536 AAGGAACACAGAGAGTGTATCTTAACAACTCTACAGTCCAACTGCTGTTCATT 595  
Db |||||  
QY 853 CCAGCAATCTGAAGATGTCTTTATAAAAGATGACCAATGGCTATCTTCCACT 912  
QY 596 CACTCTTCTGGCCAACTGTATGATGGCTGGGGGTGGCAATTTGGCCATGTGTGAAC 655  
Db |||||  
QY 913 GTTTATTTTGGCCTTCACTGACTCTGCTAGTGGTGGCTGCTGATTTGGCATGTGAGAT 972  
QY 656 TTACACAGTACTCTCCCTACTATGTGAGA 685  
Db |||||  
QY 973 TAACACACACTGCTCTTACTGTGTGAAA 1002

## RESULT 14

AAK53112

ID AAK53112 standard, cDNA, 1251 BP.

AC AAK53112;

DT 06-NOV-2001 (first entry)

DE Human polynucleotide SEQ ID NO 2641.

KW Human; cytokine; cell proliferation; cell differentiation; gene therapy;

KW vaccine; peptide therapy; stem cell growth factor; haematopoiesis;

KW tissue growth factor; immunomodulatory; cancer; leukaemia;

KW nervous system disorder; arthritis; inflammation; ss.

OS Homo sapiens.

PN W0200157190-A2.

PD 09-AUG-2001.

PF 05-FEB-2001; 2001WO-US004098.

PR 03-FEB-2000; 2000US-00496914.

PR 27-APR-2000; 2000US-00560875.

PR 20-JUN-2000; 2000US-00598075.

PR 19-JUL-2000; 2000US-00620325.

PR 01-SEP-2000; 2000US-00654936.

PR 15-SEP-2000; 2000US-00663561.

PR 20-OCT-2000; 2000US-00693325.

PR 30-NOV-2000; 2000US-00728422.

XX (HYSE-) HYSEQ INC.

XX Tang YT, Liu C, Drmanac RT, Asundi V, Zhou P, Xu C, Cao Y;

XX Ma Y, Zhao QA, Wang D, Wang J, Zhang J, Ren F, Chen R, Wang ZW;

XX Xue AJ, Yang Y, Wejhrman T, Goodrich R;

XX WPI; 2001-476283/51.

XX P-PSDE; AAM79979.

XX Nucleic acids encoding polypeptides with cytokine-like activities, useful

XX in diagnosis and gene therapy.

XX Claim 1; Page 4899-4900; 6221pp; English.

XX The invention relates to polynucleotides (AAK51456-AAK53435) and the

XX encoded polypeptides (AAM78323-AAM80302) that exhibit activity elating to

XX cytokine, cell proliferation or cell differentiation or which may induce

XX production of other cytokines in other cell populations. The

XX polynucleotides and polypeptides are useful in gene therapy, vaccines or

XX peptide therapy. The polypeptides have various cytokine-like activities,

XX e.g. stem cell growth factor activity, haematopoiesis regulating

XX activity, tissue growth factor activity, immunomodulatory activity and

XX activin/inhibin activity and may be useful in the diagnosis and/or

XX treatment of cancer, leukaemia, nervous system disorders, arthritis and

XX inflammation. Note: Records for SEQ ID NO 2110 (AAK52581), 2111

XX (AAK52582) and 3656 (AAM80020) are omitted as the relevant pages from the

XX sequence listing were missing at the time of publication

XX SQ Sequence 1251 BP; 331 A; 304 C; 310 G; 306 T; 0 U; 0 Other;

XX Query Match 19.0%; Score 134.4; DB 4; Length 1251;

XX Best Local Similarity 54.6%; Pred. No. 3.7e-31;

XX Matches 311; Conservative 2; Mismatches 248; Indels 9; Gaps 2;

QY 125 CAGGAGGACGAGCTATTCTCTGGAGCTGGCTATGATGGTGGCTCCATCATGATGT 184

Db |||||

QY 433 CTGAGAGGACGAGCGGTGATGCTGGGTTGGCCATGATGGCTTCTCAGTCCCTAATGT 492

Db |||||

QY 185 ATTTCTGTGGGAATCACACTCTCTGGCTCATATGACAGAGCGTGTGGACCGAAGAGT 244

Db |||||

QY 493 TCTTCTGTGGGAACCACTTCTAAAGCCTTTTATGCTCAGCATTCAGAGAGAAT 552

QY 245 CTCATGACACTTGTGATGGTCCATCAGGAACAT---TTAATGCTCTTCACT 301

Db |||||

QY 553 CGACCTGCACTGCCATCCACAGATATCATGGACGACTGGCTGGCTTCACT 612

Db |||||

QY 302 GTGGTCCAGACTGCTGGAAACTTTCTCAGTACCCCTGCTCCAGGTGTACCTGA 361

Db |||||

QY 613 GTGGTGTGCACTGCCAGGTGAGGGAGTACCCGTGCTTCCAGTGTGTGGAACCTCA 672

QY 362 CTTCTTCGGGGAAGCTCTCTTACACAGAGAGACAAATAAAATCAATCAGA 421

Db |||||

QY 673 GGCATCCAGGTGAGAAAGCTCTCTACATTAATGAAGAGGCTGTCCAGATAAATCCA 732

QY 422 AGTGCTCTATATACCTAAATGTGGAAAAATTTTGAAGATCCATGTCCTGGTGAATG 481

Db |||||

QY 733 AGTGCTTTTACACCTTAAGTGGCCACCAAGATAGATTTGCTCAACAGTGTCTGG 792

QY 482 TTGTCATGGAACCTT-----CAGGAAGTATCAACACTTCTCTGCTATTCTGACCCAG 535

Db |||||

QY 793 ACATAAAAGAAATCTTCGATCACAATAATGGAACCCCTTTTTCATGCTTCTACAGTCCAG 852

QY 536 AAGGAACACAGAGAGTGTATGATGGCTGGGGGTGGCAATTTGGCCATGTGTGAAC 595

Db |||||

QY 853 CCAGCAATCTGAAGATGTCTTTATAAAAGATGATGACCAAAATGGCTATCTTCCACT 912

QY 596 CACTCTTCTGGCCAACTGTATGATGGCTGGGGGTGGCAATTTGGCCATGTGTGAAC 655

Db |||||

QY 913 GTTTATTTTGGCCTTCACTGACTCTGCTAGTGGTGGCTGCTGATTTGGCATGTGAGAT 972

QY 656 TTACACAGTACTCTCCCTACTATGTGAGA 685

QY |||||

Db 973 TAACACAACACCTGCTCTTACTGTGTGAAA 1002

RESULT 15

AAAF27995  
ID AAF27995 standard; DNA; 1296 BP.

XX AC AAF27995;

XX XX 08-MAY-2001 (first entry)

XX DE Human calcium sensitive potassium channel beta3d subunit coding sequence.

XX KW Human; calcium sensitive potassium channel; beta2 subunit; asthma;

XX KW beta3a subunit; beta3b subunit; beta3c subunit; beta3d subunit; diabetes;

XX KW chromosome 3q23-ter; inhibitor; activator; glaucoma; migraine; angina;

XX KW irritable bowel syndrome; Alzheimer's disease; db.

XX OS Homo sapiens.

XX XX W0200105828-A1.

XX XX 25-JAN-2001.

XX XX 18-JUL-2000; 2000WO-US019585.

XX XX 20-JUL-1999; 99US-0144764P.

XX XX (MERI ) MERCK & CO INC.

XX XX Uebele V, Swanson R, Liu Y, Lagrutta A;

XX XX WPI; 2001-159514/16.

XX XX P-PSDB; AAB35305.

XX PT Novel human calcium sensitive potassium channel subunits for identifying

XX PT inhibitors and agonists of the potassium channel for use in treating

XX PT conditions such as asthma, hypertension, memory disorders, depression.

XX PS Claim 3; Fig 5A; 89pp; English.

XX CC The present invention provides the protein and coding sequences of the

XX CC human calcium sensitive potassium channel beta2, beta3a, beta3b, beta3c

XX CC and beta3d subunits. These can be used to identify inhibitors and

XX CC activators of the channels, which can be used in the treatment of

XX CC conditions including asthma, diabetes, glaucoma, cerebral ischaemia,

XX CC Alzheimer's disease, excessive smooth muscle tone, angina, hypertension,

XX CC incontinence, migraine and irritable bowel syndrome. The coding sequences

XX CC are found at human chromosome 3q23-ter. The present sequence is the

XX CC beta3d subunit coding sequence

XX SQ Sequence 1296 BP; 386 A; 274 C; 294 G; 342 T; 0 U; 0 Other;

Query Match 19.0%; Score 134.4; DB 4; Length 1296;

Best Local Similarity 54.6%; Pred. No. 3.7e-31;

Matches 311; Conservative 2; Mismatches 248; Indels 9; Gaps 2;

Qy 125 CAGAGAGAGCCGAGCTATTCCTCGGACCTGGCTATGCTGGTGTGCTCCATCATGATGT 184

Db 614 CTGGAGAGGACCGAGCCGCTGATGCTGGGTTTGGCATGATGGGCTTCTCAGTCTTAATGT 673

Qy 185 ATTTTCTGCTGGGATCACACTCTCGCTCATACATGAGCGTGTGGACCGAGAGT 244

Db 674 TCCTTCTGCTCGGAACCAACCTTTAAAGCGTTTATGCTCAGCATTCAGAGAGAGAT 733

Qy 245 CTCATGACACCTTGCTGAATGCGTCCATCAGGAAACAT---TTAAATGCTCTTCAGCT 301

Db 734 CGACCTGACCTGCCATCCACACAGATATCATGGACGACTGGCTGGACTGTGCCCTCACCT 793

Qy 302 GTGCTCAGAGCTGTGAAACCTTCTCAGTACCCCTGCCCTCCAGGTGTAGCTTAACCTGA 361

Db 794 GTGGTGTGCACTGCCACCGGTGAGGGAGTACCCGTGTCTTCAGGTGTTTGTGAACCTCA 853

Qy 362 CTTCTTCGGGGAAAGCTCCTCTACACACAGAGACAAATAAAATCAATCAGA 421  
Db 854 GCCATCCAGGTCAGAAAGCTCTCTTACATTATATGAAGGCTGTCCAGATAATCCCA 913  
Qy 422 AGTGCTCCTATATACCTAAATGTGAAAAAATTTTGAAGAATCCATGTCCTGGTGAATG 481  
Db 914 AGTGCTTTTACACACCTTAAGTCCACCAAGATAGAAATGATTGTCTCAACAGTGTCTGG 973  
Qy 482 TTGTCATGAAAACTT-----CAGGAGTATCAACACTTCTCCTGCTATTCTGACCCAG 535  
Db 974 ACATAAAAAATTTCTTCGATCACAAAAATGGAACCCCTTTTTCATGCTTCTACAGTCCAG 1033  
Qy 536 AAGGAAACACAGAAGAGTGTATTCTTAACMAAACTCTACAGTCCAACTGCTGTTCATT 595  
Db 1034 CCAGCCAACTCTGAAGATGCTCAITCTTATAAAAAAGTATGACCAAAATGGCTATCTTCCACT 1093  
Qy 596 CACTCTTCTGGCCAACTGTATGATGGCTGGGGTGTGGCAATTGTTCCCATGCTGAAC 655  
Db 1094 GTTTATTTGGCCTTCACTGACTCTGTAGTGGTGGCCCTGATTGTTGGCAATGGTGAAT 1153  
Qy 656 TTACACAGTACCTCTCCCTACTATGTGAGA 685  
Db 1154 TAACACAACACCTGCTCTTACTGTGAAA 1183

Search completed: November 6, 2004, 23:41:06  
Job time : 431 secs

**This Page Blank (uspto)**

GenCore version 5.1.6  
Copyright (c) 1993 - 2004 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: November 6, 2004, 23:32:22 ; Search time 2961 Seconds  
(without alignments)  
8700.740 Million cell updates/sec

Title: US-09-914-053A-6

Perfect score: 707  
Sequence: 1 atctcgatagggaccagtgtg.....atccacggatcaatagataa 707

Scoring table: IDENTITY NUC  
Gapop 10.0 , Gapext 1.0

Searched: 32822875 seqs, 18219865908 residues

Total number of hits satisfying chosen parameters: 65645750

Minimum DB seq length: 0  
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 45 summaries

Database : EST.\*

- 1: gb\_est1.\*
- 2: gb\_est2.\*
- 3: gb\_hic.\*
- 4: gb\_est3.\*
- 5: gb\_est4.\*
- 6: gb\_est5.\*
- 7: gb\_est6.\*
- 8: gb\_est7.\*
- 9: gb\_est8.\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	692	97.9	801	4	BG188850 RST7884 A
2	649.6	91.9	803	4	BG198614 RST17879
3	642.4	90.9	816	4	BG195580 RST14773
4	626.6	88.6	795	4	BG218411 RST38279
5	604.2	85.5	817	4	BG214809 RST34463
6	584.8	82.7	694	4	BG194548 4069809 B
7	567.2	80.2	2356	3	AK012400 Mus muscu
8	563	79.6	949	5	BG942589 AGENCOURT
9	556.8	78.8	1597	3	AK014106 Mus muscu
10	427.4	60.5	855	5	BG216989 603107309
c 11	382	54.0	598	4	BG903430 1e57a02.x
c 12	362.8	51.3	622	5	BG950136 1e77a08.x
13	349.4	49.4	778	4	BG502844 60250401
14	343.2	48.5	939	5	BG222329 603105389
15	338.6	47.9	562	2	BG433029 7a23h12.x
c 16	327.2	46.3	709	7	BG476300 AGENCOURT
17	311.4	44.0	852	5	BG723097 BX729097
18	305.4	43.2	870	4	BG701449 602682671
19	300.4	42.5	598	6	BG297668 12B22017
20	298.8	42.3	835	7	BG601161 AGENCOURT
21	296.8	41.9	567	2	BG446488 7g99h03.x
22	291.6	41.2	756	5	BG179892 UI-M-PMO-
23	281	39.7	558	1	AA904191 0e72h09.8
24	280	39.6	769	7	CN064012 Ag2_p46_A

ALIGNMENTS

RESULT 1  
BG188850  
LOCUS BG188850 801 bp mRNA linear EST 21-APR-2001  
DEFINITION RST7884 Athersys RAGE Library Homo sapiens cDNA, mRNA sequence.  
ACCESSION BG188850  
VERSION BG188850.1 GI:13710537  
KEYWORDS EST.  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
REFERENCE 1 (bases 1 to 801)  
AUTHORS Harrington,J.O., Sharf,B., Rundlett,S., Jackson,P.D., Perry,R., Call,S., Leventhal,C., Thornton,M., Ramachandran,R., Whittington,J., Lerner,L., Costanzo,D., McElligott,K., Booser,S., Mays,R., Smith,E., Veloso,N., Klika,A., Hess,J., Cothren,K., Lo,K., Offenbacher,J., Danzig,J. and Ducar,M.  
TITLE Creation of genome-wide protein expression libraries using random activation of gene expression  
JOURNAL Nat. Biotechnol. 19 (5), 440-445 (2001)  
MEDLINE 21227151  
PubMed 11329013  
COMMENT Contact: Scott J. Cain  
Athersys, Inc.  
3201 Carnegie Ave, Cleveland, OH 44115, USA  
Tel: 216 431 9900  
Fax: 216 361 9596  
Email: scain@atersys.com  
High quality sequence stop: 554.  
Location/Qualifiers  
FEATURES  
source  
1..801  
/organism="Homo sapiens"  
/mol\_type="mRNA"  
/db\_xref="taxon:9606"  
/cell\_line="Htt1080"  
/clone\_lib="Athersys RAGE Library"  
/note="Gee 'Creation of Genome-wide Protein Expression Libraries using Random Activation of Gene Expression', Nature Biotechnology, in press. Note that even though the cell type indicated is Htt1080, since a random activation method was used, these sequence tags are not necessarily expressed in Htt1080 under normal circumstances."

ORIGIN

Query Match 97.9%; Score 692; DB 4; Length 801;  
Best Local Similarity 99.3%; Pred. No. 1e-192;  
Matches 703; Conservative 2; Mismatches 2; Indels 1; Gaps 1;

Athersys, Inc.  
3201 Carnegie Ave., Cleveland, OH 44115, USA  
Tel: 216 431 9900  
Fax: 216 361 9596  
Email: [scain@athersys.com](mailto:scain@athersys.com)

## FEATURES

Source

## ORIGIN

Query Match 91.9%; Score 649.6; DB 4; Length 803;  
Best Local Similarity 96.6%; Pred. No. 3.3e-180;  
Matches 672; Conservative 2; Mismatches 21; Indels 1

Qy	1	ATGTCGATATGGACCAAGTGGCGGACCTCTTTCATCTTATAGACATCATGAAAAAGAAAT	60
Db	73	ATGTTTATATGGACCAAGTGGCGGACCTTTCATCTTATAGACATCATGAAAAAGAAAT	132
Qy	61	ATTTACCAGAAAAATCAGGGACCATGACCTCTCGACAAAAGGAAAAACAGTCACGACCTG	120
Db	133	ATTTACCAGAAAAATCAGGGACCATGACCTCTCGACAAAAGGAAAAACAGTCACGACCTG	192
Qy	121	AAGGAGGAGAGGACCGAGCTATTCTCTGGGACTGGCTATGATGGTGTGCTCCATCATG	180
Db	193	AAGGAGGAGAGGAAACGAGCTATTCTCTGGGACTGGCTATGATGGTGTGCTCCATCATG	252
Qy	181	ATGTATTTTCTGCTGGGAATCACACTCTCTGGCTCATACATGCAGAGCGTGTGGACCGAA	240
Db	253	ATGTATTTTCTGCTGGGAATCACACTCTCTGGCTCATACATGCAGAGCGTGTGGACCGAA	312
Qy	241	GAGTCTCAATGCACCTTGCTGAATGGTCCATCACGGAAACATTTAAATGCTCCTTCAGC	300
Db	313	GAGTCTCAATGCACCTTGCTGAATGGTCCATCACGGAAACATCTAAATGCTCCTTCAGC	372
Qy	301	TGTGTCTCAGACTGCTGGAACTTTCTCAGTACCCCTGCTCCAGGTGTACGTTAACTCTG	360
Db	373	TGTGTCTCAGACTGCTGGAACTTTCTCAGTACCCCTGCTCCAGGTGTACGTTAACTCTG	432
Qy	361	ACTTCTTCCGGGGAAAAAGCTCCTCTACACACAGAAAGAGACAATAAAAAATCAATCAG	420
Db	433	ACTTCTTCCGGGGAAAAAGCTCCTCTACACACAGAAAGAGACAATAAAAAATCAATCAG	492
Qy	421	AAGTCTCTATATACCTTAATGTGGAAAAAATTTTGAAGATCCATGTCCTGTGTGAAT	480
Db	493	AAGTCTCTCTATATACCTTAATGTGGAAAAAATTTTGAAGATCCATGTCCTGTGTGAAT	552
Qy	481	GTTGTGTCAGTAAACTTCAGGAAGTATCAACACTTCTCCTGTATTCTGACCCAGAAAGGA	540
Db	553	GTTGTGTCAGTAAACTTCAGGAAGCATCAACACTTCTCCTGTATTCTGACCCAGAAAGGA	612
Qy	541	AACACAGAGAGTGTATTCCTTAAWAAACTCTACAGTTCNAACGTGCTGTTCATTTCACCT	600
Db	613	AACACAGAGAGTGTATTCCTTAAWAAACTCTACAGTTCNAACGTGCTGTTCATTTCACCT	672
Qy	601	TTCTGGCCAAACCTGTATGATGGCTGGGGGTGGCAATTTGTCCTATGTT-GAAAACTTAC	659
Db	673	TTCTGGCCAAACCTGTATGATGGCTGGGGGTGGGGAAATTTGTTGCATGCTGGGAACTTCA	732
Qy	660	ACAGTACCTCTCCCTACTATGTATGAGAGGATCCACGG	695
Db	733	CCAGTCTCTTTTCCCTACTATGTATGAGAGGATCCACCG	768

QY	1	ATGTGCGATATGGACGAGTGGCGGACCTCTTCATCTTTATATAGACATGATGAAAAAGAAAT	60
Db	72	ATGTTTATATGGACGAGTGGCGGACCTCTTCATCTTTATAGACATGATGAAAAAGAAAT	131
QY	61	ATTTTACCAGAAATCAGGAGACCATGACCTCTGGACAAAAGGAAAAACAGTCACGACACTG	120
Db	132	ATTTTACCAGAAATCAGGAGACCATGACCTCTGGACAAAAGGAAAAACAGTCACGACACTG	191
QY	121	AAGCGAGGAGGACCGAGCTATTCTCTCTGGGACTGGCTATGATGTTGCTCCATCATG	180
Db	192	AAGCGAGGAGGACCGAGCTATTCTCTCTGGGACTGGCTATGATGTTGCTCCATCATG	251
QY	181	ATGTATTTTCTCTGGGAATCACACTCTCTGGCTCATACATGACGAGCGTTGGACCGAA	240
Db	252	ATGTATTTTCTCTGGGAATCACACTCTCTGGCTCATACATGACGAGCGTTGGACCGAA	311
QY	241	GAGTCTCAATGCACCTTCTGTAATGCGTCCATCACGGAACATTTAAATGCTCTTTCAGC	300
Db	312	GAGTCTCAATGCACCTTCTGTAATGCGTCCATCACGGAACATTTAAATGCTCTTTCAGC	371
QY	301	TGTGTTCCAGACTGCTGGAATTTCTCAGTACCCTGCTCCAGGTGTACGTTAACCTG	360
Db	372	TGTGTTCCAGACTGCTGGAATTTCTCAGTACCCTGCTCCAGGTGTACGTTAACCTG	431
QY	361	ACTTCTTTCGGGGAAAAAGCTCCTCCTTACCACACAGAAGAGACAATAAAAAATCAATCAG	420
Db	432	ACTTCTTTCGGGGAAAAAGCTCCTCCTTACCACACAGAAGAGACAATAAAAAATCAATCAG	491
QY	421	AAGTGCCTCTATATACCTAAATGTGGAAAAAATTTTGAAGATCCATGCTCCGTGTGAAT	480
Db	492	AAGTGCCTCTATATACCTAAATGTGGAAAAAATTTTGAAGATCCATGCTCCGTGTGAAT	551
QY	481	GTTGTATCTGGAAAACTTCAGAAAGTATCAACACTTCTCCTGCTATTCTGACCCAGAGA	540
Db	552	GTTGTATCTGGAAAACTTCAGAAAGTATCAACACTTCTCCTGCTATTCTGACCCAGAGA	611
QY	541	AACCGAAGAGGTATTCTTAACMAAACTCTACAGTTTCCAACTGCTGTTCATTCACCTC	600
Db	612	AACCGAAGAGGTATTCTTAACMAAACTCTACAGTTTCCAACTGCTGTTCATTCACCTC	671
QY	601	TTCTGGCCAACTGTATGATGAGTGGGGGTGGCAATGTTGCCATGTTGGAACCTTACA	660
Db	672	TTCTGGCCAACTGTATGATGAGTGGGGGTGGCAATGTTGCCATGTTGGAACCTTACA	731
QY	661	CAGTACCTCTCCCTACTATGTGAGAGGATCC-ACGGATCAATAGATAA	707
Db	732	CAGTACCTCTCCCTACTATGTGAGAGGATCAACGGATCAATAGATAA	79

RESULT 2	803 bp	linear	EST 21-APR-2001
BG198614			
LOCUS			
DEFINITION	RS17879 Athersys RAGE Library Homo sapiens CDNA, mRNA sequence.		
ACCESSION	BG198614		
VERSION	BG198614.1 GI:13720301		
KEYWORDS	EST.		
SOURCE	Homo sapiens (human)		
ORGANISM	Homo sapiens		
	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;		
	Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.		
REFERENCE	1 (bases 1 to 803)		
AUTHORS	Harrington,J.J., Sherf,B., Rundlett,S., Jackson,P.D., Perry,R., Cain,S., Leventhal,C., Thornton,M., Ramachandran,R., Whittington,J., Lerner,L., Costanzo,D., McElligott,K., Booser,S., Mays,R., Smith,E., Veloso,N., Kika,A., Hess,J., Cothren,K., Lo,K., Offenbacher,J., Danzig,J. and Ducar,M.		
TITLE	Creation of genome-wide protein expression libraries using random activation of gene expression		
JOURNAL	Nat. Biotechnol. 19 (5), 440-445 (2001)		
MEDLINE	21227151		
PMEDID	11329013		
COMMENT	Contact: Scott J. Cain		



Qy	361	ACTCTTCGCGGAAGAAGTCCCTCCTACCAACACAGAGAGACAATAAAATCAATCAG	420
Dd	432	ACTCTTCGCGGAAGAAGTCCCTCCTACCAACACAGAGAGACAATAAAATCAATCAG	491
Qy	421	AAGTGCTCCCTATATACCTAAATGTGGAAAAAATTTTGAGAAATCCATGTCCTGGTGAAT	480
Dd	492	AAGTGCTCCCTATATACCTAAATGTGGAAAAAATTTTGAGAAATCCATGTCCTGGTGAAT	551
Qy	481	GTTGTCATGGAAAACCTCAGGAAGTATCAACACTTCTCCTGCTATTCTGACCAGGAGGA	540
Dd	552	GTTGTCATGGAAAACCTCAGGAAGTATCAACACTTCTCCTGCTATTCTGACCAGGAGGA	611
Qy	541	AACACAGAAGAGTGTATTCTTAACAACTCTACAGTTCCAA--CGTGTGTGTTCCATTCACT	599
Dd	612	AACACAGAAGAGTGTATTCTTAACAACTCTACAGTTCCAA--CGTGTGTGTTCCATTCACT	671
Qy	600	CTTCTGGCCAACCTGTATGAT--CGCTGGGGGTGTGCATTTGTCATGTTGAAACTTA	658
Dd	672	CTTCTGGCCAACCTGTATGATGGGCTGGGGGCGTGCAAAATGTTGGCATGGTGAACCTTA	731
Qy	659	CACAGTACCTCTCCCTACTACTGTGAGAGGATCCA	692
Dd	732	CACAGGACCTCTNCTACTATGGAGAGGATCCA	765

RESULT 4  
 LOCUS EG218411  
 DEFINITION RST38279 Athersys RAGE Library Homo sapiens cDNA, mRNA sequence.  
 ACCESSION EG218411  
 VERSION EG218411.1 GI:13744560  
 KEYWORDS Est.  
 SOURCE Homo sapiens (human)  
 ORGANISM Homo sapiens

REFERENCE  
 AUTHORS Harrington,J.J., Sherf,B., Rundlett,S., Jackson,P.D., Perry,R., Cain,S., Leventhal,C., Thornton,M., Ramachandran,R., Whittington,J., Lerner,L., Cosanzo,D., McElligott,K., Boozer,S., Mays,R., Smith,E., Veloso,N., Klika,A., Hess,J., Cothren,K., Lo,K., Offenbacher,J., Danzig,J. and Ducar,M.  
 TITLE Creation of genome-wide protein expression libraries using random activation of gene expression  
 JOURNAL Nat. Biotechnol. 19 (5), 440-445 (2001)  
 MEDLINE 21227151  
 PUBMED 11329013  
 COMMENT Contact: Scott J. Cain  
           Athersys, Inc.  
           3201 Carnegie Ave, Cleveland, OH 44115, USA  
           Tel: 216 431 9900  
           Fax: 216 361 9596  
           Email: scain@atersys.com  
           High quality sequence stop: 483.  
           Location/Qualifiers  
               1..795  
                 /organism="Homo sapiens"  
                 /mol type="mRNA"  
                 /db xref="taxon:9606"  
                 /cell\_line="HT1080"  
                 /cloned\_lib="Athersys RAGE Library"

FEATURES  
 source

ORIGIN

Query Match 88.6%; Score 626.6; DB 4; Length 795;  
 Best Local Similarity 96.8%; Pred.No. 2.1e-173;  
 Matches 669; Conservative 2; Mismatches 16; Indels 4; Gaps 3;

QY 2 TGTGATATGACACAGTGGCGGACCTCTTCTATATGACATGATGAAAAAGAAATA 61  
Db 73 TGTATATGACACAGCGCGGACCTCTTCTATATGACATGATGAAAAAGAAATA 132  
QY 62 TTTACCAAAATCAGGACCATGACCTCTCTGGCAAAAGAAACAGTACAGCACTGA 121  
Db 133 TTTACCAAAATCAGGACCATGACCTCTCTGGCAAAAGAAACAGTACAGCACTGA 192  
QY 122 AGGAGGAGAGACCGACATATCTCTGGACCTGGCTATGATGGTGTCTCCATCATGA 181  
Db 193 AGGAGGAGAGACCGACATATCTCTGGACCTGGCTATGATGGTGTCTCCATCATGA 252  
QY 182 TGTATTTCTGCTGGAAATCACACTCTCTGGCTCATATACATGACAGCGGTGGACCGAAG 241  
Db 253 TGTATTTCTGCTGGAAAT--TCITCTCTGGCTCATATGACAGCGGTGGACCGAAG 310  
QY 242 AGTCTCAATGACACCTGCTGAATGGCTCCATCAGGAAACATTTAAATGCTCTCTCACT 301  
Db 311 AGTCTCAATGACACCTGCTGAATGGCTCCATCAGGAAACATTTAAATGCTCTCTCACT 370  
QY 302 GTGGTCCAGACTGCTGGAAATTTCTCAGTACCCCTGCTCCAGGTGACGTTAACTCTGA 361  
Db 371 GTGGTCCAGACTGCTGGAAATTTCTCAGTACCCCTGCTCCAGGTGACGTTAACTCTGA 430  
QY 362 CTTCTTCGGGGAAGAGTCTCTCTTACCAACAGAGACAAATAAAATCAATCAGA 421  
Db 431 CTTCTTCGGGGAAGAGTCTCTCTTACCAACAGAGACAAATAAAATCAATCAGA 489  
QY 422 AGTCTCTATATACCTAAATGCTGGAAATTTTGAAGATCCATGTCCTGTGTGAATG 481  
Db 490 AGTCTCTATATACCTAAATGCTGGAAATTTTGAAGATCCATGTCCTGTGTGAATG 549  
QY 482 TTGTCATGAAACATTCAGGAATGATCAACATCTCTCTGCTATTTGACCCAGAGGAA 541  
Db 550 TTGTCATGAAACATTCAGGAATGATCAACATCTCTCTGCTATTTGACCCAGAGGAA 609  
QY 542 ACCAGAGAGTGTATCTTAACMAACTCTACAGTTCACAGTCTGTCTCACTCTCT 601  
Db 610 ACCAGAGAGTGTATCTTAACMAACTCTACAGTTCACAGTCTGTCTCACTCTCT 669  
QY 602 TCTGCCAACCTGTATGATGGCTGGGGGTGGCAATTTGTCATGATGAAATTTACAC 661  
Db 670 TCTGCCAACCTGTATGATGGCTGGGGGTGGCAATTTGTCATGATGAAATTTACAC 728  
QY 662 AGTACCTCTCCTACTATGTGAGAGATCCA 692  
Db 729 AGTACCTTTCCCTACTATGTGAGAGATCCA 759

RESULT 5  
LOCUS BG214809 817 bp mRNA linear EST 21-APR-2001  
DEFINITION RST34463 Athersys RAGE Library Homo sapiens cDNA, mRNA sequence.  
ACCESSION BG214809  
VERSION BG214809.1 GI:13740830  
KEYWORDS EST.  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
REFERENCE 1 (bases 1 to 817)  
AUTHORS Harrington, J.J., Sharf, B., Rundlett, S., Jackson, P.D., Perry, R.,  
Cain, S., Leventhal, C., Thornton, M., Ramachandran, R.,  
Whittington, J., Lermer, L., Costanzo, D., McElligott, K., Booser, S.,  
Mays, R., Smith, E., Veloso, N., Klika, A., Hess, J., Cothren, K., Lo, K.,  
Offenbacher, J., Danzig, J., and Ducar, M.  
TITLE Creation of genome-wide protein expression libraries using random  
activation of gene expression  
JOURNAL Nat. Biotechnol. 19 (5), 440-445 (2001)  
MEDLINE 2127151  
PUBMED 11329013  
COMMENT Contact: Scott J. Cain  
Athersys, Inc.

3201 Carnegie Ave, Cleveland, OH 44115, USA  
Tel: 216 431 9900  
Fax: 216 361 9596  
Email: scain@atersys.com  
High quality sequence stop: 364.  
Location/Qualifiers  
1. 817  
/organism="Homo sapiens"  
/mol\_type="mRNA"  
/db\_xref="taxon:9606"  
/cell\_line="HT1080"  
/clone\_lib="Athersys RAGE Library"  
[Note="See 'Creation of Genome-wide Protein Expression  
Libraries using Random Activation of Gene Expression',  
Nature Biotechnology, in press. Note that even though the  
cell type indicated is HT1080, since a random activation  
method was used, these sequence tags are not necessarily  
expressed in HT1080 under normal circumstances."]  
FEATURES  
source

## ORIGIN

Query Match 85.5%; Score 604.2; DB 4; Length 817;  
Best Local Similarity 95.6%; Pred. No. 8.5e-167;  
Matches 681; Conservative 2; Mismatches 23; Indels 6; Gaps 6;  
QY 1 ATGTGATATGACACAGTGGCGGACCTCTTCTATATGACATGATGAAAAAGAAAT 60  
Db 72 ATGTTTATATGACACAGTGGCGGACCTCTTCTATATGACATGATGAAAAAGAAAT 131  
QY 61 ATTACCAAAATCAGGACCATGACCTCTCTGGCAAAAGAAACAGTACAGCACTG 120  
Db 132 ATTACCAAAATCAGGACCATGACCTCTCTGGCAAAAGAAACAGTACAGCACTG 191  
QY 121 AAGCAGAGAGAGACCGAGCTATCTCTGGACCTGGCTATGATGGTGTCTCCATCATG 180  
Db 192 AAGCAGAGAGAGACCGAGCTATCTCTGGACCTGGCTATGATGGTGTCTCCATCATG 251  
QY 181 ATGTATTTCTCTGGAAATCACACTCTCTGCGCTCATATACATGACAGCGGTGGACCGAA 240  
Db 252 ATGTATTTCTCTGGAAATCACACTCTCTGCGCTCATATGACAGCGGTGGACCGAA 311  
QY 241 GAGTCTCAATGACACCTGTGTAATGGTCTCATCAGGAAACATTTAATGCTCTCTCAGC 300  
Db 312 GAGTCTCAATGACACCTGTGTAATGGTCTCATCAGGAAACATTTAATGCTCTCTCAGC 371  
QY 301 TGTGTCAGAGTGTGGAACTTTCTCAGTACCCCTGCTCCAGGTGTACGTTAACTG 360  
Db 372 TGTGTCAGAGTGTGGAACTTTCTCAGTACCCCTGCTCCAGGTGTACGTTAACTG 431  
QY 361 ACTTCTTCCGGGAAAGCTCTCTCTACCAACAGAGACAAATAAAATCAATCAG 420  
Db 432 ACTTCTTCCGGGAAAGCTCTCTCTACCAACAGAGACAAATAAAATCAATCAG 491  
QY 421 AAGTCTCTATATACCTAAATGTGGAAAAATTTTGAAGATCCATGT-CCCTGGTGA 479  
Db 492 AAGTCTCTATATACCTAAATGTGGAAAAATTTTGAAGATCCATGTCCCTGGTGA 551  
QY 480 TGTGTGCA-TGGAAAACTTCAGGAAGTATCAACAC-TTCTCTGCTATTTCTGACCCAGAA 537  
Db 552 TGTGTGCA-TGGAAAACTTCAGGAAGTATCAACAC-TTCTCTGCTATTTCTGACCCAGAA 611  
QY 538 GGAACACAGAGAGTGTATCTTAACMAACTCTACAGTTCACAGTCTGTGTCTTCA 597  
Db 612 GGAACACAGAGAGTGTATCTTAACMAACTCTACAGTTCACAGTCTGTGTCTTCA 670  
QY 598 CTCTCTGCGCAACCTGTATGATGGTGGGGGTGGCAATTTGTTCCCATGTTG-AAA 656  
Db 671 CTCTCTGCGCAACCTGTATGATGGTGGGGGTGGCAATTTGTTCCCATGTTG-AAA 730  
QY 657 TACACAGTACCTCTCTCTACTATGTGAGAGATCCA-CGGATCAATAGATAA 707  
Db 731 AACACAGTACCTCTCTCTACTATGTGAGAGATCCA-CGGATCAATAGATAA 782

```
RESULT 6
CK945448
LOCUS
DEFINITION
CK945448 694 bp mRNA linear EST 15-MAR-2004
4059809 BARC 10BOV Bos taurus cDNA clone 10BOV17_N10 5', mRNA
sequence.
ACCESSION
CK945448
VERSION
CK945448.1 GI:45459828
KEYWORDS
EST.
SOURCE
Bos taurus (cow)
ORGANISM
Bos taurus
REFERENCE
1 (bases 1 to 694)
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Cetartiodactyla; Ruminantia; Pecora; Bovidae;
Bovinae; Bos.
Sonstegard, T.S., Van Tassel, C.P., Matukumalli, L.K., Harhay,
G.P., Bosak, S., Rubenfield, M. and Gasbarre, L.C.
Production of EST from cDNA libraries derived from immunologically
activated bovine gut
Unpublished (2004)
Contact: Tad S. Sonstegard
Bovine Functional Genomics Laboratory
Animal and Natural Resources Institute
Bldg. 200 Rm2A BARC-East, Beltsville, MD 20705, USA
Tel: 3015048416
Fax: 3015048414
Email: tads@nri.barc.usda.gov
Single pass sequencing. Bases called and trimmed with phred
0.000925 using options -trim_alt "-trim_fasta. Vector identified
by cross_match using options -minmatch 12 -minscore 12
Plate: 17 row: N column: 10
Seq primer: CCCAGTCACGAGTGTGAAAACG
High quality sequence stop: 694.
FEATURES
Location/Qualifiers
1..694
/organism="Bos taurus"
/mol_type="mRNA"
/strain="Holstein"
/db_xref="taxon:9913"
/clone="10BOV17_N10"
/sex="Male"
/tissue_type="Pooled"
/lab_stage="Multiple"
/lab_host="DH10B T1 phage resistant"
/clone_lib="BARC 10BOV"
/note="Organ: Small Intestine; Vector: pagen-1; Site 1:
EcoRV; Site 2: NotI; Equimolar amounts of mRNA extracted
from proximal jejunums of 18 and 21 wk old steers, and
distal ileums of 14 day old calves. proximal jejunum
exposed to C. oncophora for 3 and 6 weeks, and distal
ileum exposed to C. parvum for 7 days"
ORIGIN
Query Match 82.7%; Score 584.8; DB 7; Length 694;
Best Local Similarity 93.6%; Pred. No. 4.3e-161;
Matches 629; Conservative 2; Mismatches 39; Indels 2; Gaps 2;
Qy 1 ATGTCGATATGACACAGTGGCGGACCTCTTCATCTTATAGACATGATGAAAAAGAAAT 60
Db 17 ATGTTTATATGACACAGTGGCGGACCTCTTCATCTTACAGACATGATGAAAAGAAAT 76
Qy 61 ATTTACAGAAATCAGGACCATGACCTCTGTGACAAAAAGGAAACAGTCACGACTG 120
Db 77 ATTTACAAAAAATCAGGACCATGACCTCTGTGACAAAAAGGAAACAGTCACGACTG 136
Qy 121 AAGCAGAGAGAGGACCGAGCTATTCCTCGGACTGGCTATGATGGTGTCTCCATCATG 180
Db 137 AAACAGAGAGAGACCGGACCTCTCTGGACTGGCCATGATGGTGTCTCCATCATG 196
Qy 181 ATGTAATTTCTGTGGGAATCACACTCTCGCTCATACATGACAGCGTGTGACCGAA 240
Db 197 ATGTAATTTCTGTGGGAATCACACTCTCGCTCATACATGACAGCGTGTGACCGAG 256
Qy 241 GAGTCTCAATGCACCTTGTGTAATGCGTCCATCAGGAAACATTTAAATGCTCTCTCAGC 300
```

```
Db 257 GAGGCTCAGTCACCTTGTCTGAATGCATCCATCACAGAAACATTTAACTGCTCTTCAGC 316
Qy 301 TGTGTCACAGACTGCTGGAACTTTCTCAGTACCCCTGCTCCAGGTGTACGTTCACCTG 360
Db 317 TGTGTCACAGACTGCTGGAACTTTCTCAGTACCCCTGCTCCAGGTGTACGTTCACCTG 376
Qy 361 ACTTCTTCGGGGGAAAGCTCCTCTTACACACAGAGAGACAAATAAATAATCAATCAG 420
Db 377 ACTTCTTCGGGTGAAAGCTCCTCTTACACACAGAGAGACAAATAAATAATCAATCAG 436
Qy 421 AGTGTCTCTATATACCTTAAATGTGGAAAAATTTTGAAGAATCCATGTCCTCGTGAAT 480
Db 437 AAGTGTCTCTATATACCTTAAATGTGGAAAAATTTTGAAGAATCCATGTCCTCGTGAAT 496
Qy 481 GTTGTCTATCGAAAACTTACAGGAAGTATCAACTTCTCTCTGCTATTTCTGACCCAGGAAG 540
Db 497 GTTGTCTATCGAAAACTTACAGGAAGTATCAACTTCTCTGCTATTTCTGACCCGGAAG 556
Qy 541 AACCAAGAGAGTGTATCTCTAAACAACTCTACAGTTCACAGTGTTCCTTCATTCATC 600
Db 557 AACCAAGAGAGTGTATCTCTAAACAACTCTACAGTTCACAGTGTTCCTTCATTCATC 616
Qy 601 TTCTGSCCAACCTGTATGATGCTGGGGGTGGCAATTTGTTGCCATGCTGAAACTTACA 660
Db 617 TTTTGGCCCAACATGCAATGATGGTGGGGCGTGGCAATTTGTTGCCATGCTG-AACTACA 674
Qy 661 CAGTACCTCTCC 672
Db 675 CAGTATCTTTCC 686
RESULT 7
AK012400
LOCUS
DEFINITION
AK012400 2356 bp mRNA linear HTC 03-APR-2004
Mus musculus 11 days embryo whole body cDNA, RIKEN full-length
cDNA library, clone:2700049B16 product:LARGE CONDUCTANCE
CALCIUM-ACTIVATED K CHANNEL BETA2 SUBUNIT, full insert sequence.
ACCESSION
AK012400
VERSION
AK012400.1 GI:12849119
KEYWORDS
HTC; CAP trapper.
SOURCE
Mus musculus (house mouse)
ORGANISM
Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
REFERENCE
1 Carninci, P. and Hayashizaki, Y.
High-efficiency full-length cDNA cloning
Meth. Enzymol. 303, 19-44 (1999)
99279253
PUBMED
10349636
2 Carninci, P., Shibata, Y., Hayatsu, N., Sugahara, Y., Shibata, K.,
Itoh, M., Konno, H., Okazaki, Y., Muramatsu, M. and Hayashizaki, Y.
Normalization and subtraction of cap-trapper-selected cDNAs to
prepare full-length cDNA libraries for rapid discovery of new genes
Genome Res. 10 (10), 1617-1630 (2000)
20499374
PUBMED
11042159
3 Shibata, K., Itoh, M., Aizawa, K., Nagaoka, S., Sasaki, N., Carninci, P.,
Konno, H., Akiyama, J., Nishi, K., Kitsuai, T., Tashiro, H., Itoh, M.,
Sumi, N., Ishii, Y., Nakamura, S., Hazama, M., Nishine, T., Harada, A.,
Yamamoto, R., Matsumoto, H., Sakaguchi, S., Ikegami, T., Kashiwagi, K.,
Fujiwara, S., Inoue, K., Togawa, Y., Izawa, M., Ohara, E., Wachihi, M.,
Yoneda, Y., Iehikawa, T., Ozawa, K., Tanaka, T., Matsura, S., Kawai, J.,
Okazaki, Y., Muramatsu, M., Inoue, Y., Kira, A. and Hayashizaki, Y.
RIKEN integrated sequence analysis (RISA) system--384-format
sequencing pipeline with 384 multicapillary sequencer
Genome Res. 10 (11), 1757-1771 (2000)
20530913
PUBMED
11076851
4
```



Tissue Procurement: Susan L. Sullivan, PhD.  
 cDNA Library Preparation: ResGen, Invitrogen Corp  
 cDNA Library Arrayed by: The I.M.A.G.E. Consortium (LLNL)  
 DNA Sequencing by: Agencourt Bioscience Corporation  
 Clone distribution: MGC clone distribution information can be  
 found through the I.M.A.G.E. Consortium/LLNL at:  
<http://image.llnl.gov>  
 Plate: L1AM13735 row: n column: 08  
 High quality sequence start: 36  
 High quality sequence stop: 564.

FEATURES  
 Location/Qualifiers  
 1..949  
 /organism="Mus musculus"  
 /mol\_type="mRNA"  
 /db\_xref="taxon:10090"  
 /clone="IMAGE:6311623"  
 /lab\_hosts="DH10B (phage-resistant)"  
 /clone\_lib="NIH\_MGC\_129"  
 /note="Organ: olfactory epithelium; Vector: pCMV-SPORT6.1;  
 Site 1: EcoRV; Site 2: NotI; Cloned unidirectionally.  
 Primer: Oligo dT. Average insert size 2.2 kb. Constructed  
 by ResGen, Invitrogen Corp. Note: this is a NIH\_MGC  
 Library."

ORIGIN  
 Query Match 79.6%; Score 563; DB 5; Length 949;  
 Best Local Similarity 87.3%; Pred. No. 1.3e-154;  
 Matches 614; Conservative 2; Mismatches 87; Indels 0; Gaps 0;

QY 5 CGATATGACACAGTGGCGGACCTTTCATCTTATAGACATGATGAAGAAAGAAATATTT 64  
 DB 13 CGGATGACACAGTGGCGGACCTTTCATCTTATAGACAGGACGAGAAAGAAATATCT 72

QY 65 ACCAGAAATACAGGACCATGACCTCTCTGGACAAAGAAACAGTCACGACCTGAAGG 124  
 DB 73 ACCAGAAATACAGGACCATGACCTCTCTGGACAAAGAAACAGTCACGACCTGAAGG 132

QY 125 CAGGAGGACCGAGCTATTTCTCTGGACGCTGCTATGATGCTGTCTCCATCATGATGT 184  
 DB 133 CTGGGAGGACCGGACCATCTCTCTGGCCCTGGCCATGATGCTGTCTCCATCATGATGT 192

QY 185 ATTTCTGCTGGGAATCACACTCTCTGGCTCATATGACGAGGCTGTGGACCGAAGAGT 244  
 DB 193 ACTTCTGCTGGGAATCACACTCTCTGGCTCATATGACGAGGCTGTGGACCGAAGAGT 252

QY 245 CTCATGACCTTCTGTAAGTCGTCATCAGGAAACATTTAATGCTCTTCCCTGAGCTGTG 304  
 DB 253 CCCAGTGTGCTCTGTAATGTCAATCAGAAACGTTTAACTGTTCTCTTCCCTGAGCTGTG 312

QY 305 GTCCAGACTGCTGGAACCTTCTCAGTACCCCTCCAGGTGTAGCTTAACTGACTT 364  
 DB 313 GGCCGACTGTGGAAGCTCTCTCAGTACCTTGCCTGAGGTGTAGTGAACCTGACAT 372

QY 365 CTTCCGGGAAAAGCTCTCTCTACACAGAGAGACAAATAAATCAATCAGAGT 424  
 DB 373 CTTCCGGGAGAGCTCTCTCTACACAGGAGAGACCATGAAGATCAATCAAAAGT 432

QY 425 GCTCCTATATACCTAAATGTGGAAAATTTTGAAGATCCATGCTCCCTGCTGAATCTTG 484  
 DB 433 GCTCCTATATTTCTTAAGTGTGAAAACAACTTTGAGGAGTCCATGCTCTCTGAGTGTG 492

QY 485 TCATGGAAAACCTTCAGGAAGTATCAACACTTCTCTCTCTCTTTCGATTCGACCCAGAGAAAC 544  
 DB 493 TCATGGAAAACCTTCAGGAGACACCAACTTCTCTCTCTCTCTTTCGACCCAGAGAAAC 552

QY 545 AGAAGAGTGTATCTTACMAAATCTTACAGTTTCCAGGCTGCTTTCATCTCACTCTCTCT 604  
 DB 553 AGAAGAGTGTATCTTACMAAATCTTACAGTTTCCAGGCTGCTTTCATCTCTCTCTCTCT 612

QY 605 GGCCAACTGTATGATGCTGGGGTGTGGCAATTTGTCATGCTGCTGCTGCTGCTGCTGCTGCT 664  
 DB 613 GGCCAACTGTATGATGCTGGGGTGTGGCAATTTGTCATGCTGCTGCTGCTGCTGCTGCTGCT 672

QY 665 ACCTCTCCCTACTATGTGAGAGATCCACGGATCAATAGATAA 707  
 DB 673 ACCTCTCCCTGCTTGTGAGATCCACGGATCAATAGATAA 715

RESULT 9  
 AK014106  
 LOCUS  
 DEFINITION  
 Mus musculus 13 days embryo head cDNA, RIKEN full-length enriched  
 library, clone:3110031N04 product: LARGE CONDUCTANCE  
 CALCIUM-ACTIVATED K CHANNEL BETA2 SUBUNIT, full insert sequence.

ACCESSION  
 VERSION  
 KEYWORDS  
 SOURCE  
 ORGANISM  
 Mus musculus  
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.

REFERENCE  
 1 Carrinci, P. and Hayashizaki, Y.  
 TITLE High-efficiency full-length cDNA cloning  
 JOURNAL Meth. Enzymol. 303, 19-44 (1999)  
 MEDLINE 99279253  
 PUBMED 10349636

REFERENCE  
 2 Carrinci, P., Shibata, Y., Hayatsu, N., Sugahara, Y., Shibata, K.,  
 Itoh, M., Konno, H., Okazaki, Y., Muramatsu, M. and Hayashizaki, Y.  
 TITLE Normalization and subtraction of cap-trapper-selected cDNAs to  
 prepare full-length cDNA libraries for rapid discovery of new genes  
 JOURNAL Genome Res. 10 (10), 1617-1630 (2000)  
 MEDLINE 20499374  
 PUBMED 11042159

REFERENCE  
 3 Shibata, K., Itoh, M., Aizawa, K., Nagaoka, S., Sasaki, N., Carninci, P.,  
 Konno, H., Akiyama, J., Nishi, K., Kitsuai, T., Tashiro, H., Itoh, M.,  
 Sumi, N., Ishii, Y., Nakamura, S., Hazama, M., Nishine, T., Harada, A.,  
 Yamamoto, R., Matsumoto, H., Sakaguchi, S., Ikegami, T., Kashiwagi, K.,  
 Fujiwara, S., Inoue, K., Togawa, Y., Izawa, M., Ohara, E., Watahiki, M.,  
 Yoneda, Y., Ishikawa, T., Ozawa, K., Tanaka, T., Matsuura, S., Kawai, J.,  
 Okazaki, Y., Muramatsu, M., Inoue, Y., Kira, A. and Hayashizaki, Y.  
 TITLE RIKEN integrated sequence analysis (RISA) system--384-format  
 sequencing pipeline with 384 multipipillary sequencer  
 JOURNAL Genome Res. 10 (11), 1757-1771 (2000)  
 MEDLINE 20530913  
 PUBMED 11076861

REFERENCE  
 4 The RIKEN Genome Exploration Research Group Phase II Team and the  
 FANTOM Consortium.  
 TITLE Functional annotation of a full-length mouse cDNA collection  
 JOURNAL Nature 409, 685-690 (2001)  
 REFERENCE

5 The FANTOM Consortium and the RIKEN Genome Exploration Research  
 Group Phase I & II Team.  
 TITLE Analysis of the mouse transcriptome based on functional annotation  
 of 60,770 full-length cDNAs  
 JOURNAL Nature 420, 563-573 (2002)  
 REFERENCE

6 (bases 1 to 1597)  
 Adachi, J., Aizawa, K., Akahira, S., Akimura, T., Arai, A., Aono, H.,  
 Arakawa, T., Bono, H., Carninci, P., Fukuda, S., Fukunishi, Y.,  
 Furuno, M., Hanagaki, T., Hara, A., Hayatsu, N., Hiramoto, K.,  
 Hirooka, T., Hori, F., Imotani, K., Ishii, Y., Itoh, M., Izawa, M.,  
 Kasukawa, T., Kato, H., Kawai, J., Kojima, Y., Konno, H., Kouda, M.,  
 Koya, S., Kurihara, C., Matsuyama, T., Miyazaki, A., Nishi, K.,  
 Nomura, K., Numazaki, R., Ohno, M., Okazaki, Y., Okido, T., Owa, C.,  
 Saito, H., Saigo, R., Sakai, C., Sakai, K., Sano, H., Sasaki, D.,  
 Shibata, K., Shibata, Y., Shinagawa, A., Shiraki, T., Sogabe, Y.,  
 Suzuki, H., Tagami, M., Tagawa, A., Takahashi, F., Tanaka, T.,  
 Tejima, Y., Toya, T., Yamamura, T., Yasunishi, A., Yoshida, K.,  
 Yoshino, M., Muramatsu, M. and Hayashizaki, Y.  
 TITLE Direct Submission  
 JOURNAL Submitted (10-JUL-2000) Yoshihide Hayashizaki, The Institute of  
 Physical and Chemical Research (RIKEN), Laboratory for Genome  
 Exploration Research Group, RIKEN Genomic Sciences Center (GSC),



```
Matches 556; Conservative 2; Mismatches 128; Indels 23; Gaps 3;
QY 1 ATGTCGATATGGACAGTGGCGGACCTCTTCATCTTTATAGACATGATGAAAAAGAAAT 60
Db 152 ATGTTTATTTGGACAGTGGCGGAGCTCTACATCTTTACAGACGATGAGAAA----- 205
QY 61 ATTTACAGAAAATCAGGACCATGACCTCTGACAAAAGAAAACAGTCACAGCACTG 120
Db 206 -----AGGATCAGCATCTACTGACAAAAGAAAACAGTCACAGCCCTA 250
QY 121 AAGCAGGAGAGGACCGAGCTATTCTCTGGGACTGGCTATGATGGTGTGCTCATCATG 180
Db 251 AAAGCTGAGAGACCGGCGCATACTCTCGGGCTGGCCATGATGGTGTGCTCATCATG 310
QY 181 ATGTATTTCTGTGGGAATCACACTCTCTGGGCTATACATGTCAGAGCGGTGTGACCGAA 240
Db 311 ATGTACTTTCTCTGGGAATCACCTCTCTGGGCTATACATGTCAGAGCGGTGTGACAGAA 370
QY 241 GAGTCTCAATGCACCTGCTGAATCGGTCCATCAGGAACAATTAATGCTCTCTCAGC 300
Db 371 GAGGCTAGTCTGCTCTCAAGCATCCATCAGGAACCTTCACTGCTGCTTTAGC 430
QY 301 TGTGTCAGACTCTCGAAATTTCTCAGTACCCCTGCTCCAGGTGTACGTTAACTG 360
Db 431 TCGGCGCCAGACTCTCGAAATCTCTCAGTACCCCTGCTCCAGGTGTACGTTAACTG 490
QY 361 ACTTCTTCGGGGAAGTCTCTCTTACACACAGAGAGACAATAAATCAATCAG 420
Db 491 ACTTCTTCGGGGAAGTCTCTTACACACAGAGAGACAATAAATCAATCAG 550
QY 421 AAGTGCTCTATATACCTAAATGTGAAAAAATTTGAAGAATCCATGCTCCCTGGTGAAT 480
Db 551 GAGTGTCTGATACATCCCAAGTGTGGAAGAATTTACGAGGAATCCATGTCATGTTGAAC 610
QY 481 GTTGTATGAAAACTTCAGGAATATCACACTTCTCTGCTATTTCTGACCCAGAGGA 540
Db 611 GTTGTATGAAAACTTCAGGAATATCACACTTCTCTGCTATTTCTGACCCAGAGGC 670
QY 541 AACAGAGAGTGTATCTCTAACMAAATCTCAGGTTCACAGTCCACAGTGTTCATTCAC 600
Db 671 ACTCAGAGAGCTGTATATGACCAACTGTACAGTCCACAGTGTTCATTCAC 730
QY 601 TTCTGGGCAACTGTATGATG- GTGGGGGTGGCAATTTGTCGCAATGTGAACTTAC 659
Db 731 TTCTGGGCAACTGTATGATGATGCGGGCGGTGGCAATTTGTCGCAATGTGAACTTAC 790
QY 660 ACAGTACTCTCTCTACTATGTGAGAGATCC-ACGGATCAATAGATAA 707
Db 791 TCAATACCTTTCTCTCTCTGGGAGAAATCCAAAGGATCAACAGATAA 839

RESULT 11
CK903430/c
LOCUS
DEFINITION ie37a02.x5 Melton Normalized Human Islet 4 N4-HIS 1 Homo sapiens
CDNA clone IMAGE:5670818 3' similar to TR:Q91691 Q91691 MAXIK
CHANNEL BETA 2 SUBUNIT. ; mRNA sequence.
CK903430
ACCESSION CK903430.1 GI:45364961
VERSION
KEYWORDS EST.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1 (bases 1 to 598)
REFERENCE
Wyllie, D., Meadows, A., Clifton, S., Hillier, L., Marra, M., Pape, D.,
Ritter, E., Runko, I., Bennett, J., Cardenas, M., Gibbons, M.,
McCann, R., Cole, R., Tsagaris, R., Williams, T., Jackson, Y. and
Bowers, Y.
WashU-Harvard Pancreas EST Project
JOURNAL Unpublished (2000)
COMMENT Other_ESTs: ie57a02.y1
```

Contact: Douglas Melton, Klaus H. Kaestner, & Hiroshi Inoue  
Endocrine Pancreas Consortium  
Harvard University, Howard Hughes Medical Institute  
Dept of Molecular and Cellular Biology, 7 Divinity Ave, Cambridge,  
MA 02138  
Tel: 617-495-1812  
Fax: 617-495-8557  
Email: dmelton@biohp.harvard.edu  
This read is a 3' RESEQUENCE of a previously sequenced pancreas  
clone  
This resequenced clone has not previously been sequenced on this  
end, resequencing from this end represents new data  
Seq primer: -40UP from Gibco  
High quality sequence stop: 584.

## FEATURES

source  
1..598  
/organism="Homo sapiens"  
/mol\_type="mRNA"  
/db\_xref="taxon:9606"  
/clone="IMAGE:5670818"  
/sex="Both"  
/tissue\_type="Islets of Langerhans"  
/dev\_stage="Adult"  
/lab\_host="DH10B"  
/note="Organ: Pancreas; Vector: pSPORT1; Site 1: Not 1;  
Site 2: Sal 1; Starting library constructed using  
SuperScript Plasmid Library kit (Life Technologies). cDNA  
made by oligo-dT priming. Size-selected by column  
fractionation; average insert size 1.08 kb. Library was  
amplified once on solid support and plasmid DNA from  
library was prepared. The library DNA was normalized by  
method #4 from Bonaldo, Lennon, and Soares 1996 Genome  
Research 6:791-806; 0.5 microgram single-stranded library  
plasmid DNA was mixed with 5 micrograms PCR product  
representing library inserts and hybridized to an Ecot of  
20. Single-stranded (unhybridized) plasmids were isolated  
by hydroxyapatite chromatography and used to make this  
library."

## ORIGIN

Query Match 54.0%; Score 382; DB 7; Length 598;  
Best Local Similarity 99.2%; Pred. No. 3.2e-101;  
Matches 393; Conservative 1; Mismatches 1; Indels 1; Gaps 1;  
QY 313 TGCTGAAAATTTCTCAGTACCCCTCCAGGTGTACGTTAACTGACTTCTTCCGGG 372  
Db 598 TGCTGAAAATTTCTCAGTACCCCTCCAGGTGTACGTTAACTGACTTCTTCCGGG 539  
QY 373 GAAAAGCTCTCTCTTACCACAGAGAGACAATAAATAATCAATCAGAAGTGTCTTAT 432  
Db 538 GAAAAGCTCTCTCTTACCACAGAGAGACAATAAATAATCAATCAGAAGTGTCTTAT 479  
QY 433 ATACCTAAATGTGAAAAAATTTTGAAGAATCCATGTCCTGCTGAATTTCTCATGAA 492  
Db 478 ATACCTAAATGTGAAAAAATTTTGAAGAATCCATGTCCTGCTGAATTTCTCATGAA 419  
QY 493 AACTTCAGGAAGTATCAACACTTCTCTGCTATTTGACCCAGAGAGAAACAGAGAGT 552  
Db 418 AACTTCAGGAAGTATCAACACTTCTCTGCTATTTGACCCAGAGAGAAACAGAGAGT 359  
QY 553 GTTATCTTAACMAAATCTTACAGTTCACAGTGTTCCTCATCTCTTCTGGGCAACC 612  
Db 358 GTTATCTTAACMAAATCTTACAGTTCACAGTGTTCCTCATCTCTTCTGGGCAACC 299  
QY 613 TGTATGATGGCTGGGGGTGTGGCAATTTGTCATGTTGAAACTTACACAGTACCTCTCC 672  
Db 298 TGTATGATGGCTGGGGGTGTGGCAATTTGTCATGTTGAAACTTACACAGTACCTCTCC 239  
QY 673 CTACTATGTGAGAGATCC-ACGGATCAATAGATAA 707  
Db 238 CTACTATGTGAGAGATCCACCGATCAATAGATAA 203

```

RESULT 12
BU950136/c
LOCUS
DEFINITION
  BU950136 622 bp mRNA linear EST 21-OCT-2002
  i077a08.xl HR85 islet Homo sapiens cDNA clone IMAGE:6132374 3'
  similar to TR:Q9V691 Q9V691 MAXIK CHANNEL BETA 2 SUBUNIT. 1, mRNA
  sequence.
ACCESSION
  BU950136
VERSION
  BU950136.1 GI:24201487
KEYWORDS
  EST.
SOURCE
  Homo sapiens (human)
ORGANISM
  Eukaryota; Chordata; Craniata; Vertebrata; Euteleostomi;
  Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
  1 (bases 1 to 622)
  Melton,D., Brown,J., Kenty,G., Permutt,A., Lee,C., Kaestner,K.,
  Lemishka,I., Searce,M., Brestelli,J., Gradwohl,G., Clifton,S.,
  Hillier,L., Marra,M., Pape,D., Wylie,T., Martin,J., Blistain,A.,
  Schmitt,A., Theising,B., Ritter,E., Ronko,I., Bennett,J.,
  Cardenas,M., Gibbons,M., McCann,R., Cole,R., Tsagarishvili,R.,
  Williams,T., Jackson,Y. and Bowers,Y.
  Endocrine Pancreas Consortium
  Unpublished (2000)
  Contact: Douglas Melton, Klaus H. Kaestner, & Hiroshi Inoue
  Endocrine Pancreas Consortium
  Harvard University, Howard Hughes Medical Institute
  Dept of Molecular and Cellular Biology, 7 Divinity Ave, Cambridge,
  MA 02138
  Tel: 617-495-1812
  Fax: 617-495-8557
  Email: dmelton@bcb.harvard.edu
  Library was constructed by Dr. Hiroshi Inoue DNA sequencing by:
  Washington University Genome Sequencing Center For information on
  obtaining a clone please contact: Dr. Hiroshi Inoue
  (hinoue@im.wustl.edu)
  Seq primer: -40UP from Gibco
  High quality sequence stop: 293.
  Location/Qualifiers
    1..622
      /organism="Homo sapiens"
      /mol_type="mRNA"
      /db_xref="taxon:9606"
      /clone="IMAGE:6132374"
      /tissue_type="Purified pancreatic islet"
      /lab_host="DH10B"
      /clone_lib="HR85 islet"
      /note="Organ: Pancreas; Vector: pBluescript SK(-); Site_1:
      NotI; Site_2: XhoI; cDNA made by oligo-dT priming.
      Size: selected on agarose gel. Average insert size ~1kb. 5'
      XhoI site was destroyed after directional cloning.
      Amplified once. Contact information: Hiroshi Inoue, MD,
      Metabolism Div. (Alan Permutt Lab), Washington University
      School of Medicine, Box 8127, 660 South Euclid Ave., St.
      Louis, MO 63110, E-mail: hinoue@imgate.wustl.edu, Tel:
      314-362-1916, Fax: 314-747-2692."
FEATURES
  source
    1..622
      /organism="Homo sapiens"
      /mol_type="mRNA"
      /db_xref="taxon:9606"
      /clone="IMAGE:6132374"
      /tissue_type="embryonal carcinoma"
      /lab_host="DH10B (T1 phage-resistant)"
      /note="Organ: Testis; Vector: pDNR-LIB (Clontech); Site_1:
      SfiI (ggcgctcgcc); Site_2: SfiI (ggcgattggcc);
      Double-stranded cDNA was prepared from cell line RNA. 5'
      and 3' adaptors were used in cloning as follows: 5'
      adaptor sequence: 5'-ATTCTAGAGCGGCGGCGGCGCATG-dt(30)BN-3'
      (where B = A, C, or G and N = A, C, G, or T). Average
      insert size 1.75 kb (range 0.9-4.0 kb). 15/15 colonies
      contained inserts by PCR. This library was enriched for
      full-length clones and was constructed by Clontech
      Laboratories (Palo Alto, CA). Note: this is a NIH_MGC
      Library."
ORIGIN
  Query Match 51.3%; Score 362.8; DB 5; Length 622;
  Best Local Similarity 92.9%; Pred. No. 1.5e-95;
  Matches 390; Conservative 1; Mismatches 28; Indels 1; Gaps 1;

  QY 289 TGCTCTTCAGTGTGGTCCAGACTGCTGGAACTTCTCAGTACCCCTGCTCCAGGTG 348
  Db |
  QY 349 TACGTTACCTGACTTCTTCGGGGGAAAGCTCTCTCTACCAACAGAGAGACAATA 408
  Db |
  QY 562 TCGGTTAACTGCTCTTTTTCGGGGGAAAGGCTCTCTTTACCAACCAAGAGACAATA 503
  QY 409 AAAATCAATCAGAGTGTCTTATACCTAAATGTGAAAAAATTTTGAAGATCCATG 468
  Db |
  QY 502 TAATCAATCAGAGTGTCTTATACCTAAATGTGAAAAAATTTTGAAGATCCATG 443

```

```

QY 469 TCCTCGTGAATGTTGTCTATGGAACCTTCAGAAAGTATCAACACTTCTCTCTGCTATCT 528
Db |
QY 442 TCCTCGTGAATGTTGTCTATGGAACCTTCAGAAAGTATCAACACTTCTCTCTGCTATCT 383
QY 529 GACCCAGAAGAAACAGAAAGAGTGTATCTTAACMAAACTCTACAGTTCACACGTGTG 588
Db |
QY 382 GACCCAGAAGAAACAGAAAGAGTGTATCTTAACMAAACTCTACAGTTCACACGTGTG 323
QY 589 TTCCATTCACTCTTCTGGCCAACTGTATGATGGCTGGGGTGGCAATCTTCCCATG 648
Db |
QY 322 TTCCATTCACTGTCTGGCCAACTGTATGATGGCTGGGGTGGCAATCTTCCCATG 263
QY 649 GTGAAACTTACACAGTACCTCTCCCTACTATGTAGAGGATCC-ACGGATCAATAGATAA 707
Db |
QY 262 GTGAAACTTACGAGTGCCTCTCCCTGCTATGTGAGAAATCCACGGATCAATAGATAA 203

RESULT 13
BU9502844
LOCUS
DEFINITION
  BU9502844 778 bp mRNA linear EST 27-MAR-2001
  602550401F1 NIH_MGC_61 Homo sapiens cDNA clone IMAGE:4657825 5',
  mRNA sequence.
ACCESSION
  BU9502844
VERSION
  BU9502844.1 GI:13464361
KEYWORDS
  EST.
SOURCE
  Homo sapiens (human)
ORGANISM
  Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
  Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
  1 (bases 1 to 778)
  Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
  NIH-MGC http://mgi.nci.nih.gov/.
  National Institutes of Health, Mammalian Gene Collection (MGC)
  Unpublished (1999)
  Contact: Robert Strausberg, Ph.D.
  Email: cgabbs-r@mail.nih.gov
  Tissue Procurement: ATCC
  CDNA Library Preparation: CLONETECH Laboratories, Inc.
  CDNA Library Arrayed by: the I.M.A.G.E. Consortium (LLNL)
  DNA Sequencing by: Incyte Genomics, Inc.
  Clone Distribution: MGC clone distribution information can be
  found through the I.M.A.G.E. Consortium/LLNL at:
  http://image.llnl.gov
  Plate: LCM1451 row: b column: 02
  High quality sequence stop: 759.
  Location/Qualifiers
    1..778
      /organism="Homo sapiens"
      /mol_type="mRNA"
      /db_xref="taxon:9606"
      /clone="IMAGE:4657825"
      /tissue_type="embryonal carcinoma"
      /lab_host="DH10B (T1 phage-resistant)"
      /note="Organ: Testis; Vector: pDNR-LIB (Clontech); Site_1:
      SfiI (ggcgctcgcc); Site_2: SfiI (ggcgattggcc);
      Double-stranded cDNA was prepared from cell line RNA. 5'
      and 3' adaptors were used in cloning as follows: 5'
      adaptor sequence: 5'-ATTCTAGAGCGGCGGCGGCGCATG-dt(30)BN-3'
      (where B = A, C, or G and N = A, C, G, or T). Average
      insert size 1.75 kb (range 0.9-4.0 kb). 15/15 colonies
      contained inserts by PCR. This library was enriched for
      full-length clones and was constructed by Clontech
      Laboratories (Palo Alto, CA). Note: this is a NIH_MGC
      Library."
ORIGIN
  Query Match 49.4%; Score 349.4; DB 4; Length 778;
  Best Local Similarity 94.9%; Pred. No. 1.5e-91;
  Matches 392; Conservative 1; Mismatches 17; Indels 3; Gaps 3;

  QY 1 ATGTCGATATGACAGTGGCGGACCTCTTCATCTTATAGCATGATGAAAAAGAAAT 60

```



[illegible]

464	AAAGCAGGAGAGACCGAGCTATTCTCTGGGACTGGCTATGATGGTGTGCTCCATCATG	523
181	ATGATATTTTCTGCTGGGAATCACACTCTTGCGCTCATACATGCAGAGCGT-GTGGACCGA	239
524	ATGATATTTTCTGCTGGGAATCACACTCTTGCGCTCATACATGCAGAGCGTGGTGGACCGA	583
240	ACAGTCTCAATGCACCTTCTGTAATGCGTCCATCACGGAAACATTTAAATGTCTCTTCAG	299
584	ACAGTCTCAATGCACCTTCTGTAATGCGTCCATCACGGAAACATTTAAATGTCTCTTCAG	643
300	CTGTGGTCCAGACTGCTGAAAC-TTTCTAGTACCCCTGCCTCCAGGTGTACGTTAAAC	358
644	CTGTGGTCCAGACTGCTGAAACATTTCTCAGTACCCCTGCCTCCAGGTGTACGTTAAAC	703
359	TCACCTTTCTCCGGGAAAAGCTCCTCTCTACACACAGAAGACAAATAAAA	411
704	TGACITCTCTCCGGGAAAAGTCTCTCTTACCA-ACAGAAGAAACATTAAAA	755
RESULT 14		
BU222329	939 bp mRNA linear EST 25-NOV-2002	
LOCUS	603105389F1 CSEQCHN04 Gallus gallus cdna clone CHEST43b24 5', mRNA	
DEFINITION	sequence.	
ACCESSION	BU222329	
VERSION	BU222329.1	GI:25411618
KEYWORDS	EST	
SOURCE	Gallus gallus (chicken)	
ORGANISM	Gallus gallus	
	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;	
	Archosauria; Aves; Neognathae; Galliformes; Phasianidae;	
	Phasianinae; Gallus.	
REFERENCE	1 (bases 1 to 939)	
AUTHORS	Boardman,P.E., Sanz-Ezquerro,J., Overton,I.M., Burt,D.W., Bosch,E.,	
	Fong,W.T., Tickle,C., Brown,W.R.A., Wilson,S.A. and Hubbard,S.J.	
TITLE	A Comprehensive Collection of Chicken cDNAs	
JOURNAL	Curr. Biol. 12 (22), 1965-1969 (2002)	
MEDLINE	22335534	
PUBMED	12445392	
COMMENT	Contact: Simon Hubbard	
	Department of Biomolecular Sciences	
	University of Manchester Institute of Science and Technology	
	(UMIST)	
	PO Box 88, Manchester, M60 1QD, UK	

```

FEATURES
source
1. .939
Location/Qualifiers
/organism="Gallus gallus"
/mol_type="mRNA"
/strain="White Leghorn, Hisex"
/db_xref="taxon:9031"
/clone="CHEST43b24"
/tissue_type="whole embryo"
/dev_stage="20-21"
/lab_host="DH10B"
/clone_lib="CSECHN04"
/note="Organ: whole embryo; Vector: pBluescript II KS(+);
Site 1: EcoRI; Site 2: NotI; this normalized library was
constructed from 1 million independent clones. cDNA
synthesis was initiated using an oligo(dT) primer, using
methylated C in the first strand synthesis reaction.
Following this first strand reaction, double-stranded cDNA
was bluntend, ligated to NotI adapters, digested with

```

Email: cgapbsr@mail.nih.gov  
Tissue Procurement: Christopher Moskaluk, M.D., Ph.D., Michael R.  
Emmert-Buck, M.D., Ph.D.  
cDNA Library Preparation: M. Bento Soares, Ph.D.  
cDNA Library Arrayed by: Greg Lennon, Ph.D.  
DNA Sequencing by: Washington University Genome Sequencing Center  
Clone distribution: NCI-CGAP clone distribution information can be  
found through the I.M.A.G.E. Consortium/LLNL, send email to:  
info@image.llnl.gov

Seq primer: -40UP from Gibco  
High quality sequence stop: 498.

## FEATURES

source  
1..562  
Location/Qualifiers  
/organism="Homo sapiens"  
/mol\_type="mRNA"  
/db\_xref="taxon:9606"  
/clone="IMAGE:3565679"  
/tissue\_type="carcinoid"  
/lab\_host="DH10B"  
/clone\_lib="NCI CGAP Lu24"  
/note="Organ: lung; Vector: pTV73D-Pac (Pharmacia) with a  
modified polylinker; Plasmid DNA from the normalized  
library NCI CGAP Lu5 was prepared, and ss circles were  
made in vitro. Following HAP purification, this DNA was  
used as tracer in a subtractive hybridization reaction.  
The driver was PCR-amplified cDNAs from a pool of 5,000  
clones made from the same library (clones  
1414920-1417991 and 1520904-1522439). Subtraction by Bento  
Soares and M. Fatima Bonaldo."

## ORIGIN

Query Match 47.9%; Score 338.6; DB 2; Length 562;  
Best Local Similarity 99.4%; Pred. No. 2e-88;  
Matches 349; Conservative 1; Mismatches 0; Indels 1; Gaps 1;  
QY 358 CTGACTTCTTCGGGAAAGCTCTCTCTACACAGAGACAAATAAATCAAT 417  
DB |||||||  
562 CTGACTTCTTCGGGAAAGCTCTCTCTACACAGAGACAAATAAATCAAT 503  
QY 418 CAGAAAGTCTCTATATACCTAAATGTGGAAAAATTTTGAAGATCCATGTCCTGGTG 477  
DB |||||||  
502 CAGAAAGTCTCTATATACCTAAATGTGGAAAAATTTTGAAGATCCATGTCCTGGTG 443  
QY 478 AATGTTGTCATGAAAACTTCAGGAAGTATCAACACTTCTCTGCTATTCTGACCCGAA 537  
DB |||||||  
442 AATGTTGTCATGAAAACTTCAGGAAGTATCAACACTTCTCTGCTATTCTGACCCGAA 383  
QY 538 GGAACACAGAGAGTGTATCTCTAAACAACTCTACAGTCCACGCTGCTGTCATTCA 597  
DB |||||||  
382 GGAACACAGAGAGTGTATCTCTAAACAACTCTACAGTCCACGCTGCTGTCATTCA 323  
QY 598 CTCCTCTGCCAACCTGTATGATGGCTGGGGTGTGGCAATTTGCCATGGTGAACCT 657  
DB |||||||  
322 CTCCTCTGCCAACCTGTATGATGGCTGGGGTGTGGCAATTTGTCCATGGTGAACCT 263  
QY 658 ACACAGTACTCTCCCTACTATGTGAGAGGATCC-ACGGATCAATAGATAA 707  
DB |||||||  
262 ACACAGTACTCTCCCTACTATGTGAGAGGATCCACCGATCAATAGATAA 212

Search completed: November 7, 2004, 01:24:17  
Job time : 2971 secs

GenCore version 5.1.6  
Copyright (c) 1993 - 2004 Compugen Ltd.

OM protein - protein search, using sw model

Run on: November 6, 2004, 23:27:01 ; Search time 16 Seconds  
(without alignments)  
1413.184 Million cell updates/sec

Title: US-09-914-053A-5  
Perfect score: 1241  
Sequence: 1 MSIIWTSGRSSSYRHDKRN.....MVKLQYLSLLCERQIRNR 235  
Scoring table: BLOSUM62  
Gapop 10.0 , Gapext 0.5

Searched: 283416 seqs, 96216763 residues 283416  
Total number of hits satisfying chosen parameters:  
Minimum DB seq length: 0  
Maximum DB seq length: 200000000  
Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 45 summaries

Database : PIR 79.\*  
1: Pirl.\*  
2: Pirl.\*  
3: Pirl.\*  
4: Pirl.\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	421	33.9	191	2 S68842	calcium-regulated
2	382	30.8	191	2 A54165	charybdotoxin rece
3	93.5	7.5	255	2 T25853	hypothetical prote
4	89	7.2	286	1 C42053	gap junction prote
5	89	7.2	359	1 HLHUB4	MHC class I histoc
6	89	7.2	362	2 I37519	MHC class I histoc
7	88	7.1	362	2 I61851	MHC HLA-B*44.2 chai
8	87.5	7.1	1880	2 T18531	tractin - medicina
9	87	7.0	398	2 F90206	histidinol dehydro
10	87	7.0	497	2 G87793	protein C27A12.7 [
11	86	6.9	238	2 B36284	prolactin-like pro
12	85.5	6.9	491	2 F87793	protein C27A12.6 [
13	84.5	6.8	422	2 S24451	hypothetical prote
14	84	6.8	362	2 C35997	MHC class I histoc
15	83	6.7	362	2 T38421	gene HLA B-1519 pr
16	83	6.7	1562	2 T07323	DNA-directed RNA p
17	83	6.7	1589	1 R6Y1C5	cell division cont
18	82.5	6.6	247	2 A86809	hypothetical prote
19	82	6.6	336	2 T21531	hypothetical prote
20	82	6.6	350	2 I54308	MHC HLA B*71 - huma
21	82	6.6	354	2 S24433	class I histocompa
22	82	6.6	362	2 I84486	transmembrane glyc
23	82	6.6	362	2 I62042	MHC HLA-B cell sur
24	82	6.6	362	2 G01230	MHC class I histoc
25	82	6.6	362	2 I59654	major histocompati
26	82	6.6	362	2 I62045	gene HLA B-1517 pr
27	82	6.6	362	2 I61863	MHC HLA-B*46 - hum
28	82	6.6	362	2 S77966	MHC class I histoc
29	82	6.6	362	2 I37520	MHC class I histoc

30	82	6.6	362	2 I62041	MHC HLA-B cell sur
31	82	6.6	362	2 I62044	MHC class I histoc
32	82	6.6	362	2 S16789	class I histocompa
33	81.5	6.6	668	2 T08725	probable finger pr
34	81.5	6.6	1091	2 T30256	calcium channel al
35	81.5	6.6	1314	2 T30300	dyein heavy chain
36	81	6.5	710	2 T25734	hypothetical prote
37	80.5	6.5	366	2 I37078	HLA-C alpha chain
38	80	6.4	358	2 S75232	hypothetical prote
39	80	6.4	362	2 I62043	MHC HLA-B cell sur
40	80	6.4	436	2 H87793	protein C27A12.8 [
41	80	6.4	3744	2 S46715	hypothetical prote
42	79.5	6.4	345	2 T16074	hypothetical prote
43	79.5	6.4	368	2 C90558	lipoprotein (impor
44	79.5	6.4	849	2 T22306	hypothetical prote
45	79.5	6.4	969	2 T38478	RHO GAP/LIM domain

ALIGNMENTS

RESULT 1

S68842  
calcium-regulated potassium channel beta chain - human  
C:Species: Homo sapiens (man)  
C:Date: 04-Dec-1997 #sequence\_revision 12-Dec-1997 #text\_change 09-Jul-2004  
C:Accession: S68842; S62905  
R:Meera, P.; Wallner, M.; Jiang, Z.; Toro, L.  
FEBS Lett. 385, 124-131, 1996  
A:Title: Corrigendum to: a calcium switch for the functional coupling between alpha (hs1c  
A:Reference number: S68842  
A:Accession: S68842  
A:Molecule type: mRNA  
A:Residues: 1-191 <ME8>  
A:Cross-references: UNIPROT:Q16558  
R:Meera, P.; Wallner, M.; Jiang, Z.; Toro, L.  
FEBS Lett. 382, 84-88, 1996  
A:Title: A calcium switch for the functional coupling between alpha (hs1c) and beta subu  
A:Reference number: S62904; MUID:96196569; PMID:8612769  
A:Accession: S62905  
A>Status: nucleic acid sequence not shown  
A:Molecule type: mRNA  
A:Residues: 1-165, 'L', 167-191 <MEW>  
A:Cross-references: EMBL:U25138

Query Match	33.9%	Score 421;	DB 2;	Length 191;
Best Local Similarity	43.0%	Pred. No. 8.5e-31;		
Matches	83;	Conservative 40;	Mismatches 62;	Indels 8;
Gaps	2;			
QY	34	RTVTALKAGEDRAILLGLAMVCSIMMYFILGILLRLRSYQSVWTEREQCTLLNASITE	93	
DB	3	KKLVNAQRKGETRALCLGVTWVCAVITYILVTTLPLYQKSVWTQSKCHLIETNRD	62	
QY	94	TFNCSFSGPCDCKLSQYPCLOVYVNLTSGBKLLYHTEETIKINQKCSYIPKCGKNFE	153	
DB	63	QBELKKGK-----KVPQYFCL--WNVSAAGRWAVLYHTEDRDQNCQSYIPGSDVNYQ	114	
QY	154	ESMSLVNVVMENFRKYQHFSCYSDPEGKQKSVILTKLYSSNVLFHSLFWPTCMAGGVAI	213	
DB	115	TARADVEKVRKAFQEQVFYCFPSAPRGNETSVLFQRLYQPQALLFSLFWPTFLTTGGLLI	174	
QY	214	VAMVKLTQYLSLL	226	
DB	175	IAWVSNQYLSIL	187	

RESULT 2

A54165  
charybdotoxin receptor beta chain - bovine  
C:Species: Bos primigenius taurus (cattle)  
C:Date: 02-Aug-1994 #sequence\_revision 02-Aug-1994 #text\_change 09-Jul-2004  
C:Accession: A54165  
R:Knaus, H.G.; Folander, K.; Garcia-Calvo, M.; Garcia, M.L.; Kaczorowski, G.J.; Smith, M



F;217-282/Domain: immunoglobulin homology <IMM>  
F;305-328/Domain: transmembrane #status predicted <TM>  
F;359-359/Domain: intracellular #status predicted <INT>  
F;107/Binding site: carbohydrate (Asn) (covalent) #status predicted

Query Match 7.2%; Score 89; DB 1; Length 359;  
Best Local Similarity 21.3%; Pred. No. 2.2;  
Matches 50; Conservative 37; Mismatches 88; Indels 60; Gaps 10;

QY 1 MSITSGRTSSSYRHDEKRNIIYQKIRDHDLDRKVTALKAGEDRAILLGLAMVCSIM 60  
DB 151 LSWTAADTAQ-----ITQKWEAARVAEQDRAYLEGIC-----185  
QY 61 MYFLLGITLRSYMQSVWTEESQOTLLNASITETNFCSCGPD-----CWKLSQYPCIQ 115  
DB 186 -----VESLRYL-----ENGETLQRADPPKTHVTHHPISDHEATLRCSLGFYPA-E 233  
QY 116 VYVNLTSSEKLLLYHTEETIKINQKCSYIPKCGKPFESMSLVNVMENFRKYQHFSY 175  
DB 234 ITLTWRDGED---QIQDTLQVETR---PAGDRTQKWAAVVVPSSGE---QRYTCH 281  
QY 176 SDPEGNQKSVILTKLYSSNVLFLSHFWPTCMWAGGVAIVAMVKLTQYL-SLLCER 229  
DB 282 VQHEGLPKPLTLRWEPPSSQSTV-----PIVGIVAGLAVLVAVVIGAVVAVMCR 331

RESULT 6  
I37519  
MHC class I histocompatibility antigen HLA-B45 alpha chain precursor - human  
C;Species: Homo sapiens (man)  
C;Date: 02-Jul-1996 #sequence\_revision 02-Jul-1996 #text\_change 09-Jul-2004  
C;Accession: I37519; S16772  
E;Madrigal, J.A.; Belich, M.P.; Hildebrand, W.H.; Benjamin, R.J.; Little, A.M.; Zemmour, J.  
U;Immunol, 149, 3411-3415, 1992  
A;Title: Distinctive HLA-A,B antigens of black populations formed by interallelic conversion  
A;Reference number: I37476; MUID:93056508; PMID:11431115  
A;Accession: I37519  
A;Status: preliminary; translated from GB/EMBL/DBD  
A;Molecule type: mRNA  
A;Residues: 1-362 <RES>  
A;Cross-references: UNIPROT:P30483; EMBL:X61710; NID:g32182; PIDN:CAA43879.1; PID:g32182  
A;Note: this allele is designated B\*4501  
C;Genetics:  
A;Gene: GDB:HLA-B  
A;Cross-references: GDB:120048; OMIM:142830  
A;Map position: 6p21.3-6p21.3  
C;Superfamily: class I histocompatibility antigen; immunoglobulin homology  
C;Keywords: glycoprotein; heterodimer; transmembrane protein  
E;1-24/Domain: signal sequence #status predicted <SIG>  
F;220-285/Domain: immunoglobulin homology <IMM>  
F;110/Binding site: carbohydrate (Asn) (covalent) #status predicted

Query Match 7.2%; Score 89; DB 2; Length 362;  
Best Local Similarity 21.3%; Pred. No. 2.2;  
Matches 50; Conservative 37; Mismatches 88; Indels 60; Gaps 10;

QY 1 MSITSGRTSSSYRHDEKRNIIYQKIRDHDLDRKVTALKAGEDRAILLGLAMVCSIM 60  
DB 154 LSWTAADTAQ-----ITQKWEAARVAEQDRAYLEGIC-----188  
QY 61 MYFLLGITLRSYMQSVWTEESQOTLLNASITETNFCSCGPD-----CWKLSQYPCIQ 115  
DB 189 -----VESLRYL-----ENGETLQRADPPKTHVTHHPISDHEATLRCSLGFYPA-E 236  
QY 116 VYVNLTSSEKLLLYHTEETIKINQKCSYIPKCGKPFESMSLVNVMENFRKYQHFSY 175  
DB 237 ITLTWRDGED---QIQDTLQVETR---PAGDRTQKWAAVVVPSSGE---QRYTCH 284  
QY 176 SDPEGNQKSVILTKLYSSNVLFLSHFWPTCMWAGGVAIVAMVKLTQYL-SLLCER 229  
DB 285 VQHEGLPKPLTLRWEPPSSQSTI-----PIVGIVAGLAVLVAVVIGAVVAVMCR 334

Db 209 ISHNNAMRSSV 219

RESULT 9

F90206

Histidinol dehydrogenase (HDH) (hisD) [imported] - Sulfolobus solfataricus

C:Species: Sulfolobus solfataricus

C>Date: 24-May-2001 #sequence\_revision 24-May-2001 #text\_change 16-Aug-2004

C:Accession: F90206

R:She, Q.; Singh, R.K.; Confalonieri, F.; Zivanovic, Y.; Allard, G.; Awayez, M.J.; Chan-aret, R.A.; Jeffries, A.C.; Kozera, C.J.; Medina, N.; Peng, X.; Thi-Ngoc, H.P.; Redder, H. submitted to GenBank, April 2001

A:Description: Sulfolobus solfataricus complete genome.

A:Reference number: A99139

A:Accession: F90206

A>Status: preliminary

A:Molecule type: DNA

A:Residues: 1-398 <KUR>

A:Cross-references: UNIPROT:O33775; GB:AE006641; NID:gi3813763; PIDN:AAK40909.1; GSPDB:G9000

C:Genetics:

C:Superfamily: Histidinol dehydrogenase; histidinol dehydrogenase homology

Query Match 7.0%; Score 87; DB 2; Length 398;

Best Local Similarity 22.8%; Pred. No. 3.7;

Matches 34; Conservative 25; Mismatches 50; Indels 40; Gaps 7;

QY 102 GPCDWKLSQYPCLOVYVNLTSSEKLLYHTEETIKNQKSFESMSLVV 161

DB 248 GPD-----TYIVLLSNDDSLIRVVEEKIKNDKIIYIYIKT-KNLDEAIEIANK 294

QY 162 VVENFRKYCHFSYSDPE-----GNQKSVILTKLYSSNVLFHSLFWPTCM 206

DB 295 IAP-----EHLVYKDAYTMDKIVNAGALSNGTTPAIDYVAGNHILPTNGW--AK 347

QY 207 MAGGVAIVAMVKLTQYLSLLCERIQNRN 235

DB 348 IRGGITVYDFIKPTMYAN-----VRDINK 371

RESULT 10

G87793

protein C27A12.7 [imported] - Caenorhabditis elegans

C:Species: Caenorhabditis elegans

C>Date: 10-May-2001 #sequence\_revision 10-May-2001 #text\_change 09-Jul-2004

C:Accession: G87793

R:Anonymous, The C. elegans Sequencing Consortium.

A:Title: Genome sequence of the nematode C. elegans: a platform for investigating biology

A:Reference number: A75000; MUID:99069613; PMID:9851916

A:Note: see websites genome.wustl.edu/gsc/C\_elegans/ and www.sanger.ac.uk/Projects/C\_elegans/

A:Note: published errata appeared in Science 283, 35, 1999; Science 283, 2103, 1999; and Science 282, 2012-2018, 1998

A:Accession: G87793

A>Status: preliminary

A:Molecule type: DNA

A:Residues: 1-497 <STO>

A:Cross-references: UNIPROT:O01964; GB:chr\_I; PIDN:AAB93644.1; PID:g2105479; GSPDB:GN000

C:Genetics:

A:Gene: C27A12.7

A:Map position: 1

Query Match 7.0%; Score 87; DB 2; Length 497;

Best Local Similarity 19.4%; Pred. No. 4.7;

Matches 43; Conservative 36; Mismatches 87; Indels 56; Gaps 8;

QY 5 TSGRTSSSYRHDERRNYQKIRDHLLDKRKTVALKAGEDRAILLGLAMWCSIMVY-- 62

DB 37 TSDNDTSYAKEDKSE--NEVLNDLLLEAENWTI-----ADVQAVLQVDPGVCRIILHKY 90

QY 63 -----FLGHTLLRSYQSVWTEESQCTLLNASITET--FNCSPSC 101

DB 91 KWNKESLERLYEHPDTIAFLIDQAQVIPROQEVIPAGDAECDIC-GSMDBLSGLSCNHRA 149

QY 102 GPCDWKL-----SQYPCLOVYVNLTSSEKLLYHTEET-----IK 137

DB 150 CAECWQAVLTNKIVSDAQSEIECMAPNCKLLIEDEKVLAYIKDPTIIAKYKRWVASYIE 209

QY 138 INQKCSYIP--KQGNFESMSLVVWVWENFRKYQHFSYSD 177

DB 210 INALLKWCPEVDCGRTVKVSHGPELWVCTGSRFCFCGQD 251

RESULT 11

B36284

Prolactin-like protein II, placental - bovine

C:Species: Bos primigenius taurus (cattle)

C>Date: 18-Jan-1991 #sequence\_revision 18-Jan-1991 #text\_change 09-Jul-2004

C:Accession: B36284

R:Yamakawa, M.; Tanaka, M.; Koyama, M.; Kagesato, Y.; Watahiki, M.; Yamamoto, M.; Nakashijima, J. Biol. Chem. 265, 8915-8920, 1990

A:Title: Expression of new members of the prolactin growth hormone gene family in bovine

A:Reference number: A36284; MUID:90256825; PMID:2341410

A:Accession: B36284

A>Status: preliminary

A:Molecule type: mRNA

A:Residues: 1-238 <YAM>

A:Cross-references: UNIPROT:P19159; GB:M33269; GB:J05458; NID:gi163630; PIDN:AAA30740.1; I

C:Superfamily: prolactin

Query Match 6.9%; Score 86; DB 2; Length 238;

Best Local Similarity 24.3%; Pred. No. 2.5;

Matches 36; Conservative 19; Mismatches 59; Indels 34; Gaps 7;

QY 72 SYMQSVWT---EESQCTLL-----NASITENFNCSCGDCWKLQYPCLOVYVNLTS 123

DB 6 SFRGHQWTVNVRGSCLLLLVSNLLICQGISCP-SCGPDVFLQKSLDVFVNAASL 64

QY 124 GKLLLYHTEETIKNQKSVIPKCGKNFESMSLVVWVWENFRKYQHFSYSDPEGNQK 183

DB 65 SHD---FHNLSITMENE-----FDEKYAQGLYYINATKSCHTNSFHTPEERDK 110

QY 184 SV-----ILTKLYS-SNVLFHSL 200

DB 111 AQOMNEDLSKWTLLVLLSWNPFLIYLL 138

RESULT 12

F87793

protein C27A12.6 [imported] - Caenorhabditis elegans

C:Species: Caenorhabditis elegans

C>Date: 10-May-2001 #sequence\_revision 10-May-2001 #text\_change 09-Jul-2004

C:Accession: F87793

R:Anonymous, The C. elegans Sequencing Consortium.

A:Title: Genome sequence of the nematode C. elegans: a platform for investigating biology

A:Reference number: A75000; MUID:99069613; PMID:9851916

A:Note: see websites genome.wustl.edu/gsc/C\_elegans/ and www.sanger.ac.uk/Projects/C\_elegans/

A:Note: published errata appeared in Science 283, 35, 1999; Science 283, 2103, 1999; and Science 282, 2012-2018, 1998

A:Accession: F87793

A>Status: preliminary

A:Molecule type: DNA

A:Residues: 1-491 <STO>

A:Cross-references: UNIPROT:O01963; GB:chr\_I; PIDN:AAB93643.1; PID:g2105478; GSPDB:GN000

C:Genetics:

A:Gene: C27A12.6

A:Map position: 1

Query Match 6.9%; Score 85.5; DB 2; Length 491;

Best Local Similarity 18.5%; Pred. No. 6.3;

Matches 36; Conservative 37; Mismatches 57; Indels 65; Gaps 9;

QY 14 RHDEKRNYY-----QKIRHDLL--DKRTVTALKAGEDRAILLGLAMWCSIMVY-- 62

DB 32 RHDSASDYLNNKDKNEVLHDHSLDLEAMKKAISEVA-----VLQVKTGVCRIILHKY 85

Qy 63 -----FLGILTLRSYMQSVWTEESQCTLLNASITET--FNCSPSC 101  
Db 86 KWNKESLLERYEHPDTIAFLDAQVIPROCEVIPAGDAEDIC-CSDMELSLGNSHRA 144  
Qy 102 GPCDCWKL-----SQVCLQVYVNLTSSEKLLYHTET-----IK 137  
Db 145 CAECQAYLTKNVISDQASIECAPNCKLLIEDEKVLVSIDPTWYKYRKLWVASYVE 204  
Qy 138 INQKCSYIP--KCK 150  
Db 205 INCILLRWCPGIDCGK 219  
RESULT 13  
S24451  
hypochemical protein - phase SPPI  
C/Species: phage SPPI  
C/Date: 13-Jan-1995 #sequence\_revision 13-Jan-1995 #text\_change 09-Jul-2004  
C/Accession: S24451; T42263  
R/Chai, S.; Bravo, A.; Lueder, G.; Nedlin, A.; Trautner, T.A.; Alonso, J.C.  
J. Mol. Biol. 224, 87-102, 1992  
A/Title: Molecular analysis of the Bacillus subtilis bacteriophage SPPI region encompassing the *hly* gene  
A/Reference number: S24450; MUID:92194332; PMID:1548711  
A/Accession: S24451  
A/Status: preliminary  
A/Molecule type: DNA  
A/Residues: 1-422 <CHA>  
A/Cross-references: UNIPROT:P54308; EMBL:X56064; NID:gl5464; PIDN:CAA39537.1; PID:gl5466  
R/Alonso, J.C.; Luder, G.; Stiege, A.C.; Chai, S.; Weise, F.; Trautner, T.A.  
Gene 204, 201-212, 1997  
A/Title: The complete nucleotide sequence and functional organization of Bacillus subtilis *hly* gene  
A/Reference number: T42263; MUID:98094274; PMID:9434185  
A/Accession: T42263  
A/Status: preliminary; translated from GB/EMBL/DBJ  
A/Molecule type: DNA  
A/Residues: 1-422 <ALO>  
A/Cross-references: EMBL:X97918; PIDN:CAA66573.1  
Query Match 6.8%; Score 84.5; DB 2; Length 422;  
Best Local Similarity 23.1%; Pred. No. 6.6;  
Matches 48; Conservative 29; Mismatches 90; Indels 41; Gaps 9;  
Qy 17 EKNRIYKIRHDLKRVKIVTA-----LKAGEDRAILLGLAMVCSIMYFLGIL 69  
Db 2 KKVLSKFTPH-FLEVNRIVKAAQHLKYVLKGGSGAKSTHAMWILLMMWPIIFLV 60  
Qy 70 LRSYMQSVWTEESQCTLLNASITETFCSPGDCWKLSQYPCLOVYVNLTSSEKLL 129  
Db 61 IRRYNTV--EQSVPEQLKKAID-----MLEVG-HLWKVSKSPRLTYI---PRGNSIIF 109  
Qy 130 YHTEETKINQ-KCSYIPKCKNFER-----SMSLVNVVNMENFRKYQHFSY 175  
Db 110 RGGDDVQKIRKISKASKFPVAGMWTEELAEFKTEBEVSVEIKSVLRALPPGCRYIFFYSY 169  
Qy 176 SDPEGNOKSVILTKLYSSNVLFHSLFWP 203  
Db 170 NPPRKQSWV-----NKVFNSFLP 189  
RESULT 14  
C35997  
MHC class I histocompatibility antigen HLA-B\*37 alpha chain precursor - human  
C/Species: Homo sapiens (man)  
C/Date: 16-Nov-1990 #sequence\_revision 13-Jan-1993 #text\_change 09-Jul-2004  
C/Accession: C35997  
R/Ennis, P.D.; Zemmour, J.; Salter, R.D.; Parham, P.  
Proc. Natl. Acad. Sci. U.S.A. 87, 2833-2837, 1990  
A/Title: Rapid cloning of HLA-A,B cDNA by using the polymerase chain reaction: frequency of polymorphism in the coding region  
A/Reference number: A35997; MUID:90207291; PMID:2320591  
A/Accession: C35997  
A/Status: preliminary  
A/Molecule type: mRNA  
A/Residues: 1-362 <ENN>

A/Cross-references: UNIPROT:P18463; GB:M32320; NID:gl87792; PIDN:AAA36233.1; PID:g307224  
C/Genetics:  
A/Gene: GDB:HLA-B  
A/Cross-references: GDB:120048; OMIM:142830  
A/Map position: 6p21.3-6p21.3  
C/Superfamily: class I histocompatibility antigen; immunoglobulin homology  
C/Keywords: transmembrane protein  
F/220-285/Domain: immunoglobulin homology <IMV>  
Query Match 6.8%; Score 84; DB 2; Length 362;  
Best Local Similarity 21.3%; Pred. No. 6.2;  
Matches 50; Conservative 37; Mismatches 88; Indels 60; Gaps 11;  
Qy 1 MSIWTSGRSSSYRDEKRNIVQKIRHDLKRVKIVTAALKAGEDRAILLGLAMVCSIM 60  
Db 154 LSSWTAADTAQ-----ITQRWEAREAEQWRALEG-----TC--- 188  
Qy 61 MYFLGILTLRSYMQSVWTEESQCTLLNASITETFCSPGDP-----CWKLSYPCLO 115  
Db 189 -----VEWLRRYL-----ENGETLQRADPPKTHVTHHPISDHEATLRCWALGFYPA-E 236  
Qy 116 VYVNLTSSEKLLYHTETIKINOKCSYIPKCGNFFESMSLVNVVNMENFRKYQHFSY 175  
Db 237 IILTQWQDGED-----QTQTELVETR-----PAGDTRFKNAAVVPSGEE-----QRYTCH 284  
Qy 176 SDPEGNOKSVILTKLYSSNVLFHSLFWPTCMAGGVAIVAMVKLYQL-SL-CER 229  
Db 285 VQHEGLPKPLTLRWEPSSQSTI-----PIVGIVAGLAVLVVIGAVVATVCMCR 334  
RESULT 15  
I38421  
gene HLA B-1519 protein - human  
C/Species: Homo sapiens (man)  
C/Date: 21-Feb-1997 #sequence\_revision 21-Feb-1997 #text\_change 09-Jul-2004  
C/Accession: I38421  
R/Hildebrand, W.H.; Domene, J.D.; Shen, S.Y.; Lau, M.; Terasaki, P.I.; Bunce, M.; Marsh, Tissue Antigens 43, 209-218, 1994  
A/Title: HLA-B\*15: a widespread and diverse family of HLA-B alleles.  
A/Reference number: I38421; MUID:94367483; PMID:7521976  
A/Accession: I38421  
A/Status: preliminary; translated from GB/EMBL/DBJ  
A/Molecule type: mRNA  
A/Residues: 1-362 <RES>  
A/Cross-references: UNIPROT:P30464; EMBL:U03027; NID:g413769; PIDN:AAA18902.1; PID:g4137  
C/Genetics:  
A/Gene: HLA-B-1519  
C/Superfamily: class I histocompatibility antigen; immunoglobulin homology  
F/220-285/Domain: immunoglobulin homology <IMV>  
Query Match 6.7%; Score 83; DB 2; Length 362;  
Best Local Similarity 20.9%; Pred. No. 7.6;  
Matches 49; Conservative 39; Mismatches 87; Indels 60; Gaps 10;  
Qy 1 MSIWTSGRSSSYRDEKRNIVQKIRHDLKRVKIVTAALKAGEDRAILLGLAMVCSIM 60  
Db 154 LSSWTAADTAQ-----ITQRWEAREAEQWRALEG----- 188  
Qy 61 MYFLGILTLRSYMQSVWTEESQCTLLNASITETFCSPGDP-----CWKLSYPCLO 115  
Db 189 -----VDGLRRYL-----ENGETLQRADPPKTHVTHHPISDHEATLRCWALGFYPA-E 236  
Qy 116 VYVNLTSSEKLLYHTETIKINOKCSYIPKCGNFFESMSLVNVVNMENFRKYQHFSY 175  
Db 237 IILTQWQDGED-----QTQTELVETR-----PAGDTRFKNAAVVPSGEE-----QRYTCH 284  
Qy 176 SDPEGNOKSVILTKLYSSNVLFHSLFWPTCMAGGVAIVAMVKLYQL-SL-CER 229  
Db 285 VQHEGLPKPLTLRWEPSSQSTI-----PIVGIVAGLAVLVVIGAVVATVCMCR 334

Search completed: November 6, 2004, 23:32:42  
Job time : 20 secs





GenCore version 5.1.6  
Copyright (c) 1993 - 2004 Compugen Ltd.

OM protein - protein search, using sw model

Run on: November 6, 2004, 23:22:16 ; Search time 65 Seconds  
(without alignments)  
1296.944 Million cell updates/sec

Title: US-09-914-053A-5  
Perfect score: 1241  
Sequence: 1 MSINSGRTSSSYRDEKKN.....MVKLTQYLILLCRIQRIINR 235

Scoring table: BLOSUM62  
Gapop 10.0 , Gapext 0.5

Searched: 2002273 seqs, 358729299 residues

Total number of hits satisfying chosen parameters: 2002273

Minimum DB seq length: 0  
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 45 summaries

Database : A\_Geneseq\_23Sep04:.\*  
1: Genesecp1980s:.\*  
2: Genesecp1990s:.\*  
3: Genesecp2000s:.\*  
4: Genesecp2001s:.\*  
5: Genesecp2002s:.\*  
6: Genesecp2003a:.\*  
7: Genesecp2003b:.\*  
8: Genesecp2004s:.\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

## SUMMARIES

Result No.	Score	Query Match %	Length	DB ID	Description
1	1241	100.0	235	3 AAB08820	Aab08820 Amino aci
2	1235	99.5	235	4 AAB35301	Aab35301 Human cal
3	1228	99.0	235	3 AAY70466	Aay70466 Human mem
4	971	78.2	182	6 ADA56755	Ada56755 Human sec
5	971	78.2	182	6 ADA40606	Ada40606 Human sec
6	971	78.2	183	3 AAY91460	Aay91460 Human sec
7	971	78.2	183	8 ADL71532	Adl71532 Novel hum
8	886	71.4	165	3 AAY91601	Aay91601 Human sec
9	886	71.4	165	8 ADL71677	Adl71677 Novel hum
10	484	39.0	137	4 ABB12189	Abb12189 Human K c
11	478.5	38.6	277	4 AAB35302	Aab35302 Human cal
12	477.5	38.5	277	4 AAM78995	Aam78995 Human pro
13	477.5	38.5	301	4 ABB11970	Abb11970 Human Ca-
14	477.5	38.5	301	4 AAM79979	Aam79979 Human pro
15	475	38.3	275	4 AAB35304	Aab35304 Human cal
16	474	38.2	257	3 AAB08818	Aab08818 Amino aci
17	474	38.2	257	4 AAB35303	Aab35303 Human cal
18	474	38.2	279	4 AAB35305	Aab35305 Human cal
19	435.5	35.1	220	2 AAY34131	Aay34131 Human cal
20	421	33.9	190	7 ADE54752	Ades4752 Human pro
21	421	33.9	191	2 AAR85306	Aar85306 Human cal
22	421	33.9	191	5 ABP33982	Abp33982 Human Max
23	421	33.9	191	5 ABP33982	Abp33982 Human Max
24	421	33.9	191	5 ABP51818	Abp51818 Human Max
25	421	33.9	191	5 ADJ33391	Adj33391 Human Max

26 421 33.9 191 7 ADD14147  
27 418 33.7 191 7 ADE54750  
28 382 30.8 191 2 AAR85305  
29 352 28.4 202 4 AAM96297  
30 318 25.6 218 3 AAB41606  
31 317 25.5 210 7 ADJ69109  
32 316 25.5 210 2 AAY21839  
33 316 25.5 210 3 AAY77561  
34 316 25.5 210 3 AAB08819  
35 177 14.3 85 3 AAG03607  
36 125 10.1 928 4 AAG13226  
37 125 10.1 928 4 AAG13406  
38 125 10.1 928 4 AAG18125  
39 120.5 9.7 185 2 AAY07968  
40 93.5 7.5 496 8 ADQ08798  
41 92 7.4 897 6 ABU40481  
42 92 7.4 897 7 ADF03964  
43 91.5 7.4 448 4 ABB67183  
44 91 7.3 347 4 AAM41242  
45 91 7.3 807 8 ADJ66497

## ALIGNMENTS

RESULT 1  
AAB08820  
ID AAB08820 standard; protein; 235 AA.  
XX  
AC AAB08820;  
XX  
XX  
DT 02-JAN-2001 (first entry)  
XX  
DE Amino acid sequence of a human BK beta-4 polypeptide.  
XX  
KW Human; BK beta-2; beta subunit; Slo potassium channel; BK beta-3;  
KW BK beta-4; ion flux; migraine; hearing; vision problem; seizure; stroke;  
KW asthma; cell proliferation; hormone secretion; cancer; viral infection.

XX Homo sapiens.

XX Key Location/Qualifiers  
FT Misc-difference 230  
FT /note= "encoded by CA"

XX WO200050444-A1.

XX 31-AUG-2000.

XX 22-FEB-2000; 200CWO-US004441.

XX 23-FEB-1999; 99US-0121224P.

XX 03-NOV-1999; 99US-0163367P.

XX (ICAG-) ICAGEN INC.

XX Jegla TJ, Wickenden A, Liu Y;

XX WPI; 2000-533179/48.

XX N-PSDB; AAA75011.

XX Isolated beta subunit polynucleotides and polypeptides of Slo potassium channels are used to determine the effects of compounds on ion flux through a potassium channel and in computer modelling systems.

XX Claim 17; Page 79; 84pp; English.

XX The present sequence represents a human BK beta-4 polypeptide. The polypeptide is a beta subunit of a Slo potassium channel. The specification also describes BK beta-3 and BK beta-2 polypeptides. BK beta subunits are auxiliary subunits or monomers of Slo potassium channels. The polypeptides, when expressed in cells and cell membranes, are used to determine the effects of compounds on ion flux through a

CC potassium channel. The compounds identified may be useful as therapeutic  
 CC agents e.g. modulators that target specific S10 channels are useful for  
 CC treating migraines, hearing and vision problems, seizures, stroke,  
 CC asthma, cell proliferation and hormone secretion. The computer generated  
 CC 3-dimensional structures of BK beta 2, BK beta 3 or BK beta 4 are used to  
 CC identify ligands that bind to the beta subunit. The characterized BK beta  
 CC subunits are used to determine how S10 potassium channels function in  
 CC different environments and how they respond to different activation  
 CC mechanisms. The polynucleotides are used to transfect cells in vivo and  
 CC in vitro to mitigate effects of absent, partial inactivation or abnormal  
 CC expression of the BK beta subunit gene e.g. to correct genetic defects,  
 CC cancer and viral infection  
 XX

XX Sequence 235 AA;

Query Match 100.0%; Score 1241; DB 3; Length 235;  
 Best Local Similarity 100.0%; Pred. No. 3.9e-129;  
 Matches 235; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MSIMTSGRTSSSYRDEKRNIIQKIRHDLDDKRTVTALKAGEDRAILLGLAMVCSIM 60  
 DB 1 MSIMTSGRTSSSYRDEKRNIIQKIRHDLDDKRTVTALKAGEDRAILLGLAMVCSIM 60  
 QY 61 MYFLGITLLRSYMQSVWTEESQCTLLNASITETFNCSFSGPCDWKLSQYPCLOVYVNL 120  
 DB 61 MYFLGITLLRSYMQSVWTEESQCTLLNASITETFNCSFSGPCDWKLSQYPCLOVYVNL 120  
 QY 121 TSSGEKLLHYTETIKINOKCSYIPKCGKNFESMSLVNVMENFRKYOHFSCYSDPEG 180  
 DB 121 TSSGEKLLHYTETIKINOKCSYIPKCGKNFESMSLVNVMENFRKYOHFSCYSDPEG 180  
 QY 181 NOKSVILTKLYSSNVLFHSLFWPTCMAGGVAIVAMVKLTQYLSLLCERQIRNR 235  
 DB 181 NOKSVILTKLYSSNVLFHSLFWPTCMAGGVAIVAMVKLTQYLSLLCERQIRNR 235

RESULT 2

AAB35301  
 ID AAB35301 standard; protein; 235 AA.

XX AC AAB35301;

XX DT 08-MAY-2001 (first entry)

XX DE Human calcium sensitive potassium channel beta2 subunit.

XX KW Human; calcium sensitive potassium channel; beta2 subunit; asthma;  
 KW beta3a subunit; beta3b subunit; beta3c subunit; beta3d subunit; diabetes;  
 KW chromosome 3q23-ter; inhibitor; activator; glaucoma; migraine; angina;  
 KW irritable bowel syndrome; Alzheimer's disease.

XX OS Homo sapiens.

XX PN W0200105828-A1.

XX PD 25-JAN-2001.

XX PF 18-JUL-2000; 2000WO-US019585.

XX PR 20-JUL-1999; 99US-0144764P.

XX PA (MERI ) MERCK & CO INC.

XX PI Uebele V, Swanson R, Liu Y, Lagrutta A;

XX DR WPI; 2001-159514/16.

XX DR N-PSDB; AAF27991.

XX PT Novel human calcium sensitive potassium channel subunits for identifying  
 PT inhibitors and agonists of the potassium channel for use in treating  
 PT conditions such as asthma, hypertension, memory disorders, depression.

XX PS Claim 9; Fig 1B; 89pp; English.

XX The present invention provides the protein and coding sequences of the  
 CC human calcium sensitive potassium channel beta2, beta3a, beta3b, beta3c  
 CC and beta3d subunits. These can be used to identify inhibitors and  
 CC activators of the channels, which can be used in the treatment of  
 CC conditions including asthma, diabetes, glaucoma, cerebral ischemia,  
 CC Alzheimer's disease, excessive smooth muscle tone, angina, hypertension,  
 CC incontinence, migraine and irritable bowel syndrome. The coding sequences  
 CC are found at human chromosome 3q23-ter. The present sequence is the beta2  
 CC subunit  
 XX

XX Sequence 235 AA;

Query Match 99.5%; Score 1235; DB 4; Length 235;  
 Best Local Similarity 99.6%; Pred. No. 1.8e-128;  
 Matches 234; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 MSIMTSGRTSSSYRDEKRNIIQKIRHDLDDKRTVTALKAGEDRAILLGLAMVCSIM 60  
 DB 1 MSIMTSGRTSSSYRDEKRNIIQKIRHDLDDKRTVTALKAGEDRAILLGLAMVCSIM 60  
 QY 61 MYFLGITLLRSYMQSVWTEESQCTLLNASITETFNCSFSGPCDWKLSQYPCLOVYVNL 120  
 DB 61 MYFLGITLLRSYMQSVWTEESQCTLLNASITETFNCSFSGPCDWKLSQYPCLOVYVNL 120  
 QY 121 TSSGEKLLHYTETIKINOKCSYIPKCGKNFESMSLVNVMENFRKYOHFSCYSDPEG 180  
 DB 121 TSSGEKLLHYTETIKINOKCSYIPKCGKNFESMSLVNVMENFRKYOHFSCYSDPEG 180  
 QY 181 NOKSVILTKLYSSNVLFHSLFWPTCMAGGVAIVAMVKLTQYLSLLCERQIRNR 235  
 DB 181 NOKSVILTKLYSSNVLFHSLFWPTCMAGGVAIVAMVKLTQYLSLLCERQIRNR 235

RESULT 3

AAY70466  
 ID AAY70466 standard; protein; 235 AA.

XX AC AAY70466;

XX DT 21-JUN-2000 (first entry)

XX DE Human membrane channel protein-16 (MECHP-16).

XX KW Membrane channel protein-16; MECHP-16; diagnosis; treatment; lymphoma;  
 KW cell proliferative disorder; bursitis; atherosclerosis; cancer; sarcoma;  
 KW inflammatory disorder; AIDS; Addison's disease; cystic fibrosis; asthma;  
 KW diabetes mellitus; osmoregulatory disorder; diarrhoea; renal failure;  
 KW muscular disorder; myocarditis; Duchenne's muscular dystrophy; nontropic;  
 KW cardiovascular disorder; hypertension; bronchitis; vasculitis; cardiac;  
 KW neurological disorder; Alzheimer's disease; Parkinson's disease; human;  
 KW Huntington's disease; antiarteriosclerotic; hepatotropic; cytostatic;  
 KW anti-HIV; antianaemic; neuroprotective; immunomodulator; antidiabetic;  
 KW hypotensive; vasotropic; antiasthmatic; antiinflammatory; antidepressant;  
 KW anticonvulsant; thrombolytic; antiParkinsonian; immunostimulant.

XX OS Homo sapiens.

XX PH Key Location/Qualifiers

FT Modified-site 6 /note= "Phosphorylation site"  
 FT Modified-site 12 /note= "Phosphorylation site"  
 FT Modified-site 36 /note= "Phosphorylation site"  
 FT Domain 48..68 /label= Transmembrane\_domain  
 FT Modified-site 88 /note= "Glycosylation site"  
 FT Modified-site 90 /note= "Phosphorylation site"  
 FT Modified-site 96 /note= "Glycosylation site"



CC ftp.wipo.int/pub/published\_pct\_sequences.

XX Sequence 182 AA;

Query Match 78.2%; Score 971; DB 6; Length 182;

Best Local Similarity 100.0%; Pred. No. 2.9e-99;

Matches 182; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 54 MMVCSIMMYFLIGITLLRSYQSWVTESQCTLLNASITETFNCSFGGPDCKWLSQYPC 113  
 DB 1 MMVCSIMMYFLIGITLLRSYQSWVTESQCTLLNASITETFNCSFGGPDCKWLSQYPC 60  
 QY 114 LOVYVNLTSSEKLLLYHTEETIKINOKCSYIPKCGKNFEESMLVNVVWENFRKYQHS 173  
 DB 61 LOVYVNLTSSEKLLLYHTEETIKINOKCSYIPKCGKNFEESMLVNVVWENFRKYQHS 120  
 QY 174 CYSDEGNGKSVILTKLYSSNVLFHSLFWPTCMAGGVAIVAMVKLTQYLSLLCERIQRI 233  
 DB 121 CYSDEGNGKSVILTKLYSSNVLFHSLFWPTCMAGGVAIVAMVKLTQYLSLLCERIQRI 180  
 QY 234 NR 235  
 DB 181 NR 182

RESULT 5

ADA40606  
 ID ADA40606 standard; protein; 182 AA.

AC ADA40606;

XX 20-NOV-2003 (first entry)

XX Human secreted protein.

XX Human; secreted protein; cancer; hyperproliferative disorder;  
 KW rheumatoid arthritis; autoimmune disorder; haematopoietic disorder;  
 KW anaemia; allergic reaction; asthma; cardiovascular disorder;  
 KW wound healing; cytostatic; immunosuppressive; neutropenic; neutrophilic;  
 KW antiviral; antiallergic; hepatotropic; antidiabetic; antiinflammatory;  
 KW vulnery; cardiant; gene therapy.

XX Homo sapiens.

XX WO2002102993-A2.

XX 27-DEC-2002.

XX 19-MAR-2002; 2002WO-US008123.

XX 21-MAR-2001; 2001US-0277340P.

XX 19-JUL-2001; 2001US-0306171P.

XX 13-NOV-2001; 2001US-0331287P.

XX (HUMA-) HUMAN GENOME SCI INC.

XX Rosen CA, Ruben SM;

XX WPI; 2003-175238/17.

XX New human secreted proteins and nucleic acid molecules, useful for  
 PT preparing a diagnostic or pharmaceutical composition for diagnosing,  
 PT preventing or treating cancer or other hyperproliferative disorder,  
 PT asthma, allergies or AIDS.

XX Claim 1; SEQ ID NO 988; 3205pp; English.

XX The invention relates to novel genes ADA39629-ADA40565 and proteins  
 CC ADA40566-ADA41501 for human secreted proteins, useful for preventing,  
 CC treating or ameliorating medical conditions e.g. by protein or gene  
 CC therapy. The polypeptides, nucleic acid molecules, antibodies or their  
 CC fragments, and agonists or antagonists that bind to the polypeptide are  
 CC useful for preparing a diagnostic or pharmaceutical composition for

CC diagnosing or treating cancer or other hyperproliferative disorder. The  
 CC polypeptides and nucleic acid molecules are also useful for detecting,  
 CC preventing, diagnosing, prognosticating, treating or ameliorating cancer  
 CC or other hyperproliferative disorders including neoplasms, autoimmune  
 CC disorders (e.g. diabetes, rheumatoid arthritis, systemic lupus  
 CC erythematosus, multiple sclerosis, autoimmune thyroiditis or haemolytic  
 CC anaemia), haematopoietic or haematological disorders (e.g. anaemia,  
 CC thrombocytopenia), allergic reactions including asthma or eczema,  
 CC inflammatory disorders (e.g. ischaemia-reperfusion injury, inflammatory  
 CC bowel disease or Crohn's disease), neurodegenerative disorders (e.g.  
 CC Alzheimer's disease or Parkinson's disease), cardiovascular disorders  
 CC (e.g. atherosclerosis, myocarditis), infectious diseases (bacterial,  
 CC fungal or viral infections including HIV/AIDS), or wound healing and  
 CC disorders of epithelial cell proliferation. The nucleic acids are also  
 CC useful for chromosome identification, radiation hybrid mapping or long-  
 CC range restriction mapping, as molecular weight markers, or as  
 CC hybridization or diagnostic probes. The polypeptides and antibodies are  
 CC useful for providing immunological probes for differential identification  
 CC of the tissues immunohistochemistry assays. Note: The sequence data for  
 CC this patent did not form part of the printed specification, but was  
 CC obtained in electronic format directly from WIPO at  
 CC ftp.wipo.int/pub/published\_pct\_sequences.

XX Sequence 182 AA;

Query Match 78.2%; Score 971; DB 6; Length 182;

Best Local Similarity 100.0%; Pred. No. 2.9e-99;

Matches 182; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 54 MMVCSIMMYFLIGITLLRSYQSWVTESQCTLLNASITETFNCSFGGPDCKWLSQYPC 113  
 DB 1 MMVCSIMMYFLIGITLLRSYQSWVTESQCTLLNASITETFNCSFGGPDCKWLSQYPC 60  
 QY 114 LOVYVNLTSSEKLLLYHTEETIKINOKCSYIPKCGKNFEESMLVNVVWENFRKYQHS 173  
 DB 61 LOVYVNLTSSEKLLLYHTEETIKINOKCSYIPKCGKNFEESMLVNVVWENFRKYQHS 120  
 QY 174 CYSDEGNGKSVILTKLYSSNVLFHSLFWPTCMAGGVAIVAMVKLTQYLSLLCERIQRI 233  
 DB 121 CYSDEGNGKSVILTKLYSSNVLFHSLFWPTCMAGGVAIVAMVKLTQYLSLLCERIQRI 180  
 QY 234 NR 235  
 DB 181 NR 182

RESULT 6

AA91460  
 ID AA91460 standard; protein; 183 AA.

XX AA91460;

XX 29-JUN-2000 (first entry)

XX Human secreted protein sequence encoded by gene 10 SEQ ID NO:133.

XX Human; secreted protein; diagnosis; cytostatic; immunosuppressive;  
 KW antiHIV; antiinflammatory; neutropenic; neuroprotective; antiallergic;  
 KW osteopathic; antiaesthetic; antibacterial; antidiabetic; antiasthma;  
 KW antipsoriatic; cardiant; gene therapy; cancer; neurological disorder;  
 KW immune disease; inflammation; blood disorder; tumour.

XX Homo sapiens.

XX WO200006698-A1.

XX 10-FEB-2000.

XX 29-JUL-1999; 99WO-US017130.

XX 30-JUL-1998; 98US-0094657P.

XX 05-AUG-1998; 98US-0095486P.

XX 06-AUG-1998; 98US-0095454P.

PR 06-AUG-1998; 98US-0095455P.  
PR 12-AUG-1998; 98US-0096319P.  
XX (HUMA-) HUMAN GENOME SCI INC.  
XX Komatsoulis GA, Rosen CA, Ruben SM, Duan R, Moore PA, Shi Y;  
PI Lafleur D, Wei Y, Ni J, Florence KA, Young PE, Brewer LA;  
PI Soppet DR, Endress GA, Ebner R, Olsen HS, Mucenski M;  
XX WPI; 2000-195282/17.  
DR N-PSDB; AAA26355.  
XX New isolated human genes and the secreted polypeptides they encode,  
PT useful for diagnosis and treatment of e.g. cancers, neurological  
PT disorders, immune diseases, inflammation or blood disorders.  
XX Claim 11; Page 463; 634pp; English.  
XX The polynucleotide sequences given in AAA26346 to AAA26458 encode the  
CC human secreted proteins given in AAY91451 to AAY91691. The human secreted  
CC proteins can have activities based on the tissues and cells they are  
CC expressed in. Examples of the activities are: cytostatic;  
CC immunosuppressive; antiHIV; antiinflammatory; neurotropic; neuroprotective;  
CC antiatheric; osteopathic; antiarthritic; antibacterial; antidiabetic;  
CC antiasthma; antipsoriatic; and cardiant. The polynucleotides and their  
CC corresponding secreted proteins are useful for preventing, treating or  
CC ameliorating medical conditions, e.g. by protein or gene therapy. Also  
CC pathological conditions can be diagnosed by determining the amount of the  
CC proteins in a sample or by determining the presence of mutations in the  
CC polynucleotides. Specific uses are described for each of the  
CC polynucleotides, based on which tissues they are most highly expressed  
CC in, and include developing products for the diagnosis or treatment of  
CC cancer, tumors, neurodegenerative disorders, developmental abnormalities  
CC and foetal deficiencies, blood disorders, diseases of the immune system,  
CC autoimmune diseases, hepatic and renal disease, inflammation, allergies,  
CC Alzheimer's and behavioural disorders, schizophrenia, osteoporosis,  
CC arthritis, infections, AIDS, spinal cord injuries, transplant rejection,  
CC diabetes, asthma, sepsis, acne, psoriasis, cardiovascular disorders,  
CC reproductive disorders, gastrointestinal disorders, respiratory disorders  
CC and metabolic disorders. The proteins or polynucleotides can also be used  
CC as food additives or preservatives. The proteins are also useful for  
CC identifying their binding partners. AAA26337 to AAA26345 and AAY91450 are  
CC sequences used in the exemplification of the present invention  
XX Sequence 183 AA;  
QY Query Match  
DB Best Local Similarity 78.2%; Score 971; DB 3; Length 183;  
Matches 182; Conservative 100.0%; Pred. No. 2.9e-99;  
Mismatches 0; Indels 0; Gaps 0;  
QY 54 MMVCSIMMYFLGTLILRSYQSVWTEESQCTLLNASITETNCSCGPDCKWLSQYPC 113  
DB 1 MMVCSIMMYFLGTLILRSYQSVWTEESQCTLLNASITETNCSCGPDCKWLSQYPC 60  
QY 114 LQVYVNLTSSEKLLLYHTETIKINQKCSYIPKCGKNFESLSLVNVMENFRKYQHS 173  
DB 61 LQVYVNLTSSEKLLLYHTETIKINQKCSYIPKCGKNFESLSLVNVMENFRKYQHS 120  
QY 174 CYSPEGNQKSVILTKLYSSNVLPHSLFWPTCMAGGVAIVAMVKLTQYLSLCERTQRI 233  
DB 121 CYSPEGNQKSVILTKLYSSNVLPHSLFWPTCMAGGVAIVAMVKLTQYLSLCERTQRI 180  
QY 234 NR 235  
DB 181 NR 182  
RESULT 7  
ADL71532  
ID ADL71532 standard; protein; 183 AA.  
XX AC ADL71532;  
XX

DT 20-MAY-2004 (first entry)  
XX Novel human secreted protein seqid 136.  
DE  
XX  
KW antinflammatory; neuroprotective; neurotropic; antiparkinsonian;  
KW anticonvulsant; antilipemic; CNS; gynaecological; antiarthritic;  
KW antiasthmatic; anti-HIV; virucide; endocrine; cytostatic;  
KW immunosuppressive; antiatheric; cardiovascular; respiratory;  
KW dermatological; antimicrobial; gastrointestinal; gene therapy;  
KW neurodegenerative disease; behavioral disorder; inflammatory condition;  
KW hyperproliferative disorder; Alzheimer's disease; Parkinson's disease;  
KW Huntington's disease; metabolic disorder; Tay-Sach's disease;  
KW Leash-Nyhan syndrome; reproductive disorder; immunological disorder;  
KW arthritis; asthma; AIDS; endocrine disorder; immune disorder;  
KW Hodgkin's lymphoma; haematopoietic disorder; muscular disorder;  
KW leukaemia; autoimmune disorder; allergy; cancer; cardiovascular disorder;  
KW respiratory disorder; pulmonary disorder; connective tissue disorder;  
KW skin disorder; CNS disorder; congenital disorder; infectious disorder;  
KW gastrointestinal disorder; human; secreted protein.  
XX Homo sapiens.  
XX US2004034196-A1.  
XX 19-FEB-2004.  
XX 27-JAN-2003; 2003US-00351334.  
XX 30-JUL-1998; 98US-0094657P.  
PR 05-AUG-1998; 98US-0095486P.  
PR 06-AUG-1998; 98US-0095454P.  
PR 06-AUG-1998; 98US-0095455P.  
PR 12-AUG-1998; 98US-0096319P.  
PR 29-JUL-1999; 99WO-US017130.  
PR 24-JAN-2000; 2000US-00489847.  
PR 25-JAN-2002; 2002US-0350898P.  
XX (KOMA/) KOMATSOUIS G A.  
PA (ROSE/) ROSEN C A.  
PA (RUBE/) RUBEN S M.  
PA (DUAN/) DUAN D R.  
PA (MOOR/) MOORE P A.  
PA (SHI/) SHI Y.  
PA (LAF/) LAFLEUR D W.  
PA (WEI/) WEI Y.  
XX Komatsoulis GA, Rosen CA, Ruben SM, Duan DR, Moore PA, Shi Y;  
PI Lafleur DW, Wei Y;  
XX WPI; 2004-180094/17.  
DR N-PSDB; ADL71416.  
XX New human secreted nucleic acid, useful for diagnosing and treating  
PT neurodegenerative, inflammatory, hyperproliferative, metabolic, or  
PT reproductive, cardiovascular, respiratory or immunological disorders or  
PT diseases.  
XX Claim 11; SEQ ID NO 136; 234pp; English.  
XX The invention describes an isolated human nucleic acid molecule (I)  
CC comprising a polynucleotide having a nucleotide sequence at least 95%  
CC identical to: a sequence polynucleotide fragment of SEQ ID NO: X or of  
CC the cDNA sequence included in ATCC Deposit No: Z, which is hybridisable  
CC to SEQ ID NO: X; or a sequence encoding a polypeptide fragment, domain or  
CC epitope of SEQ ID NO: Y or a polypeptide sequence encoded by the cDNA  
CC sequence included in ATCC Deposit No: Z, which is hybridisable to SEQ ID  
CC NO: X, having a biological activity. The nucleic acids and polypeptides,  
CC pharmaceutical formulations and kits are useful in diagnosing and  
CC treating neurodegenerative diseases states, behavioral disorders,  
CC inflammatory conditions, hyperproliferative disorders (e.g. Alzheimer's  
CC disease, Parkinson's disease or Huntington's disease), metabolic  
CC disorders (e.g. Tay-Sach's disease or Leash-Nyhan syndrome), reproductive  
CC disorders, immunological disorders (e.g. arthritis, asthma or AIDS),

CC endocrine and immune disorders (e.g. Hodgkin's lymphoma), haematopoietic  
 CC or muscular disorders (e.g. leukaemia), autoimmune disorders, allergy,  
 CC cancer, cardiovascular, respiratory or pulmonary disorders, disorders or  
 CC conditions affecting connective tissue, skin disorders, CNS disorders,  
 CC congenital disorders, infectious disorders and gastrointestinal  
 CC disorders. This is the amino acid sequence of a novel human secreted  
 CC protein of the invention. Note: This sequence does not appear in the  
 CC printed specification but is available in electronic format from the US  
 CC patent office at ftp.segdata.uspto.gov/segdata.html?docID=20040034196.  
 XX  
 SQ Sequence 183 AA;

Query Match 78.2%; Score 971; DB 8; Length 183;  
 Best Local Similarity 100.0%; Pred. No. 2.9e-99;  
 Matches 182; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 54 MMVCSIMMYFLIGITLLRSYMSQVWTEESQCTLLNASITETFNCSFGPCDWKLSQYPC 113  
 Db 1 MMVCSIMMYFLIGITLLRSYMSQVWTEESQCTLLNASITETFNCSFGPCDWKLSQYPC 60  
 QY 114 LOVYNLTSSGKLLLYTEETIKINQKCSYIPKCGKNFEESMLVNVVWENFRKYQHS 173  
 Db 61 LOVYNLTSSGKLLLYTEETIKINQKCSYIPKCGKNFEESMLVNVVWENFRKYQHS 120  
 QY 174 CYSDEPGNQKSVILTKLYSSNVLFHSLFPTCMWAGGVAIVAMVKLTQYLSLLCERIORI 233  
 Db 121 CYSDEPGNQKSVILTKLYSSNVLFHSLFPTCMWAGGVAIVAMVKLTQYLSLLCERIORI 180  
 QY 234 NR 235  
 Db 181 NR 182

RESULT 8  
 ID AAY91601 standard; protein; 165 AA.  
 AC AAY91601;  
 DT 29-JUN-2000 (first entry)  
 XX Human secreted protein sequence encoded by gene 10 SEQ ID NO:274.  
 DE Human; secreted protein; diagnosis; cytostatic; immunosuppressive;  
 KW antiHIV; antiinflammatory; nontropic; neuroprotective; antiatheric;  
 KW osteopathic; antiarthritic; antibacterial; antidiabetic; antiasthma;  
 KW antipneumatic; cardians; gene therapy; cancer; neurological disorder;  
 KW immune disease; inflammation; blood disorder; tumour.  
 XX Homo sapiens.  
 OS WO200006698-A1.  
 FN 10-FEB-2000.  
 PD 29-JUL-1999; 99WO-US017130.  
 PF 30-JUL-1998; 98US-0094657P.  
 PR 05-AUG-1998; 98US-0095486P.  
 PR 06-AUG-1998; 98US-0095454P.  
 PR 06-AUG-1998; 98US-0095455P.  
 PR 12-AUG-1998; 98US-0096319P.  
 XX (HUMA-) HUMAN GENOME SCI INC.  
 FA Komatsulis GA, Rosen CA, Ruben SM, Duan R, Moore PA, Shi Y;  
 PI Lafleur D, Wei Y, Ni J, Florence KA, Young PE, Brewer LA;  
 PI Soppet DR, Endress GA, Ebner R, Olsen HS, Mucenski M;  
 XX WI; 2000-195282/17.  
 XX New isolated human genes and the secreted polypeptides they encode,  
 PT useful for diagnosis and treatment of e.g. cancers, neurological

PT disorders, immune diseases, inflammation or blood disorders.  
 XX Disclosure; Page 29; 634pp; English.  
 PS  
 XX The polynucleotide sequences given in AA26346 to AAA26458 encode the  
 CC human secreted proteins given in AAY91451 to AAY91691. The human secreted  
 CC proteins can have activities based on the tissues and cells they are  
 CC expressed in. Examples of the activities are: cytostatic;  
 CC immunosuppressive; antiHIV; antiinflammatory; nontropic; neuroprotective;  
 CC antiatheric; osteopathic; antiarthritic; antibacterial; antidiabetic;  
 CC antiasthma; antipneumatic; and cardiantic. The polynucleotides and their  
 CC corresponding secreted proteins are useful for preventing, treating or  
 CC ameliorating medical conditions, e.g. by protein or gene therapy. Also  
 CC pathological conditions can be diagnosed by determining the amount of the  
 CC proteins in a sample or by determining the presence of mutations in the  
 CC polynucleotides. Specific uses are described for each of the  
 CC polynucleotides, based on which tissues they are most highly expressed  
 CC in, and include developing products for the diagnosis or treatment of  
 CC cancer, tumour, neurodegenerative disorders, developmental abnormalities  
 CC and foetal deficiencies, blood disorders, diseases of the immune system,  
 CC autoimmune diseases, hepatic and renal disease, inflammation, allergies,  
 CC Alzheimer's and behavioural disorders, schizophrenia, osteoporosis,  
 CC arthritis, infections, AIDS, spinal cord injuries, transplant rejection,  
 CC diabetes, asthma, sepsis, acne, psoriasis, cardiovascular disorders,  
 CC reproductive disorders, gastrointestinal disorders, respiratory disorders  
 CC and metabolic disorders. The proteins or polynucleotides can also be used  
 CC as food additives or preservatives. The proteins are also useful for  
 CC identifying their binding partners. AAA26337 to AAA26345 and AAY91450 are  
 CC sequences used in the exemplification of the present invention  
 XX  
 SQ Sequence 165 AA;

Query Match 71.4%; Score 886; DB 3; Length 165;  
 Best Local Similarity 100.0%; Pred. No. 7.1e-90;  
 Matches 165; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 71 RSYMSQVWTEESQCTLLNASITETFNCSFGPCDWKLSQYPCLOVYNLTSSGKLLLY 130  
 Db 1 RSYMSQVWTEESQCTLLNASITETFNCSFGPCDWKLSQYPCLOVYNLTSSGKLLLY 60  
 QY 131 HTEETIKINQKCSYIPKCGKNFEESMLVNVVWENFRKYQHSYSDPEGNQKSVILTKL 190  
 Db 61 HTEETIKINQKCSYIPKCGKNFEESMLVNVVWENFRKYQHSYSDPEGNQKSVILTKL 120  
 QY 191 YSSNVLFHSLFPTCMWAGGVAIVAMVKLTQYLSLLCERIORINR 235  
 Db 121 YSSNVLFHSLFPTCMWAGGVAIVAMVKLTQYLSLLCERIORINR 165

RESULT 9  
 ADL71677  
 ID ADL71677 standard; protein; 165 AA.  
 XX ADL71677;  
 AC ADL71677;  
 DT 20-MAY-2004 (first entry)  
 XX Novel human secreted protein fragment seqid 281.  
 DE antiinflammatory; neuroprotective; nontropic; antiparkinsonian;  
 XX anticonvulsant; antilipemic; CNS; gynaecological; antiarthritic;  
 KW antischmatic; anti-HIV; virucide; endocrine; cytostatic;  
 KW immunosuppressive; antiatheric; cardiovascular; respiratory;  
 KW dermatological; antimicrobial; gastrointestinal; gene therapy;  
 KW neurodegenerative disease; behavioral disorder; inflammatory condition;  
 KW hyperproliferative disorder; Alzheimer's disease; Parkinson's disease;  
 KW Huntington's disease; metabolic disorder; Tay-Sach's disease;  
 KW Leash-Nyhan syndrome; reproductive disorder; immunological disorder;  
 KW arthritis; asthma; AIDS; endocrine disorder; muscular disorder;  
 KW Hodgkin's lymphoma; haematopoietic disorder; cancer; cardiovascular disorder;  
 KW leukaemia; autoimmune disorder; allergy; cancer; connective tissue disorder;  
 KW respiratory disorder; pulmonary disorder; congenital disorder; infectious disorder;  
 KW skin disorder; CNS disorder; congenital disorder; infectious disorder;

KW gastrointestinal disorder; human; secreted protein.  
XX Homo sapiens.  
OS US2004034196-A1.  
FN 19-FEB-2004.  
PD 27-JAN-2003; 2003US-00351334.  
XX 30-JUL-1998; 98US-0094657P.  
PR 06-AUG-1998; 98US-0095486P.  
PR 06-AUG-1998; 98US-0095454P.  
PR 06-AUG-1998; 98US-0095455P.  
PR 12-AUG-1998; 98US-0096319P.  
PR 29-JUL-1999; 99WO-US017130.  
PR 24-JAN-2000; 2000US-00489847.  
PR 25-JAN-2002; 2002US-0350898P.  
XX (KOMA/) KOMATSOULIS G A.  
PA (ROSE/) ROSEN C A.  
PA (ROBE/) RUBEN S M.  
PA (DUAN/) DUAN D R.  
PA (MOOR/) MOORE P A.  
PA (SHIY/) SHI Y.  
PA (LAFU/) LAFLEUR D W.  
PA (WEIY/) WEI Y.  
XX Komatsoulis GA, Rosen CA, Ruben SM, Duan DR, Moore PA, Shi Y;  
PI Lafleur DW, Wei Y;  
PI WPI; 2004-180094/17.  
XX New human secreted nucleic acid, useful for diagnosing and treating  
PT neurodegenerative, inflammatory, hyperproliferative, metabolic,  
PT reproductive, cardiovascular, respiratory or immunological disorders or  
PT diseases.  
XX Disclosure; SEQ ID NO 281; 234pp; English.  
PS The invention describes an isolated human nucleic acid molecule (I)  
XX comprising a polynucleotide having a nucleotide sequence at least 95%  
CC identical to: a sequence polynucleotide fragment of SEQ ID NO: X or of  
CC the cDNA sequence included in ATCC Deposit No: Z, which is hybridisable  
CC to SEQ ID NO: X; or a sequence encoding a polypeptide fragment, domain or  
CC epitope of SEQ ID NO: Y or a polypeptide sequence encoded by the cDNA  
CC sequence included in ATCC Deposit No: Z, which is hybridisable to SEQ ID  
CC NO: X, having a biological activity. The nucleic acids and polypeptides,  
CC pharmaceutical formulations and kits are useful in diagnosing and  
CC treating neurodegenerative diseases states, behavioral disorders,  
CC inflammatory conditions, hyperproliferative disorders (e.g. Alzheimer's  
CC disease, Parkinson's disease or Huntington's disease), metabolic  
CC disorders (e.g. Tay-Sach's disease or Leash-Nyhan syndrome), reproductive  
CC disorders, immunological disorders (e.g. arthritis, asthma or AIDS),  
CC endocrine and immune disorders (e.g. Hodgkin's lymphoma), haematopoietic  
CC or muscular disorders (e.g. leukaemia), autoimmune disorders, allergy,  
CC cancer, cardiovascular, respiratory or pulmonary disorders, disorders or  
CC conditions affecting connective tissue, skin disorders, CNS disorders,  
CC congenital disorders, infectious disorders and gastrointestinal  
CC disorders. This is the amino acid sequence of a novel human secreted  
CC protein fragment of the invention. Note: This sequence does not appear in  
CC the printed specification but is available in electronic format from the  
CC US patent office at ftp.segdata.uspto.gov/segdata.html?DocID=20040034196.  
XX  
SQ Sequence 165 AA;  
Query Match 71.4%; Score 886; DB 8; Length 165;  
Best Local Similarity 100.0%; Freq. No. 7.1e-90;  
Matches 165; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
OY 71 RSYMQSVWTEBSQCTLLNASITFNCFSFGPCGDKWLSQVPCIQVYVNLTSSEKLLY 130  
DB 1 RSYMQSVWTEBSQCTLLNASITFNCFSFGPCGDKWLSQVPCIQVYVNLTSSEKLLY 60

OY 131 HTEETIKINQCSYIPKCGKNFEESMLNVNVMENFRKYQHFCYSDBEGNKSVILTKL 190  
DB 61 HTEETIKINQCSYIPKCGKNFEESMLNVNVMENFRKYQHFCYSDBEGNKSVILTKL 120  
OY 191 YSSNVLPHSLFWPTCMAGGVAIVAMVKLTQYLSLLCERIQINR 235  
DB 121 YSSNVLPHSLFWPTCMAGGVAIVAMVKLTQYLSLLCERIQINR 165  
RESULT 10  
ABB12189  
ID ABB12189 standard; peptide; 137 AA.  
XX ABB12189;  
AC ABB12189;  
XX 11-JAN-2002 (first entry)  
XX Human K channel subunit homologue, SEQ ID NO:2559.  
XX Human; cytokine; cell proliferation; cell differentiation; growth factor;  
KW haematopoiesis regulation; tissue growth; immunomodulator; activin;  
KW inhibin; chemotaxis; chemokinesis; thrombolysis; oncogenesis;  
KW proliferation; metastasis; cancer; tumour; haematopoietic disorder;  
KW myeloid cell disorder; lymphoid cell disorder; asthma; arthritis;  
KW chronic inflammatory condition; proliferative retinopathy;  
KW atherosclerosis; coronary heart disease; arterial ischaemia;  
KW bone disorder; osteoporosis; vascular growth disorder;  
KW tissue regeneration; wound healing; infection; immune disorder;  
KW cell culture; drug screening; gene therapy; antiinflammatory;  
KW antiasthmatic; antiarthritic; haemostatic; antiarteriosclerotic;  
KW cytostatic; osteopathic; vasotropic; cardiant; virucide; antibacterial;  
KW antifungal; vulnery; antiulcer.  
XX Homo sapiens.  
OS WO200157188-A2.  
XX 09-AUG-2001.  
XX 05-FEB-2001; 2001WO-US003800.  
XX 03-FEB-2000; 2000US-00496914.  
PR 27-APR-2000; 2000US-00560875.  
XX (HYSE-) HYSEQ INC.  
XX Tang YT, Liu C, Drmanac RT;  
PI WPI; 2001-457740/49.  
XX N-PSDB; ABA09433.  
PT Human proteins and DNA encoding sequences useful for preventing, treating  
PT or ameliorating a medical condition in a mammalian subject e.g. arthritis  
PT and cancer.  
XX Claim 20; Page 314; 1963pp; English.  
XX Sequences ABB10981-ABB12330 represent 1350 novel human polypeptides, and  
CC sequences ABA08225-ABA09574 represent nucleic acids encoding them. The  
CC invention also relates to vectors and recombinant host cells comprising a  
CC nucleotide of the invention, methods of producing the novel polypeptides,  
CC antibodies against the polypeptides, methods of detecting the nucleotides  
CC or polypeptides in a sample, and methods of identifying compounds which  
CC bind to polypeptides of the invention. Although novel, many of the  
CC polypeptides of the invention have homology to known proteins, thereby  
CC giving an insight into their probable biological activities, and hence  
CC potential therapeutic applications. The polypeptides of the invention may  
CC have various activities including cytokine, cell proliferation or cell  
CC differentiation activities; stem cell growth factor activity;  
CC haematopoiesis regulatory activity; tissue growth activity;  
CC immunomodulatory activity; activin- or inhibin-related activities;  
CC chemotactic or chemokinetic activities; haemostatic, thrombotic or

CC thrombolytic activities; receptor or ligand activities; or may be  
 CC involved in oncogenesis, cancer cell proliferation or metastasis.  
 CC Depending on their biological activities, polypeptides and nucleotides of  
 CC the invention are useful for preventing, treating or ameliorating medical  
 CC conditions, e.g., by protein or gene therapy. Such conditions include  
 CC cancers, haematopoietic disorders (e.g., myeloid or lymphoid cell  
 CC disorders), chronic inflammatory conditions (e.g., asthma or arthritis),  
 CC proliferative retinopathy, atherosclerosis, coronary heart disease,  
 CC arterial ischaemia, bone disorders (e.g., osteoporosis), and abnormal  
 CC vascular growth. Polypeptides involved with tissue regeneration and  
 CC repair (or nucleic acids encoding them) may be used to promote wound  
 CC healing (e.g., of burns, incisions and ulcers), while those with  
 CC immunomodulatory activities may be used in the treatment of viral,  
 CC bacterial and fungal infections in addition to immune disorders.  
 CC Polypeptides with growth factor activity may be used in cell cultures to  
 CC promote cell growth. For example, such polypeptides may be used to  
 CC manipulate stem cells in culture to give rise to neuroepithelial cells  
 CC that can be used to augment or replace cells damaged by illness,  
 CC autoimmune disease or accidental damage. The polypeptides and nucleotides  
 CC may also be used in the diagnosis of the above conditions, and in drug  
 CC screening techniques. The present sequence represents a novel human  
 CC polypeptide of the invention  
 XX  
 SQ Sequence 137 AA;

Query Match 39.0%; Score 484; DB 4; Length 137;  
 Best Local Similarity 96.9%; Pred. No. 2.8e-45;  
 Matches 94; Conservative 1; Mismatches 2; Indels 0; Gaps 0;  
 QY 1 MSINTSGRTSSYRDEKRNIVQKIRHDLDDKKTVTALKAGEDRAILLGLAMVCSIM 60  
 DB 41 MSINTSGRTSSYRDEKRNIVQKIRHDLDDKKTVTALKAGEDRAILLGLAMVCSIM 100  
 QY 61 MYFLIGITLLRSYMQSVWTESSQCTLLNASITETFC 97  
 DB 101 MXFLIGITLLRSYMQSVWTESSQCTLLNASITETFC 137

RESULT 11  
 AAB35302  
 ID AAB35302 standard; protein; 277 AA.  
 AC AAB35302;  
 XX  
 DT 08-MAY-2001 (first entry)  
 XX  
 DE Human calcium sensitive potassium channel beta3a subunit.  
 XX  
 KW Human; calcium sensitive potassium channel; beta2 subunit; asthma;  
 KW beta3a subunit; beta3b subunit; beta3c subunit; beta3d subunit; diabetes;  
 KW chromosome 3q23-ter; inhibitor; activator; glaucoma; migraine; angina;  
 KW irritable bowel syndrome; Alzheimer's disease.  
 XX  
 OS Homo sapiens.  
 XX  
 PN WO200105828-A1.  
 XX  
 PD 25-JAN-2001.  
 XX  
 PF 18-JUL-2000; 2000WO-US019585.  
 XX  
 PR 20-JUL-1999; 99US-0144764P.  
 XX  
 PA (MERI) MERCK & CO INC.  
 XX  
 PI Uebele V, Swanson R, Liu Y, Lagrutta A;  
 XX  
 DR WFI; 2001-159514/16.  
 DR N-PSDE; AAF27592.  
 XX

PT Novel human calcium sensitive potassium channel subunits for identifying  
 PT inhibitors and agonists of the potassium channel for use in treating  
 PT conditions such as asthma, hypertension, memory disorders, depression.  
 PT

XX  
 PS Claim 9; Fig 2B; 89pp; English.  
 XX  
 CC The present invention provides the protein and coding sequences of the  
 CC human calcium sensitive potassium channel beta2, beta3a, beta3b, beta3c  
 CC and beta3d subunits. These can be used to identify inhibitors and  
 CC activators of the channels, which can be used in the treatment of  
 CC conditions including asthma, diabetes, glaucoma, cerebral ischaemia,  
 CC Alzheimer's disease, excessive smooth muscle tone, angina, hypertension,  
 CC incontinence, migraine and irritable bowel syndrome. The coding sequences  
 CC are found at human chromosome 3q23-ter. The present sequence is the  
 CC beta3a subunit  
 XX  
 SQ Sequence 277 AA;

Query Match 38.6%; Score 478.5; DB 4; Length 277;  
 Best Local Similarity 41.3%; Pred. No. 3.3e-44;  
 Matches 97; Conservative 44; Mismatches 81; Indels 13; Gaps 5;  
 QY 7 GRTSSYRDEKRNIVQKIRHDLDDKKTVTALKAGEDRAILLGLAMVCSIMMYFLIG 66  
 DB 20 GRTAPASGKKRETDYS---DGDPLDVHKRLPS-STGEDRAVMLGFAMNGSVLNFLLG 75  
 QY 67 ITLLRSYMQSVWTESSQCTLLNASITETFC-NCSPSCGPDCKWLSQYPCLOVYVNTSSGE 125  
 DB 76 TILKPFMLSIQREESTCTAHTDMDLDCAFTCGVHCHGQKYPCLQVFNLSHFQ 135  
 QY 126 KLLLYHTETIKINOKSVIPKCGKNFESMSLVNVVNERKYOH----FSCYSDPEG 180  
 DB 136 KALLHNEAVINPCFYTPKC---HQDRSLNSALDIKEFPDKNKGTFFSCFYSPAS 192  
 QY 181 NOKSVILTKLYSSNVFHSFLWPTCMAGGVAIVAMVKLTQYLSLLCBRIQRINR 235  
 DB 193 QSEDEVILIKYDQMAIFHCLEWPSLTLGGALIVGMVRLTQHLSELLCEKYSTVVR 247

RESULT 12  
 AAM78995  
 ID AAM78995 standard; protein; 277 AA.  
 AC AAM78995;  
 XX  
 DT 06-NOV-2001 (first entry)  
 XX  
 DE Human protein SEQ ID NO 1657.  
 XX  
 KW Human; cytokine; cell proliferation; cell differentiation; gene therapy;  
 KW vaccine; peptide therapy; stem cell growth factor; haematopoiesis;  
 KW tissue growth factor; immunomodulatory; cancer; leukaemia;  
 KW nervous system disorder; arthritis; inflammation.  
 XX  
 OS Homo sapiens.  
 XX  
 PN WO200157190-A2.  
 XX  
 PD 09-AUG-2001.  
 XX  
 PF 05-FEB-2001; 2001WO-US004098.  
 XX  
 PR 03-FEB-2000; 2000US-00496914.  
 PR 27-APR-2000; 2000US-00560875.  
 PR 20-JUN-2000; 2000US-00598075.  
 PR 19-JUL-2000; 2000US-00620325.  
 PR 01-SEP-2000; 2000US-00654936.  
 PR 15-SEP-2000; 2000US-00863561.  
 PR 20-OCT-2000; 2000US-00893325.  
 PR 30-NOV-2000; 2000US-00728422.  
 XX  
 PA (HYSE-) HYSEQ INC.  
 XX  
 PI Tang YT, Liu C, Drmanac RT, Asundi V, Zhou P, Xu C, Cao Y;  
 PI Ma Y, Zhao QA, Wang D, Wang J, Zhang J, Ren F, Chen R, Wang ZW;  
 PI Xue AJ, Yang Y, Wejhrman T, Goodrich R;



```
XX DR WPI; 2001-476283/51.
XX DR N-PSDB; AAK52128.
XX PT Nucleic acids encoding polypeptides with cytokine-like activities, useful
XX PT in diagnosis and gene therapy.
XX PS Claim 20; Page 4002-4003; 6221pp; English.
XX CC The invention relates to polynucleotides (AAK51456-AAK53435) and the
XX CC encoded polypeptides (AAM78323-AAM80302) that exhibit activity relating to
XX CC cytokine, cell proliferation or cell differentiation or which may induce
XX CC production of other cytokines in other cell populations. The
XX CC polynucleotides and polypeptides are useful in gene therapy, vaccines or
XX CC peptide therapy. The polypeptides have various cytokine-like activities,
XX CC e.g. stem cell growth factor activity, haematopoiesis regulating
XX CC activity, tissue growth factor activity, immunomodulatory activity and
XX CC activin/inhibin activity and may be useful in the diagnosis and/or
XX CC treatment of cancer, leukaemia, nervous system disorders, arthritis and
XX CC inflammation. Note: Records for SEQ ID NO 2110 (AAK52581), 2111
XX CC (AAK52582) and 3666 (AAM80020) are omitted as the relevant pages from the
XX CC sequence listing were missing at the time of publication
XX SQ Sequence 277 AA;

Query Match 38.5%; Score 477.5; DB 4; Length 277;
Best Local Similarity 41.3%; Pred. No. 4.2e-44;
Matches 97; Conservative 44; Mismatches 81; Indels 13; Gaps 5;

QY 7 GRTSSYRDEKRNHYQKIRDLDRKVTALKAGEDRAILLGLAMVCSIMMYFLLG 66
DB 20 GRTAFPSGKKRETDYS---DGDPLDVHKRLPS-STGEDRAVLMGFAMGFSVLMFLFG 75
QY 67 ITLLRSYMQSVWTEESQCTLLNASITETFCNSFSCGPDCKWLSQYPCLOVYNLTSSGE 125
DB 76 TTILKPFMLSIQREESTCTAIHTDMDLDCAFTGCHGQKYPCLQVFNLSHPGQ 135
QY 126 KLLLYHTETIKNOKSYTPCKGNFEESNLVNVNENFRKYQH-----FSCYSDEP 180
DB 136 KALLHYNEEAQINPKCFYTPKC---HQDRNDLLNSALDIKEFDHKNGFPSCFYSPAS 192
QY 181 NQKSVILTKYSSNVLFHSFWFTCMAGGVAIVAMVKLTQYLSLLCERIQNR 235
DB 193 QSEDVILIKKYDQMAIFHCLFWPSLTLGGALIVGMVRLTQHLSCERKSTVVR 247

RESULT 13
ABBI1970
XX AC ABB11970 standard; peptide; 301 AA.
XX DT 11-JAN-2002 (first entry)
XX XX Human Ca-activated K channel homologue, SEQ ID NO:2340.
XX KW Human; cytokine; cell proliferation; cell differentiation; growth factor;
XX KW haematopoiesis regulation; tissue growth; immunomodulator; activin;
XX KW inhibin; chemotaxis; chemokinesis; thrombolysis; oncogenesis;
XX KW proliferation; metastasis; cancer; tumour; haematopoietic disorder;
XX KW myeloid cell disorder; lymphoid cell disorder; asthma; arthritis;
XX KW chronic inflammatory condition; proliferative retinopathy;
XX KW atherosclerosis; coronary heart disease; arterial ischaemia;
XX KW bone disorder; osteoporosis; vascular growth disorder;
XX KW tissue regeneration; wound healing; infection; immune disorder;
XX KW cell culture; drug screening; gene therapy; anti-inflammatory;
XX KW antiarthritic; haemostatic; antiarteriosclerotic;
XX KW cytostatic; osteopathic; vasotropic; cardiant; virucide; antibacterial;
XX KW antifungal; vulnery; antiulcer.
XX OS Homo sapiens.
XX XX WO200157188-A2.

XX PD 09-AUG-2001.
XX PF 05-FEB-2001; 2001WO-US003800.
XX PR 03-FEB-2000; 2000US-00496914.
XX PR 27-APR-2000; 2000US-00560875.
XX PA (HYSE-) HYSEQ INC.
XX XX Tang YT, Liu C, Drmanac RT;
XX PI WPI; 2001-457740/49.
XX DR N-PSDB; ABA09214.
XX DR Human proteins and DNA encoding sequences useful for preventing, treating
XX PT or ameliorating a medical condition in a mammalian subject e.g. arthritis
XX PT and cancer.
XX PS Claim 20; Page 288-289; 1963pp; English.
XX CC Sequences ABB10981-ABB12330 represent 1350 novel human polypeptides, and
XX CC sequences ABA08225-ABA09574 represent nucleic acids encoding them. The
XX CC invention also relates to vectors and recombinant host cells comprising a
XX CC nucleotide of the invention, methods of producing the novel polypeptides,
XX CC antibodies against the polypeptides, methods of detecting the nucleotides
XX CC or polypeptides in a sample, and methods of identifying compounds which
XX CC bind to polypeptides of the invention. Although novel, many of the
XX CC polypeptides of the invention have homology to known proteins, thereby
XX CC giving an insight into their probable biological activities, and hence
XX CC potential therapeutic applications. The polypeptides of the invention may
XX CC have various activities, including cytokine, cell proliferation or cell
XX CC differentiation activities; stem cell growth factor activity;
XX CC haematopoiesis regulatory activity; tissue growth activity;
XX CC immunomodulatory activity; activin- or inhibin-related activities;
XX CC chemotactic or chemokinetic activities; haemostatic, thrombotic or
XX CC thrombolytic activities; receptor or ligand activities; or may be
XX CC involved in oncogenesis, cancer cell proliferation or metastasis.
XX CC Depending on their biological activities, polypeptides and nucleotides of
XX CC the invention are useful for preventing, treating or ameliorating medical
XX CC conditions, e.g. by protein or gene therapy. Such conditions include
XX CC cancers, haematopoietic disorders (e.g. myeloid or lymphoid cell
XX CC disorders), chronic inflammatory conditions (e.g., asthma or arthritis),
XX CC proliferative retinopathy, atherosclerosis, coronary heart disease,
XX CC arterial ischaemia, bone disorders (e.g., osteoporosis), and abnormal
XX CC vascular growth. Polypeptides involved with tissue regeneration and
XX CC repair (or nucleic acids encoding them) may be used to promote wound
XX CC healing (e.g., of burns, incisions and ulcers), while those with
XX CC immunomodulatory activities may be used in the treatment of viral,
XX CC bacterial and fungal infections in addition to immune disorders.
XX CC Polypeptides with growth factor activity may be used in cell cultures to
XX CC promote cell growth. For example, such polypeptides may be used to
XX CC manipulate stem cells in culture to give rise to neuroepithelial cells
XX CC that can be used to augment or replace cells damaged by illness,
XX CC autoimmune disease or accidental damage. The polypeptides and nucleotides
XX CC may also be used in the diagnosis of the above conditions, and in drug
XX CC screening techniques. The present sequence represents a novel human
XX CC polypeptide of the invention
XX SQ Sequence 301 AA;

Query Match 38.5%; Score 477.5; DB 4; Length 301;
Best Local Similarity 41.3%; Pred. No. 4.7e-44;
Matches 97; Conservative 44; Mismatches 81; Indels 13; Gaps 5;

QY 7 GRTSSYRDEKRNHYQKIRDLDRKVTALKAGEDRAILLGLAMVCSIMMYFLLG 66
DB 44 GRTAFPSGKKRETDYS---DGDPLDVHKRLPS-STGEDRAVLMGFAMGFSVLMFLFG 99
QY 67 ITLLRSYMQSVWTEESQCTLLNASITETFCNSFSCGPDCKWLSQYPCLOVYNLTSSGE 125
DB 100 TTILKPFMLSIQREESTCTAIHTDMDLDCAFTGCHGQKYPCLQVFNLSHPGQ 159
```

QY 126 KLLVHTETIKINOKCSYIPKCGKNFESMGLVNVVWENFRKYQH-----FSCYSDPEG 180  
 Db 160 KALLHYNEBAVQINPKCFYTPKC---HQDRNDLLNSALDIKEFFDHKNGTFFSCFYSPAS 216  
 QY 181 NOKSVILTXYSSNVLFHSLFWPTCMAGGVAIVAMVKLTQVLSLLCERIQRIINR 235  
 Db 217 QSEDEVILIKKYDQMAIFHCLFWPSLTLGGALIVGMVRLTQHLSSLCEKYSTVVR 271

RESULT 14  
 AAM79979  
 ID AAM79979 standard; protein; 301 AA.  
 AC AAM79979;  
 XX  
 XX  
 DT 06-NOV-2001 (first entry)  
 XX  
 DE Human protein SEQ ID NO 3625.  
 XX  
 XX Human; cytokine; cell proliferation; cell differentiation; gene therapy;  
 KW vaccine; peptide therapy; stem cell growth factor; haematopoiesis;  
 KW tissue growth factor; immunomodulatory; cancer; leukaemia;  
 KW nervous system disorder; arthritis; inflammation.  
 XX  
 OS Homo sapiens.  
 XX  
 XX WO200157190-A2.  
 XX  
 XX 09-AUG-2001.  
 XX  
 XX 05-FEB-2001; 2001WO-US004098.  
 XX  
 XX 03-FEB-2000; 2000US-00496914.  
 PR 27-APR-2000; 2000US-00560875.  
 PR 20-JUN-2000; 2000US-00598075.  
 PR 19-JUL-2000; 2000US-00620325.  
 PR 01-SEP-2000; 2000US-00654936.  
 PR 15-SEP-2000; 2000US-00663561.  
 PR 20-OCT-2000; 2000US-00693325.  
 PR 30-NOV-2000; 2000US-00728422.  
 XX  
 PA (HYSE-) HYSEQ INC.  
 XX  
 XX Tang YT, Liu C, Drmanac RT, Asundi V, Zhou P, Xu C, Cao Y;  
 PI Ma Y, Zhao QP, Wang D, Wang J, Zhang J, Ren F, Chen R, Wang ZW;  
 PI Xue AJ, Yang Y, Wejhrman T, Goodrich R;  
 XX  
 XX WPI; 2001-476283/51.  
 DR N-PSDB; AAK53112.  
 XX  
 XX Nucleic acids encoding polypeptides with cytokine-like activities, useful  
 PT in diagnosis and gene therapy.  
 XX  
 XX Claim 20; Page 401; 6221pp; English.  
 XX  
 XX The invention relates to polynucleotides (AAK51456-AAK53435) and the  
 CC encoded polypeptides (AAM78323-AAK80302) that exhibit activity elating to  
 CC cytokine, cell proliferation or cell differentiation or which may induce  
 CC production of other cytokines in other cell populations. The  
 CC polynucleotides and polypeptides are useful in gene therapy, vaccines or  
 CC peptide therapy. The polypeptides have various cytokine-like activities,  
 CC e.g. stem cell growth factor activity, haematopoiesis regulating  
 CC activity, tissue growth factor activity, immunomodulatory activity and  
 CC activin/inhibin activity and may be useful in the diagnosis and/or  
 CC treatment of cancer, leukaemia, nervous system disorders, arthritis and  
 CC inflammation. Note: Records for SEQ ID NO 2110 (AAK52581), 2111  
 CC (AAK52582) and 3666 (AAM80020) are omitted as the relevant pages from the  
 CC sequence listing were missing at the time of publication  
 XX  
 XX Sequence 301 AA;  
 XX  
 XX Query March 38.5%; Score 477.5; DB 4; Length 301;  
 XX Best Local Similarity 41.3%; Pred. No. 4.7e-44;  
 XX Matches 93; Conservative 41; Mismatches 71; Indels 10; Gaps 4;

Matches 97; Conservative 44; Mismatches 81; Indels 13; Gaps 5;  
 QY 7 GRTSSSYRDEKKNYQKIRDHLLDKRKTVTALKAGEDRAILLGLAMVVCIMMYFLIG 66  
 Db 44 GRTAFPASGKKRETDYS--DGPDLVDVHKRLPS-STGEDRAVNLGFMAMGFVLMFFLIG 99  
 QY 67 ITLLRSMOSVWTEESOCITLLNASITETP-NCFSFGCPDCKLSQYPCLOVYVNLTSCE 125  
 Db 100 TTLKPFMLSIQREESTCTAIHTDINDWDDCAFTCGVCHGCGKYPCLQVFNUSHPGQ 159  
 QY 126 KLLVHTETIKINOKCSYIPKCGKNFESMGLVNVVWENFRKYQH-----FSCYSDPEG 180  
 Db 160 KALLHYNEBAVQINPKCFYTPKC---HQDRNDLLNSALDIKEFFDHKNGTFFSCFYSPAS 216  
 QY 181 NOKSVILTXYSSNVLFHSLFWPTCMAGGVAIVAMVKLTQVLSLLCERIQRIINR 235  
 Db 217 QSEDEVILIKKYDQMAIFHCLFWPSLTLGGALIVGMVRLTQHLSSLCEKYSTVVR 271

RESULT 15  
 AAB35304  
 ID AAB35304 standard; protein; 275 AA.  
 XX AAB35304;  
 AC AAB35304;  
 XX  
 XX 08-MAY-2001 (first entry)  
 DT  
 XX  
 DE Human calcium sensitive potassium channel beta3c subunit.  
 XX  
 XX Human; calcium sensitive potassium channel; beta2 subunit; asthma;  
 KW beta3a subunit; beta3b subunit; beta3c subunit; beta3d subunit; diabetes;  
 KW chromosome 3q23-ter; inhibitor; activator; glaucoma; migraine; angina;  
 KW irritable bowel syndrome; Alzheimer's disease.  
 XX  
 XX Homo sapiens.  
 XX  
 XX WO200105828-A1.  
 XX  
 XX 25-JAN-2001.  
 XX  
 XX 18-JUL-2000; 2000WO-US019585.  
 XX  
 XX 20-JUL-1999; 99US-0144764P.  
 XX  
 XX (MERI) MERCK & CO INC.  
 XX  
 XX Uebele V, Swanson R, Liu Y, Lagrutta A;  
 XX  
 XX WPI; 2001-159514/16.  
 DR N-PSDB; AAF27994.  
 XX  
 XX Novel human calcium sensitive potassium channel subunits for identifying  
 PT inhibitors and agonists of the potassium channel for use in treating  
 PT conditions such as asthma, hypertension, memory disorders, depression.  
 XX  
 XX Claim 9; Fig 4B; 89pp; English.  
 XX  
 XX The present invention provides the protein and coding sequences of the  
 CC human calcium sensitive potassium channel beta2, beta3a, beta3b, beta3c  
 CC and beta3d subunits. These can be used to identify inhibitors and  
 CC activators of the channels, which can be used in the treatment of  
 CC conditions including asthma, diabetes, glaucoma, cerebral ischaemia,  
 CC Alzheimer's disease, excessive smooth muscle tone, angina, hypertension,  
 CC incontinence, migraine and irritable bowel syndrome. The coding sequences  
 CC are found at human chromosome 3q23-ter. The present sequence is the  
 CC beta3c subunit  
 XX  
 XX Sequence 275 AA;  
 XX  
 XX Query Match 38.3%; Score 475; DB 4; Length 275;  
 XX Best Local Similarity 43.3%; Pred. No. 7.9e-44;  
 XX Matches 93; Conservative 41; Mismatches 71; Indels 10; Gaps 4;

Qy	27	DHLLDKRKVTALKAGEDRAILGLAMVCSIMMYELLGITLLIRSYMOSVWTEESQCTL	86
Db	35	DGDFLDVHKRLPS-STGEDRAVNLGFAMGFSVLMFFLLGTTLKPFMLSIQREESTCTA	93
Qy	87	LNASITETP-NCSPSCGPDCKLSQYPCLOVYNLTSSGKLLYHTEETIKINQCSYI	145
Db	94	IHTDMDWLDCAFTCGVHCHGQKYPCLQVFNLSHPGOKALLHYNEEAVQINPKCFYT	153
Qy	146	PKCGKNFEESMSLVNVNENFRKYOH-----FSCYSDPEGNQKSVILTKLYSSNVLFHSL	200
Db	154	PKC---HQDRSDDLNSALDIKEFPDHKNGTFFSCFYSPASQSEVDVILIKKYDQMAIFHCL	210
Qy	201	FWPTCMAGGVAIVAMVKLTQYLSLLCERIQRINR	235
Db	211	FWPSLTLLGGALIVGMVRLTQHLSSLCEKYSTVVR	245

Search completed: November 6, 2004, 23:31:01  
Job time : 71 secs

This Page Blank (uspio)

GenCore version 5.1.6  
Copyright (c) 1993 - 2004 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: November 6, 2004, 23:26:11 ; Search time 64 Seconds

(without alignments)  
2112.704 Million cell updates/sec

Title: US-09-914-053A-5

Perfect score: 1241

Sequence: 1 MSITSGRTSSSRHDEKRN.....MVKLTQYLSLCLERIORINR 235

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 1825181 seqs, 575374646 residues

Total number of hits satisfying chosen parameters: 1825181

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

UniProt\_02:\*

1: uniprot\_sprot:\*

2: uniprot\_trembl:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

#### SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	1235	99.5	235	1	CKB2_HUMAN
2	1186	95.6	235	1	CKB2_MOUSE
3	1185	95.5	235	1	CKB2_RAT
4	507	40.9	200	1	CKB1_COTJA
5	490	39.5	200	2	CKB3333
6	474	38.2	279	1	CKB3_HUMAN
7	421	33.9	190	1	CKB3_HUMAN
8	421	33.9	191	2	AAS20193
9	418	33.7	190	1	CKB1_RAT
10	415	33.4	190	1	CKB1_MOUSE
11	406	32.7	190	1	CKB1_RABIT
12	396	31.9	190	1	CKB1_CANFA
13	382	30.8	190	1	CKB1_BOVIN
14	316	25.5	210	1	CKB4_HUMAN
15	312	25.1	210	1	CKB4_RAT
16	309	24.9	210	2	O6QXK8
17	309	24.9	210	2	AAS55654
18	308	24.8	210	1	CKB4_MOUSE
19	94.5	7.6	482	2	O8GWF7
20	93.5	7.5	526	2	O9NJF1
21	92	7.4	897	2	O85661
22	91.5	7.4	448	2	O9VZG8
23	91	7.3	828	2	O94886
24	90.5	7.3	895	2	O6FUN7
25	90.5	7.3	895	2	O9CIS1
26	89	7.2	285	1	CXA6_RAT
27	89	7.2	362	1	1B45_HUMAN
28	89	7.2	550	2	O6BWF2
29	89	7.2	949	2	O7RRD8
30	88	7.1	362	1	1B44_HUMAN
31	88	7.1	362	2	Q29849

#### RESULT 1

ID	CKB2_HUMAN	STANDARD;	PRT;	235 AA.
AC	Q9Y691;			
DT	05-JUL-2004 (Rel. 44, Created)			
DT	05-JUL-2004 (Rel. 44, Last sequence update)			
DT	01-OCT-2004 (Rel. 45, Last annotation update)			
DE	Calcium-activated potassium channel beta subunit 2 (Calcium-activated potassium channel, subfamily M, beta subunit 2) (Maxi K channel beta subunit 2) (BK channel beta subunit 2) (Slo-beta 2) (K(VCA)beta 2) (Charybdotoxin receptor beta subunit 2) (BKbeta2) (Hbeta2) (Hbeta3).			
GN	Name=KCNMB2;			
OS	Homo sapiens (Human).			
OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;			
OC	Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.			
OX	NCBI_TaxID=9606;			
RN	[1]			
RP	SEQUENCE FROM N.A., FUNCTION, DOMAIN, TISSUE SPECIFICITY, AND INTERACTION WITH KCNM1.			
RP	TISSUE=Neuroepithelium;			
RX	MEDLINE=99199323; PubMed=10097176;			
RA	Wallner M., Meera P., Toro L.;			
RT	"Molecular basis of fast inactivation in voltage and Ca2+-activated K+ channels: a transmembrane beta-subunit homolog."			
RL	Proc. Natl. Acad. Sci. U.S.A. 96:4137-4142(1999).			
RN	[2]			
RP	SEQUENCE FROM N.A., AND TISSUE SPECIFICITY.			
RC	TISSUE-Ovary;			
RX	MEDLINE=20158960; PubMed=10692449;			
RA	Brenner R., Jegla T.J., Wickenden A., Liu Y., Aldrich R.W.;			
RT	"Cloning and functional characterization of novel large conductance calcium-activated potassium channel subunits, hKCNMB3 and hKCNMB4."			
RL	J. Biol. Chem. 275:6453-6461(2000).			
RN	[3]			
RP	SEQUENCE FROM N.A.			
RC	TISSUE=Embryonic testis;			
RX	MEDLINE=23388257; PubMed=12477932; DOI=10.1073/pnas.242603899;			
RA	Strausberg R.D., Feingold E.A., Grouse L.H., Derge J.G.,			
RA	Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,			
RA	Ahtshul S.F., Zeeb B., Buetow K.H., Schaefer C.F., Bhat N.K.,			
RA	Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,			
RA	Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,			
RA	Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,			
RA	Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,			
RA	Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullaly S.J.,			
RA	Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,			
RA	Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,			
RA	Villalon D.K., Wuzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,			
RA	Fahy J., Helton E., Kettman M., Madan A., Rodrigues S., Sanchez A.,			
RA	Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,			
RA	Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,			
RA	Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,			
RA	Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smailus D.E.,			
RA	Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.;			

#### ALIGNMENTS

32	88	7.1	563	2	Q8IL46
33	88	7.1	591	2	Q9LL51
34	87.5	7.1	548	2	Q8WWQ1
35	87.5	7.1	592	2	Q9HB37
36	87.5	7.1	592	2	Q8WWQ2
37	87.5	7.1	593	2	Q7RKK3
38	87.5	7.1	1880	2	O18465
39	87	7.0	398	1	HISX_SULSO
40	87	7.0	497	2	O01964
41	87	7.0	500	2	Q96CS4
42	87	7.0	500	2	Q99PJ7
43	86.5	7.0	438	2	Q91VC4
44	86	6.9	238	1	CSH2_BOVIN
45	86	6.9	494	2	O01965



```
RT channel (Maxik, BK).";
RL Submitted (NOV-2001) to the EMBL/GenBank/DBJ databases.
RN [2]
RP SEQUENCE FROM N.A.
RC STRAIN=C57BL/6J; TISSUE=Embryo;
RA MEDLINE=22354683; PubMed=12466851; DOI=10.1038/nature01266;
RA Okazaki Y., Furuno M., Kasukawa T., Adachi J., Bono H., Kondo S.,
RA Nikaide I., Oeato Y., Saiko R., Suzuki H., Yamanaka I., Kiyosawa H.,
RA Yagi K., Tomaru Y., Hasegawa Y., Nogami A., Schonbach C., Gojobori T.,
RA Baldarelli R., Hilli D.P., Bult C., Hume D.A., Quackenbush J.,
RA Leland L.M., Kanapin A., Matsuda H., Batalov S., Beisel K.W.,
RA Blake J.A., Bradt D., Brusci V., Clothia C., Corbani L.E., Cousins S.,
RA Dalla E., Dragani T.A., Fletcher C.F., Forrest A., Frazer K.S.,
RA Gaasterland T., Gariboldi M., Gissi C., Godzik A., Gough J.,
RA Grimmer S., Gustincich S., Hirokawa N., Jackson I.J., Jarvis E.D.,
RA Kanai A., Kawai H., Kawasawa Y., Kedzierski R.M., King B.L.,
RA Konagaya A., Kurochkin I.V., Lee Y., Lenhard B., Lyons P.A.,
RA Meglath D.R., Maltais L., Marchionni L., McKenzie L., Miki H.,
RA Nagashima T., Numata K., Okido T., Pavan W.J., Perte G., Pesole G.,
RA Petrovsky N., Pillai R., Pontius J.U., Qi D., Ramachandran S.,
RA Ravasi T., Reed J.C., Reed D.J., Reid J., Ring B.Z., Ringwald M.,
RA Sadelin A., Schneider C., Sempke C.A., Setou M., Shimada K.,
RA Sultana R., Takenaka Y., Taylor M.S., Teasdale R.D., Tomita K.,
RA Verardo R., Wagner L., Wahlestedt C., Wang Y., Watanabe Y., Wells C.,
RA Wilming L.G., Wynshaw-Boris A., Yanagisawa M., Yang L., Yang L.,
RA Yuan Z., Zavalon M., Zhu Y., Zimmer A., Carninci P., Hayatsu N.,
RA Hirozane-Kishikawa T., Konno H., Nakamura M., Sakazume N., Sato K.,
RA Shiraki T., Waki K., Kawai J., Aizawa K., Arakawa T., Fukuda S.,
RA Hara A., Hashizume W., Imotani K., Ishii Y., Itoh M., Kagawa I.,
RA Miyazaki A., Sakai K., Sasaki D., Shibata K., Shinagawa A.,
RA Yasunishi A., Yoshino M., Waterston R., Lander E.S., Rogers J.,
RA Birney E., Hayashizaki Y.;
RT "Analysis of the mouse transcriptome based on functional annotation of
RT 60,770 full-length cDNAs";
RL Nature 420:563-573 (2002).
RN [3]
RP SEQUENCE FROM N.A.
RC STRAIN=C57BL/6; TISSUE=Brain;
RA MEDLINE=22386257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA Klausner R.D., Collins F.S., Wagner L., Schenker C.M., Schuler G.D.,
RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Heieh F.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA Brownstein M.J., Udén T.B., Toshlyuk S., Carninci P., Frange C.,
RA Raha S., Lequellano N.A., Peters G.J., Abramson R.D., Mullaly S.J.,
RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Pahey J., Helton E., Kettman M., Madan A., Rodriguez S., Sanchez A.,
RA Whitting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA Rodriguez A.C., Gramwood J., Schmutz J., Myers R.M.,
RA Butterfield Y.S.N., Krzywinski M.I., Skalek U., Smallos D.E.,
RA Schnerch A., Schein J.B., Jones S.J.M., Marra M.A.;
RT "Generation and initial analysis of more than 15,000 full-length human
RT and mouse cDNA sequences";
RL proc. Natl. Acad. Sci. U.S.A. 99:16899-16903 (2002).
CC -1- FUNCTION: Regulatory subunit of the calcium activated potassium
CC KCNMA1 (maxik) channel. Modulates the calcium sensitivity and
CC gating kinetics of KCNMA1, thereby contributing to KCNMA1 channel
CC diversity. Acts as a negative regulator that confers rapid and
CC complete inactivation of KCNMA1 channel complex (By similarity).
CC -1- SUBUNIT: Interacts with KCNMA1 tetramer. There are probably 4
CC molecules of KCNB2 per KCNMA1 tetramer (By similarity).
CC -1- SUBCELLULAR LOCATION: Integral membrane protein (By similarity).
CC -1- DOMAIN: The ball and chain domain mediates the inactivation of
CC KCNMA1. It occludes the conduction pathway of KCNMA1 channels, and
CC comprises the pore-blocking ball domain (residues 1-17) and the
CC chain domain (residues 20-45) linking it to the transmembrane
CC segment. The ball domain is made up of a flexible N-terminus
CC anchored at a well ordered loop-helix motif. The chain domain
```





```
QY 94 TFNCSFGPCDCKWLSOYPCLOVYVNLTSSEKLLVHTETIKINOKSVIPKCGKNFE 153
Db 64 KTHCTNBSGSEDEDFHYPCQVWNLVNTASQGVNLVHTEDTLERNPKCSFVPGNSNSK 123
QY 154 ESMGLVNVVMMENFRKYQHFCSPYDEGKQSVILTKLYSSNVLFHSLFWPTCMAGGVAI 213
Db 124 EVKARIEFIASFKYQTFPCYDPGGQNTVILSRVPPKGLLFTFLWPLMTFTGGLI 183
QY 214 VAMVKLTQYLSLCLER 229
Db 184 IVLVKISQYFVSLSAR 199

RESULT 5
Q93393 PRELIMINARY; PRT; 200 AA.
AC O93393
DT 01-NOV-1998 (TRENBLrel. 08, Created)
DT 01-NOV-1998 (TRENBLrel. 08, Last sequence update)
DT 05-JUL-2004 (TRENBLrel. 27, Last annotation update)
DE Putative calcium-activated potassium channel regulatory subunit
DE (Calcium-activated potassium channel beta subunit).
GN Name=CO6;
OS Gallus gallus (Chicken).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Archosauria; Aves; Neognathae; Galliformes; Phasianidae;
OC Gallus.
OX NCBI_TaxID=9031;
RN [1]
RP SEQUENCE FROM N.A. (ISOFORM 1); AND TISSUE SPECIFICITY.
RX MEDLINE=97224079; PubMed=90708660;
RA Oberst C., Weiskirchen R., Hartl M., Bister K.;
RT "Suppression in transformed avian fibroblasts of a gene (CO6) encoding
RT a membrane protein related to mammalian potassium channel regulatory
RT subunits.";
RL Oncogene 14:1109-1116 (1997).
RN [2]
RP SEQUENCE FROM N.A.
RA Oberst C., Bister K.;
RL Submitted (JUL-1998) to the EMBL/GenBank/DBJ databases.
RN [3]
RP SEQUENCE FROM N.A.
RA Bait S.L., Hudspeth A.J.;
RL Submitted (SEP-2001) to the EMBL/GenBank/DBJ databases.
DR EMBL; AF077369; AAC27490.1; -
DR EMBL; AF420468; AAL16898.1; -
DR GO; GO:0016020; C:membrane; IEA.
DR GO; GO:0015269; F:calcium-activated potassium channel activity; IEA.
DR GO; GO:0005216; F:ion channel activity; IEA.
DR GO; GO:0006813; P:potassium ion transport; IEA.
DR InterPro; IPR003930; BK_channel_beta.
DR Pfam; PF03185; CaKb; 1.
DR PRINTS; PR01450; BKCHANNELB.
KW Ionic channel.
SQ SEQUENCE 200 AA; 22663 MW; CFD676158C5E0535 CRC64;

Query Match 39.5%; Score 490; DB 2; Length 200;
Best Local Similarity 46.4%; Pred. No. 2.9e-35;
Matches 91; Conservative 41; Mismatches 64; Indels 0; Gaps 0;

QY 34 RKTVTALKAGDRAILLGLAMVCSIMYFLLGILLRSYMQSVMTTESQTLNAGSITE 93
Db 4 KKLVTAKRGETRALCLGLGVACSMWYFFIGITVFPFKSVWTTETICKLVKNKD 63

QY 94 TFNCSFGPCDCKWLSOYPCLOVYVNLTSSEKLLVHTETIKINOKSVIPKCGKNFE 153
Db 64 KALCSNBSGSEDEDFHYPCQVWNLVNTASQGVNLVHTEDTLERNPKCSFVPGNSNAK 123
QY 154 ESMGLVNVVMMENFRKYQHFCSPYDEGKQSVILTKLYSSNVLFHSLFWPTCMAGGVAI 213
Db 124 EVKARIEFIASFKYQTFPCYDPGGQNTVILSRVPPKGLLFTFLWPLMTFTGGLI 183
```

```
QY 214 VAMVKLTQYLSLCLER 229
Db 184 IVLVKISQYFVSLSAR 199

RESULT 6
CKB3_HUMAN STANDARD; PRT; 279 AA.
ID CKB3_HUMAN
AC Q9NPJ1; Q9NPG7; Q9NRM9; Q9UHN3;
DT 05-JUL-2004 (Rel. 44, Created)
DT 05-JUL-2004 (Rel. 44, Last sequence update)
DE Calcium-activated potassium channel beta subunit 3 (Calcium-activated
DE potassium channel, subfamily M, beta subunit 3) (Maxi K channel beta
DE subunit 3) (BK channel beta subunit 3) (Slo-beta 3) (K(VCA)beta 3)
DE (Charybdotoxin receptor beta subunit 3) (BKbeta3) (Hbeta3).
GN Name=KCNMB3; (Human).
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A. (ISOFORM 3); AND TISSUE SPECIFICITY.
RX MEDLINE=20054359; PubMed=10585773; DOI=10.1006/geno.1999.5975;
RA Riaz M.A., Brinkman-Mills F., Johnson A., Naylor S.L., Minoshima S.,
RA Shimizu N., Baldini A., McDermid H.E.;
RT "Identification of a putative regulatory subunit of a calcium-
RT activated potassium channel in the dup(3q) syndrome region and a
RT related sequence on 22q11.2.";
RL Genomics 62:90-94 (1999).
RN [2]
RP SEQUENCE FROM N.A. (ISOFORM 4); TISSUE SPECIFICITY, AND INTERACTION
RP WITH KCNNAL.
RC TISSUE=Brain;
RX MEDLINE=20158960; PubMed=10692449;
RA Brenner R., Jegla T.J., Wickenden A., Liu Y., Aldrich R.W.;
RT "Cloning and functional characterization of novel large conductance
RT calcium-activated potassium channel subunits, hKCNMB3 and hKCNMB4.";
RL J. Biol. Chem. 275:6453-6461 (2000).
RN [3]
RP SEQUENCE FROM N.A. (ISOFORMS 1; 2; 3 AND 4); FUNCTION, ALTERNATIVE
RP SPLICING, TISSUE SPECIFICITY, AND VARIANT SER-165.
RC TISSUE=Spleen;
RX MEDLINE=20390083; PubMed=10766764; DOI=10.1074/jbc.M910187199;
RA Uebele V.N., Lagrutta A.A., Wade T., Figueroa D.J., Liu Y.,
RA McKenna E., Austin C.P., Bennett P.B., Swanson R.;
RT "Cloning and functional expression of two families of Beta-subunits of
RT the large conductance calcium-activated potassium channel.";
RL J. Biol. Chem. 275:23211-23218 (2000).
RN [4]
RP SEQUENCE FROM N.A. (ISOFORM 1); AND GLYCOSYLATION.
RX MEDLINE=20266405; PubMed=10792058; DOI=10.1073/pnas.100118597;
RA Meera P., Wallner M., Toro L.;
RT "A neuronal beta subunit (KCNMB4) makes the large conductance,
RT voltage- and Ca2+-activated K+ channel resistant to charybdotoxin and
RT iberiotoxin.";
RL Proc. Natl. Acad. Sci. U.S.A. 97:5562-5567 (2000).
RN [5]
RP SEQUENCE FROM N.A. (ISOFORM 4).
RX PubMed=10828459;
RA Behrens R., Nolting A., Reimann F., Schwarz M., Waldschuetz R.,
RA Pongs O.;
RT "hKCNMB3 and hKCNMB4, cloning and characterization of two members of
RT the large-conductance calcium-activated potassium channel beta subunit
RT family.";
RL FEBS Lett. 474:99-106 (2000).
RN [6]
RP FUNCTION.
RX PubMed=10864947;
RA Xia X.-M., Ding J.-P., Zeng X.-H., Duan X.-L., Lingle C.J.;
RT "Rectification and rapid activation at low Ca2+ of Ca2+-activated,
RT voltage-dependent BK currents: consequences of rapid inactivation by a
RT novel beta subunit.";
```

RL J. Neurosci. 20:4890-4903 (2000).  
 RN [7]  
 RN DOMAIN.  
 RP PubMed=11382808;  
 RX Lingle C.J., Zeng X.-H., Ding J.-P., Xia X.-M.;  
 RA "Inactivation of BK channels mediated by the NH(2) terminus of the  
 RT beta3b auxiliary subunit involves a two-step mechanism: possible  
 RT separation of binding and blockade.";  
 RL J. Gen. Physiol. 117:583-606 (2001).  
 RN [8]  
 RN DOMAIN.  
 RP PubMed=11382809;  
 RX Zeng X.-H., Ding J.-P., Xia X.-M., Lingle C.J.;  
 RA "Gating properties conferred on BK channels by the beta3b auxiliary  
 RT subunit in the absence of its NH(2)- and COOH termini.";  
 RL J. Gen. Physiol. 117:607-628 (2001).  
 RN [9]  
 RN VARIANTS VAL-75; SER-165 AND THR-230.  
 RP PubMed=14612589; DOI=10.1152/physiolgenomics.00110.2003;  
 RX Hu S., Labuda M.Z., Pandolfo M., Goss G.G., Mcdermid H.E., Ali D.W.;  
 RA "Variants of the KCNB3 regulatory subunit of maxi BK channels affect  
 RT channel inactivation.";  
 RL Physiol. Genomics 15:191-198 (2003).  
 RN [10]  
 RN DISULFIDE BONDS, AND DOMAIN.  
 RP PubMed=12740608; DOI=10.1038/nsb932;  
 RX Zeng X.-H., Xia X.-M., Lingle C.J.;  
 RA "Redox-sensitive extracellular gates formed by auxiliary beta subunits  
 RT of calcium-activated potassium channels.";  
 RL Nat. Struct. Biol. 10:448-454 (2003).  
 RN [11]  
 RN REVIEW.  
 RP PubMed=12136044;  
 RX Orio P., Rojas P., Ferreira G., Latorre R.;  
 RA "New disguises for an old channel: MaxiK channel beta-subunits.";  
 RL News Physiol. Sci. 17:156-161 (2002).  
 CC -!- FUNCTION: Regulatory subunit of the calcium activated potassium  
 CC KCNA1 (maxiK) channel. Modulates the calcium sensitivity and  
 CC gating kinetics of KCNA1 thereby contributing to KCNA1 channel  
 CC diversity. Alters the functional properties of the current  
 CC expressed by the KCNA1 channel. Isoform 2, isoform 3 and isoform  
 CC 4 partially inactivate the current of KCNEA. Isoform 4 induces a  
 CC fast and incomplete inactivation of KCNA1 channel that is  
 CC detectable only at large depolarizations. In contrast, isoform 1  
 CC does not induce detectable inactivation of KCNA1. Two or more  
 CC subunits of KCNEB3 are required to block the KCNA1 tetramer.  
 CC -!- SUBUNIT: Interacts with KCNA1 tetramer. There are probably 4  
 CC molecules of KCNEB3 per KCNA1 tetramer.  
 CC -!- SUBCELLULAR LOCATION: Integral membrane protein.  
 CC -!- ALTERNATIVE PRODUCTS:  
 CC Event=Alternative splicing; Named isoforms=4;  
 CC Name=1; Synonyms=3d;  
 CC IsoId=Q3NPAL-1; Sequence=Displayed;  
 CC Name=2; Synonyms=3a;  
 CC IsoId=Q3NPAL-2; Sequence=VSP\_009827;  
 CC Name=3; Synonyms=3c;  
 CC IsoId=Q3NPAL-3; Sequence=VSP\_009828;  
 CC Name=4; Synonyms=3b;  
 CC IsoId=Q3NPAL-4; Sequence=VSP\_009830;  
 CC -!- TISSUE SPECIFICITY: Isoform 1, isoform 3 and isoform 4 are widely  
 CC expressed. Isoform 2 is expressed in placenta, pancreas, kidney and  
 CC heart. Isoform 1 and isoform 3 are highly expressed in pancreas  
 CC and testis.  
 CC -!- DOMAIN: The cytoplasmic N-terminus domain of isoform 4  
 CC participates to the partial inactivation of KCNA1, possibly by  
 CC binding of to a receptor site.  
 CC -!- DOMAIN: The extracellular domain forms gates to block ion  
 CC permeation, providing a mechanism by which current can be rapidly  
 CC diminished upon cellular repolarization.  
 CC -!- PTM: N-Glycosylated.  
 CC -!- PTM: The extracellular domain contains disulfide bond essential  
 CC for the gating mechanism.  
 CC -!- SIMILARITY: Belongs to the KCNB family.

CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -  
 CC the European Bioinformatics Institute. There are no restrictions on its  
 CC use by non-profit institutions as long as its content is in no way  
 CC modified and this statement is not removed. Usage by and for commercial  
 CC entities requires a license agreement (See http://www.isb-sib.ch/announce/  
 CC or send an email to license@isb-sib.ch).  
 CC -----  
 DR EMBL; AF139471; AAD54771.1; -  
 DR EMBL; AF214561; AAF36598.1; -  
 DR EMBL; AF204159; AAF97031.1; -  
 DR EMBL; AF204160; AAF97032.1; -  
 DR EMBL; AF204161; AAF97033.1; -  
 DR EMBL; AF204162; AAF97034.1; -  
 DR EMBL; AF160968; AAF67811.1; -  
 DR EMBL; AF170916; AAF89698.1; -  
 DR Genew; HGNC:6287; KCNB3.  
 DR MIM; 603222; -  
 DR GO; GO:0016020; C:membrane; NAS.  
 DR GO; GO:0015459; P:potassium channel regulator activity; NAS.  
 DR GO; GO:0006813; P:potassium ion transport; NAS.  
 DR InterPro; IPR003930; BK\_channel\_beta.  
 DR Pfam; PF03185; CakB; 1.  
 KW Alternative splicing; Glycoprotein; Ionic channel; Polymorphism;  
 KW Transmembrane.  
 KX DOMAIN 1 60 Cytoplasmic (Potential).  
 FT TRANSMEM 61 81 1 (Potential).  
 FT DOMAIN 82 207 Extracellular (Potential).  
 FT TRANSMEM 208 228 2 (Potential).  
 FT DOMAIN 229 279 Cytoplasmic (Potential).  
 FT CARBOHYD 131 131 N-linked (GlcNAc...) (Potential).  
 FT VARSPPLIC 1 22 MDPSPSELGFHFVAFILLTRH -> MDPSPSPVQITLQGS  
 FT RRRQG (in isoform 2).  
 FT FTID=VSP\_009827.  
 FT VARSPPLIC 1 22 MDPSPSELGFHFVAFILLTRH -> MPFLLYELTAVSPSP  
 FT FPQ (in isoform 3).  
 FT FTID=VSP\_009828.  
 FT Missing (in isoform 4).  
 FT VARSPPLIC 23 23 FTID=VSP\_009829.  
 FT R -> M (in isoform 4).  
 FT FTID=VSP\_009830.  
 FT VARIANT 44 44 D -> G (in dbSNP:1170672).  
 FT FTID=VAR\_018173.  
 FT VARIANT 53 53 T -> A (in dbSNP:7645550).  
 FT FTID=VAR\_018174.  
 FT VARIANT 75 75 L -> V (in dbSNP:2276802).  
 FT FTID=VAR\_018175.  
 FT N -> S.  
 FT FTID=VAR\_018176.  
 FT M -> T.  
 FT FTID=VAR\_018177.  
 FT A6FSA0F64E19AB86 CRC64;  
 SQ SEQUENCE 279 AA; 31633 MW; 31633 MW;  
 Query Match 38.2%; Score 474; DB 1; Length 279;  
 Best Local Similarity 43.3%; Pred. No. 1.1e-33;  
 Matches 93; Conservative 41; Mismatches 71; Indels 10; Gaps 4;  
 QY 27 DHDLDKRTVTALKAGEDRALLLGLAMVVCISIMVYFLLGITLLRSYMQSVWTEBSQCTL 86  
 DB 39 DGDPLDVHKLIPS-STGEDRAVLMGFAMMGFVLMFFLLGITLLRPFMLSLQREESTCTA 97  
 QY 87 INASITETP-NCFSFGCPDWKLSOYPCLVQVYVNLTSSEKLLLYHTTETIKNKCSYI 145  
 DB 98 IHTDIMDDLDCAFTCGVHCCHQCKYPCGLQVFNLSHPGKQALLHYNEAAVQINPKCYT 157  
 QY 146 PKCGKNFEESMLVNVWVENFRKYOH-----PSCVSDPEGNCKSVILNKLXSSNVLFHSL 200  
 DB 158 PKC---HQNDLLNSALDIKEFFDHKNGTFFSCFYPASQSEVDILLIKKYDQVAIFHCL 214  
 QY 201 FWPTCMAGGVAIVAMVKLTQVLSLLCERIQINR 235  
 DB 215 FWPSLTLLGGALIVGNVRLTQHLSLCEKYSTVVR 249

## RESULT 7

CKB1\_HUMAN  
 ID\_CKB1\_HUMAN STANDARD; PRT; 190 AA  
 AC Q16558; O00707; O00708; P78475; Q8TAX3; Q93005;  
 DT 01-NOV-1997 (Rel. 35, Created)  
 DT 01-NOV-1997 (Rel. 35, Last sequence update)  
 DT 01-OCT-2004 (Rel. 45, Last annotation update)  
 DE Calcium-activated potassium channel beta subunit 1 (Calcium-activated  
 DE potassium channel, subfamily M, beta subunit 1) (Maxi K channel beta  
 DE subunit 1) (BK channel beta subunit 1) (Slo-beta 1) (K(VCA)beta 1)  
 DE (Charybdotoxin receptor beta subunit 1) (BKbeta) (Slo-beta) (Calcium-  
 DE activated potassium channel beta subunit) (BKbeta) (Slo-beta).  
 GN Name=KCNMB1;  
 OS Homo sapiens (Human).  
 OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;  
 OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
 OX NCBI\_TaxID=9606;  
 RN [1]  
 RP SEQUENCE FROM N.A. (ISOFORM 1).  
 RC TISSUE=Uterus;  
 RX MEDLINE=96196569; PubMed=8612769;  
 RA Meera P., Wallner M., Jiang Z., Toro L.;  
 RT "A calcium switch for the functional coupling between alpha (halo) and  
 RT beta subunits (KV,Ca beta) of maxi K channels.";  
 RL FEBS Lett. 382:84-88(1996).  
 RN [2]  
 RP SEQUENCE FROM N.A. (ISOFORM 1).  
 RC TISSUE=Uterus;  
 RX MEDLINE=96335638; PubMed=8764643;  
 RA Dworetzky S.I., Boissard C.G., Lum-Ragan J.T., McKay M.C.,  
 RA Post-Munson D.J., Trojnecki J.T., Chang C.P., Gribkoff V.K.;  
 RT "Phenotypic alteration of a human BK (hSlo) channel by hSlobeta  
 RT subunit coexpression: changes in blocker sensitivity,  
 RT activation/relaxation and inactivation kinetics, and protein kinase A  
 RT modulation.";  
 RL J. Neurosci. 16:4543-4550(1996).  
 RN [3]  
 RP SEQUENCE FROM N.A. (ISOFORM 1).  
 RC TISSUE=Brain;  
 RX MEDLINE=96392390; PubMed=8799178;  
 RA Metzger-Crank J., Godinot N., Johansen T.E., Ahning P.K., Strobaek D.,  
 RA Tszeng-Rank J., Foster C.D., Olesen S.P., Reinhardt P.H.;  
 RT "Cloning, expression, and distribution of a Ca(2+)-activated K+  
 RT channel beta-subunit from human brain.";  
 RL Proc. Natl. Acad. Sci. U.S.A. 93:9200-9205(1996).  
 RN [4]  
 RP SEQUENCE FROM N.A. (ISOFORM 1).  
 RC TISSUE=Aortic smooth muscle;  
 RA Folander K., Biazio D., Swanson R.;  
 RL Submitted (JUN-1997) to the EMBL/GenBank/DBJ databases.  
 RN [5]  
 RP SEQUENCE FROM N.A. (ISOFORM 1).  
 RC TISSUE=Myometrium;  
 RX PubMed=12434576;  
 RA Mazonne J.N., Kaiser R.A., Buxton I.L.;  
 RT "Calcium-activated potassium channel expression in human myometrium:  
 RT effect of pregnancy";  
 RL Proc. West. Pharmacol. Soc. 45:184-186(2002).  
 RN [6]  
 RP SEQUENCE FROM N.A. (ISOFORM 2).  
 RC TISSUE=Pancreas;  
 RX MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;  
 RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,  
 RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,  
 RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,  
 RA Hopkins R.F., Jordan H.K., Moore T., Max S.I., Wang J., Hsieh F.,  
 RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,  
 RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,  
 RA Brownstein M.J., Udwin T.B., Toshiyuki S., Carninci P., Prange C.,  
 RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullany S.J.,  
 RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,

Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,  
 RA Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,  
 RA Fahey J., Helton E., Kettman M., Madan A.C., Rodrigues S., Sanchez A.,  
 RA Whitling M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,  
 RA Blakeley R.W., Touchman J.W., Green E.D., Dickson M.C.,  
 RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,  
 RA Butterfield Y.S.N., Krzywinski M.L., Skalska U., Smailus D.E.,  
 RA Scherch A., Schein J.E., Jones S.J.M., Marra M.A.;  
 RT "Generation and initial analysis of more than 15,000 full-length human  
 RT and mouse cDNA sequences.";  
 RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).  
 RN [7]  
 RP GLYCOSYLATION  
 RX MEDLINE=20286405; PubMed=10792058; DOI=10.1073/pnas.100118597;  
 RA Meera P., Wallner M., Toro L.;  
 RT "A neuronal beta subunit (KCNMB4) makes the large conductance,  
 RT voltage- and Ca2+-activated K+ channel resistant to charybdotoxin and  
 RT iberiotoxin.";  
 RL Proc. Natl. Acad. Sci. U.S.A. 97:5562-5567(2000).  
 RN [8]  
 RP E2-BINDING.  
 RX PubMed=10489376;  
 RA Valverde M.A., Rojas P., Amigo J., Cosmelli D., Orio P.,  
 RA Bahamonde M.I., Mann G.E., Vergara C., Latorre R.;  
 RT "Acute activation of Maxi-K channels (hSlo) by estradiol binding to  
 RT the beta subunit.";  
 RL Science 285:1929-1931(1999).  
 RN [9]  
 RP REVIEW.  
 RX PubMed=12136044;  
 RA Orio P., Rojas P., Ferreira G., Latorre R.;  
 RT "New disguises for an old channel: MaxiK channel beta-subunits.";  
 RL News Physiol. Sci. 17:156-161(2002).  
 RN [10]  
 RP VARIANT LYS-64.  
 RX PubMed=15057310; DOI=10.1172/JCI200420347;  
 RA Fernandez-Fernandez J.M., Tomas M., Vazquez E., Orio P., Latorre R.,  
 RA Senti M., Marrugat J., Valverde M.A.;  
 RT "Gain-of-function mutation in the KCNMB1 potassium channel subunit is  
 RT associated with low prevalence of diastolic hypertension.";  
 RL J. Clin. Invest. 113:1032-1039(2004).  
 CC -1- FUNCTION: Regulatory subunit of the calcium activated potassium  
 CC KCNMB1 (maxiK) channel. Modulates the calcium sensitivity and  
 CC gating kinetics of KCNMB1, thereby contributing to KCNMB1 channel  
 CC diversity. Increases the apparent Ca(2+)/voltage sensitivity of  
 CC the KCNMB1 channel. It also modifies KCNMB1 channel kinetics and  
 CC alters its pharmacological properties. It slows down the  
 CC activation and the deactivation kinetics of the channel. Acts as a  
 CC negative regulator of smooth muscle contraction by enhancing the  
 CC calcium sensitivity to KCNMB1. Its presence is also a requirement  
 CC for internal binding of the KCNMB1 channel opener  
 CC dehydroscaponein I (DHS-1) triterpene glycoside and for external  
 CC binding of the agonist hormone 17-beta-estradiol (E2). Increases  
 CC the binding activity of charybdotoxin (CTX) toxin to KCNMB1  
 CC peptide blocker by increasing the CTX association rate and  
 CC decreasing the dissociation rate.  
 CC -1- SUBUNIT: Interacts with KCNMB1 tetramer. There are probably 4  
 CC molecules of KCNMB1 per KCNMB1 tetramer.  
 CC -1- SUBCELLULAR LOCATION: Integral membrane protein.  
 CC -1- ALTERNATIVE PRODUCTS:  
 CC Event-Alternative splicing; Named isoforms=2;  
 CC Name=1;  
 CC IsoId=Q16558-1; Sequence=Displayed;  
 CC Name=2;  
 CC IsoId=Q16558-2; Sequence=VSP\_009822; VSP\_009823;  
 CC Note=No experimental confirmation available;  
 CC -1- TISSUE SPECIFICITY: Abundantly expressed in smooth muscle. Low  
 CC levels of expression in most other tissues. Within the brain,  
 CC relatively high levels found in hippocampus and corpus callosum.  
 CC -1- PTM: N-glycosylated.  
 CC -1- POLYMORPHISM: Genetic variation in KCNMB1 can influence the  
 CC severity of diastolic hypertension.  
 CC -1- SIMILARITY: Belongs to the KCNMB family.







```
Db 174 IANVKLNRSLSIL 186
:|||||:|:|
RESULT 11
CKB1_RABIT STANDARD; PRT; 190 AA.
AC 046372;
DT 05-JUL-2004 (Rel. 44, Last sequence update)
DT 05-JUL-2004 (Rel. 44, Last annotation update)
DE Calcium-activated potassium channel beta subunit 1 (Calcium-activated
DE potassium channel, subfamily M, beta subunit 1) (Maxi K channel beta
DE subunit 1) (BK channel beta subunit 1) (Slo-beta 1) (K(VCA)beta 1)
DE (Charybdotoxin receptor beta subunit 1) (BKbeta) (Calcium-activated
DE potassium channel beta-subunit) (BKbeta) (Slo-beta).
GN Name=KCNMB1;
OS Oryctolagus cuniculus (Rabbit);
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Lagomorpha; Leporidae; Oryctolagus.
OX NCBI_TaxID=9986;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=New Zealand white; TISSUE=Brain;
RX PubMed=10821684; DOI=10.1021/bi92865z;
RA Giangiacomo K.M., Fremont V., Mullmann T.J., Hanmer M., Cox R.H.,
RA Garcia M.L.;
RT "Interaction of charybdotoxin S10A with single maxi-K channels:
RT kinetics of blockade depend on the presence of the beta 1 subunit.";
RL Biochemistry 39:6115-6122(2000).
RN [2]
RP SEQUENCE FROM N.A.
RX PubMed=11294242;
RA Ohya S., Yamamura H., Muraki K., Watanabe M., Imaizumi Y.;
RT "Comparative study of the molecular and functional expression of L-
RT type Ca2+ channels and large-conductance, Ca2+-activated K+ channels
RT in rabbit aorta and vas deferens smooth muscle.";
RL Pflugers Arch. 441:611-620(2001).
RN [3]
RP SEQUENCE FROM N.A.
RC TISSUE=Skeletal muscle;
RA Sakamoto H., Ide T., Kasai M.;
RL Submitted (NOV-1997) to the EMBL/GenBank/DBJ databases.
CC -!- FUNCTION: Regulatory subunit of the calcium activated potassium
CC channel. Modulates the calcium sensitivity and
CC gating kinetics of KCNNM1, thereby contributing to KCNNM1 channel
CC diversity. Increases the apparent Ca(2+)/voltage sensitivity of
CC the KCNNM1 channel. It also modifies KCNNM1 channel kinetics and
CC alters its pharmacological properties. It slows down the
CC activation and the deactivation kinetics of the channel. Acts as a
CC negative regulator of smooth muscle contraction by enhancing the
CC calcium sensitivity to KCNNM1. Its presence is also a requirement
CC for internal binding of the KCNNM1 channel opener
CC dehydroxyasaponin I (DHS-1) triterpene glycoside and for external
CC binding of the agonist hormone 17-beta-estradiol (E2). Increases
CC the binding activity of charybdotoxin (CTX) toxin to KCNNM1
CC peptide blocker by increasing the CTX association rate and
CC decreasing the dissociation rate (By similarity).
CC -!- SUBUNIT: Interacts with KCNNM1 tetramer. There are probably 4
CC molecules of KCNNM1 per KCNNM1 tetramer (By similarity).
CC -!- SUBCELLULAR LOCATION: Integral membrane protein.
CC -!- SIMILARITY: Belongs to the KCNNB family.
CC
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.ebi.ac.uk/announcements/
CC or send an email to license@ebi.ac.uk).
CC
CC EMBL; AF107300; AAD17994.1; -
EMBL; AB001934; BAA25630.1; -
EMBL; AB009313; BAA23748.1; -
InterPro: IPR003930; BK_channel_beta.
DR Pfam: PF03185; CakB; 1.
KW Glycoprotein; Ionic channel; Transmembrane.
FT INILMET 0 0 By similarity.
FT DOMAIN 1 14 Cytoplasmic (Potential).
FT TRANSMEM 15 35 1 (Potential).
FT DOMAIN 36 156 Extracellular (Potential).
FT TRANSMEM 157 177 2 (Potential).
FT DOMAIN 178 190 Cytoplasmic (Potential).
FT CARBOHYD 79 79 N-linked (GlcNAc...) (Potential).
FT CARBOHYD 141 141 N-linked (GlcNAc...) (Potential).
SQ SEQUENCE 190 AA; 21697 MW; 687C2F406E5A4FC9 CRC64;
Query Match 32.7%; Score 406; DB 1; Length 190;
Best Local Similarity 42.0%; Pred. No. 7.5e-28;
Matches 81; Conservative 42; Mismatches 62; Indels 8; Gaps 2;
QY 34 RKTIVTALKAGEDRAILLGLAMVCSIMVYFLIGITLLRSYMQSVMTESQCTLLNASITE 93
DB 2 KKLVAQKRGEGTRALCLGVAMVCAVITYIIGTITMLPLYQKSVMTQSLCLRIETNRD 61
QY 94 TFNCSFGCPDCWKLQSYPCQLQVYVNLTSSEKLLYHTEETIKINQKCSYFKGQKNE 153
DB 62 QBELECK-----KVPQYFCL--WNVSAVGKAWLYHTEETDRNQCSYIPGSLDNQY 113
QY 154 EMSLVNVVNMENFRKQHCSCYSDPEGNOKSVILKLYSSNVLPFSLFWPTCMAGGVAI 213
DB 114 MALADVEKVRKAFHERQVCFYFTQENETSVLYQRLYQPOLALLASFLFWPTFLTGLLI 173
QY 214 VAMVKLTQYLSLL 226
DB 174 IANVKLNRSLSIL 186
RESULT 12
CKB1_CANFA STANDARD; PRT; 190 AA.
AC Q282Z6;
DT 01-NOV-1997 (Rel. 35, Created)
DT 01-NOV-1997 (Rel. 35, Last sequence update)
DT 05-JUL-2004 (Rel. 44, Last annotation update)
DE Calcium-activated potassium channel beta subunit 1 (Calcium-activated
DE potassium channel, subfamily M, beta subunit 1) (Maxi K channel beta
DE subunit 1) (BK channel beta subunit 1) (Slo-beta 1) (K(VCA)beta 1)
DE (Charybdotoxin receptor beta subunit 1) (BKbeta) (Calcium-activated
DE potassium channel beta-subunit) (BKbeta) (Slo-beta).
GN Name=KCNMB1;
OS Canis familiaris (Dog).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Carnivora; Fissipedia; Canidae; Canis.
OX NCBI_TaxID=9615;
RN [1]
RP SEQUENCE FROM N.A.
RC MEDLINE=97053370; PubMed=897882;
RX Vogalis F., Vincent T., Qureshi I., Schmalz F.M., Ward M.W.,
RA Sanders K.M., Horowitz B.;
RT "Cloning and expression of the large-conductance Ca(2+)-activated K+
RT channel from colonic smooth muscle.";
RL Am. J. Physiol. 271:G629-G639(1996).
CC -!- FUNCTION: Regulatory subunit of the calcium activated potassium
CC channel (maxiK) channel. Modulates the calcium sensitivity and
CC gating kinetics of KCNNM1, thereby contributing to KCNNM1 channel
CC diversity. Increases the apparent Ca(2+)/voltage sensitivity of
CC the KCNNM1 channel. It also modifies KCNNM1 channel kinetics and
CC alters its pharmacological properties. It slows down the
CC activation and the deactivation kinetics of the channel. Acts as a
CC negative regulator of smooth muscle contraction by enhancing the
CC calcium sensitivity to KCNNM1. Its presence is also a requirement
CC for internal binding of the KCNNM1 channel opener
CC dehydroxyasaponin I (DHS-1) triterpene glycoside and for external
CC binding of the agonist hormone 17-beta-estradiol (E2). Increases
```

CC the binding activity of charybdotoxin (CTX) toxin to KCNNM1  
 CC peptide blocker by increasing the CTX association rate and  
 CC decreasing the dissociation rate (By similarity).  
 CC  
 CC -!- SUBUNIT: Interacts with KCNNM1 tetramer. There are probably 4  
 CC molecules of KCNNM1 per KCNNM1 tetramer (By similarity).  
 CC -!- SUBCELLULAR LOCATION: Integral membrane protein (By similarity).  
 CC -!- PTM: N-glycosylated (By similarity).  
 CC -!- SIMILARITY: Belongs to the KCNNB family.

CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -  
 CC the European Bioinformatics Institute. There are no restrictions on its  
 CC use by non-profit institutions as long as its content is in no way  
 CC modified and this statement is not removed. Usage by and for commercial  
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>  
 CC or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).  
 CC  
 CC EMBL; U41002; AAA84001.1; -;  
 CC InterPro; IPR003930; BK\_channel\_beta.  
 CC Pfam; PF03185; CakB; 1.  
 CC Glycoprotein; Ionic channel; Transmembrane.  
 CC INIT MET 0 0  
 CC DOMAIN 1 14 Cytoplasmic (Potential).  
 CC TRANSMEM 15 35 1 (Potential).  
 CC DOMAIN 36 156 Extracellular (Potential).  
 CC TRANSMEM 157 177 2 (Potential).  
 CC DOMAIN 178 190 Cytoplasmic (Potential).  
 CC FT CARBOHYD 79 79 N-linked (GlcNAc...) (Potential).  
 CC FT CARBOHYD 141 141 N-linked (GlcNAc...) (Potential).  
 CC SEQUENCE 190 AA; 21803 MW; 087715070A35D3C8 CRC64;

Query Match 31.9%; Score 396; DB 1; Length 190;  
 Best Local Similarity 40.9%; Pred. No. 5.8e-27;  
 Matches 79; Conservative 41; Mismatches 65; Indels 8; Gaps 2;

QY 34 RKTVTALRAGEDRAILLGLAMVVCISIMYFLIGITLLRSYMQSVWTERESQCTLLNASITE 93  
 Db 2 KKLVAQRGETRALCLGVAMVCAIYIYILGTTMLPLYOKSVWTKSTCHLTETIRE 61  
 QY 94 TPNCSFSCGPDCKLSQYPCLOVYVNLFTSSGKLLYHTETIKINOKCSYIPKCGKNFE 153  
 Db 62 QBELECK-----KVPQVPCF--WNVSAVGKRWAVLXHTEDTRDQNHQCSYIPGSLNYQ 113  
 QY 154 ESMISLVNVMENFRKYQHFSCYSDPEGNKQSVILTKLYSSNVLFHSLFWPTCMAGGVAI 213  
 Db 114 VARADVEKVRKAFHQEQIFCFSTTRENETTTLVRLYGPQTLLFLFWPTFLTLTGGLLI 173  
 QY 214 VAMVKLTQVLSLL 226  
 Db 174 IAWVKINQSLSL 186

RESULT 13  
 CKB1\_BOVIN  
 ID CKB1\_BOVIN STANDARD; PRT; 190 AA.  
 AC Q28067;  
 DT 01-NOV-1997 (Rel. 35, Created)  
 DT 01-NOV-1997 (Rel. 35, Last sequence update)  
 DT 05-JUL-2004 (Rel. 44, Last annotation update)  
 DE Calcium-activated potassium channel beta subunit 1 (Calcium-activated  
 DE potassium channel, subfamily M, beta subunit 1) (Maxi K channel beta  
 DE subunit 1) (BK channel beta subunit 1) (Slo-beta 1) (K(VCA)beta 1)  
 DE (Charybdotoxin receptor beta subunit 1) (BKbeta) (Calcium-activated  
 DE potassium channel beta-subunit) (BKbeta) (Slo-beta).  
 GN Name=KCNMB1.  
 OS Bos taurus (Bovine).  
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 OC Mammalia; Eutheria; Cetartiodactyla; Ruminantia; Pecora; Bovidae;  
 OC Bovinae; Bos.  
 OX NCBI\_TaxID=9913;  
 RN [1]  
 RP SEQUENCE FROM N.A., AND SEQUENCE OF 1-28.  
 RC TISSUE=Aorta, and Trachea;

RX MEDLINE=94274724; PubMed=8006036;  
 RA Knaus H.-G., Folander K., Garcia-Calvo M., Garcia M.L.,  
 RA Kaczorowski G.J., Smith M., Swanson R.;  
 RT "Primary sequence and immunological characterization of beta-subunit  
 RT of high conductance Ca(2+)-activated K+ channel from smooth muscle.";  
 RL J. Biol. Chem. 269:17274-17278(1994).  
 CC -!- FUNCTION: Regulatory subunit of the calcium activated potassium  
 CC KCNNM1 (maxiK) channel. Modulates the calcium sensitivity and  
 CC gating kinetics of KCNNM1, thereby contributing to KCNNM1 channel  
 CC diversity. Increases the apparent Ca(2+)/voltage sensitivity of  
 CC the KCNNM1 channel. It also modifies KCNNM1 channel kinetics and  
 CC alters its pharmacological properties. It slows down the  
 CC activation and the deactivation kinetics of the channel. Acts as a  
 CC negative regulator of smooth muscle contraction by enhancing the  
 CC calcium sensitivity to KCNNM1. Its presence is also a requirement  
 CC for internal binding of the KCNNM1 channel opener  
 CC denodrosapoinin 1 (DHS-1) triterpene glycoside and for external  
 CC binding of the agonist hormone 17-beta-estradiol (E2). Increases  
 CC the binding activity of charybdotoxin (CTX) toxin to KCNNM1  
 CC peptide blocker by increasing the CTX association rate and  
 CC decreasing the dissociation rate (By similarity).  
 CC -!- SUBUNIT: Interacts with KCNNM1 tetramer. There are probably 4  
 CC molecules of KCNNM1 per KCNNM1 tetramer (By similarity).  
 CC -!- SUBCELLULAR LOCATION: Integral membrane protein (By similarity).  
 CC -!- PTM: N-glycosylated (By similarity).  
 CC -!- SIMILARITY: Belongs to the KCNNB family.  
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -  
 CC the European Bioinformatics Institute. There are no restrictions on its  
 CC use by non-profit institutions as long as its content is in no way  
 CC modified and this statement is not removed. Usage by and for commercial  
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>  
 CC or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).  
 CC  
 CC EMBL; L26101; AAA21741.1; -;  
 CC PIR; A54165; A54155.  
 CC InterPro; IPR003930; BK\_channel\_beta.  
 CC Pfam; PF03185; CakB; 1.  
 CC Glycoprotein; Glycoprotein; Glycoprotein; Glycoprotein; Glycoprotein.  
 CC INIT MET 0 0  
 CC DOMAIN 1 17 Cytoplasmic (Potential).  
 CC TRANSMEM 18 38 1 (Potential).  
 CC DOMAIN 39 156 Extracellular (Potential).  
 CC TRANSMEM 157 177 2 (Potential).  
 CC DOMAIN 178 190 Cytoplasmic (Potential).  
 CC FT CARBOHYD 79 79 N-linked (GlcNAc...) (Potential).  
 CC FT CARBOHYD 141 141 N-linked (GlcNAc...) (Potential).  
 CC SEQUENCE 190 AA; 21826 MW; 288A154B52D06EF8 CRC64;  
 Query Match 30.8%; Score 382; DB 1; Length 190;  
 Best Local Similarity 40.4%; Pred. No. 1e-25;  
 Matches 78; Conservative 39; Mismatches 66; Indels 8; Gaps 2;

QY 34 RKTVTALRAGEDRAILLGLAMVVCISIMYFLIGITLLRSYMQSVWTERESQCTLLNASITE 93  
 Db 2 KKLVAQRGETRALCLGVAMVCAIYIYILGTTMLPLYOKSVWTKSTCHLTETIRE 61  
 QY 94 TPNCSFSCGPDCKLSQYPCLOVYVNLFTSSGKLLYHTETIKINOKCSYIPKCGKNFE 153  
 Db 62 QBELECK-----RVQVPCF--WNVSAVGKRWAVLXHTEDTRDQNHQCSYIPGSLNYQ 113  
 QY 154 ESMISLVNVMENFRKYQHFSCYSDPEGNKQSVILTKLYSSNVLFHSLFWPTCMAGGVAI 213  
 Db 114 VARADVEKVRKAFHQEQIFCFSTTRENETTTLVRLYGPQTLLFLFWPTFLTLTGGLLI 173  
 QY 214 VAMVKLTQVLSLL 226  
 Db 174 IAWVKINQSLSL 186

RESULT 14  
 CKB34\_HUMAN



ID AC CKB4 HUMAN STANDARD; PRT; 210 AA.  
DT 05-JUL-2004 (Rel. 44, Q9P0G5;  
DT 05-JUL-2004 (Rel. 44, last sequence update)  
DT 05-JUL-2004 (Rel. 44, last sequence update)  
DE DE Calcium-activated potassium channel beta subunit 4 (Calcium-activated  
DE DE potassium channel, subfamily M, beta subunit 4) (Maxi K channel beta  
DE DE subunit 4) (BK channel beta subunit 4) (Slo-beta 4) (K(VCA)beta 4)  
DE DE Charybdotoxin receptor beta subunit 4 (BKbeta4) (Hbeta4).  
GN Name=KCNMB4;  
OS Homo sapiens (Human).  
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
OX NCBI\_TaxID=9606;  
RN [1]  
RP SEQUENCE FROM N.A., FUNCTION, GLYCOSYLATION, AND VARIANT ILE-199.  
RX MEDLINE=20264505; PubMed=10792058; DOI=10.1073/pnas.100118597;  
RA Meera P., Wallner M., Toro L.;  
RT "A neuronal beta subunit (KCNMB4) makes the large conductance,  
RT voltage- and Ca2+-activated K+ channel resistant to charybdotoxin and  
RT iberiotoxin";  
RL Proc. Natl. Acad. Sci. U.S.A. 97:5562-5567(2000).  
RN [2]  
RP SEQUENCE FROM N.A., FUNCTION, GLYCOSYLATION, AND TISSUE SPECIFICITY.  
RX PubMed=10828459;  
RA Behrens R., Nolting A., Reimann F., Schwarz M., Waldechuetz R.,  
RA Pongs O.;  
RT "hKCNMB3 and hKCNMB4, cloning and characterization of two members of  
RT the large-conductance calcium-activated potassium channel beta subunit  
RT family";  
RL FEBS Lett. 474:99-106(2000).  
RN [3]  
RP SEQUENCE FROM N.A., FUNCTION, INTERACTION WITH KCNMAL, AND TISSUE  
RP SPECIFICITY.  
RX MEDLINE=20158960; PubMed=10692449;  
RA Brenner R., Jegla T.J., Wickenden A., Liu Y., Aldrich R.W.;  
RT "Cloning and functional characterization of novel large conductance  
RT calcium-activated potassium channel beta subunits, hKCNMB3 and  
RT hKCNMB4";  
RL J. Biol. Chem. 275:6453-6461(2000).  
RN [4]  
RP SEQUENCE FROM N.A., AND INTERACTION WITH KCNMAL.  
RC TISSUE=CNS;  
RX MEDLINE=20266164; PubMed=10804197;  
RA Weiger T.M., Holmqvist M.H., Levitan I.B., Clark F.T., Sprague S.,  
RA Huang W.-J., Ge P., Wang C., Lawson D., Jurman M.E., Glucksmann M.A.,  
RA Silos-Santiago I., DiStefano P.S., Curtis R.;  
RT "A novel nervous system beta subunit that downregulates human large  
RT conductance calcium-dependent potassium channels";  
RL J. Neurosci. 20:3563-3570(2000).  
RN [5]  
RP SEQUENCE FROM N.A.  
RC TISSUE=Eye, and Lymph;  
RX MEDLINE=2238257; PubMed=12477932; DOI=10.1073/pnas.242603899;  
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,  
RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,  
RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,  
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Heide F.,  
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,  
RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,  
RA Brownstein M.J., Ustin T.B., Toshiyuki S., Carninci P., Frange C.,  
RA Raha S.S., Lequellano N.A., Peters G.J., Abramson R.D., Mullaly S.J.,  
RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,  
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,  
RA Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,  
RA Fahey J., Hulton E., Kettunen M., Madan A., Rodriguez S., Sanchez A.,  
RA Whitting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,  
RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,  
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,  
RA Butterfield J.S.N., Krzywinski M.I., Skalska U., Smalley D.E.,  
RA Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.;  
RT "Generation and initial analysis of more than 15,000 full-length human  
RT and mouse cDNA sequences";

Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).  
[6]  
RP PHOSPHORYLATION, AND MUTAGENESIS OF THR-11; SER-17 AND SER-210.  
RX PubMed=11790768; DOI=10.1074/jbc.M10768200;  
RA Jin P., Weiger T.M., Wu Y., Levitan I.B.;  
RT "Phosphorylation-dependent functional coupling of hSlo calcium-  
RT dependent potassium channel and its beta 4 subunit";  
RL J. Biol. Chem. 277:10014-10020(2002).  
RN [7]  
RP GLYCOSYLATION, AND MUTAGENESIS OF ASN-53 AND ASN-90.  
RX PubMed=12223479; DOI=10.1074/jbc.M205795200;  
RA Jin P., Weiger T.M., Levitan I.B.;  
RT "Reciprocal modulation between the alpha and beta 4 subunits of hSlo  
RT calcium-dependent potassium channels";  
RL J. Biol. Chem. 277:43724-43729(2002).  
RN [8]  
RP REVIEW.  
RX PubMed=12136044;  
RA Orio P., Rojas P., Ferreira G., Latorre R.;  
RT "New disguises for an old channel: MaxiK channel beta-subunits";  
RL News Physiol. Sci. 17:156-161(2002).  
CC -!- FUNCTION: Regulatory subunit of the calcium activated potassium  
CC KCNMAL (maxik) channel. Modulates the calcium sensitivity and  
CC gating kinetics of KCNMAL, thereby contributing to KCNMAL channel  
CC diversity. Decreases the gating kinetics and calcium sensitivity  
CC of the KCNMAL channel, but with fast deactivation kinetics. May  
CC decrease KCNMAL channel openings at low calcium concentrations but  
CC increases channel openings at high calcium concentrations. Makes  
CC KCNMAL channel resistant to 100 nM charybdotoxin (CTX) toxin  
CC concentrations.  
CC -!- SUBUNIT: Interacts with KCNMAL tetramer. There are probably 4  
CC molecules of KCNMAL per KCNMAL tetramer.  
CC -!- SUBCELLULAR LOCATION: Integral membrane protein.  
CC -!- TISSUE SPECIFICITY: Predominantly expressed in brain. In brain, it  
CC is expressed in the cerebellum, cerebral cortex, medulla, spinal  
CC cord, occipital pole, frontal lobe, temporal lobe, putamen,  
CC amygdala, caudate nucleus, corpus callosum, hippocampus,  
CC substantia nigra and thalamus. Weakly or not expressed in other  
CC tissues.  
CC -!- DOMAIN: Resistance to charybdotoxin (CTX) toxin is mediated by the  
CC extracellular domain.  
CC -!- PTM: Phosphorylated. Phosphorylation modulates its effect on  
CC KCNMAL activation kinetics.  
CC -!- PTM: N-glycosylated. A highly glycosylated form is promoted by  
CC KCNMAL Glycosylation, which is not required for the interaction  
CC with KCNMAL and subcellular location, increases protection against  
CC charybdotoxin.  
CC -!- MISCELLANEOUS: Treatment with okadaic acid reduces its effect on  
CC KCNMAL.  
CC -!- SIMILARITY: Belongs to the KCNM family.  
CC  
CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -  
CC the European Bioinformatics Institute. There are no restrictions on its  
CC use by non-profit institutions as long as its content is in no way  
CC modified and this statement is not removed. Usage by and for commercial  
CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>  
CC or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).  
CC  
CC EMBL; AF160967; AAF69805.1; --  
CC EMBL; AF170917; AAF89699.1; --  
CC EMBL; AF207992; AAF28333.1; --  
CC EMBL; AF215891; AAF75596.1; --  
CC EMBL; BC042446; AAF42446.2; --  
CC EMBL; BC050621; AAF50621.2; --  
CC Genbank; F6289; KCNM4.  
CC MIM; 603223; --  
CC GO; GO:0008076; C: voltage-gated potassium channel complex; IDA.  
CC GO; GO:0015269; F: calcium-activated potassium channel activity; IDA.  
CC GO; GO:0005515; F: protein binding; IDA.  
CC GO; GO:0005513; P: calcium ion sensing; IDA.  
CC GO; GO:0019228; P: generation of action potential; IDA.  
CC GO; GO:0006813; P: potassium ion transport; IDA.

DR GO; GO:0001508; P:regulation of action potential; IDA.  
 DR GO; GO:0046928; P:regulation of neurotransmitter secretion; TAS.  
 DR GO; GO:0019229; P:regulation of vasoconstriction; TAS.  
 DR InterPro: IPR003930; BK\_channel\_beta.  
 DR Pfam: PF03185; CaxB; 1.  
 KW Glycoprotein; Ionic channel; Phosphorylation; Polymorphism; Transmembrane.  
 FT DOMAIN 1 19 Cytosolic (Potential).  
 FT TRANSMEM 20 40 1 (Potential).  
 FT DOMAIN 167 167 Extracellular (Potential).  
 FT TRANSMEM 168 168 2 (Potential).  
 FT DOMAIN 189 210 Cytosolic (Potential).  
 FT CARBOHYD 53 53 N-linked (GlcNAc...).  
 FT CARBOHYD 90 90 N-linked (GlcNAc...).  
 FT VARIANT 199 199 V -> I.  
 FT /FTID=VAR 018178.  
 FT T->A: Suppresses the effect of okadaic acid and increases activation time constant; when associated with A-17 and A-210.  
 FT T->D: Suppresses its effect on KCNNM1 channel activation and on deactivation kinetics; when associated with E-17 and E-210.  
 FT S->A: Suppresses the effect of okadaic acid and increases activation time constant; when associated with A-11 and A-210.  
 FT S->E: Suppresses its effect on KCNNM1 channel activation and on deactivation kinetics; when associated with D-11 and E-210.  
 FT N->A: Loss of N-glycosylation and reduced protection against charybdotoxin; when associated with A-90.  
 FT N->A: Loss of N-glycosylation and reduced protection against charybdotoxin; when associated with A-53.  
 FT S->A: Suppresses the effect of okadaic acid and increases activation time constant; when associated with A-11 and A-17.  
 FT S->E: Suppresses its effect on KCNNM1 channel activation and on deactivation kinetics; when associated with D-11 and E-17.  
 SQ SEQUENCE 210 AA; 23948 MW; A59D56DD034F027A CRC64;  
 Query Match 25.5%; Score 316; DB 1; Length 210;  
 Best Local Similarity 33.0%; Pred. No. 7.8e-20;  
 Matches 65; Conservative 40; Mismatches 80; Indels 12; Gaps 3;  
 QY 44 EDRATLLGLAMVCSIMMYFLLGTLRLSYNGSVWTEESQCTLNA-SITETNCSPSCG 102  
 DB 14 EDKSRGLGLIISGVLSLFFGFCWLSPAQDLQATEANCCTVLSVQIGVEFCTPG 73  
 QY 103 PDCWKLQYPCQVYVNLTSXGKLLAYHTETIKINQKCSYIPKCGNFEESMLVNVV 162  
 DB 74 ADCRGTSQYPCQVYVNVNSENRRALLHSDEHQLLTNPCKSYIPCKXENQKNLESV--- 130  
 QY 163 MEFKRY-----QHSCYSDPEGNQKSVLLTKLYSNVLFHSLFWPTCMAGGVAIVA 215  
 DB 131 -NNQYQWKDIEIGSQPFCTCYFNQHQRPDDVLLHRTHEIVLLHCFLLPPLVTVVGVLLIV 169  
 QY 216 NVKLTQVLSLCEIRQI 232  
 DB 190 LTICAKSLAVKAEAMKK 206  
 RESULT 15  
 CKB4\_RAT ID CKB4\_RAT STANDARD; PRT; 210 AA.  
 AC Q95SK8;

DT 05-JUL-2004 (Rel. 44, Created)  
 DT 05-JUL-2004 (Rel. 44, Last sequence update)  
 DT 05-JUL-2004 (Rel. 44, Last annotation update)  
 DE Calcium-activated potassium channel beta subunit 4 (Calcium-activated potassium channel, subfamily M, beta subunit 4) (Maxi K channel beta subunit 4) (BK channel beta subunit 4) (Slo-beta 4) (K(VCA)beta 4) (Charybdotoxin receptor beta subunit 4) (BKbeta4).  
 GN Names:Kcnmb4;  
 OS Rattus norvegicus (Rat).  
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Rattus.  
 OX NCBI\_TaxID=10116;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RC TISSUE=Brain;  
 RA Ohya S., Ohi Y., Imaizumi Y.;  
 RT "rat calcium activated potassium channel beta 4 subunit (KCNMB4).";  
 RL Submitted (OCT-2000) to the EMBL/GenBank/DBJ databases.  
 RN [2]  
 RP SEQUENCE FROM N.A.  
 RA Ha T.S., Park C.-S.;  
 RT "Molecular cloning of large-conductance calcium-activated potassium channel beta 4 subunit from rat brain.";  
 RL Submitted (MAR-2001) to the EMBL/GenBank/DBJ databases.  
 CC -I- FUNCTION: Regulatory subunit of the calcium activated potassium channel (maxiK) channel. Modulates the calcium sensitivity and gating kinetics of KCNNM1, thereby contributing to KCNNM1 channel diversity. Decreases the gating kinetics and calcium sensitivity of the KCNNM1 channel, but with fast deactivation kinetics. May decrease KCNNM1 channel openings at low calcium concentrations but increases channel openings at high calcium concentrations. Makes KCNNM1 channel resistant to 100 nM charybdotoxin (CTX) toxin concentrations (By similarity).  
 CC -I- SUBUNIT: Interacts with KCNNM1 tetramer. There are probably 4 molecules of KCNNM1 per KCNNM1 tetramer (By similarity).  
 CC -I- SUBCELLULAR LOCATION: Integral membrane protein (By similarity).  
 CC -I- DOMAIN: Resistance to charybdotoxin (CTX) toxin is mediated by the extracellular domain (By similarity).  
 CC -I- PTM: Phosphorylated. Phosphorylation modulates its effect on KCNNM1 activation kinetics (By similarity).  
 CC -I- PTM: N-glycosylated. A highly glycosylated form is promoted by KCNNM1. Glycosylation, which is not required for the interaction with KCNNM1 and subcellular location, increases protection against charybdotoxin (By similarity).  
 CC -I- SIMILARITY: Belongs to the KCNNB family.  
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration between the Swiss Institute of Bioinformatics and the EMBL outstation - the European Bioinformatics Institute. There are no restrictions on its use by non-profit institutions as long as its content is in no way modified and this statement is not removed. Usage by and for commercial entities requires a license agreement (See <http://www.isb-sib.ch/announce/> or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).  
 CC EMBL; AB050633; BAB17595.1; -;  
 CC EMBL; AY028605; AAK21964.1; -;  
 CC RGD; 620728; Kcnmb4.  
 CC GO; GO:0008076; C:Voltage-gated potassium channel complex; ISS.  
 CC GO; GO:0015269; P:calcium-activated potassium channel activity; ISS.  
 CC GO; GO:0005515; P:protein binding; ISS.  
 CC GO; GO:0005513; P:calcium ion sensing; ISS.  
 CC GO; GO:0019228; P:generation of action potential; ISS.  
 CC GO; GO:0006813; P:potassium ion transport; ISS.  
 CC GO; GO:0001508; P:regulation of action potential; ISS.  
 CC GO; GO:0046928; P:regulation of neurotransmitter secretion; ISS.  
 CC GO; GO:0019229; P:regulation of vasoconstriction; ISS.  
 CC InterPro: IPR003930; BK\_channel\_beta.  
 CC Pfam; PF03185; CaxB; 1.  
 KW Glycoprotein; Ionic channel; Phosphorylation; Transmembrane.  
 FT DOMAIN 1 19 Cytosolic (Potential).  
 FT TRANSMEM 20 40 1 (Potential).  
 FT TRANSMEM 41 167 Extracellular (Potential).  
 FT TRANSMEM 168 168 2 (Potential).



This Page Blank (uspto)

GenCore version 5.1.6  
Copyright (c) 1993 - 2004 Compugen Ltd.

OM protein - nucleic search, using frame\_plus\_p2n model

Run on: November 7, 2004, 00:34:47 ; Search time 2961 Seconds  
(without alignments)

2892.042 Million cell updates/sec

Title: US-09-914-053A-5

Perfect score: 1241

Sequence: 1 MSITSGRTSSSVRHDEKRN.....MVKLTQYLLCERIQIRNR 235

Scoring table: BLOSUM62

Xgapop 10.0 , Xgapext 0.5

Ygapop 10.0 , Ygapext 0.5

Fgapop 6.0 , Fgapext 7.0

Delop 6.0 , Delext 7.0

Searched: 32822875 seqs, 18219865908 residues

Total number of hits satisfying chosen parameters: 65645750

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Command line parameters:

-MODEL=frame+ p2n.model -DEV=xlp

-Q=/cgn2\_1/USPTO.spool\_P/US09914053/runat\_04112004\_183922\_18233/app\_query.fasta\_1.391

-DB=EST -OPMT=fastap -SUFFIX=est -MINMATCH=0.1 -LOPCPL=0 -LOPEXT=0

-UNITS=bits -START=1 -END=1 -MATRIX=blosum62 -TRANS=human40.cdi -LIST=45

-DOALIGN=200 -THR SCORE=pct -THR MAX=100 -THR MIN=0 -ALIGN=15 -MODE=LOCAL

-OUTFM=ptc -NOR=ext -HEADSIZE=500 -MINLEN=0 -MAXLEN=2000000000

-USER=US09914053@cgn\_1\_15180 @runat\_04112004\_183922\_18233 -NCPU=6 -ICPU=3

-NO MMAP -LARGEQUERY -NEG SCORES=0 -WAIT -DSPBLOCK=100 -LONGLOG

-DEV TIMEOUT=120 -WARN TIMEOUT=30 -THREADS=1 -XGAPOP=10 -XGAPEXT=0.5 -FGAPOF=6

-FGAPEXT=7 -YGAPOP=10 -YGAPEXT=0.5 -DELOP=6 -DELEXT=7

Database :

EST:

1: gb\_est1.\*

2: gb\_est2.\*

3: gb\_hic.\*

4: gb\_est3.\*

5: gb\_est4.\*

6: gb\_est5.\*

7: gb\_est6.\*

8: gb\_gss1.\*

9: gb\_gss2.\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

#### SUMMARIES

Result No.	Query Match	Score	Length	ID	Description
1	1235	99.5	801	4	RG188850 RST7884 A
2	1186	95.6	2356	3	AK012400 Mus muscu
3	1174	94.6	949	5	BQ942589 AGENCOURT
4	1156	93.2	1597	3	AK014106 Mus muscu
5	1131.5	91.2	694	7	CK945448 4069809 B
6	1123	90.5	803	4	RG198614 RST17879
7	1122	90.4	816	4	RG195580 RST14773
8	1100.5	88.7	795	4	BG218411 RST38279
9	1093.5	88.1	855	5	BU216989 603107309

10	1089	87.8	817	4	BG214809
11	972.5	78.4	939	5	BU222329
12	695	56.0	598	7	CK903430
13	695	56.0	709	7	CK476300
14	688	55.4	852	5	BX729097
15	656	52.9	835	7	CK601161
16	650	52.4	769	7	CK964012
17	648	52.2	622	5	BU950136
18	624.5	50.3	778	4	BG502844
19	608	49.0	562	2	BQ433029
20	608	49.0	756	5	BQ179892
21	527	42.5	870	4	BG701449
22	513	41.3	598	6	CB297668
23	508	40.9	567	2	BF446488
24	488.5	39.4	608	7	CK903431
25	481	38.8	558	1	AA904191
26	474	38.2	591	4	BI964810
27	471	38.0	992	6	BY713099
28	466.5	37.6	884	7	CF548250
29	466.5	37.6	1253	3	BC075236
30	464	37.4	796	5	BU205207
31	461	37.1	824	5	BU355397
32	451.5	36.4	446	7	CK898372
33	451	36.3	294	6	CA780337
34	443	35.7	856	7	CK331278
35	421	33.9	885	6	CB516242
36	415	33.4	666	2	BB632101
37	415	33.4	1552	3	AK038987
38	408	32.9	446	1	AI299145
39	403.5	32.5	807	5	BU750277
40	388.5	31.3	547	1	AL641479
41	388.5	31.3	686	5	BU445726
42	387	31.2	829	5	BF17468
43	369	29.7	495	2	BF477842
44	349	28.1	784	5	BU483866
45	344.5	27.8	788	5	BX716835

#### ALIGNMENTS

RESULT 1

BG188850

LOCUS

DEFINITION

ACCESSION

VERSION

KEYWORDS

SOURCE

ORGANISM

REFERENCE

AUTHORS

TITLE

JOURNAL

MEDLINE

PUBMED

COMMENT

BG188850 801 bp mRNA linear EST 21-APR-2001  
RST7884 Athersys RAGE Library Homo sapiens cDNA, mRNA sequence.

RG188850.1 GI:13710537

EST.

Homo sapiens (human)

Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;

Mammalia; Eutheria; Primates; Catarrhini; Homidae; Homo.

1 (bases 1 to 801)

Harrington, J.J., Sharf, B., Rundlett, S., Jackson, P.D., Perry, R.,

Cain, S., Leventhal, C., Thornton, M., Ramachandran, R.,

Whittington, J., Lerner, L., Costanzo, D., McElligott, K., Booser, S.,

Mays, R., Smith, E., Veloso, N., Klika, A., Hess, J., Cothren, K., Lo, K.,

Offenbacher, J., Danzig, J. and Ducar, M.

Creation of genome-wide protein expression libraries using random

activation of gene expression

Nat. Biotechnol. 19 (5), 440-445 (2001)

21227151

11329013

Contact: Scott J. Cain

Athersys, Inc.

3201 Carnegie Ave, Cleveland, OH 44115, USA

Tel: 216 431 9900

Fax: 216 361 9596

Email: scain@atersys.com

High quality sequence stop: 554.

Location/Qualifiers

1..801

/organism="Homo sapiens"

/mol\_type="mRNA"

/db\_xref="taxon:9606"  
 /cell\_line="HT1080"  
 /clone\_lib="Athersys RAGE Library"  
 /note="See 'Creation of Genome-wide Protein Expression Libraries using Random Activation of Gene Expression', Nature Biotechnology, in press. Note that even though the cell type indicated is HT1080, since a random activation method was used, these sequence tags are not necessarily expressed in HT1080 under normal circumstances."

## ORIGIN

## Alignment Scores:

Pred. No.: 5,08e-131 Length: 801  
 Score: 1235.00 Matches: 234  
 Percent Similarity: 99.57% Conservative: 0  
 Best Local Similarity: 99.57% Mismatches: 1  
 Query Match: 99.52% Indels: 0  
 Db: 4 Gaps: 0

US-09-914-053A-5 (1-235) x BG188850 (1-801)

Qy 1 MetSerIleTrrThrSerGlyArgThrSerSerSerTyrArgHisAspGluLysArgAsn 20  
 Db 72 ATGTTTATATGACACGATGCGCGACCTCTTCATCTTATAGCATGATGAAAAAGAAAT 131  
 Qy 21 IleTyrGlnLysIleArgAspHisAspLeuLeuAspLysArgLysThrValThrAlaLeu 40  
 Db 132 ATTTACAGAAAATCAGGACCATGCTCTCTGGACAAAAGAAAACAGTCACAGCACTG 191  
 Qy 41 LysAlaGlyGluAspArgAlaIleLeuLeuGlyLeuAlaMetValCysSerIleMet 60  
 Db 192 AAGCAGAGAGAGACCGACGATTTCTCTGGACTGCTATGATGGTGCTCTCATCATG 251  
 Qy 61 MetTyrPheLeuLeuGlyIleThrLeuLeuArgSerTyrMetGlnSerValTrrThrGlu 80  
 Db 252 ATGTATTTCTGCTGGGAATCACACTCTCGCTCATACATGACAGCGTGTGGACGAA 311  
 Qy 81 GluSerGlnCysThrLeuLeuAsnAlaSerIleThrGluThrPheAsnCysSerPheSer 100  
 Db 312 GAGTCTCAATGACCTTGTGTAATGCGTCATCATCGGAACATTTAATTCCTCTCTCAGC 371  
 Qy 101 CysGlyProAspCysTrrPysLysLeuSerGlnTyrProCysLeuGlnValTrrValAsnLeu 120  
 Db 372 TGTGTCACAGACTGCGAAACTTCTCAGTACCCCTGCTCCAGGTGTACCTTAACCTG 431  
 Qy 121 ThrSerSerGlyGluLysLeuLeuTyrHisThrGluThrIleLysIleAsnGln 140  
 Db 432 ACTTCTTCCGGGAAAAGCTCTCTCTACACAGAGAGACAATAAAATCAATCAG 491  
 Qy 141 LysCysSerTrrIleProLysCysGlyLysAsnPhelGluSerMetSerLeuValAsn 160  
 Db 492 AAGTCTCTCTATATACCTAATGTGGAAAATTTTGAAGAAATCCATGTCCTCTGGTGAAT 551  
 Qy 161 ValValMetGluAsnPhelArgLysTyrGlnHisPheSerCysTrrSerAppProGluGly 180  
 Db 552 GTTCTCATGAAAACCTTCAGGAAGTATCAACTTCTCTCTGCTATTCTGACCCAGGAAGA 611  
 Qy 181 AsnGlnLysSerValIleLeuThrLysLeuTyrSerSerAsnValLeuPheHisSerLeu 200  
 Db 612 AACAGAGAGGTATTCCTAACAAAATCTACAGTTCCAACTGCTGTTCTCAATTCATC 671  
 Qy 201 PheTrrProThrCysMetMetAlaGlyLysValAlaIleValAlaMetValLysLeuThr 220  
 Db 672 TTTCTGGCAACCTGTATGATGCTGGGGGTGTGGCAATTTGTCATGTTGGTGAACCTTACA 731  
 Qy 221 GlnTrrLeuSerLeuLeuCysGluArgIleGlnArgIleAsnArg 235  
 Db 732 CAGTACCTCTCCCTACTGATGTGAGAGGATCCAAACGGATCAATAGA 776

## RESULT 2

AK012400 2356 bp mRNA linear HTC 03-APR-2004  
 LOCUS Mus musculus 11 days embryo whole body cDNA, RIKEN full-length  
 DEFINITION

ACCESSION  
 VERSION  
 KEYWORDS  
 SOURCE  
 ORGANISM

## REFERENCE

## AUTHORS

## TITLE

## JOURNAL

## MEDLINE

## PUBMED

## REFERENCE

## AUTHORS

## TITLE

## JOURNAL

## MEDLINE

## PUBMED

## REFERENCE

## AUTHORS

## TITLE

## JOURNAL

## MEDLINE

## PUBMED

## REFERENCE

## AUTHORS

## TITLE

## JOURNAL

## MEDLINE

## PUBMED

## REFERENCE

## AUTHORS

## TITLE

## JOURNAL

## MEDLINE

## PUBMED

## REFERENCE

## AUTHORS

## TITLE

## JOURNAL

## MEDLINE

## PUBMED

## REFERENCE

## AUTHORS

## TITLE

## JOURNAL

## MEDLINE

## PUBMED

## REFERENCE

## AUTHORS

## TITLE

## JOURNAL

## MEDLINE

## PUBMED

## REFERENCE

## AUTHORS

## TITLE

## JOURNAL

## MEDLINE

## PUBMED

## REFERENCE

## AUTHORS

## TITLE

## JOURNAL

## MEDLINE

## PUBMED

## REFERENCE

## AUTHORS

## TITLE

## JOURNAL

## MEDLINE

## PUBMED

## REFERENCE

## AUTHORS

enriched library, clone:2700049B16 product:LARGE CONDUCTANCE  
 CALCIUM-ACTIVATED K CHANNEL BETA2 SUBUNIT, full insert sequence.

AK012400  
 AK012400.1 GI:12849119  
 HTC; CAP trapper.  
 Mus musculus (house mouse)  
 Mus musculus  
 Mus musculus  
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.

## REFERENCE

## AUTHORS

## TITLE

## JOURNAL

## MEDLINE

## PUBMED

## REFERENCE

## AUTHORS

## TITLE

## JOURNAL

## MEDLINE

## PUBMED

## REFERENCE

## AUTHORS

## TITLE

## JOURNAL

## MEDLINE

## PUBMED

## REFERENCE

## AUTHORS

## TITLE

## JOURNAL

## MEDLINE

## PUBMED

## REFERENCE

## AUTHORS

## TITLE

## JOURNAL

## MEDLINE

## PUBMED

## REFERENCE

## AUTHORS

## TITLE

## JOURNAL

## MEDLINE

## PUBMED

## REFERENCE

## AUTHORS

## TITLE

## JOURNAL

## MEDLINE

## PUBMED

## REFERENCE

## AUTHORS

## TITLE

## JOURNAL

## MEDLINE

## PUBMED

## REFERENCE

## AUTHORS

## TITLE

## JOURNAL

## MEDLINE

## PUBMED

## REFERENCE

## AUTHORS

## TITLE

## JOURNAL

## MEDLINE

## PUBMED

## REFERENCE

## AUTHORS

## TITLE

## JOURNAL

## MEDLINE

## PUBMED

## REFERENCE

## AUTHORS

Submitted (10-JUL-2000) Yoshihide Hayashizaki, The Institute of  
 Physical and Chemical Research (RIKEN), Laboratory for Genome  
 Exploration and Research Group, RIKEN Genomic Sciences Center (GSC),  
 RIKEN Yokohama Institute, 1-7-22 Suehiro-cho, Tsurumi-ku, Yokohama,  
 Kanagawa 230-0045, Japan (E-mail: genome-res@gs.c.riken.jp,  
 URL: http://genome.gsc.riken.jp/, Tel: 81-45-503-9222,  
 Fax: 81-45-503-9216)  
 Please visit our web site (http://genome.gsc.riken.jp/) for further  
 details.  
 cDNA library was prepared and sequenced in Mouse Genome  
 Encyclopedia Project of Genome Exploration Research Group in Riken  
 Genomic Sciences Center and Genome Science Laboratory in RIKEN.







```
/tissue type="head"  
/clone_lib="RIKEN full-length enriched mouse cDNA library"  
/dev_stage="13 days embryo"  
488..1194  
/note="LARGE CONDUCTANCE CALCIUM-ACTIVATED K CHANNEL BETA2  
SUBUNIT (SPTR)AL38982, evidence: FASTY, 100%ID,  
100%length, match=705)  
putative"
```

## misc\_feature

## ORIGIN

## Alignment Scores:

```
Pred. No.: 1.73e-121 Length: 1597  
Score: 1156.00 Matches: 222  
Percent Similarity: 96.60% Conservative: 5  
Best Local Similarity: 94.47% Mismatches: 8  
Query Match: 93.15% Indels: 1  
DB: 3 Gaps: 0
```

US-09-914-053A-5 (1-235) x AK014106 (1-1597)

```
Qy 1 MetSerIleThrPThrSerGlyArgThrSerSerSerTyrArgHisAspGluLysArgAsn 20  
Db ATGTTTATATGAGCAGGAGCGGACCTCTTCATCTTACAGACGAGGAGAAAGAAAT 547  
Qy 21 IleTyrGlnLysIleAAspHisAspLeuLysArgLysThrValThrAlaLeu 40  
Db ATCTACGAGAAATCAGGACCATGACCTCTGACAAAGGAAACTGTGACAGCTCTG 607  
Qy 41 LysAlaGlyGluAspArgAlaIleLeuLeuGlyLeuAlaMetValCysSerIleMet 60  
Db AAGCTGGGAGGAGCGGACATCTCTGCGCTGGCCATGATGGTGTCTCCATCATG 667  
Qy 61 MetTyrPheLeuLeuGlyIleThrLeuLeuArgSerTyrMetGlnSerValThrGlu 80  
Db ATGTAATCTCTCTGGGATACACTGCTGGCTCTCATCATGACGACGGTGGACAGAA 727  
Qy 81 GluSerGlnCysThrLeuLeuAsnAlaSerIleThrGluThrPheAsnCysSerPheSer 100  
Db GAGCC-CAGTGTGCGCTGCTGAATGTGTCAATCACAGAAACGTTTAACTGTCTTCAGC 786  
Qy 101 CysGlyProAspCysTyrLeuSerGlnTyrProCysLeuGlnValTyrValAsnLeu 120  
Db TGTGGCCGCGACTGTGGAAGCTCTCAGTACCCCTTGCCTGAGGTGACGGAACCTG 846  
Qy 121 ThrSerSerGlyGluLysLeuLeuTyrHisThrGluGluThrIleLysIleAsnGln 140  
Db ACATCTTCGGGAGAGGCTCTCTCTTACCACAGGAGAGACCATGAAGATCAATCAA 906  
Qy 141 LysCysSerTyrIleProLysCysGlyLysAsnPheGluSerMetSerLeuValAsn 160  
Db AAGTGCTCCTATATTCCTAAGTGTGGAACAACTTTGAGGAGTCCATGTCTCTCGTAGT 966  
Qy 161 ValValMetGluAsnPheArgLysTyrGlnHisPheSerCysTyrSerAspProGluGly 180  
Db GTGTCATGGAACACTTCAGAGAGACCAACACTTCCCTGCTATTCTGACCCAGAGGA 1026  
Qy 181 AsnGlnLysSerValIleLeuThrLysLeuTyrSerSerAsnValLeuPheHisSerLeu 200  
Db AACCAGAGAGTGTCTCTGACCAAACTCTACAGCTCCCAATGTGCTGTTCCATTCCTC 1086  
Qy 201 PheTrpProThrCysMetMetAlaGlyValAlaIleValAlaMetValLysLeuThr 220  
Db TTCTGGCCAACTTGTATGATGGCTGGGGGTGTGGCAATCGTTGCTATGTGGTAACACT 1146  
Qy 221 GlnTyrLeuSerLeuLeuCysGluArgIleGlnArgIleAsnArg 235  
Db CAGTACCTCTCCCTGCTTTGTGAGAGGATCCACGGATCAACAGA 1191
```

## RESULT 5

```
CK945448  
LOCUS 4069809 BARC 10BOV Bos taurus cDNA clone 10BOV17_N10 5', mRNA  
DEFINITION 594 bp mRNA linear EST 15-MAR-2004  
sequence.
```

```
ACCESSION CK945448  
VERSION CK945448.1 GI:45459828  
EST.  
KEYWORDS Bos taurus (cow)  
SOURCE Bos taurus  
ORGANISM Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Cetartiodactyla; Ruminantia; Pecora; Bovidae;  
Bovinae; Bos.
```

## REFERENCE

## AUTHORS

## TITLE

## JOURNAL

## COMMENT

Contact: Tad S. Sonstegard

Bovine Functional Genomics Laboratory

Animal and Natural Resources Institute

Bldg. 200 Rm2A BARC-East, Beltsville, MD 20705, USA

Tel: 3015048416

Fax: 3015048414

Email: tad@ari.barc.usda.gov

Single pass sequencing. Bases called and trimmed with phred

0.000925 using options -trim alt - -trim fasta. Vector identified

by cross\_match using options -minmatch 12 -minscore 12

Plate: 17 row: N column: 10

Seq primer: CCCAGTCACGACGTTGTAAACG

High quality sequence stop: 694.

## FEATURES

## source

1..694

/organism="Bos taurus"

/mol\_type="mRNA"

/strain="Holstein"

/db\_xref="taxon:9913"

/clone="10BOV17\_N10"

/sex="Male"

/tissue\_type="Pooled"

/dev\_stage="Multiple"

/lab\_host="DH10B fl phage resistant"

/clone\_lib="BARC 10BOV"

/note="Organ: Small Intestine; Vector: pagen-1; Site 1:

ECORV, Site 2: NotI; Equimolar amounts of mRNA extracted

from proximal jejunum of 18 and 21 wk old steers, and

distal ileums of 14 day old calves; proximal jejunum

exposed to C. oncophora for 3 and 6 weeks, and distal

ileum exposed to C. parvum for 7 days"

## ORIGIN

## Alignment Scores:

```
Pred. No.: 3.21e-119 Length: 694  
Score: 1131.50 Matches: 220  
Percent Similarity: 98.66% Conservative: 1  
Best Local Similarity: 98.21% Mismatches: 3  
Query Match: 91.18% Indels: 2  
DB: 7 Gaps: 0
```

US-09-914-053A-5 (1-235) x CK945448 (1-694)

Qy 1 MetSerIleThrPThrSerGlyArgThrSerSerSerTyrArgHisAspGluLysArgAsn 20

Db ATGTTTATATGAGCAGGAGCGGACCTCTTCATCTTACAGACATGATGAGAAAAAGAAAT 76

Qy 21 IleTyrGlnLysIleAAspHisAspLeuLysArgLysThrValThrAlaLeu 40

Db ATTTACAAAAATCAGGAGCCACGACCTCTTGGACAAAGGAAACTGTACAGCAGCTG 136

Qy 41 LysAlaGlyGluAspArgAlaIleLeuLeuGlyLeuAlaMetValCysSerIleMet 60

Db AAAGCAGGAGAGACCGGGCCATTCCTCTGGACTGGCCATGATGTGTCTCCATCATG 196

Qy 61 MetTyrPheLeuLeuGlyIleThrLeuLeuArgSerTyrMetGlnSerValThrPThrGlu 80

Db ATGTACTTCTTCTGGGAATCACTCTCTGCGCTCATACATGACAGAGTGTATGGACCGAG 256

QY 81 GluSerGlnCysThrLeuLeuAsnAlaSerIleThrGluThrPheAsnCysSerPheSer 100  
 DB 257 GAGGCTCAGTCACCTTCTGCTGAATGCATCCATCAGAAACATTAATGCTCTTCAGC 316

QY 101 CysGlyProAspCysThrLysLeuSerGlnTyrProCysLeuGlnValTyrValAsnLeu 120  
 DB 317 TGTGCTCCGGACTGCTGGAACTCTCTCAGTATCCCTGCTACAGGTGATGTTAACTG 376

QY 121 ThrSerSerGlyGluLeuLeuLeuTyrHisThrGluGluThrIleLysIleAsnGln 140  
 DB 377 ACTTCTCCGGTGAAGAAGCTCTCTCTACACACAGAGAGACATAAATAATCAATCAG 436

QY 141 LysCysSerTyrIleProLysCysGlyLysAsnPheGluGluSerMetSerLeuValAsn 160  
 DB 437 AAGTCTCTATATACCTAAGTGTGGAATAATTTTGAAGATCAATGCTCCTGTAAT 496

QY 161 ValValMetGluAsnPheArgLysTyrGlnHisPheSerCysTyrSerAspProGluGly 180  
 DB 497 GTTGTCAATGGAAACTTTCAGGAAGTACCAACACTTCTCTGCTACTCTGACCCGGAAGGA 556

QY 181 AsnGlnLysSerValIleLeuThrLysLeuTyrSerSerAsnValLeuPheHisSerLeu 200  
 DB 557 AACCAAGAGAGTGCATCTTACCAAACTCTACAGTTCACAGTCTTCCATTCATC 616

QY 201 PheTyrProThrCysMetMetAlaGlyValAlaIleValAlaMetValLysLeuThr 220  
 DB 617 TTTTGCCCAACATGCATGATGCTGGGGCGTGGCAATTGT-GCCATGGTGAA-CTCACA 674

QY 221 GlnTyrLeuSer 224  
 DB 675 CAGTATCTTTC 686

RESULT 6  
 LOCUS BG198614 803 bp mRNA linear EST 21-APR-2001  
 DEFINITION RST17879 Athersys RAGE Library Homo sapiens cDNA, mRNA sequence.  
 ACCESSION BG198614  
 VERSION BG198614.1 GI:13720301  
 KEYWORDS EST.  
 SOURCE Homo sapiens (human)  
 ORGANISM Homo sapiens  
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.  
 1 (bases 1 to 803)  
 Harrington,J.J., Sherf,B., Rundlett,S., Jackson,P.D., Perry,R.,  
 Cain,S., Leventhal,C., Thornton,M., Ramachandran,R.,  
 Whittington,J., Lerner,L., Costanzo,D., McElligott,K., Booser,S.,  
 Mays,R., Smith,E., Veloso,N., Klika,A., Hess,J., Cothren,K., Lo,K.,  
 Offenbacher,J., Danzig,J. and Ducar M.  
 Creation of genome-wide protein expression libraries using random  
 activation of gene expression  
 Nat. Biotechnol. 19 (5), 440-445 (2001)  
 2127151  
 11329013  
 Contact: Scott J. Cain  
 Athersys, Inc.  
 3201 Carnegie Ave, Cleveland, OH 44115, USA  
 Tel: 216 431 9900  
 Fax: 216 361 9596  
 Email: scain@atersys.com  
 High quality sequence stop: 553.  
 Location/Qualifiers  
 1. 803  
 /organism="Homo sapiens"  
 /mol\_type="mRNA"  
 /db\_xref="taxon:9606"  
 /cell\_line="HT1080"  
 /clone\_lib="Athersys RAGE Library"  
 /note="Tsee 'Creation of Genome-wide Protein Expression'  
 Libraries using Random Activation of Gene Expression',  
 Nature Biotechnology, in press. Note that even though the  
 cell type indicated is HT1080, since a random activation  
 method was used, these sequence tags are not necessarily

expressed in HT1080 under normal circumstances."

ORIGIN  
 Alignment Scores: 3.8e-118 Length: 803  
 Pred. No.: 1123.00 Matches: 217  
 Score: 1123.00 Conservative: 3  
 Percent Similarity: 94.02% Mismatches: 13  
 Best Local Similarity: 92.74% Indels: 1  
 Query Match: 90.45% Gaps: 0  
 DB: 4

US-09-914-053A-5 (1-235) x BG198614 (1-803)

QY 1 MetSerIleTyrThrSerGlyArgThrSerSerSerTyrArgHisAspGluLysArgAsn 20  
 DB 73 ATGTTATATGACACAGTGGCCGGACCTCTTCATCTTATAGACATGATGAAAGAAAT 132

QY 21 IleTyrGlnLysIleArgAspHisAspLeuLeuAspLysArgLysThrValThrAlaLeu 40  
 DB 133 ATTTACCAAAAAATCAGGACCATGACCTCTCTGGACAAAAGGAAACAGTTCACAGCATG 192

QY 41 LysAlaGlyGluAspArgAlaIleLeuLeuGlyLeuAlaMetMetValCysSerIleMet 60  
 DB 193 AAGGACGAGGAGAGACGAGCTATTCTCCGGACCTGGCTATGTTGGTCTCCATCATG 252

QY 61 MetTyrPheLeuLeuGlyIleThrLeuLeuArgSerTyrMetGlnSerValTyrThrGlu 80  
 DB 253 ATGTAATTTTCTCTGGAAATCACATCTCTCGCTCATACATGACAGCGGTGGGACCGAA 312

QY 81 GluSerGlnCysThrLeuLeuAsnAlaSerIleThrGluThrPheAsnCysSerPheSer 100  
 DB 313 GAGTCTCAATGACCTTGTGTAATGCTCCATCAGGAAACATCTAATTCCTCTTCAGC 372

QY 101 CysGlyProAspCysThrLysLeuSerGlnTyrProCysLeuGlnValTyrValAsnLeu 120  
 DB 373 TGTGCTCCAGACTGCTGGAACTTTCTCAGTACCTCTGCTCCAGGTGACGTTAACTG 432

QY 121 ThrSerSerGlyGluLysLeuLeuTyrHisThrGluGluThrIleLysIleAsnGln 140  
 DB 433 ACTTCTTCCGGGAAAGCTCTCTCTACCAACAGAGACAAATAAATCAATCAG 492

QY 141 LysCysSerTyrIleProLysCysGlyLysAsnPheGluGluSerMetSerLeuValAsn 160  
 DB 493 AAGTCTCTCTATATACCTAAATGTGGAAAAATTTTGAAGATCCATGCCCTCTGTAAT 552

QY 161 ValValMetGluAsnPheArgLysTyrGlnHisPheSerCysTyrSerAspProGluGly 180  
 DB 553 GTTGTCAATGAAAACTTCAGGAAGCATCAACACTTCTCTGCTATTCTGACCCAGAACGA 612

QY 181 AsnGlnLysSerValIleLeuThrLysLeuTyrSerSerAsnValLeuPheHisSerLeu 200  
 DB 613 AACCAAGAGAGTGTATCTTCAAAAACTTCAAGTTCACAGCGGTGTTCCATTCATC 672

QY 201 PheTyrProThrCysMetMetAlaGlyValAlaIleValAlaMetVal-LysLeuTh 220  
 DB 673 TTTCTGCCCAACCTGTATGATGCTGGGGTGGGGAATTTGTTGATGTTGGGAACCTTCA 732

QY 220 rGlnTyrLeuSerLeuLeuCysGluArgIleGlnArgile 233  
 DB 733 CCAGTCTCTTTTCCCTACTATGTGAGAGGATCCACCGGATC 772

RESULT 7  
 LOCUS BG195580 816 bp mRNA linear EST 21-APR-2001  
 DEFINITION RST14773 Athersys RAGE Library Homo sapiens cDNA, mRNA sequence.  
 ACCESSION BG195580  
 VERSION BG195580.1 GI:13717267  
 KEYWORDS EST.  
 SOURCE Homo sapiens (human)  
 ORGANISM Homo sapiens  
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.  
 1 (bases 1 to 816)

AUTHORS Harrington,J.J., Sherf,B., Rundlett,S., Jackson,P.D., Perry,R., Cain,S., Leventhal,C., Thornton,M., Ramachandran,R., Whittington,J., Lerner,L., Costanzo,D., McElligott,K., Booser,S., Mays,R., Smith,E., Veloso,N., Klika,A., Hess,J., Cothren,K., Lo,K., Offenbacher,J., Danzig,J. and Ducar,M.  
Creation of genome-wide protein expression libraries using random activation of gene expression  
Nat. Biotechnol. 19 (5), 440-445 (2001)  
11329013  
Contact: Scott J. Cain  
Athersys, Inc.  
3201 Carnegie Ave, Cleveland, OH 44115, USA  
Tel: 216 431 9900  
Fax: 216 361 9596  
Email: scain@atersys.com  
High quality sequence stop: 364.  
Location/Qualifiers  
1..816  
/organism="Homo sapiens"  
/mol\_type="mRNA"  
/db\_xref="taxon:9606"  
/cell\_line="HT1080"  
/clone\_lib="Athersys RAGE Library"  
/note="See 'Creation of Genome-wide Protein Expression Libraries using Random Activation of Gene Expression', the Nature Biotechnology, in press. Note that even though the cell type indicated is HT1080, since a random activation method was used, these sequence tags are not necessarily expressed in HT1080 under normal circumstances."

TITLE  
JOURNAL  
MEDLINE  
PUBMED  
COMMENT

FEATURES  
source  
1..816  
Length: 816  
Matches: 220  
Score: 1122.00  
Percent Similarity: 93.25%  
Best Local Similarity: 92.83%  
Query Match: 90.41%  
Indels: 2  
Gaps: 0

US-09-914-053A-5 (1-235) x BG195580 (1-816)

QY 1 MetSerIleTrpThrSerGlyArgThrSerSerSerTyrArgHisAspGluLysArgAsn 20  
Db 72 ATGTTATATGACGAGGCGACACCTTCACTTATACATGATGATGAAAAAGAAAT 131  
QY 21 IleTyrGlnLysIleArgAspHisAspLeuLeuAspLysArgLysThrValThrAlaIleu 40  
Db 132 ATTTACCAAGAAATCAGGAGCCATGACCTCTGGACAAAAGGAAACAGTCACAGCACTG 191  
QY 41 LysAlaGlyGluAspArgAlaIleLeuLeuGlyLeuAlaMetValCysSerIleuMet 60  
Db 192 AAGCAGGAGGAGGACCGAGCTATTCCTCGGACTGGCTATGATGGTGTCTCCATCATG 251  
QY 61 MetTyrPheLeuLeuGlyIleThrLeuLeuArgSerTyrMetGlnSerValTrpThrGlu 80  
Db 252 ATGATTTTCTGCTGGGAATCACACTCTCGGCTCATACATGCGAGCGTGTGACCGAA 311  
QY 81 GluSerGlnCysThrLeuLeuAsnAlaSerIleThrGluThrPheAsnCysSerPheSer 100  
Db 312 GAGTCTCAATGACCTTCTGATGCGTCCATCAGGAAACATTTAATGCTCTCTCAGC 371  
QY 101 CysGlyProAspCysTrpLysLeuSerGlnTyrProCysLeuGlnValTyrValAsnLeu 120  
Db 372 TGTGTCCAGACTGCTGGAAACTTCTCAGTACCCCTCCCTCCAGGTACGTAACTG 431  
QY 121 ThrSerSerGlyLysLeuLeuLeuTyrHisThrGluGluThrIleLysIleAsnGln 140  
Db 432 ACTCTTCNCGNGAAAGCTCTCTCTACACACAGAGAGACAATAAAAAATCAATCAG 491  
QY 141 LysCysSerTyrIleProLysCysGlyLysAsnPheGluGluGluSerMetSerLeuValAsn 160  
Db 492 AAGTCTCTATATACCTAAATGTGGAAAAATTTTGAAGATCCATGTCCTCTGCTGAT 551

QY 161 ValValMetGluAsnPheArgLysTyrGlnHisPheSerCysTyrSerAspProGluGly 180  
Db 552 GTTGTATGAAAACCTTCAAGAGATATCAACTTCTCTCTCTCTCTCTCTCTCTCTCTCT 611  
QY 181 AsnGlnLysSerValIleLeuThrLysLeuTyrSerSerAsn-ValLeuPheHisSerLe 200  
Db 612 AACCAAGAGAGTGTATNCTAACAACAACTCTACAGTTCACCGTGCNTGTCCATTCAT 671  
QY 200 uPheTrpProThrCysMetMet-AlaGlyGlyValAlaIleValAlaMetValLysLeuT 220  
Db 672 TCTCTGGCAACCTGTATGATGGCTGGGGCGTGCAAAATTGTGCGATGGTGAACCTTA 731  
QY 220 hrGlnTyrLeuSerLeuLeuCysGluArgIleGlnArgIleAsnArg 235  
Db 732 CACAGGACCTCTNCTACTATGCGAGAGATCCAAACCGATCANTAGA 778

RESULT 8  
BG218411 795 bp mRNA linear EST 21-APR-2001  
LOCUS RST382779 Athersys RAGE Library Homo sapiens cDNA, mRNA sequence.  
DEFINITION BG218411  
ACCESSION BG218411  
VERSION BG218411.1 GI:113744560  
KEYWORDS EST.  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
REFERENCE 1 (bases 1 to 795)  
AUTHORS Harrington,J.J., Sherf,B., Rundlett,S., Jackson,P.D., Perry,R., Cain,S., Leventhal,C., Thornton,M., Ramachandran,R., Whittington,J., Lerner,L., Costanzo,D., McElligott,K., Booser,S., Mays,R., Smith,E., Veloso,N., Klika,A., Hess,J., Cothren,K., Lo,K., Offenbacher,J., Danzig,J. and Ducar,M.  
Creation of genome-wide protein expression libraries using random activation of gene expression  
Nat. Biotechnol. 19 (5), 440-445 (2001)  
21227151  
PUBMED 11329013  
COMMENT Contact: Scott J. Cain  
Athersys, Inc.  
3201 Carnegie Ave, Cleveland, OH 44115, USA  
Tel: 216 431 9900  
Fax: 216 361 9596  
Email: scain@atersys.com  
High quality sequence stop: 483.  
Location/Qualifiers  
1..795  
/organism="Homo sapiens"  
/mol\_type="mRNA"  
/db\_xref="taxon:9606"  
/cell\_line="HT1080"  
/clone\_lib="Athersys RAGE Library"  
/note="See 'Creation of Genome-wide Protein Expression Libraries using Random Activation of Gene Expression', the Nature Biotechnology, in press. Note that even though the cell type indicated is HT1080, since a random activation method was used, these sequence tags are not necessarily expressed in HT1080 under normal circumstances."

Alignment Scores:  
Pred. No.: 1.44e-115 Length: 795  
Score: 1100.50 Matches: 222  
Percent Similarity: 95.71% Conservative: 1  
Best Local Similarity: 95.28% Mismatches: 8  
Query Match: 88.68% Indels: 4  
DB: 4 Gaps: 1  
US-09-914-053A-5 (1-235) x BG218411 (1-795)  
QY 3 IleTrpThrSerGlyArgThrSerSerSerTyrArgHisAspGluLysArgAsnIleTyr 22

```

Db      78 ATATGACCACCGCGCGGACCTCTTCATCTTATAGACATGATGAAAAAGAAATATTATC 137
QY      23 GlnLysIleArgAspHisAspLeuLeuAepLysArgLysThrValThrAlaLeuLysAla 42
Db      138 CAGAAATCAGGACCATGACTCTCTGGACAAAGAAACAGTACAGCATCTGAAGCA 197
QY      43 GlyGluAspArgAlaIleLeuLeuGlyLeuAlaMetMetValCysSerIleMetMetTyr 62
Db      198 CGAGAGACCGAGCTTTCTCTGGAGCTGGCTATGATGATGCTGCTCCATCATGATGAT 257
QY      63 PheLeuLeuGlyIleThrLeuLeuArgSerTyrMetGlnSerValThrGluGluSe 82
Db      258 TTCTCTCTGGGATTT---CTTCTGGCTGTCATACATGAGAGCGGTGGCCGAGATC 314
QY      82 rGlnCysThrLeuLeuAsnAlaSerIleThrGluThrPheAsnCysSerPheSerCysG1 102
Db      315 TCAATGCACCTTGTGTAATGCGTCCATCAGCAAAACATTTAATTCCTTCAGCTGG 374
QY      102 yProaspCysTrpLysLeuSerGlnTyrProCysLeuGlnValTyrValAsnLeuThrSe 122
Db      375 TCAGAGCTGCTGGAACCTTCTCAGTACCCCTGCTCCAGGTGTAGTAACTGACTTC 434
QY      122 rSerGlyGluLysLeuLeuLeuTyrHisThrGluGluThrIleLysIleAsnGlnLysCy 142
Db      435 TTCCGGGGA-AGCTCCCTCTCTACACACAGAGACATATAAATCAATCAGAGTG 493
QY      142 sSerTyrIleProLysCysGlyLysAsnPheGluGluSerMetSerLeuValAsnValva 162
Db      494 CTCCTATATACCTAAATGTGGAATAAATTTGAAGATCCATGCTCCCTGGTGAATGTGT 553
QY      162 lMetGluAsnPheArgLysTyrGlnHisPheSerCysTyrSerAspProGluGlyAsnG1 182
Db      554 CAITGGAATACTTCAGAGATCAACACTTCTTCGTATTCTGACCCAGAGAAACCA 613
QY      182 nLysSerValIleLeuThrLysLeuTyrSerSerAsnValLeuPheHisSerLeuPheTr 202
Db      614 GAAGAGTGTATCTTAACAAACTCTACAGTTCACAGTGTCTGTTCCATTCTTCTG 673
QY      202 pProThrCysMetMetAlaGlyGlyValAlaIleValAlaMetValLysLeuThrGlnTy 222
Db      674 GCAACCTGTGATGTGGCTGGCGGGTGGCAATTTGCCATGGGAAACT-ACACAGTA 732
QY      222 rLeuSerLeuLeuCysGluArgIleGlnArgIleAsn 234
Db      733 CTTTTCCTTACTATGTGAGAGGATCCACGGATCCAT 769

RESULT 9
BU216989 LOCUS
DEFINITION
603107309F1 CSEQHN04 Gallus gallus cDNA clone CHEST48b 5', mRNA
sequence.
ACCESSION
BU216989
VERSION
BU216989.1 GI:25398033
KEYWORDS
EST.
SOURCE
Gallus gallus (chicken)
ORGANISM
Gallus gallus
Eukarya; Chordata; Chordata; Craniata; Vertebrata; Euteleostomi;
Archosauria; Aves; Neognathae; Galliformes; Phasianidae;
Phasianinae; Gallus.
1 (bases 1 to 855)
Boardman, P.E., Sanz-Ezquerro, J., Overton, I.M., Burt, D.W., Bosch, E.,
Fong, W.T., Tickle, C., Brown, W.R.A., Wilson, S.A. and Hubbard, S.J.
A Comprehensive Collection of Chicken cDNAs
Curr. Biol. 12 (22), 1965-1969 (2002)
22335534
MEDLINE
12445392
PUBMED
Contact: Simon Hubbard
Department of Biomolecular Sciences
University of Manchester Institute of Science and Technology
(UMIST)
PO Box 88, Manchester, M60 1QD, UK
Tel: 0161208930
Fax: 01612360409

```

```

FEATURES
source
Location/Qualifiers
1..855
/organism="Gallus gallus"
/mol_type="mRNA"
/strain="White Leghorn, Hisex"
/db_xref="taxon:9031"
/clone="CHEST48b4"
/tissue_type="whole embryo"
/dev_stage="20-21"
/lab_host="DH108"
/clone_lib="CSEQHN04"
Notes: Organ: whole embryo; Vector: pBluescript II KS(+);
Site 1: EcoRI; Site 2: NotI; This normalized library was
constructed from 1 million independent clones. cDNA
synthesis was initiated using an oligo(dT) primer, using
methylated C in the first strand synthesis reaction
Following this first strand reaction, double-stranded cDNA
was blunted, ligated to NotI adapters, digested with
EcoRI, size-selected, and cloned into the NotI and EcoRI
compatible sites of a custom modified MCS of the
pBluescript (KS+) vector. The library was normalized in 2
rounds using conditions adapted from Soares et al., PNAS
(1994) 91: 9228-9232 and Bonaldo et al., Genome Research 6
(1996): 791, except that a significantly longer
reannealing hybridization was used."
ORIGIN
Alignment Scores:
Pred. No.: 1,03e-114 Length: 855
Score: 1093.50 Matches: 209
Percent Similarity: 93.64% Conservative: 12
Best Local Similarity: 88.56% Mismatches: 7
Query Match: 88.11% Indels: 8
DB: 5 Gaps: 1
US-09-914-053A-5 (1-235) x BU216989 (1-855)
QY 1 MetSerIleTrpThrSerGlyArgThrSerSerSerTyrArgHisAspGluLysArgAsn 20
Db 152 ATGTTTATTGGACCATGTCGCGGAGCTCTACATCTTACAGACACGATGAGAAA----- 205
QY 21 IleTyrGlnLysIleArgAspHisAspLeuLeuAepLysArgLysThrValThrAlaLeu 40
Db 206 -----AGGATCAGCATCTCTGGACAAAGAAACAGTACAGCCCTA 250
QY 41 LysAlaGlyGluAspArgAlaIleLeuLeuGlyLeuAlaMetMetValCysSerIleMet 60
Db 251 AAAGCTGGAGAAACCGGCGCCATCTCTCGGGCTGGCCATGATGCTGCTCATCATG 310
QY 61 MetTyrPheLeuLeuGlyIleThrLeuLeuArgSerTyrMetGlnSerValTrpThrGlu 80
Db 311 ATGTACTTCTCTGGGAATCACCTGTCGCGTCTCTACATGACAGAGCGTCTGGACAGAA 370
QY 81 GluSerGlnCysThrLeuLeuAsnAlaSerIleThrGluThrPheAsnCysSerPheSer 100
Db 371 GAGGCTCAGTCTCGCTTCTCAACGCATCATCACGAAACCTTCAACTGCTCGTTAGC 430
QY 101 CysGlyProAspCysTrpLysLeuSerGlnTyrProCysLeuGlnValTyrValAsnLeu 120
Db 431 TCGGGCCCAAGATGCTGGAAAATCTCTCAGTACCCCTGCTCGAGGTGATGCTCAATCTC 490
QY 121 ThrSerSerGlyGluLysLeuLeuLeuTyrHisThrGluGluThrIleLysIleAsnGln 140
Db 491 ACTTCTTCTGGCCAGAGCTTCTGCTTACACACCGAAGAAACAATGAAATTAATTC 550
QY 141 LysCysSerTyrIleProLysCysGlyLysAsnPheGluGluSerMetSerLeuValAsn 160
Db 551 GAGTGTGCTACATACCCCAAGTGTGGCAAGAAATACGAGGAATCCATGCTCAATGTGAAC 610
QY 161 ValValMetGluAsnPheArgLysTyrGlnHisPheSerCysTyrSerAspProGluGly 180
Db 611 GTTGTGATGGAAAACCTTCGGAAGATATCAGCGCTTCTCTGCTTCTATGATCTTGAGGCG 670

```

Email: Simon.Hubbard@umist.ac.uk.



```

/mol_type="mRNA"
/strain="White Leghorn, HiseX"
/db_xref="taxon:9031"
/clone="ChST43b24"
/tissue_type="whole embryo"
/dev_stage="20-21"
/lab_host="DH10B"
/clone_lib="CSQCHN04"
/notes="Organ: whole embryo; Vector: pBluescript II KS(+); Site 1: EcoRI; Site 2: NotI; This normalized library was constructed from 1 million independent clones. cDNA synthesis was initiated using an oligo(dT) primer, using methylated C in the first strand synthesis reaction. Following this first strand reaction, double-stranded cDNA was blunt-ended, ligated to NotI adapters, digested with EcoRI, size-selected, and cloned into the NotI and EcoRI compatible sites of a custom modified MCS of the pBluescript (KS+) vector. The library was normalized in 2 rounds using conditions adapted from Soares et al., PNAS (1994) 91: 9228-9232 and Bonaldo et al., Genome Research 6 (1996): 791, except that a significantly longer reannealing hybridization was used."

```

## ORIGIN

```

Alignment Scores:
Pred. No.: 9,52e-101 Length: 939
Score: 972.50 Matches: 205
Percent Similarity: 88.98% Conservatives: 13
Best Local Similarity: 83.67% Mismatches: 10
Query Match: 78.36% Indels: 17
DB: 5 Gaps: 3

```

US-09-914-053A-5 (1-235) x BU222329 (1-939)

```

QY 1 MetSerIleTyrThrSerGlyArgThrSerSerSerTyrArgHisAspGluLysArgAsn 20
DB 152 ATGTTATTTCGACGAGTGGCGGAGCTCTACATCTTACAGACGATGAGAA----- 205
QY 21 IleTyrGlnLysIleArgAspHisAspLeuLeuAspLysArgLysThrValThrAlaLeu 40
DB 206 -----AGGATCATCATCTACTGACAAAGAAAGAAACAGTCACAGCCCTA 250
QY 41 LysAlaGlyGluAspArgAlaIleLeuLeuGlyLeuAlaMetMetValCysSerIleMet 60
DB 251 AAAGTCGAGAAGACCGCGCCATCTCTCGGGTGGCCATGATGGTGTCTCTATCATG 310
QY 61 MetTyrPheLeuGlyIleThrLeuLeuArgSerTyrMetGlnSerValTyrThrGlu 80
DB 311 ATGACTTCTTCCTGGGAATCACCTGTGCGGTCCTACATGACGAGCGTCTGGACAGAA 370
QY 81 GluSerGlnCysThrLeuLeuAsnAlaSerIleThrGluThrPheAsnCysSerPheSer 100
DB 371 GAGGTCAGTCTGCTCTTCAACGATCCATCACCGAAACCTTCAACTGCTGTTTACG 430
QY 101 CysGlyProAspCysTyrPheLeuSerGlnTyrProCysLeuGlnValTyrValAsnLeu 120
DB 431 TCGCGCCAGACTGCTGGAATTTCTTCAGTACCCCTGCTGCGTGGAGGTACGTCATCTC 490
QY 121 ThrSerSerGlyGluLysLeuLeuLeuTyrHisThrGluGluThrIleLys-IleAsnG1 140
DB 491 ACTTCTTCTGCGCAGACTTCTCTCTACACACCGAAGAAACATGAAACATTATTC 550
QY 140 nLysCysSerTyrIleProLysCysGlyLysAsnPheGluGluSerMetSerLeuValAs 160
DB 551 TGAGTGTTCGTACATACCAAGTGTGCAAGAAATACGAGGAATCCATGTCATGTGTGA 610
QY 160 nValValMetGluAsnPheArgLysTyrGlnHisPheSerCysTyrSerAspProGluG1 180
DB 611 CGTTGTGATGAAACACTCCGAAGATATCAACGCTTCTCTGCTTCTATGATCTGAGGG 670
QY 180 yAsnGlnLysSerValIleLeuThr-LysLeuTyrSerSer-AsnVal---LeuPheHis 198
DB 671 CACTCAGAAGAACGTGATATTGACCAAAACTGTACAGCTCCCAACGCTGGCTTGTTCACAC 730

```

```

QY 199 SerLeuPheTrp--ProThrCysMetMetAlaGlyValAla---IleValAlaMetV 217
DB 731 TCGCTCTTCTGGGCCCCCGTCATGATCGCGGGCTTCCCATTTTTCGGAATGG 790
QY 217 allys-LeuThrGlnTyrLeu-SerLeuLeuCysGluArgIle-GlnArgIleAsnArg 235
DB 791 TAAAGCGTCACTCAATACCTTTTCTCTCTCTCGGAGAGATCCCAAGGATCAACAGA 849

```

## RESULT 12

```

LOCUS CK903430/c
DEFINITION 1e57a02.x5 Melton Normalized Human Islet 4 N4-HIS 1 Homo sapiens
CHANNEL BETA 2 SUBUNIT. 1, mRNA sequence.

```

## ACCESSION

```

VERSION CK903430
KEYWORDS EST.
SOURCE CK903430.1 GI:45364961

```

## ORGANISM

```

Homo sapiens (human)

```

```

REFERENCE 1 (bases 1 to 598)
AUTHORS Melton,D., Meadows,A., Clifton,S., Hillier,L., Marra,M., Pape,D.,
Wyllie,T., Martin,J., Blistain,A., Schmitt,A., Theising,B.,
Ritter,E., Ronko,I., Bennett,J., Cardenas,M., Gibbons,M.,
McCann,R., Cole,R., Tsagarisvilli,R., Williams,T., Jackson,Y. and
Bowers,F.

```

```

TITLE WashU-Harvard Pancreas EST Project
JOURNAL Unpublished (2000)
COMMENT Other ESTs: 1e57a02.y1

```

```

Contact: Douglas Melton, Klaus H. Kaestner, & Hiroshi Inoue
Endocrine Pancreas Consortium
Harvard University, Howard Hughes Medical Institute
Dept of Molecular and Cellular Biology, 7 Divinity Ave, Cambridge,
MA 02138
Tel: 617-495-1812
Fax: 617-495-8557
Email: dmelton@iobp.harvard.edu

```

```

This read is a 3' RESEQUENCE of a previously sequenced pancreas
clone

```

```

This resequenced clone has not previously been sequenced on this
end, resequencing from this end represents new data
Seq primer: -40UP from Gibco
High quality sequence stop: 594.

```

## FEATURES

```

Location/Qualifiers
1..598
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
/clone="IMAGE:5670818"
/sex="Both"
/tissue_type="Islets of Langerhans"
/dev_stage="Adult"
/lab_host="DH10B"
/clone_lib="Melton Normalized Human Islet 4 N4-HIS 1"
/notes="Organ: Pancreas; Vector: pSPORT1; Site 1: Not 1; Site 2: Sal 1; Starting library constructed using SuperScript Plasmid Library kit (Life Technologies). cDNA made by oligo-dT priming. Size-selected by column fractionation; average insert size 1.08 kb. Library was amplified once on solid support and plasmid DNA from library was prepared. The library DNA was normalized by method #4 from Bonaldo, Lennon, and Soares 1996 Genome Research 6:791-806; 0.5 microgram single-stranded library plasmid DNA was mixed with 5 micrograms PCR product representing library inserts and hybridized to an Ecot of 20' single-stranded (unhybridized) plasmids were isolated by hydroxyapatite chromatography and used to make this library."

```

## source

## ORIGIN

Alignment Scores:



## COMMENT

Contact: Croning MDR  
Sanger Institute  
Hinxton, Cambridgeshire, CB10 1SA, UK  
Email: trop@anger.ac.uk  
Sanger Xenopus tropicalis EST project 2001  
TROPICALIS\_SEQUENCE\_ID: TtpA078h06.plk9p6  
Sequencing primer: SP6  
This sequence is from a Xenopus Gene Collection (XGC) library  
constructed by Nigel Garrett.  
cDNA was oligo dT primed from 5' of poly A+ RNA from tadpole  
embryos. EcoRI-NotI cut cDNA was then ligated into pCS107 with  
EcoRI at the 5' end and NotI at the 3' end.  
Vector: pCS107; Site 1: EcoRI; Site 2: NotI  
Host: Escherichia coli DH10B.  
Location/Qualifiers

## FEATURES

source  
1..852  
/organism="Xenopus tropicalis"  
/mol\_type="mRNA"  
/db\_xref="taxon:8364"  
/clone="TtpA078h06"  
/dev\_stage="tadpole (stage 35-40)"  
/lab\_host="E. coli DH10B"  
/clone\_lib="XGC-tadpole"  
/note="Vector: pCS107; Site 1: EcoRI; Site 2: NotI; cDNA  
was oligo dT primed from 5' of poly A+ RNA from tadpole  
embryos. EcoRI-NotI cut cDNA was then ligated into pCS107  
with EcoRI at the 5' end and NotI at the 3' end"

## ORIGIN

Alignment Scores:  
Pred. No.: 4,1e-68 Length: 852  
Score: 688.00 Matches: 127  
Percent Similarity: 95.17% Conservative: 11  
Best Local Similarity: 87.59% Mismatches: 7  
Query Match: 55.44% Indels: 0  
DB: 5 Gaps: 0

US-09-914-053A-5 (1-235) x BX729097 (1-852)

QY 1 MetSerIleTTPThrSerGlyArgThrSerSerSerTyrArgHisAspGluLysArgAsn 20  
DB 416 ATGTTTATTTGGACGAGTGGCGGCTCTCGTCATCATACAGCCGATGAAGAAGAAAT 475

QY 21 IleTyrGlnLysIleArgAspHisAspLeuLeuAspLysArgLysThrValThrAlaLeu 40  
DB 476 TTCTACCAAAAATCAAGATCATGATCTTCTGGACAAAGGAAACTGTGACGGCACTA 535

QY 41 LysAlaGlyGluAspArgAlaIleLeuLeuGlyLeuAlaMetMetValCysSerIleMet 60  
DB 536 AAGCAGGAGAGACAGACGCTATCTCTGGGACTTGCATGATGGTGTCTCCATTATG 595

QY 61 MetTyrPheLeuLeuGlyIleThrLeuLeuArgSerTyrMetGlnSerValTTPThrGlu 80  
DB 596 ATGTTATTTCTCTAGGATTAACATTTCTGGATCATCATGACCGATGACAGAA 655

QY 81 GluSerGlnCysThrLeuLeuAsnAlaSerIleThrGluThrPheAsnCysSerPheSer 100  
DB 656 GAGACACAATGCACATTAATGAATGATCATATACAGAAACCTTCAACTGCTCCTCAGT 715

QY 101 CysGlyP-TpAspCysTyrLysLeuSerGlnTyr-ProCysLeuGlnValTyrValAsnLeu 120  
DB 716 TGTGGTTCAGATTCTGTAATCTCTCAGTACCCCTGTCTACAGGTTTATGAACCTG 775

QY 121 ThrSerSerGlyGluLysLeuLeuLeuTyrHisThrGluThrIleLysIleAsnGln 140  
DB 776 AATCTTTCAGGACAGAGGTCCTTCTCTACACACAGAAACTATGAAGTGAATCT 835

QY 141 LysCysSerTyrIle 145  
DB 836 GAGTNGTCATACATA 850

RESULT 15  
CK601161

## LOCUS

CK601161 835 bp mRNA linear EST 22-JAN-2004  
AGENCOURT 17898293 NIH MGC 234 Rattus norvegicus cDNA clone  
IMAGE:7190722 5', mRNA sequence.

## DEFINITION

ACCESSION CK601161  
VERSION CK601161.1 GI:41114346

## KEYWORDS

SOURCE Rattus norvegicus (Norway rat)

## ORGANISM

Rattus norvegicus  
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae;  
Rattus.

## REFERENCE

1 (bases 1 to 835)

## AUTHORS

NIH-MGC <http://mgc.nci.nih.gov/>.

## TITLE

National Institutes of Health, Mammalian Gene Collection (MGC)

## JOURNAL

Unpublished (1999)

## COMMENT

Contact: Daniela S. Gerhard, Ph.D.  
Office of Cancer Genomics  
National Cancer Institute / NIH  
Bldg. 31 Rm10A07 Bethesda, MD 20892  
Email: cgsbbs-remail.nih.gov  
Tissue Procurement: Howard Jacobs  
cDNA Library Preparation: Express Genomics  
DNA Sequencing by: Agencourt Bioscience Corporation  
Clone distribution: MGC clone distribution information can be  
found through the I.M.A.G.E. Consortium/LLNL at:  
<http://image.llnl.gov>  
Plate: LLAM15048 row: k column: 08  
High quality sequence stop: 681.

## FEATURES

Location/Qualifiers

1..835  
/organism="Rattus norvegicus"  
/mol\_type="mRNA"  
/db\_xref="taxon:10116"  
/clone="IMAGE:7190722"  
/tissue\_type="heart, pooled"  
/lab\_host="DH10B Tona"  
/clone\_lib="NIH MGC 234"  
/note="Organ: heart; Vector: pExpress-1; Site 1: EcoRV;  
Site 2: NotI; RNA obtained from pooled heart tissue from a  
mix of male and female animals at 8 wk old. Tissues were  
snap-frozen and kept at -80C for two days before RNA  
extraction and purification (TRI-reagent method). cDNA was  
primed using oligo-dT primer:  
5'-TGACTAGTTCTAGATCGGCGGCCGCC(T)25-3' and cloned into  
the EcoRV/NotI sites of pExpress-1. Size-selection >1.4kb  
resulted in an average insert size of 2.2 kb. This primary  
library is normalized (non-normalized primary library is  
NIH MGC 233) and was constructed by Express Genomics  
(Frederick, MD). Note: this is a NIH\_MGC library."

## ORIGIN

Alignment Scores:  
Pred. No.: 1,89e-64 Length: 835  
Score: 656.00 Matches: 135  
Percent Similarity: 75.54% Conservative: 4  
Best Local Similarity: 73.37% Mismatches: 21  
Query Match: 52.86% Indels: 24  
DB: 7 Gaps: 4

US-09-914-053A-5 (1-235) x CK601161 (1-835)

QY 1 MetSerIleTTPThrSerGlyArgThrSerSerSerTyrArgHisAspGluLysArgAsn 20  
DB 298 ATGTTTATATGACCCAGTGGCGGACCTCTTCACTTACACACACGACGAGAAAT 357

QY 21 IleTyrGlnLysIleArgAspHisAspLeuLeuAspLysArgLysThrValThrAlaLeu 40  
DB 358 ATCTACCAAGAAATCAGGACCATGACCTCTGACAAAAGAAACTGTGACAGCTCTG 417

QY 41 LysAlaGlyGluAspArgAlaIleLeuLeuGlyLeuAlaMetMetValCysSerIleMet 60  
DB 418 AAGGCTGGGAGGACCGGCCCATCTCTTGGACTGGCCATGATGCTGTCTCCATCATG 477



```
Qy 61 MetTyrPheLeuLeuGlyIleThrLeuLeuArgSerTyrMetGlnSerValThrThrGlu 80
Db 478 ATGTACTTCTTACTTGGGAATCACACTGCTGCGCTCGTACATGGCAGAGTGTATGGACAGAA 537
Qy 81 GluSerGlnCysThrLeuLeuAsnAlaSerIleThrGluThrPheAsnCysSerPheSer 100
Db 538 GAGCCAGTGTGCCCTGCTGAATGTCTCAATCACAGAAACATTAACTGTTCTTCAGC 597
Qy 101 CysGlyProAspCysTrpLysLeuSerGlnTyrProCysLeuGlnValTyrValAsnLeu 120
Db 598 TGTGGGCTGACTGCTGGAAGCTCTCTCAGTACCTTGCCTGCAGGTATACGTGAACCTG 657
Qy 121 ThrSerSerGlyGluLysLeuLeuLeuTyrHisThrGlu-----GluThrIleLysIle 138
Db 658 ACATCTTCTGGGAGAGCTCCTCTCTA---CACACAGAGACATGAGATCATCAAGTG 714
Qy 139 AsnGlnLysCysSerTyrIleProLysCysGlyLysAsnPheGluGluSerMetSerLeu 158
Db 715 -----CTC 717
Qy 159 ValAsnValValMetGluAsnPheArgLysTyrGlnHisPheSer-----CysTyrSer 176
Db 718 TATATCTAGTGTGGAAACACTTTGAGATCATGTCCTAGTCTTTTCATCAGACTGCTACGGT 777
Qy 177 AspProGluGly 180
Db 778 GAGACAGCTGGA 789
```

Search completed: November 7, 2004, 03:20:13  
Job time : 2967 secs

**This Page Blank (uspto)**

GenCore version 5.1.6  
Copyright (c) 1993 - 2004 Compugen Ltd.

OM protein - nucleic search, using frame\_plus\_p2n model

Run on: November 6, 2004, 23:41:12 ; Search time 3107 Seconds

(without alignments)  
3576.788 Million cell updates/sec

Title: US-09-914-053A-5

Perfect score: 1241

Sequence: 1 MSITSGRTSSSVRHDEKRN.....MVKLTQYLSLLCERIQIRNR 235

Scoring table: BLOSUM62  
Xgapop 10.0 , Xgapext 0.5  
Ygapop 10.0 , Ygapext 0.5  
Fgapop 6.0 , Fgapext 7.0  
Delop 6.0 , Delext 7.0

Searched: 4526729 seqs, 23644849745 residues

Total number of hits satisfying chosen parameters: 9053458

Minimum DB seq length: 0

Maximum DB seq length: 20000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Command line parameters:

-MODEL=frame+ p2n.model -DEV=xlp  
-Q=/cgn2.1/USPTO.spool.p/US09914053/runat\_04112004.183921.18221/app.query.fasta\_1.391  
-DB=GenEmbl -PEMT=fastap -SUFFIX=rge -MINMATCH=0.1 -LOOPCL=0 -LOOPEXT=0  
-UNITS=bits -START=1 -END=1 -WATRIX=blosum62 -TRANS=human40.cdi -LIST=45  
-DOCALIGN=200 -THR\_SCORE=pct -THR\_MAX=100 -THR\_MIN=0 -ALIGN=15 -MODE=LOCAL  
-OUTFMT=ptc -NORM=ext -HEAPSIZ=500 -MINLEN=0 -MAXLEN=2000000000  
-USPR=US09914053@cgn 1.1 5600 @runat\_04112004.183921.18221 -NCPU=3  
-NO MMAP -LARGEQUERY -NEG SCORES=0 -WAIT -DSPBLOCK=100 -LONGLOG  
-DEV\_TIMEOUT=120 -WARN\_TIMEOUT=30 -THREADS=1 -XGAPEXT=10 -XGAPEXT=0.5 -FGAPOP=6  
-FGAPEXT=7 -YGAPOP=10 -YGAPEXT=0.5 -DELOP=6 -DELEXT=7

Database :

GenEmbl.\*  
1: gb.ba.\*  
2: gb.htg.\*  
3: gb.in.\*  
4: gb.em.\*  
5: gb.ov.\*  
6: gb.pat.\*  
7: gb.ph.\*  
8: gb.pl.\*  
9: gb.pr.\*  
10: gb.ro.\*  
11: gb.sts.\*  
12: gb.sy.\*  
13: gb.un.\*  
14: gb.vi.\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

#### SUMMARIES

Result No.	Score	Match	Length	ID	Description
1	1235	99.5	1075	9 AF099137	AF099137 Homo sapi
2	1235	99.5	1285	9 BC017825	BC017825 Homo sapi
3	1235	99.5	2574	9 AF209747	AF209747 Homo sapi
4	1196	96.4	1062	6 C0714334	C0714334 Sequence

5	1186	95.6	708	10 AY062429	AY062429 Mus muscu
6	1186	95.6	2947	10 BC046227	BC046227 Mus muscu
7	1186	95.6	2947	10 BC058957	BC058957 Mus muscu
8	1185	95.5	708	10 AY191836	AY191836 Rattus no
9	1117.5	90.0	1546	5 BX950825	BX950825 Gallus ga
10	1117.5	90.0	1546	5 BX950833	BX950833 Gallus ga
11	1012	81.5	2098	6 BD223084	BD223084 98 human
12	1012	81.5	2098	6 AR243782	AR243782 Sequence
13	821	66.2	487	10 RNO517198	RJ217198 Rattus no
14	510.5	41.1	204899	9 AC117457	AC117457 Homo sapi
15	509	41.0	815	5 CCUG7865	U67865 Coturnix co
16	492.5	39.7	191186	2 AC115077	AC115077 Mus muscu
17	492	39.6	826	5 AF077369	AF077369 Gallus ga
18	492	39.6	1290	5 AF420468	AF420468 Gallus ga
19	487.5	39.3	297398	2 AC097578	AC097578 Rattus no
20	482.5	38.9	227094	2 AC126508	AC126508 Rattus no
21	481.5	38.8	1246	6 AR212367	AR212367 Sequence
22	478.5	38.6	1022	6 C0715541	C0715541 Sequence
23	478	38.5	1111	6 AR212368	AR212368 Sequence
24	477.5	38.5	1225	9 AF204159	AF204159 Homo sapi
25	474.5	38.2	1022	9 AF139471	AF139471 Homo sapi
26	474.5	38.2	1747	9 AF204161	AF204161 Homo sapi
27	474	38.2	952	9 AF214561	AF214561 Homo sapi
28	474	38.2	1160	9 AF170916	AF170916 Homo sapi
29	474	38.2	1311	9 AF204162	AF204162 Homo sapi
30	474	38.2	1488	9 AF160968	AF160968 Homo sapi
31	474	38.2	1620	9 AF204160	AF204160 Homo sapi
32	421	33.9	576	9 AF026002	AF026002 Homo sapi
33	421	33.9	576	9 HSU38907	U38907 Human beta-
34	421	33.9	715	9 AY044441	AY044441 Homo sapi
35	421	33.9	835	9 AY515264	AY515264 Homo sapi
36	421	33.9	1041	9 HSU42600	U42600 Human calci
37	421	33.9	1092	9 HSU61536	U61536 Human potas
38	421	33.9	1106	6 AR016453	AR016453 Sequence
39	421	33.9	1106	6 I45572	I45572 Sequence 3
40	421	33.9	1276	6 C0726048	C0726048 Sequence
41	421	33.9	1277	6 AX337509	AX337509 Sequence
42	421	33.9	1277	9 HSU25138	U25138 Human MaxiK
43	418	33.7	602	10 RNJ46602	U46062 Rattus norv
44	418	33.7	1278	10 AF020712	AF020712 Rattus no
45	415	33.4	680	10 MMCAXBETA	AJ001291 Mus muscu

#### ALIGNMENTS

RESULT 1	AF099137	1075 bp	linear	PRI 06-APR-1999
LOCUS	AF099137	Homo sapiens MaxiK channel beta 2 subunit (KCNMB2) mRNA, complete cds.		
DEFINITION	AF099137.1	GI:4566496		
ACCESSION	AF099137			
VERSION	AF099137.1			
KEYWORDS				
SOURCE				
ORGANISM				
REFERENCE				
AUTHORS				
TITLE				
JOURNAL				
MEDLINE				
PUBMED				
REFERENCE				
AUTHORS				
TITLE				
JOURNAL				
FEATURES				
source				

1 (bases 1 to 1075)  
Wallner,M., Veera,P. and Toro,L.  
Molecular basis of fast inactivation in voltage and Ca2+-activated  
X+ channels: a transmembrane beta-subunit homolog  
Proc. Natl. Acad. Sci. U.S.A. 96 (7), 4137-4142 (1999)  
99199323  
PUBMED  
10097176  
2 (bases 1 to 1075)  
Wallner,M.  
Direct Submission  
Submitted (16-OCT-1998) Dept. of Anesthesiology, UCLA, BH-612, CHS  
Box 951778, Los Angeles, CA 90095-1778, USA  
Location/Qualifiers  
1..1075  
/organism="Homo sapiens"  
/mol\_type="mRNA"

```

/db xref="taxon:9606"
/clone="IMAGE Consortium ID 1417217"
/tissue type="neuroendocrine lung carcinoid"
1..1075
/gene="KCMB2"
CDS
146..853
/gene="KCMB2"
/function="coexpression with the pore forming Maxik
channel alpha subunit leads to fast inactivating currents
and to an increase in apparent Ca2+ sensitivity"
/note="modulatory subunit of the voltage and Ca2+
activated K+ (Maxik) channel"
/codon_start=1
/product="Maxik channel beta 2 subunit"
/protein_id="AAD23380.1"
/db xref="GI:4566497"
/translation="MFITWTSRTSSVHDEKRNLYOKIRDHLDLDRKTVTALKAGE
DRAILLGLAMVCSIMWYFLGILLLSYMQSWTBSQCTLLNASITFNCSPSCG
PDCWLSQPCQLQVYNLTSSGKLLYHTBETIKQKCSYIPKCKGNFEESMLVN
VVMENFRYQHFSQSDPEGNQKSVILTKLYSSNVLPHSLFWPTCMWAGGVAIVAMVK
LTQVLSLCEIRIQINR"
146..202
/gene="KCMB2"
/note="intracellular inactivating 'ball' domain;
unclassified site"
misc_feature
287..355
/gene="KCMB2"
/note="transmembrane-region site"
misc_feature
728..796
/gene="KCMB2"
/note="transmembrane-region site"
ORIGIN
Alignment Scores:
Pred. No.: 9,98e-126 Length: 1075
Score: 1235.00 Matches: 234
Percent Similarity: 99.57% Conservative: 0
Best Local Similarity: 99.57% Mismatches: 1
Query Match: 99.52% Indels: 0
DB: 9 Gaps: 0
US-09-914-053A-5 (1-235) x AF099137 (1-1075)
QY 1 MetSerIleTrrpThrSerGlyArgThrSerSerSertYrArgHisAspGluLysArgAsn 20
DB 146 ATGTTTATATGACGAGTGGCGGACCTCTTCATCTTATACATGATGAAAAGAAAT 205
QY 21 IleTyrGlnLysIleArgAspHisAspLeuLeuAspLysArgLysThrValThrAlaLeu 40
DB 206 ATTTACCAAGAAATCAGGACCATGCTCTCGACAAAAGGAAAACAGTCACGACACTG 265
QY 41 LysAlaGlyGluAspArgAlaIleLeuLeuGlyLeuAlaMetMetValCysSerIleMet 60
DB 266 AAGCAGAGAGAGACCGAGCTATCTCTGGGATGGCTAATGATGGTCTCATCATG 325
QY 61 MetTyrPheLeuLeuGlyIleThrLeuLeuArgSerTyrMetGlnSerValTrrpThrGlu 80
DB 326 ATGTTATTTCTGCTGGGAATCACACTCTCGGCTCATACATGACAGCGGTGGACCGAA 385
QY 81 GluSerGlnCysThrLeuLeuAsnAlaSerIleThrGluThrPheAsnCysSerPheSer 100
DB 386 GAGTCTCAATGACCTTGCTGAATGCGTTCATCATCGGAAACATTTAACTGCTCTTCAGC 445
QY 101 CysGlyProAspCysTrrpLysLeuSerGlnTrrpProCysLeuGlnValTrrpValAsnLeu 120
DB 446 TGTGGTCCAGACTGCTGGAATCTTCTCAGTACCCCTGCTCCAGGTTGACGTTAACCTG 505
QY 121 ThrSerSerGlyGluLysLeuLeuLeuTyrHisThrGluGluThrIleLysIleAsnGln 140
DB 506 ACTTCTTCCGGGAAAAGCTCTCTCTACACACAGAGACAAATAAAATCAATCAG 565
QY 141 LysCysSerTrrpIleProLysCysGlyLysAsnPheGluGluSerMetSerLeuValAsn 160

```

```

Db 566 AAGTGTCTCTATATACCTAAATGTGGAAAAAATTTTGAAGAATCCATGTCCCTGCTGAAT 625
QY 161 ValValMetGluAsnPheArgLysTyrGlnHisPheSerCysTrrpSerAspProGluGly 180
DB 626 GTTGTCTATGGAACACTTCAGGAAGTATCAACACTTCTCTCTGCTATCTGACCCAGAGA 685
QY 181 AsnGlnLysSerValIleLeuThrLysLeuTrrpSerSerAsnValLeuPheHisSerLeu 200
DB 686 AACCAAGAGAGTGTATCTCAACCAAACTCTACAGTTCACAGTCTGTGTCTCATTCACTC 745
QY 201 PheTrrpProThrCysMetMetAlaGlyGlyValAlaIleValAlaMetValLysLeuThr 220
DB 746 TTCTGGCCCAACTGTATGATGCTGGGGTGGGAATTTGTGCCATGTGTGAATTCATA 805
QY 221 GlnTyrLeuSerLeuLeuCysGluArgIleGlnArgIleAsnArg 235
DB 806 CAGTACTCTCTCTACTATGTGAGAGGATCCAAACGATCAATAGA 850
RESULT 2
BC017825
LOCUS
DEFINITION
Homo sapiens potassium large conductance calcium-activated channel,
subfamily M, beta member 2, transcript variant 1, mRNA (cDNA clone
MGC:22431 IMAGE:4657825), complete cds.
BC017825
ACCESSION
VERSION
BC017825.1 GI:17389593
MGC.
KEYWORDS
SOURCE
Homo sapiens (human)
ORGANISM
Homo sapiens
REFERENCE
1 (bases 1 to 1285)
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
Strausberg,R.D., Feingold,E.A., Grouse,L.H., Derge,J.G.,
Klausner,R.D., Collins,F.S., Wagner,L., Shenmen,C.M., Schuler,G.D.,
Altschul,S.F., Zeeberg,B., Buetow,K.H., Schaefer,C.F., Bhat,N.K.,
Hopkins,R.F., Jordan,H., Moore,T., Max,I., Wang,J., Hsieh,F.,
Diatchenko,L., Marusina,K., Farmer,A.A., Rubin,G.M., Hong,L.,
Stapleton,M., Soares,M.B., Bonaldo,M.F., Casavant,T.L.,
Schaeetz,T.E., Brownstein,M.J., Usdin,T.B., Toshiyuki,S.,
Carninci,P., Prange,C., Raha,S.S., Loquellano,N.A., Peters,G.J.,
Abramson,R.D., Mullany,S.J., Bosak,S.A., McEwan,P.J.,
McKernan,K.J., Malek,J.A., Gunaratne,P.H., Richards,S.,
Worley,K.C., Hale,S., Garcia,A.M., Gay,L.J., Hulyk,S.W.,
Villalón,D.K., Muzny,D.M., Sodergren,E.J., Lu,X., Gibbs,R.A.,
Fahney,J., Helton,E., Kettman,M., Madan,A., Rodriguez,S.,
Sanchez,A., Whiting,M., Madan,A., Young,A.C., Shevchenko,Y.,
Bouffard,G.G., Blakesley,R.W., Touchman,J.W., Green,E.D.,
Dickson,M.C., Rodriguez,A.C., Grimwood,J., Schmutz,J., Myers,R.M.,
Butterfield,Y.S., Krzywinski,M.I., Skalska,U., Smalls,D.E.,
Schnurch,A., Schein,J.E., Jones,S.J. and Marra,M.A.
Generation and initial analysis of more than 15,000 full-length
human and mouse cDNA sequences
Proc. Natl. Acad. Sci. U.S.A. 99 (26), 16899-16903 (2002)
12477932
2 (bases 1 to 1285)
Strausberg,R.
Direct Submission
Submitted (03-DEC-2001) National Institutes of Health, Mammalian
Gene Collection (MGC), Cancer Genomics Office, National Cancer
Institute, 31 Center Drive, Room 11A03, Bethesda, MD 20892-2590,
USA
NIH-MGC Project URL: http://mgc.nci.nih.gov
Contact: MGC help Desk
Email: cgabbs@mail.nih.gov
Tissue Procurement: ATCC
cDNA Library Preparation: CLONTECH Laboratories, Inc.
cDNA Library Arrayed by: The I.M.A.G.E. Consortium (LNL)
DNA Sequencing by: Sequencing Group at the Stanford Human Genome
Center, Stanford University School of Medicine, Stanford, CA 94305
Web site: http://www-sngc.stanford.edu
Contact: (Dickson, Mark) mcd@paxil.stanford.edu
Dickson, M., Schmutz, J., Grimwood, J., Rodriguez, A., and Myers,
R. M.

```

Clone distribution: MGC clone distribution information can be found through the I.M.A.G.E. Consortium/BLIN at: <http://image.llnl.gov>  
Series: IRAL Plate: 36 Row: 1 Column: 8  
This clone was selected for full length sequencing because it passed the following selection criteria: matched mRNA gi: 19923319.

FEATURES

Location/Qualifiers

1..1285 /organism="Homo sapiens"  
/mol\_type="mRNA"  
/db\_xref="taxon:9606"  
/clone="MGC:22431 IMAGE:4657825"  
/tissue\_type="Testis, embryonal carcinoma"  
/clone\_lib="NIH\_MGC\_61"  
/lab\_host="DH10B"  
/notes="vector: pDNR-LIB"  
1..1285 /gene="KCNMB2"  
/notes="synonym: MGC22431"  
/db\_xref="LocusID:10242"  
/db\_xref="MIM:605214"  
344..1051 /gene="KCNMB2"  
/codon\_start=1  
/product="calcium-activated potassium channel beta 2 subunit"  
/protein\_id="AAH17825.1"  
/db\_xref="GI:17389594"  
/db\_xref="LocusID:10242"  
/db\_xref="MIM:605214"

gene

CDS

1..1285 Length: 1285  
1235..00 Matches: 234  
Percent Similarity: 99.57%  
Best Local Similarity: 99.57%  
Query Match: 99.52%  
DB: 9 Gaps: 0  
US-09-914-053A-5 (1-235) x BC017825 (1-1285)  
21 MetSerIleThrSerGlyArgThrSerSerSerTyrArgHisAspGluLysArgAsn 20  
344 ATGTTTATATGACCATGCGCGACCTCTTCATCTTATAGCATGATGAAAAAGAAAT 403  
21 IleTyrGlnLysIleArgAspHisAspLeuLeuAspLysArgLysThrValThrAlaLeu 40  
404 ATTACCAAGAAATCAGGACCATGACCTCTGACAAAGGAAACAGTCACGACACTG 463  
41 LysAlaGlyGluAspArgAlaIleLeuLeuGlyLeuAlaMetMetValCysSerIleMet 60  
464 AAGCAGGAGAGGACCGAGTATTCCTCGGACTGGCTATGATGGTGTCTCCATCATG 523  
61 MetTyrPheLeuLeuGlyIleThrLeuLeuArgSerTyrMetGlnSerValTyrThrGlu 80  
524 ATGATTTTCTGCGGAATACACACTCTCGGCTCATACATGACGACGGTGTGACCGAA 583  
81 GluSerGlnCysThrLeuLeuAsnAlaSerIleThrGluThrPheAsnCysSerPheSer 100  
584 GAGTCTCAATGCACCTTGTGATGCGTCCATCAGGAAACATTTAACTGCTCTCTCAGC 643  
101 CysGlyProAspCysTyrLysLeuSerGlnTyrProCysLeuGlnValTyrValAsnLeu 120  
644 TGTGGTCCAGACTGCTGGAACATTTCTCAGTACCCCTGCTCAGGGTACGTTACCTG 703  
121 ThrSerSerGlyGluLysLeuLeuLeuTyrHisThrGluThrIleLysIleAsnGln 140

ORIGIN

Alignment Scores:

Pred. No.: 1.25e-125 Length: 1285  
Score: 1235.00 Matches: 234  
Percent Similarity: 99.57%  
Best Local Similarity: 99.57%  
Query Match: 99.52%  
DB: 9 Gaps: 0

US-09-914-053A-5 (1-235) x BC017825 (1-1285)

21 MetSerIleThrSerGlyArgThrSerSerSerTyrArgHisAspGluLysArgAsn 20  
344 ATGTTTATATGACCATGCGCGACCTCTTCATCTTATAGCATGATGAAAAAGAAAT 403  
21 IleTyrGlnLysIleArgAspHisAspLeuLeuAspLysArgLysThrValThrAlaLeu 40  
404 ATTACCAAGAAATCAGGACCATGACCTCTGACAAAGGAAACAGTCACGACACTG 463  
41 LysAlaGlyGluAspArgAlaIleLeuLeuGlyLeuAlaMetMetValCysSerIleMet 60  
464 AAGCAGGAGAGGACCGAGTATTCCTCGGACTGGCTATGATGGTGTCTCCATCATG 523  
61 MetTyrPheLeuLeuGlyIleThrLeuLeuArgSerTyrMetGlnSerValTyrThrGlu 80  
524 ATGATTTTCTGCGGAATACACACTCTCGGCTCATACATGACGACGGTGTGACCGAA 583  
81 GluSerGlnCysThrLeuLeuAsnAlaSerIleThrGluThrPheAsnCysSerPheSer 100  
584 GAGTCTCAATGCACCTTGTGATGCGTCCATCAGGAAACATTTAACTGCTCTCTCAGC 643  
101 CysGlyProAspCysTyrLysLeuSerGlnTyrProCysLeuGlnValTyrValAsnLeu 120  
644 TGTGGTCCAGACTGCTGGAACATTTCTCAGTACCCCTGCTCAGGGTACGTTACCTG 703  
121 ThrSerSerGlyGluLysLeuLeuLeuTyrHisThrGluThrIleLysIleAsnGln 140

Alignment Scores:

Db 704 ACTTCTTCGGGAAAAGCTCTCTCTACACACAGAGACAAATAAAATCAATCAG 763  
Qy 141 LysCysSerTyrIleProLysCysGlyLysAsnHeGluGluSerMetSerLeuValAsn 160  
Db 764 AAGTCTCTCTATATACCTAAATGTGAAAAAATTTTGAAGATCCATCTCCTGTGAAT 823  
Qy 161 ValValMetGluAsnPheArgLysTyrGlnHisPheSerCysTyrSerAspProGluGly 180  
Db 824 GTTGTCATGGAAACTTCAGGAAGTATCAACATCTCTCTGCTATCTTGACCCAGAAAGA 883  
Qy 181 AsnGlnLysSerValIleLeuThrLysLeuTyrSerSerAsnValLeuPheHisSerLeu 200  
Db 884 AACACAGAGAGTGTATTCTTAACCAAACTCTACAGTTCACACGCTGCTTCCATTCACCTC 943  
Qy 201 PheTyrProThrCysMetMetAlaGlyGlyValAlaIleValAlaMetValLysLeuThr 220  
Db 944 TTCTGCGCAACCTGATGATGCTGGGGGTGTGGCAATGTGTGCGATGCTGAAACTTACA 1003  
Qy 221 GlnTyrLeuSerLeuLeuCysGluArgIleGlnArgIleAsnArg 235  
Db 1004 CAGTACCTCTCCCTACTATGTGAGAGGATCCACCGATCAATAGA 1048

RESULT 3  
AF209747

LOCUS

DEFINITION

ACCESSION

VERSION

KEYWORDS

SOURCE

ORGANISM

REFERENCE

AUTHORS

TITLE

JOURNAL

MEDLINE

PUBMED

AUTHORS

TITLE

JOURNAL

FEATURES

source

gene

CDS

ORIGIN

Alignment Scores:

Pred. No.:

Score:

Percent Similarity:

Best Local Similarity:

Query Match:

DB:

Gaps:

US-09-914-053A-5 (1-235) x BC017825 (1-1285)

21 MetSerIleThrSerGlyArgThrSerSerSerTyrArgHisAspGluLysArgAsn 20

344 ATGTTTATATGACCATGCGCGACCTCTTCATCTTATAGCATGATGAAAAAGAAAT 403

21 IleTyrGlnLysIleArgAspHisAspLeuLeuAspLysArgLysThrValThrAlaLeu 40

404 ATTACCAAGAAATCAGGACCATGACCTCTGACAAAGGAAACAGTCACGACACTG 463

41 LysAlaGlyGluAspArgAlaIleLeuLeuGlyLeuAlaMetMetValCysSerIleMet 60

464 AAGCAGGAGAGGACCGAGTATTCCTCGGACTGGCTATGATGGTGTCTCCATCATG 523

61 MetTyrPheLeuLeuGlyIleThrLeuLeuArgSerTyrMetGlnSerValTyrThrGlu 80

524 ATGATTTTCTGCGGAATACACACTCTCGGCTCATACATGACGACGGTGTGACCGAA 583

81 GluSerGlnCysThrLeuLeuAsnAlaSerIleThrGluThrPheAsnCysSerPheSer 100

584 GAGTCTCAATGCACCTTGTGATGCGTCCATCAGGAAACATTTAACTGCTCTCTCAGC 643

101 CysGlyProAspCysTyrLysLeuSerGlnTyrProCysLeuGlnValTyrValAsnLeu 120

644 TGTGGTCCAGACTGCTGGAACATTTCTCAGTACCCCTGCTCAGGGTACGTTACCTG 703

121 ThrSerSerGlyGluLysLeuLeuLeuTyrHisThrGluThrIleLysIleAsnGln 140

Pred. No.: 2,996-125 Length: 2574  
 Score: 1235.00 Matches: 234  
 Percent Similarity: 99.57% Conservative: 0  
 Best Local Similarity: 99.57% Mismatches: 1  
 Query Match: 99.52% Indels: 0  
 DB: 9 Gaps: 0

US-09-914-053A-5 (1-235) x AF209747 (1-2574)

QY 1 MetSerIleThrThrSerGlyArgThrSerSerSerTyrArgHisAspGluLysArgAsn 20  
 DB 353 ATGTTTATATGACGAGTGGCGGACCTCTTCATCTTATAGACATGATGAAAAAGAAAT 412

QY 21 IleTyrGlnLysIleArgAspHisAspLeuAspLysThrValThrAlaLeu 40  
 DB 413 ATTTACCAAAATCAGGACATGACCTCTGGACAAAGGAAAAAGAGTCACAGCACTG 472

QY 41 LysAlaGlyGluAspArgAlaIleLeuLeuGlyLeuAlaMetMetValCysSerIleMet 60  
 DB 473 AAGGACGAGAGGACCGAGCTATTCTCTGGACCTGGCTATGATGCTGTGCTCCATCATG 532

QY 61 MetTyrPheLeuLeuGlyIleThrLeuLeuArgSerTyrMetGlnSerValThrGlu 80  
 DB 533 ATGATATTTCTGCTGGGAATCACACTCTCTGGCTCATACATGACGAGCGGTGGACCGAA 592

QY 81 GluSerGlnCysThrLeuLeuAsnAlaSerIleThrGluThrPheAsnCysSerPheSer 100  
 DB 593 GAGTCTCAATGACCTTGCTGAATCGCTCCATCACGGAACATTTAACTGCTCTTCAGC 652

QY 101 CysGlyProAspCysThrPheLeuSerGlnTyrProCysLeuGlnValTyrValAsnLeu 120  
 DB 653 TGTGCTCCAGACTGCTGGAATCTTCTCAGTACCCCTCCCTCCAGGTGTACGTTAACTG 712

QY 121 ThrSerSerGlyGluLysLeuLeuLeuTyrHisThrGluGluThrIleLysIleAsnGln 140  
 DB 713 ACTTCTCCGGGAAAGCTCTCTCTACACACAGAGAGACAAATATAAAATCATCAG 772

QY 141 LysCysSerTyrIleProLysCysGlyLysAsnPheGluGluSerMetSerLeuValAsn 160  
 DB 773 AAGTCTCCTATATACCTAAATATGAAAAAATTTGAAGAAATCCATGCTCCCTGCTGAAT 832

QY 161 ValValMetGluAsnPheArgLysTyrClnHisPheSerCysTyrSerAspProGluGly 180  
 DB 833 GTTGTTCATGGAAACTTCAGGAAGTATCAACACTTCTCTGCTATTTCTGACCCAGAGGA 892

QY 181 AsnGlnLysSerValIleLeuThrLysLeuTyrSerSerAsnValLeuPheHisSerLeu 200  
 DB 893 AACAGAGAGTGTATCTTAACCAAACTCTACAGTCCAGTCCAGTGTGTTCCATTCATC 952

QY 201 PheTrpProThrCysMetMetAlaGlyValAlaIleValAlaMetValLysLeuThr 220  
 DB 953 TTCTGGCCAACTGATGATGCTGGGGGTGTGGCAATTTGTGCCATGGTGAACATTACA 1012

QY 221 GlnTyrLeuSerLeuLysGluGluArgIleGlnArgIleAsnArg 235  
 DB 1013 CAGTACCTCTCCCTACTATGTGAGAGATCCACGGATCAATAGA 1057

RESULT 4  
 CQ714334  
 LOCUS  
 DEFINITION  
 ACCESSION  
 VERSION  
 KEYWORDS  
 SOURCE  
 ORGANISM

CQ714334 1062 bp DNA linear PAT 03-FEB-2004  
 Sequence 268 from Patent WO02068579.  
 CQ714334  
 CQ714334.1 GI:42275191

Hom sapiens (human)  
 Homo sapiens  
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE  
 AUTHORS  
 TITLE  
 Venter, C.J., Adams, M.C., Li, P.W. and Myers, E.W.  
 Kites, such as nucleic acid arrays, comprising a majority of  
 humanexons or transcripts, for detecting expression and other uses  
 thereof

JOURNAL Patent: WO 02068579-A 268 06-SEP-2002;  
 PE Corporation (NY) (US)

FEATURES  
 source  
 1..1062  
 /organism="Homo sapiens"  
 /mol\_type="unassigned DNA"  
 /db\_xref="taxon:9606"

## ORIGIN

Alignment Scores:  
 Pred. No.: 1,886-121 Length: 1062  
 Score: 1196.00 Matches: 234  
 Percent Similarity: 98.32% Conservative: 0  
 Best Local Similarity: 98.32% Mismatches: 1  
 Query Match: 96.37% Indels: 3  
 DB: 6 Gaps: 0

US-09-914-053A-5 (1-235) x CQ714334 (1-1062)

QY 1 MetSerIleThrThrSerGlyArgThrSerSerSerTyrArgHisAspGluLysArgAsn 20  
 DB 147 ATGTTTATATGACGAGTGGCGGACCTCTTCATCTTATAGACATGATGAAAAAGAAAT 206

QY 21 IleTyrGlnLysIleArgAspHisAspLeuLeuAspLysThrValThrAlaLeu 40  
 DB 207 ATTTACCAAAATCAGGACCATGACCTCTGGACAAAGGAAAAAGAGTCACAGCACT 266

QY 40 uLysAlaGlyGluAspArgAlaIleLeuLeuGlyLeuAlaMetMetValCysSerIleMe 60  
 DB 267 GAAGCAGAGAGGAGGACCGAGCTATTCTCTGGACTGCTATGATGGTGTGCTCCATCAT 326

QY 60 tMetTyrPheLeuLeuGlyIleThrLeuLeuArgSerTyrMetGlnSerValThrGln 80  
 DB 327 GATGATATTTCTGCTGGGAATCACACTCTCTGCGCTCATACATGACAGCGGTGTGACCGA 386

QY 80 uGluSerGlnCysThrLeuLeuAsnAlaSerIleThrGluThrPheAsnCysSerPheSe 100  
 DB 387 AGAGTCTCAATGCACCTTGCTGAATGCTGCATCATCGGAACATTTAACTGCTCTTCAG 446

QY 100 rCysGlyProAspCysThrLysLeuSerGlnTyrProCysLeuGlnValTyrValAsnLe 120  
 DB 447 CTGTGGTCCAGACTGCTGGAACCTTCTCAGTACCCCTCCCTCCAGGTGTACGTTAACT 506

QY 120 uThrSerSerGlyGluLysLeuLeuTyrHisThrGluGluThrIleLysIleAsnGln 140  
 DB 507 GACTTCTTCCGGGAAAAAGCTCTCTCTACACAGAGAGACAAATAAAATCAATCA 566

QY 140 nLysCysSerTyrIleProLysCysGlyLysAsnPheGluGluSerMetSerLeuValAs 160  
 DB 567 GAAGTCTCTATATATACCTAAATGTGAAAAAATTTTGAAGAAATCCATGTCCTGTGTA 626

QY 160 nValValMetGluAsnPheArgLysTyrGlnHisPheSerCysTyrSerAspProGluGln 180  
 DB 627 TTTTCTCATGAAAACTTCAGGAAGTATCAACACTTCTCTGCTATTTCTGACCCAGAGG 686

QY 180 yAsnGlnLysSerValIleLeuThrLysLeuTyrSerSerAsnValLeuPheHisSerLe 200  
 DB 687 AAACAGAGAGTGTATCTTAACCAAACTCTACAGTTCCAACGTCGTGTTCCATTCAT 746

QY 200 uPheTrpProThrCysMetMetAla-GlyGlyValAlaIleValAlaMetValLysLeuT 220  
 DB 747 CTCTGCGCAACCTGATGATGCTGGGGGTGTGGCAATTTGTGCCATGGTGAACACTTA 806

QY 220 hGlnTyrLeuSerLeuLeuCysGluArgIleGlnArg-IleAsnArg 235  
 DB 807 CACAGTACCTCTCCCTACTATGTGAGAGATCCCAACGGGATCAATAGG 854

RESULT 5  
 AY062429  
 LOCUS  
 DEFINITION  
 subunit mRNA, complete cds.  
 ACCESSION  
 AY062429

AY062429 708 bp mRNA linear ROD 12-DEC-2001  
 Mus musculus large conductance calcium-activated K channel beta2  
 subunit mRNA, complete cds.

VERSION	AY062429.1	GI:17644138	
KEYWORDS	Mus musculus (house mouse)		
SOURCE	Mus musculus		
ORGANISM	Mus musculus		
REFERENCE	1 (bases 1 to 708)		
AUTHORS	Garcia-Valdes J., Eghbali M., Stefani E. and Toro L.		
TITLE	Mouse kcnmb2 subunit of the large conductance calcium-activated K channel (Maxik, BK)		
JOURNAL	Unpublished		
REFERENCE	2 (bases 1 to 708)		
AUTHORS	Garcia-Valdes J., Eghbali M., Stefani E. and Toro L.		
TITLE	Direct Submission		
JOURNAL	Submitted (14-NOV-2001) Anesthesiology, UCLA, PO Box 957115, BH-509A CHS, Los Angeles, CA 90095-7115, USA		
FEATURES	Location/Qualifiers		
source	1..708		
	/organism="Mus musculus"		
	/mol_type="mRNA"		
	/strain="C57BL/6"		
	/db_xref="taxon:10090"		
	/tissue_type="kidney"		
	/dev_stage="fetus"		
	1..708		
	/notes="inactivating subunit; Maxik, BK; kcnmb2"		
	/codon_start=1		
	/product="large conductance calcium-activated K channel beta2 subunit"		
	/protein_id="AA138982.1"		
	/db_xref="GI:17644139"		
	/translation="MFTWTSRTSSRYQDEKNIYQKIRHDLDPKRTVTKALKE DRAILLGLAMVGSIMVYFLGTLTSSRYQSWTEBAQCALLNVEITFPNCSFG PDCKLSQYPCLOVYVNLTSGERLLLYHTEWTKINQKCSYIPKCGNNPESMSIYS VVENFRHOFHPCYSDPEGNQKSVILTKLYSSNVLFSFLFWPTCMWAGGVAIVAMVK LTQYLSLLCERIQINR"		
CDS			
	1..41e-120	Length: 708	
	1186.00	Matches: 223	
	Percent Similarity: 97.45%	Conservative: 6	
	Best Local Similarity: 94.89%	Mismatches: 6	
	Query Match: 95.57%	Indels: 0	
	DB: 10	Gaps: 0	
ORIGIN			
Alignment Scores:			
Pred. No.:	1.41e-120	Length: 708	
Score:	1186.00	Matches: 223	
Percent Similarity:	97.45%	Conservative: 6	
Best Local Similarity:	94.89%	Mismatches: 6	
Query Match:	95.57%	Indels: 0	
DB:	10	Gaps: 0	
US-09-914-053A-5 (1-235) x AY062429 (1-708)			
Qy	1	MetSerIleThrSerGlyArgThrSerSerSerTyArgHisAspGluLysArgAsn 20	
Db	1	ATGTTTATATGACCAATCAGGACCTCTCTTACAGACGAGACGAGAAAGAAAT 60	
Qy	21	IleTyrglnLysIleArgAspHisAspLeuAspLysArgLysThrValThrAlaLeu 40	
Db	61	ATCTACCAAGAAATCAGGACCATGACCTCTGGACAAAGGAAACCTGTGACAGCTCTG 120	
Qy	41	LysIleGluAspArgAlaIleLeuLeuGlyLeuAlaMetMetValCysSerIleMet 60	
Db	121	AAGCTGGGAGGACCGGCATCTCTCGGCTGGCCATGATGTTGCTCCATCATG 180	
Qy	61	MetTyrrPheLeuLeuGlyIleThrLeuLeuArgSerTyrrMetGlnSerValTprThrGlu 80	
Db	181	ATGTACTTCTCTGGGAATACACTGCTCGCTCTTACATGACAGCGGTGGACAGAA 240	
Qy	81	GluSerGlnCysThrLeuLeuAspAlaSerIleThrGluThrPheAsnCysSerPheSer 100	
Db	241	GAAGCCAGTGTGCGCTGCTGAATGTGTCATCAATCACAGAAACGTTTAACTGCTTCAGC 300	
Qy	101	CysGlyProAspCysTprLysLeuSerGlnTyrrProCysLeuGlnValTyrrValAsnLeu 120	
Db	301	TGTGGGCGGCACTGTTGAAGCTCTCTCAGTACCCCTTGCCTGAGGAGTACGAGACCTG 360	
Qy	121	ThrSerSerGlyGluLysLeuLeuTyrrHisThrGluGluThrIleLysIleAsnGln 140	

361 ACATCTTCGGGAGAGGCTCTCTCTTACACACGAGAGACCATGAATCAATCAA 420

141 LysCysSerTyrrIleProLysCysGlyLysAsnPheGluGluSerMetSerIleuValAsn 160

421 AAGTGTCTCTATATCTTAAGTGTGGAACAACCTTTGAGGAGTCCATGCTCTCTGAGT 480

161 ValValMetGluAsnPheArgLysTyrrGlnHisPheSerCysTyrrSerAspProGluGly 180

481 GTTCGTATGGAATACTTACGAGACACCAACACTTCCCTGCTATCTTGACCAAGAGA 540

181 AsnGlnLysSerValIleLeuThrLysLeuTyrrSerSerAsnValLeuPheHisSerIleu 200

541 AACCAAGAGAGTGTCTCTGACCAAACTCTACAGCTCCATGCTGCTCTCTCTCTCTC 600

201 PheTprProThrCysMetMetAlaGlyValAlaIleValAlaMetValLysLeuThr 220

601 TTCTGGCAACTTGTATGATGCTGGGGTGGCAATCGTGTATGTTGAACTAACT 660

221 GlnTyrrLeuSerLeuLeuCysGluArgIleGlnArgIleAsnArg 235

661 CAGTACCTCTCTCTCTTTGTGAGAGGATCCAAACGATCAACAGA 705

BC046227 2947 bp mRNA linear ROD 30-JUN-2004

Mus musculus potassium large conductance calcium-activated channel, IMAGE:5703879, complete cds.

BC046227.1 GI:28279339

MGC.

Mus musculus (house mouse)

MGC.

Mus musculus

Mus musculus

Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus. 1 (bases 1 to 2947)

Strausberg, R.D., Feingold, E.A., Grouse, L.H., Derge, J.G., Klausner, R.D., Collins, F.S., Wagner, D., Shenmen, C.M., Schuler, G.D., Altschul, S.F., Zeeberg, B., Buetow, K.H., Schaefer, C.F., Bhat, N.K., Hopkins, R.F., Jordan, H., Moore, T., Max, S.I., Wang, J., Hsieh, F., Diatchenko, L., Marusina, K., Farmer, A.A., Rubin, G.M., Hong, L., Stapleton, M., Soares, M.B., Bonaldo, M.F., Casavant, T.L., Scheetz, T.E., Brownstein, M.J., Ustin, I.B., Loquellano, N.A., Peters, G.J., Abramson, R.D., Mullaly, S.J., Bosak, S.A., McEwan, P.J., McKernan, K.J., Malek, J.A., Gunaratne, P.H., Richards, S.W., Worley, K.C., Hale, S., Garcia, A.M., Gay, L.J., Hulyk, S.W., Villalón, D.K., Muzny, D.M., Sodergren, E.J., Lu, X., Gibbs, R.A., Fahy, J., Helton, E., Kettner, M., Madan, A., Rodriguez, S., Sanchez, A., Whitting, M., Madan, A., Young, A.C., Shevchenko, Y., Bouffard, G.G., Blakesley, R.W., Touchman, J.W., Green, E.D., Dickson, M.C., Rodriguez, A.C., Grimwood, J., Schmutz, J., Myers, R.M., Butterfield, Y.S., Kzywinski, M.I., Skalska, U., Smalish, D.E., Schnerch, A., Schein, J.E., Jones, S.J. and Marra, M.A.

Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences

Proc. Natl. Acad. Sci. U.S.A. 99 (26), 16999-16903 (2002)

12477932

2 (bases 1 to 2947)

Strausberg, R.

Direct Submission

Submitted (31-JAN-2003) National Institutes of Health, Mammalian Gene Collection (MGC), Cancer Genomics Office, National Cancer Institute, 31 Center Drive, Room 11A03, Bethesda, MD 20892-2590, USA

NIH-MGC Project URL: <http://mgc.nci.nih.gov>

Contact: MGC help desk

Email: [cgabbs@mail.nih.gov](mailto:cgabbs@mail.nih.gov)

Tissue Procurement: Dr. Jim Lin, University of Iowa

CDNA Library Preparation: M. Bento Soares, University of Iowa

CDNA Library Arrayed by: The I.M.A.G.E. Consortium (LNL)

DNA Sequencing by: University of Iowa, Dr. M. Bento Soares and Dr.

Thomas L. Casavant.

Web site: <http://genome.uiowa.edu>

Contact: [bento-soares@uiowa.edu](mailto:bento-soares@uiowa.edu); [tom-casavant@uiowa.edu](mailto:tom-casavant@uiowa.edu)

Bonaldi, M.F., Akabogu, I., Bair, T., Bair, J., Crouch, K., Davis, A., Fishler, K., Keppel, C., Kucaba, T., Lebeck, M., Melo, A., Schaefer, K., Scheetz, T., Smith, C., Snit, E., Tack, D., Trout, K., Walters, J., Casavant, T., Soares, M.B.

Clone distribution: MGC clone distribution information can be found

through the I.M.A.G.E. Consortium/LLNL at: <http://image.llnl.gov>

Series: Plate: Row: Column: 0

This clone was selected for full length sequencing because it

passed the following selection criteria: matched mRNA gi: 21312299.

#### FEATURES

source

1.2947  
/organism="Mus musculus"  
/mol\_type="mRNA"  
/strain="C57BL/6"  
/db\_xref="taxon:10090"  
/clone="MGC:57945 IMAGE:5703879"  
/tissue\_type="Brain, mouse 15.5 dpc"  
/clone\_lib="NIH SWAP\_EWC"  
/lab\_host="DH10B"  
/note="vector: pYX-ASC"  
1.2947  
/gene="Kcnmb2"  
/note="synonym: MGC57945"  
/db\_xref="LocusID:72413"  
/db\_xref="MGI:1919663"  
391..1098  
/gene="Kcnmb2"  
/codon\_start=1  
/product="potassium large conductance calcium-activated  
channel, subfamily M, beta member 2"  
/protein\_id="AAH46227.1"  
/db\_xref="GI:28279340"  
/db\_xref="LocusID:72413"  
/db\_xref="MGI:1919663"  
translation="MFTWTSRTSSVRQDEKNIYKIRHDLKDKTKVTLAKAG  
DRAILLGLAMVCSIMVYFLLGSLYMQSVWTEAQCALLNVSTFTFNCSPG  
PDCNKLQYPCLOVYVNLTSGERLLYHTETKINQKXSYIPKCGNFEESMLVS  
VVMENFRHQHPCISDPENQKRSVILTKLYSSNVLPHSLFWPTCMAGGVAIVAVK  
LTQYLULLCERIQINR"

#### CDS

1098..11098  
/product="potassium large conductance calcium-activated  
channel, subfamily M, beta member 2"  
/protein\_id="AAH46227.1"  
/db\_xref="GI:28279340"  
/db\_xref="LocusID:72413"  
/db\_xref="MGI:1919663"  
translation="MFTWTSRTSSVRQDEKNIYKIRHDLKDKTKVTLAKAG  
DRAILLGLAMVCSIMVYFLLGSLYMQSVWTEAQCALLNVSTFTFNCSPG  
PDCNKLQYPCLOVYVNLTSGERLLYHTETKINQKXSYIPKCGNFEESMLVS  
VVMENFRHQHPCISDPENQKRSVILTKLYSSNVLPHSLFWPTCMAGGVAIVAVK  
LTQYLULLCERIQINR"

#### ORIGIN

Alignment Scores:  
Pred. No.: 8.5e-120 Length: 2947  
Score: 1186.00 Matches: 223  
Percent Similarity: 97.45% Conservative: 6  
Best Local Similarity: 94.89% Mismatches: 6  
Query Match: 95.57% Indels: 0  
DB: 10 Gaps: 0  
US-09-914-053a-5 (1-235) x BC046227 (1-2947)

QY 1 MetSerIleThrThrSerGlyArgThrSerSerSerThrArgHisAspGluLysArgAsn 20  
DB 391 ATGTTTATATGACGACGAGTGGCCGACCTTTCATCTTACACAGGACGAGAAAGAAAT 450  
QY 21 IleTyrGlnLysIleArgAspHisAspLeuLeuAspLysThrValThrAlaLeu 40  
DB 451 ATCTACCGAGAAATCAGGACCATGACCTCTGACAAAGAGAAATCTGACAGCTCTG 510  
QY 41 LysAlaGlyGluAspArgAlaIleLeuLeuGlyLeuAlaMetMetValCysSerIleMet 60  
DB 511 AAGCTGGGAGGACCGGGCCATCTCTCGCCCTGGCCCATGATGGTGTCTCCATCATG 570  
QY 61 MetTyrPheLeuLeuGlyIleThrLeuLeuArgSerTyrMetGlnSerValThrThrGlu 80  
DB 571 ATGACTTCCTGCTGGGATCAGACTGCTGGCTCTCATATGACGACGCTGTGGACAGAA 630  
QY 81 GluSerGlnCysThrLeuLeuAsnAlaSerIleThrGluThrPheAsnCysSerPheSer 100

DB 631 GAAGCCAGTGTGCCCTGCTGAATGTGATCATCATCAGAAACGTTTAAGTGTCTTCAGC 690  
QY 101 CysGlyProAspCysTrpLysLeuSerGlnTyrProCysLeuGlnValTyrValAsnLeu 120  
DB 691 TGTGGCCCGAGTGTGGAGGCTCTCTCAGTACCTTGCCTGCGAGTGTACGTGAACCTG 750  
QY 121 ThrSerSerGlyGluLysLeuLeuTyrHisThrGluGluThrIleLysIleAsnGln 140  
DB 751 ACATCTTCGGGAGAGGCTCTCTCTACACAGGAGACCATGAAGTCAATCAA 810  
QY 141 LysCysSerTyrIleProLysCysGlyLysAsnPheGluSerMetSerLeuValAsn 160  
DB 811 AAGTGTCTCTATATTCCTAAGTGTGGAAACAACTTGAGGAGTCCATGTCTCTCGTGA 870  
QY 161 ValValMetGluAsnPheArgLysTyrGlnHisPheSerCysTyrSerAspProGluGly 180  
DB 871 GTGTCATGGAACATTCAGGAGACCAACAACTTCCCTGCTATCTTGACCCAGAGA 930  
QY 181 AsnGlnLysSerValIleLeuThrLysLeuTyrSerSerAsnValLeuPheHisSerLeu 200  
DB 931 AACCAAGAGAGTGTCTATCTGACCAAACTCTACAGCTCCAATGTCTGTCTCCATCTC 990  
QY 201 PheTrpProThrCysMetMetAlaGlyValAlaIleValAlaMetValLysLeuThr 220  
DB 991 TTCTGCCCAACTTGTATGATGCTGGGGTGTGGCAATCGTGTGATGGTGAACAACT 1050  
QY 221 GlnTyrLeuSerLeuLeuCysGluArgIleGlnArgIleAsnArg 235  
DB 1051 CAGTACCTCTCCCTGCTTGTGAGAGGATCAACAGGATCAACAGA 1095

#### RESULT 7

BC058957

LOCUS

DEFINITION

Mus musculus potassium large conductance calcium-activated channel,

subfamily M, beta member 2, mRNA (CDNA clone MGC:66775

IMAGE:5703879), complete cds.

BC058957

ACCESSION

VERSION

KEYWORDS

SOURCE

ORGANISM

REFERENCE

AUTHORS

1 (bases 1 to 2947)

Strausberg, R.L., Feingold, B.A., Grouse, L.H., Derge, J.G.,

Klausner, R.D., Collins, F.S., Wagner, L., Shenmen, C.M., Schuler, G.D.,

Altshul, S.F., Zeeberg, B., Buetow, K.H., Schaefer, C.F., Bhat, N.K.,

Hopkins, R.F., Jordan, H., Moore, T., Wax, S.I., Wang, J., Hsieh, F.,

Diatchenko, L., Marusina, K., Farmer, A.A., Rubin, G.M., Hong, L.,

Stapleton, M., Soares, M.B., Bonaldo, M.F., Usdin, T.B., Toshiyuki, S.,

Scheetz, T.E., Brownstein, M.J., Usdin, T.B., Casavant, T.L.,

Carninci, P., Prange, C., Raha, S.S., Loquellano, N.A., Peters, G.J.,

Abramson, R.D., Mullaly, S.J., Bosak, S.A., McEwan, P.J.,

McKernan, K.J., Malek, J.A., Gunaratne, P.H., Richards, S.,

Worley, K.C., Hale, S., Garcia, A.M., Gay, L.J., Hulyk, S.W.,

Villalón, D.K., Muzny, D.M., Sodergren, E.J., Lu, X., Gibbs, R.A.,

Fahy, J., Hulton, E., Kettman, M., Madan, A., Rodriguez, S.,

Sanchez, A., Whiting, M., Madan, A., Young, A.C., Shevchenko, Y.,

Bouffard, G.G., Blakesley, R.W., Touchman, J.W., Green, E.D.,

Dickson, M.C., Rodriguez, A.C., Grimwood, J., Schmutz, J., Myers, R.M.,

Butterfield, Y.S., Krzywinski, M.I., Skalska, U., Smalls, D.E.,

Schneerch, A., Schein, J.E., Jones, S.J. and Marra, M.A.

Generation and initial analysis of more than 15,000 full-length

human and mouse cDNA sequences

Proc. Natl. Acad. Sci. U.S.A. 99 (26), 16899-16903 (2002)

12477932

2 (bases 1 to 2947)

Strausberg, R.

Direct Submission

Submitted (01-OCT-2003) National Institutes of Health, Mammalian

Gene Collection (MGC), Cancer Genomics Office, National Cancer

Institute, 31 Center Drive, Room 11A03, Bethesda, MD 20892-2590,

USA



REMARK  
COMMENT  
NIH-MGC Project URL: <http://mgc.nci.nih.gov>  
Contact: MGC help desk  
Email: [cgasc-remail.nih.gov](mailto:cgasc-remail.nih.gov)  
Tissue Procurement: Dr. Jim Lin, University of Iowa  
cDNA Library Preparation: M. Bento Soares, University of Iowa  
cDNA Library Arrayed by: The I.M.A.G.E. Consortium (LNL)  
DNA Sequencing by: Genome Sequence Centre,  
BC Cancer Agency, Vancouver, BC, Canada  
[info@cgsc.bc.ca](mailto:info@cgsc.bc.ca)

Steve Jones, Sarah Barber, Mabel Brown-John, Yaron Butterfield,  
Andy Chan, Steve S. Chand, William Chow, Alison Cloutier, Ruth  
Featherstone, Malachi Griffith, Obi Griffith, Ran Guin, Nancy Liao,  
Kim MacDonald, Amara Masson, Mike R. Mayo, Josh Moran, Ryan Morin,  
Teika Olson, Diana Palmquist, Anca Petrescu, Anna Liisa Prabhua,  
Parvaneh Saeedi, JR Santos, Angeliue Schnerch, Ursula Skalska,  
Duane Smailus, Jeff Stott, Miranda Tsai, George Yang, Jacquie  
Schein, Asim Siddiqui, Rob Holt, Marco Marra.

Clone distribution: MGC clone distribution information can be found  
through the I.M.A.G.E. Consortium/LNL at: <http://image.lnl.gov>  
Series: IRAC Plate: 124 Row: i Column: 16  
This clone was selected for full length sequencing because it  
passed the following selection criteria: matched mRNA gi: 21312299.

FEATURES

source  
1. 2947  
/organism="Mus musculus"  
/mol\_type="mRNA"  
/strain="C57BL/6"  
/db\_xref="taxon:10090"  
/clone="MGC:66775 IMAGE:5703879"  
/tissue\_type="Brain, mouse 15.5 dpc"  
/clone\_lib="NIH\_BMAP\_EWO"  
/lab\_host="DH10B"  
/note="Vector: pYX-ASC"  
1. 2947  
/gene="Kcnmb2"  
/note="synonym: MGC57945"  
/db\_xref="LocusID:72413"  
/db\_xref="MGI:1919663"  
391. 1098  
/gene="Kcnmb2"  
/codon\_start=1  
/product="potassium large conductance calcium-activated  
channel, subfamily M, beta member 2"  
/protein\_id="AAH8957.1"  
/db\_xref="GI:37589335"  
/db\_xref="LocusID:72413"  
/db\_xref="MGI:1919663"  
/translation="MEFTSGRTSSSVRODEKRNIVOKIRDHLLDKRTVTALKAGE  
DRAILLGAMVCSIMYFLIGITLLSYMQSVWTEAQCALLNVSTFENCFSQCG  
PDKWLSQYFCLQVNLTSGERLLIHTETWKNQKCSYIPKCNPFERSMLVS  
VYMFNRRHQHPFCYSDPEGNQKSVILTKLYSSNVLPFSLFWPTCMWAGGVAIVAMVK  
LTQVLSLLCERIQIRN"

gene

1. 2947  
/gene="Kcnmb2"  
/note="synonym: MGC57945"  
/db\_xref="LocusID:72413"  
/db\_xref="MGI:1919663"  
391. 1098  
/gene="Kcnmb2"  
/codon\_start=1  
/product="potassium large conductance calcium-activated  
channel, subfamily M, beta member 2"  
/protein\_id="AAH8957.1"  
/db\_xref="GI:37589335"  
/db\_xref="LocusID:72413"  
/db\_xref="MGI:1919663"  
/translation="MEFTSGRTSSSVRODEKRNIVOKIRDHLLDKRTVTALKAGE  
DRAILLGAMVCSIMYFLIGITLLSYMQSVWTEAQCALLNVSTFENCFSQCG  
PDKWLSQYFCLQVNLTSGERLLIHTETWKNQKCSYIPKCNPFERSMLVS  
VYMFNRRHQHPFCYSDPEGNQKSVILTKLYSSNVLPFSLFWPTCMWAGGVAIVAMVK  
LTQVLSLLCERIQIRN"

CDS

1. 2947  
/gene="Kcnmb2"  
/note="synonym: MGC57945"  
/db\_xref="LocusID:72413"  
/db\_xref="MGI:1919663"  
391. 1098  
/gene="Kcnmb2"  
/codon\_start=1  
/product="potassium large conductance calcium-activated  
channel, subfamily M, beta member 2"  
/protein\_id="AAH8957.1"  
/db\_xref="GI:37589335"  
/db\_xref="LocusID:72413"  
/db\_xref="MGI:1919663"  
/translation="MEFTSGRTSSSVRODEKRNIVOKIRDHLLDKRTVTALKAGE  
DRAILLGAMVCSIMYFLIGITLLSYMQSVWTEAQCALLNVSTFENCFSQCG  
PDKWLSQYFCLQVNLTSGERLLIHTETWKNQKCSYIPKCNPFERSMLVS  
VYMFNRRHQHPFCYSDPEGNQKSVILTKLYSSNVLPFSLFWPTCMWAGGVAIVAMVK  
LTQVLSLLCERIQIRN"

ORIGIN

Alignment Scores:  
Pred. No.: 8.5e-120 Length: 2947  
Score: 1186.00 Matches: 223  
Percent Similarity: 97.45% Conservative: 6  
Best Local Similarity: 94.89% Mismatches: 6  
Query Match: 95.57% Indels: 0  
DB: 10 Gaps: 0

US-09-914-053A-5 (1-235) x BC058957 (1-2947)  
Qy 1 MetSerIleThrThrSerGlyArgThrSerSerSerTyrArgHisAspGluLysArgAsn 20  
Db 391 ATGTTATATGACGAGCGGACCTCTTCATCTTACAGACAGGACGAGAAAGAAAT 450  
Qy 21 IletYrGlnLysIleArgAspHisAspLeuLeuAspLysArgLysThrValThrAlaLeu 40  
Db 451 ATCTACAGAAATACGAGGACCATGACCTCTCTGACAAAGAAACTGTGACAGCTCTG 510

Qy 41 LysAlaGlyGluAspArgAlaIleLeuLeuGlyLeuAlaMetMetValCysSerIleMet 60  
Db 511 AAGGCTGGGAGGACCGGGCCATCTCTCGGCTGGCCATGATGCTGCTCCATCATG 570  
Qy 61 MetTyrPheLeuLeuGlyIleThrLeuLeuArgSerTyrMetGlnSerValTrpThrGlu 80  
Db 571 ATGTACTTCTCTGCTGGGAATCACACTGCTGGGCTCTCTACATGTCAGAGGCTGTGGACAGAA 630  
Qy 81 GluSerGlnCysThrLeuLeuAsnAlaSerIleThrGluThrPheAsnCysSerPheSer 100  
Db 631 GAAGCCCTAGTGGCCCTCTGTAATGTGCAATACAGAAAGCTTTAACTGTTCCTTCAGC 690  
Qy 101 CysGlyProAspCysTyrPheLeuSerGlnTyrProCysLeuGlnValTrpValAsnLeu 120  
Db 691 TGTGGGCGGACCTGTGTGAAGCTCTCTCAGTACCCTTGCCTGCAGGTGTACGTGAACCTG 750  
Qy 121 ThrSerSerGlyGluLysLeuLeuLeuTyrHisThrGluThrIleLysIleLeuGln 140  
Db 751 ACATCTTCGGGAGAGGCTCTCTCTACACACGAGAGACCATGAAGATCAATCAA 810  
Qy 141 LysCysSerTyrIleProLysCysGlyLysAsnPheGluSerMetSerLeuValAsn 160  
Db 811 AAGTCTCTCTATATCTTAAAGTGTGAAACAACTTTGAGGAGTCCATGCTCTCTCGTGT 870  
Qy 161 ValValMetGluAsnPheArgLysTyrGlnHisPheSerCysTyrSerAspProGluGly 180  
Db 871 GTCGTCTATGAGAAACTTCAGGACACCAACACTTCCCTGCTATCTGACCCAGAGGA 930  
Qy 181 AsnGlnLysSerValIleLeuThrLysLeuTyrSerSerAsnValLeuPheHisSerLeu 200  
Db 931 AACCCAGAGAGTGTCTCTGACCAACTCTACAGCTCCATGCTGCTGCTCCATCTCTC 990  
Qy 201 PheTrpProThrCysMetMetAlaGlyGlyValAlaIleValAlaMetValLysLeuThr 220  
Db 991 TTCTGCCCAACTGTATGATGCTGGGGGTGTGGCAATCGTTGCTATGCTGTAACAACTA 1050  
Qy 221 GlnTyrLeuSerLeuLeuCysGluArgIleGlnArgIleAsnArg 235  
Db 1051 CAGTACCTCTCTCTCTGTTGTGAGAGATCCAAACGATCAACAGA 1095  
RESULT 8  
LOCUS  
AY191836 708 bp mRNA linear ROD 26-FEB-2003  
DEFINITION  
Rattus norvegicus inactivating beta 2 subunit of large conductance  
Ca2+-activated K+ channel mRNA, complete cds.  
ACCESSION  
AY191836  
VERSION  
AY191836.1 GI:28565441  
KEYWORDS  
Rattus norvegicus (Norway rat)  
ORGANISM  
Rattus norvegicus  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae;  
Rattus.  
REFERENCE  
1 (bases 1 to 708)  
AUTHORS  
Eghbali,M., Foroughi,S., Toro,L. and Stefani,E.  
TITLE  
Rat inactivating beta 2 subunit of large conductance Ca2+-activated  
K+ channel (KCNMB2, rSlo beta 2 subunit)  
JOURNAL  
Unpublished  
REFERENCE  
2 (bases 1 to 708)  
AUTHORS  
Eghbali,M., Foroughi,S., Toro,L. and Stefani,E.  
TITLE  
Direct Submission  
JOURNAL  
Submitted (06-DEC-2002) Anesthesiology, UCLA, PO Box 957115, Room  
BH-509A CHS, Los Angeles, CA 90095-7115, USA  
FEATURES  
Location/Qualifiers  
1. 708  
/organism="Rattus norvegicus"  
/mol\_type="mRNA"  
/strain="Sprague-Dawley"  
/db\_xref="taxon:10116"  
/tissue\_type="heart; myometrium"  
1. 708  
/note="KCNMB2; rSlo beta 2 subunit"  
/codon\_start=1  
CDS

/product="inactivating beta 2 subunit of large conductance  
Ca2+-activated K+ channel"  
/protein\_id="AA043501.1"  
/db\_xref="GI:28565442"  
/translation="WFIVTSRTSSSYHDEKRNYYQIRHDLIDRKTWTALKAGE  
DRAILGAMWCVSMMYFLIGITLLRSYMQSVMTBAQALLNVSITETNCFSCG  
PCWKLSQPLQVNVNLTSSGKLLYHTBEETKQKQSYIPKGNPFESNSLVS  
VMENFRHOFPCYSDPEGNQKSVILTKLYSSNVLFHSLFWPTCMAGGVAIVAMVK  
LTQYLSLCCERIQIRNR"  
48  
variation  
/replace="t"  
171  
variation  
/replace="t"  
175  
variation  
/replace="g"  
231  
variation  
/replace="g"  
250  
variation  
/replace="c"

## ORIGIN

## Alignment Scores:

Pred. No.: 1.82e-120 Length: 708  
Score: 1185.00 Matches: 224  
Percent Similarity: 97.45% Conservative: 5  
Best Local Similarity: 95.32% Mismatches: 6  
Query Match: 95.43% Indels: 0  
DB: 10 Gaps: 0

US-09-914-053A-5 (1-235) x AY191836 (1-708)

QY 1 MetSerIleTrrThrSerGlyArgThrSerSerTyrArgHisAspGluLysArgAsn 20  
DB 1 ATGTTTATATGACAGCGGCGGACCTCTTCACTTACACAGCAGGAGAAAGAAT 60  
QY 21 IleTyrGlnLysIleArgAspHisAspLeuLeuAspLysArgLysThrValThrAlaLeu 40  
DB 61 ATCTACCAAGAAATCAGGAGCATGACCTCTCGACAAAGAAAGAACTGTGACAGCTGTG 120  
QY 41 LysAlaGlyGluAspArgAlaIleLeuLeuGlyLeuAlaMetMetValCysSerIleMet 60  
DB 121 AAGGCTGAGAGGACCGGCGCATCTGCTTGGACTGGCCATGATGGTGTCTCCATCATG 180  
QY 61 MetTyrPheLeuLeuGlyIleThrLeuLeuArgSerTyrMetGlnSerValTrrThrGlu 80  
DB 181 ATGTACTTCTTACTGGGAATCACACTGCTGGCTCGTACATGCAGAGTGTATGGACAGAA 240  
QY 81 GluSerGlnCysThrLeuLeuAsnAlaSerIleThrGluThrPheAsnCysSerPheSer 100  
DB 241 GAAGCCACGCTGCTCTCTGAAATGTGTCATACAGAAACATTTAACTGTCTTCCAGC 300  
QY 101 CysGlyProAspCysTrrLysLeuSerGlnTyrProCysLeuGlnValTyrValAsnLeu 120  
DB 301 TGTGGCTCTGACTGCTGGAAGCTCTCTCAGTACCTTGCCTGCAAGTATACGTGAACCTG 360  
QY 121 ThrSerSerGlyGluLysLeuLeuTyrHisThrGluGluThrIleLysIleAsnGln 140  
DB 361 ACATCTTCTGGGAGAGCTCTCTCTTACCACAGAGAGACCATGAAGATCAATCAA 420  
QY 141 LysCysSerTrrIleProLysCysGlyLysAsnPheGluGluSerMetSerLeuValAsn 160  
DB 421 AAGTCTCTATATCTTAACTGAGGAAACAACTTTGAGAGTCCATGTCCTTGTGAGT 480  
QY 161 ValValMetGluAsnPheArgLysTyrGlnHisPheSerCysTyrSerAspProGluGly 180  
DB 481 GTCGTCAATGAAACCTTCAGGAGACCAACACATCCCTCTATTCTGACCCAGAGGG 540  
QY 181 AsnGlnLysSerValIleLeuThrLysLeuTyrSerSerHisValLeuPheHisSerLeu 200  
DB 541 AACCAAAAGACGGTCATCTCTGACCAAACTCTATAGCTCCCAATGCTGTGTTCCATTCTCTC 600  
QY 201 PheTrrProThrCysMetMetAlaGlyGlyValAlaIleValAlaMetValLysLeuThr 220

DB 601 TTCTGGCCCAACGTGTATGATGCTGGGGGTGTGGCAATCGTTGCTATGTGAACTAACT 660  
QY 221 GlnTyrLeuSerLeuLeuCysGluArgIleGlnArgIleAsnArg 235  
DB 661 CAGTACCTCTCCCTGCTGTTTGTAGAGGATCCCAACGGATCAACAGA 705

## RESULT 9

## LOCUS

EX950825 1546 bp mRNA linear VRT 17-FEB-2004  
Gallus gallus finished cDNA, clone CHEST48b4.

## ACCESSION

## VERSION

## SOURCE

## KEYWORDS

## ORGANISM

## REFERENCE

## AUTHORS

## TITLE

## JOURNAL

## COMMENT

EX950825.1 GI:42600510  
Gallus gallus (chicken)  
Gallus gallus  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Archosauria; Aves; Neognathae; Galliformes; Phasianidae;  
Phasianinae; Gallus.  
1 (bases 1 to 1546)  
Boardman,P.E., Bonfield,J.K., Brown,W.R.A., Carder,C., Chalk,S.B.,  
Croning,M.D.R., Davies,R.M., Francis,M.D., Graham,D.V.,  
Hubbard,S.J., Humphray,S.J., Hunt,P.J., Maddison,M., McLaren,S.R.,  
Niblett,D., Overton,I.M., Rogers,J., Scott,C.E., Taylor,R.G.,  
Tickle,C. and Wilson,S.A.  
Direct Submission  
Submitted (16-FEB-2004) Sanger Institute, Hinxton, Cambridgeshire,  
CB10 1SA, UK. E-mail enquiries: chickens@ems.umb.ac.uk  
BBSRC/Dundee/Nottingham/Sanger/Sheffield/UMIST Gallus gallus cDNA  
sequencing project.  
This sequence is from the  
BBSRC/Dundee/Nottingham/Sanger/Sheffield/UMIST cDNA collection,  
from a library constructed by Elizabeth Bosch. cDNA was prepared  
from RNA extracted from whole embryo, normalised, and poly  
A-trimmed. Ecoli-NotI cut cDNA was then ligated into the vector.  
Vector: pBluescript II KS(+); Site\_1: EcoRI; Site\_2: NotI Host:  
Escherichia coli DH10B.

## FEATURES

## source

1..1546  
/organism="Gallus gallus"  
/mol\_type="mRNA"  
/strain="White Leghorn, Hisex"  
/db\_xref="taxon:9031"  
/clone="CHEST48b4"  
/clone\_lib="CSBQCHN04"  
/dev\_stage="stage 10"

## ORIGIN

## Alignment Scores:

Pred. No.: 1.25e-112 Length: 1546  
Score: 1117.50 Matches: 210  
Percent Similarity: 94.4% Conservative: 12  
Best Local Similarity: 89.36% Mismatches: 6  
Query Match: 90.05% Indels: 7  
DB: 5 Gaps: 1

US-09-914-053A-5 (1-235) x BX950825 (1-1546)

QY 1 MetSerIleTrrThrSerGlyArgThrSerSerTyrArgHisAspGluLysArgAsn 20  
DB 144 ATGTTTATTTGACAGCGGCGGAGCTCTACATCTTACACAGCAGATGAGAAA----- 197  
QY 21 IleTyrGlnLysIleArgAspHisAspLeuLeuAspLysArgLysThrValThrAlaLeu 40  
DB 198 -----AGGGATCAGCATCTACTGGCAAAAGAAACAGTCCACAGCCCTA 242  
QY 41 LysAlaGlyGluAspArgAlaIleLeuLeuGlyLeuAlaMetMetValCysSerIleMet 60  
DB 243 AAGGCTGAGAGAGACCGGCGCATCTCTCGGGCTGGCCATGATGGTGTCTCTATCATG 302  
QY 61 MetTyrPheLeuLeuGlyIleThrLeuLeuArgSerTyrMetGlnSerValTrrThrGlu 80  
DB 303 ATGTACTTCTCTCTGGGAATCACCTGCTGGGCTCTACATGCAGAGCGTCTGGACAGAA 362

Qy	81	GlusSerGlnCysThrLeuLeuAsnAlaSerIleThrGluThrPheAsnCysSerPheSer	100
Db	363	GAGGCTCAGTGGCTGCTTCACAGCATCCATCAGCGAAACCTTCACTGCTCGTTAGC	422
Qy	101	CysGlyProAspCysTrpLysLeuSerGlnTyrProCysLeuGlnValTyrValAsnLeu	120
Db	423	TGGGCCCCAGACTGCTGGAATATCTCTCAGTACCCCTGCTGCTGAGGTGACGTCATCTC	482
Qy	121	ThrSerSerGlyGluLysLeuLeuLeuTyrHisThrGluThrLysIleAsnGln	140
Db	483	ACTTCTCTGGCCAGAGCTTCTGCTTACACACCGAGAAACAAATGAATAATCTTCT	542
Qy	141	LysCysSerTrpIleProLysCysGlyLysAsnPheGluGluSerMetSerLeuValAsn	160
Db	543	GAGTGTTCGTACATACCAAGTGTGGCAAGATTCAGGAGATCCATGTCATGTTGAC	602
Qy	161	ValValMetGluAsnPheArgLysTyrGlnHisPheSerCysTyrSerAspProGluGly	180
Db	603	GTGTGTGATGGAACACTTCGAAAGATCAACCTTCTCTGCTTCTATGATCTGAGGCG	662
Qy	181	AsnGlnLysSerValIleLeuThrLysLeuTyrSerSerAsnValLeuPheHisSerLeu	200
Db	663	ACTCAGAGACAGCTGATATTGACCAACTGTACAGCTCCACAGCTGCTGTTCCACTGCTC	722
Qy	201	PheTrpProThrCysMetMetAlaGlyLysValAlaIleValAlaMetValLysLeuThr	220
Db	723	TTCTGCCCCACGTGATGATGATCGCGCGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT	782
Qy	221	GlnTyrLeuSerLeuLeuCysGluArgIleGlnArgIleAsnArg	235
Db	783	CAATACCTTCT	827
US-09-914-053a-5 (1-235) x BX950833 (1-1546)			
Qy	1	MetSerIleTrpThrSerGlyArgThrSerSerSerTyrArgHisAspGluLysArgAsn	20
Db	144	ATGTTTATTTGACAGTGGCGGAGCTCTACTCTTACAGACAGCATGAGAAA-----	197
Qy	21	IleTyrGlnLysIleArgAspHisLeuLeuLeuAspLysArgLysThrValThrAlaLeu	40
Db	198	-----AGGATCAGCATCTACTTGGCAAAAGAAACAGTACACCCCTA	242
Qy	41	LysAlaGlyGluAspArgAlaIleLeuLeuGlyLeuAlaMetMetValCysSerIleMet	60
Db	243	AAAGTGGAGAGACCGGCCATCTCTCGGCTGGCCATGATGCTGCTCTATCATG	302
Qy	61	MetTyrPheLeuLeuGlyIleThrLeuLeuArgSerTyrMetGlnSerValTrpThrGlu	80
Db	303	ATGTACTTCTCTCGGAAATCACCCTGCTGGGCTCTACATGACAGAGCGTCTGGACAA	362
Qy	81	GluSerGlnCysThrLeuLeuAsnAlaSerIleThrGluThrPheAsnCysSerPheSer	100
Db	363	GAGGCTCAGTGTGCTTCTCAACGATCCATCAGGAAACCTTCACTGCTGTTAGC	422
Qy	101	CysGlyProAspCysTrpLysLeuSerGlnTyrProCysLeuGlnValTyrValAsnLeu	120
Db	423	TGGGCCCCAGACTGCTGGAATATCTCTCAGTACCCCTGCTGCTGCTGCTGCTGCTGCT	482
Qy	121	ThrSerSerGlyGluLysLeuLeuLeuTyrHisThrGluThrLysIleAsnGln	140
Db	483	ACTTCTCTGGCCAGAGCTTCTCTACACCGAGAAACAAATGAATAATCTTCT	542
Qy	141	LysCysSerTrpIleProLysCysGlyLysAsnPheGluGluSerMetSerLeuValAsn	160
Db	543	GAGTGTTCGTACATACCAAGTGTGGCAAGATTCAGGAGATCCATGTCATGTTGAC	602
Qy	161	ValValMetGluAsnPheArgLysTyrGlnHisPheSerCysTyrSerAspProGluGly	180
Db	603	GTGTGTGATGGAACACTTCGAAAGATCAACCTTCTCTGCTTCTATGATCTGAGGCG	662
Qy	181	AsnGlnLysSerValIleLeuThrLysLeuTyrSerSerAsnValLeuPheHisSerLeu	200
Db	663	ACTCAGAGACAGCTGATATTGACCAACTGTACAGCTCCACAGCTGCTGTTCCACTGCTC	722
Qy	201	PheTrpProThrCysMetMetAlaGlyLysValAlaIleValAlaMetValLysLeuThr	220
Db	723	TTCTGCCCCACGTGATGATGATCGCGCGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT	782
Qy	221	GlnTyrLeuSerLeuLeuCysGluArgIleGlnArgIleAsnArg	235
Db	783	CAATACCTTCT	827
RESULT 11			
BD223084			
LOCUS			
DEFINITION			
ACCESSION			
VERSION			
KEYWORDS			
SOURCE			
ORGANISM			
REFERENCE			
AUTHORS			
TITLE			
JOURNAL			
COMMENT			
FEATURES			
source			
1..1546			
/organism="Gallus gallus"			
/mol_type="mRNA"			
/strain="White Leghorn, Hisex"			
/db_xref="taxon:9031"			
/clone="CHEST43b24"			
/clone_lib="CSEQCHN04"			
/dev_stage="stage 10"			
ORIGIN			

Alignment Scores:  
 Pred. No.: 1,25e-112 Length: 1546  
 Score: 1117.50 Matches: 210  
 Percent Similarity: 94.47% Conservative: 12  
 Best Local Similarity: 89.36% Mismatches: 6  
 Query Match: 90.05% Indels: 7  
 DB: 5 Gaps: 1

US-09-914-053a-5 (1-235) x BX950833 (1-1546)

Qy 1 MetSerIleTrpThrSerGlyArgThrSerSerSerTyrArgHisAspGluLysArgAsn 20  
 Db 144 ATGTTTATTTGACAGTGGCGGAGCTCTACTCTTACAGACAGCATGAGAAA----- 197  
 Qy 21 IleTyrGlnLysIleArgAspHisLeuLeuLeuAspLysArgLysThrValThrAlaLeu 40  
 Db 198 -----AGGATCAGCATCTACTTGGCAAAAGAAACAGTACACCCCTA 242  
 Qy 41 LysAlaGlyGluAspArgAlaIleLeuLeuGlyLeuAlaMetMetValCysSerIleMet 60  
 Db 243 AAAGTGGAGAGACCGGCCATCTCTCGGCTGGCCATGATGCTGCTCTATCATG 302  
 Qy 61 MetTyrPheLeuLeuGlyIleThrLeuLeuArgSerTyrMetGlnSerValTrpThrGlu 80  
 Db 303 ATGTACTTCTCTCGGAAATCACCCTGCTGGGCTCTACATGACAGAGCGTCTGGACAA 362  
 Qy 81 GluSerGlnCysThrLeuLeuAsnAlaSerIleThrGluThrPheAsnCysSerPheSer 100  
 Db 363 GAGGCTCAGTGTGCTTCTCAACGATCCATCAGGAAACCTTCACTGCTGTTAGC 422  
 Qy 101 CysGlyProAspCysTrpLysLeuSerGlnTyrProCysLeuGlnValTyrValAsnLeu 120  
 Db 423 TGGGCCCCAGACTGCTGGAATATCTCTCAGTACCCCTGCTGCTGCTGCTGCTGCTGCT 482  
 Qy 121 ThrSerSerGlyGluLysLeuLeuLeuTyrHisThrGluThrLysIleAsnGln 140  
 Db 483 ACTTCTCTGGCCAGAGCTTCTCTACACCGAGAAACAAATGAATAATCTTCT 542  
 Qy 141 LysCysSerTrpIleProLysCysGlyLysAsnPheGluGluSerMetSerLeuValAsn 160  
 Db 543 GAGTGTTCGTACATACCAAGTGTGGCAAGATTCAGGAGATCCATGTCATGTTGAC 602  
 Qy 161 ValValMetGluAsnPheArgLysTyrGlnHisPheSerCysTyrSerAspProGluGly 180  
 Db 603 GTGTGTGATGGAACACTTCGAAAGATCAACCTTCTCTGCTTCTATGATCTGAGGCG 662  
 Qy 181 AsnGlnLysSerValIleLeuThrLysLeuTyrSerSerAsnValLeuPheHisSerLeu 200  
 Db 663 ACTCAGAGACAGCTGATATTGACCAACTGTACAGCTCCACAGCTGCTGTTCCACTGCTC 722  
 Qy 201 PheTrpProThrCysMetMetAlaGlyLysValAlaIleValAlaMetValLysLeuThr 220  
 Db 723 TTCTGCCCCACGTGATGATGATCGCGCGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 782  
 Qy 221 GlnTyrLeuSerLeuLeuCysGluArgIleGlnArgIleAsnArg 235  
 Db 783 CAATACCTTCT 827

BD223084 2098 bp DNA linear PAT 17-JUL-2003  
 98 human secretory proteins.  
 BD223084  
 BD223084.1 GI:33032854  
 JP 2002521055-A/19.  
 Homo sapiens  
 Homo sapiens (human)  
 ORGANISM  
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
 1 (bases 1 to 2098)  
 Komatsoulis, G.A., Rosen, C.A., Ruben, S.M., Duan, R., Moore, P.A.,  
 Shi, Y., Lafleur, D., Wei, Y.F., Ni, J., Florence, K.A., Young, P.E.,

Brewer, L.A., Soppet, D.R., Endress, G.A., Ebner, R., Olsen, H.S. and Mucenski, M.  
 98 human secretory proteins  
 Patent: JP 2002521055-A 19 16-JUL-2002;  
 HUMAN GENOME SCIENCES INC  
 OS Homo sapiens (human)  
 PN JP 2002521055-A/19  
 PD 16-JUL-2002  
 PF 29-JUL-1999 JP 2000562480  
 PR 30-JUL-1998 US 60/094657, 05-AUG-1998 US 60/095486 PR  
 06-AUG-1998 US 60/095455, 06-AUG-1998 US 60/095454 PR  
 12-AUG-1998 US 60/096319  
 PI GEORGE A. KOMATSOULIS, CRAIG A. ROSEN, STEVEN  
 M. RUBEN, ROXANNE DUAN,  
 PI PAUL A. MOORE, YANGGU SHI, DAVID LAFLEUR, YING PEI WEI, JIAN NI, PI  
 KIMBERLY A. FLORENCE, PAUL E. YOUNG, LAURIE A. BREWER, DANIEL R. PI  
 Soppet,  
 PI GREGORY A. ENDRESS, REINHARD EBNER, HENRIK S. OLSEN, MICHAEL PI  
 MUCENSKI  
 PC C12N15/09, A61K31/713, A61K38/00, A61K48/00, C07K14/47, C07K16/18,  
 PC C12N1/15,  
 PC C12N1/19, C12N1/21, C12N5/10, C12P21/02, C12P21/08, C12Q1/68, G01N33/ PC  
 15,  
 G01N33/50, G01N33/53//A61P1/18, A61P5/02, A61P5/06, A61P5/14, A61P9/ PC  
 10,  
 PC A61P11/06, A61P17/06, A61P19/02, A61P25/02, A61P25/14, A61P25/16,  
 PC A61P25/24,  
 PC A61P25/28, A61P27/02, A61P29/00, A61P31/18, A61P35/02, C12N15/00,  
 PC C12N5/00,  
 PC A61K37/02  
 CC 98 human secretory proteins  
 FH key Location/Qualifiers  
 FT source 1..2098  
 FT Location/Qualifiers  
 /organism="Homo sapiens (human)"  
 1..2098  
 /organism="Homo sapiens"  
 /mol\_type="genomic DNA"  
 /db\_xref="taxon:9606"

## ORIGIN

## Alignment Scores:

Pred. No.: 7.01e-101 Length: 2098  
 Score: 1012.00 Matches: 191  
 Percent Similarity: 100.00% Conservative: 0  
 Best Local Similarity: 100.00% Mismatches: 0  
 Query Match: 81.55% Indels: 0  
 DB: 6 Gaps: 0

US-09-914-053A-5 (1-235) x BD223084 (1-2098)

QY 45 AspArgAlaIleLeuLeuGlyLeuAlaMetMetValCysSerIleMetMetTyrPheLeu 64  
 DB 10 GACCGAGCTATTCCTGGGACTGGCTATGATGATGGTGCTCCATCATGATGATTTCTG 69  
 QY 65 LeuGlyIleThrLeuLeuAArgSerTyrMetGlnSerValTrpThrGluGluSerGlnCys 84  
 DB 70 CTGGGAATCACACTCTCGCTCATACATGACAGCGGTGTGGACGGAAGAGTCTCAATGC 129  
 QY 85 ThrLeuLeuAsnAlaSerIleThrGluThrPheAsnCysSerPheSerCysGlyProAsp 104  
 DB 130 ACCTTGCTGAATGCTCCATCAGGAACAATTAAATGCTTCCTTCAGCTGTGGTCCAGAC 189  
 QY 105 CysTrpLysLeuSerGlnTyrProCysLeuGlnValTyrValAsnLeuThrSerSerGly 124  
 DB 190 TGCTGGAAACTTCTCAGTACCCCTGCTCCAGGTGTACGTTAACTTCTTCTTCTCCGG 249  
 QY 125 GluLysLeuLeuLeuTyrHisThrGluThrIleLysIleAsnGlnLysCysSerTyr 144  
 DB 250 GAAAGCTCTCTCTACACACAGAGAGACAATAAATAATCAATCAAGAGTCTCTCTAT 309

QY 145 IleProLysCysGlyLysAsnPheGluGluSerMetSerLeuValAsnValValMetGlu 164  
 DB 310 ATACCTAAATGTGGAATAAATTTTGAAGAATCCATGCTCCCTGGTGAATGTTGTCTATGGA 369  
 QY 165 AsnPheArgLysTyrGlnHisPheSerCysTyrSerAspProGluGlyAsnGlnLysSer 184  
 DB 370 AACTTCAGGAAGTATCAACACTTCTCTCTCTATTCGACCCAGAGAAACAGAGAGT 429  
 QY 185 ValIleLeuThrLysLeuTyrSerSerAsnValLeuPheHisSerLeuPheTrpProThr 204  
 DB 430 GTTATCTTAACAAAACCTACAGTTCACAGTTCACAGTTCCTCAATTCCTCTTGTGGCAAC 489  
 QY 205 CysMetMetAlaGlyGlyValAlaIleValAlaMetValLysLeuThrGlnTyrLeuSer 224  
 DB 490 TGTATGATGCTGGGGGTGTGGCAATTTGTCATGTTGAACTTACACAGTACCTCTCTCC 549  
 QY 225 LeuLeuCysGluArgIleGlnArgIleAsnArg 235  
 DB 550 CTACTATGTGAGAGGATCCACGGATCAATAGA 582  
 RESULT 12  
 AR243782  
 LOCUS  
 DEFINITION  
 Sequence 20 from patent US 6476195.  
 AR243782  
 ACCESSION  
 AR243782.1 GI:27291275  
 VERSION  
 KEYWORDS  
 SOURCE  
 ORGANISM  
 Unknown.  
 Unclassified.  
 REFERENCE  
 1 (bases 1 to 2098)  
 Komatsoulis, G., Rosen, C.A., Ruben, S.M., Duan, R.D., Moore, P.A.,  
 Shi, Y., Lafleur, D.W., Wei, Y.-F., Ni, J., Florence, K.A., Young, P.,  
 Brewer, L.A., Soppet, D.R., Endress, G.A., Ebner, R., Olsen, H. and  
 Mucenski, M.  
 TITLE  
 Secreted protein HNGF20  
 JOURNAL  
 Patent: US 6476195-A 20 05-NOV-2002;  
 FEATURES  
 Location/Qualifiers  
 1..2098  
 /organism="unknown"  
 /mol\_type="genomic DNA"

## ORIGIN

## Alignment Scores:

Pred. No.: 7.01e-101 Length: 2098  
 Score: 1012.00 Matches: 191  
 Percent Similarity: 100.00% Conservative: 0  
 Best Local Similarity: 100.00% Mismatches: 0  
 Query Match: 81.55% Indels: 0  
 DB: 6 Gaps: 0

US-09-914-053A-5 (1-235) x AR243782 (1-2098)

QY 45 AspArgAlaIleLeuLeuGlyLeuAlaMetMetValCysSerIleMetMetTyrPheLeu 64  
 DB 10 GACCGAGCTATTCCTGGGACTGGCTATGATGATGGTGCTCCATCATGATGATTTCTG 69  
 QY 65 LeuGlyIleThrLeuLeuAArgSerTyrMetGlnSerValTrpThrGluGluSerGlnCys 84  
 DB 70 CTGGGAATCACACTCTCGCTCATACATGACAGCGGTGTGGACGGAAGAGTCTCAATGC 129  
 QY 85 ThrLeuLeuAsnAlaSerIleThrGluThrPheAsnCysSerPheSerCysGlyProAsp 104  
 DB 130 ACCTTGCTGAATGCTCCATCAGGAACAATTAAATGCTTCCTTCAGCTGTGGTCCAGAC 189  
 QY 105 CysTrpLysLeuSerGlnTyrProCysLeuGlnValTyrValAsnLeuThrSerSerGly 124  
 DB 190 TGCTGGAAACTTCTCAGTACCCCTGCTCCAGGTGTACGTTAACTTCTTCTTCTCCGG 249  
 QY 125 GluLysLeuLeuLeuTyrHisThrGluThrIleLysIleAsnGlnLysCysSerTyr 144  
 DB 250 GAAAGCTCTCTCTACACACAGAGAGACAATAAATAATCAATCAAGAGTCTCTCTAT 309

```
QY 145 IleProLysCysGlyLysAsnPhesGluGluSerMetSerLeuValAsnValMetGlu 164
Db 310 ATACCTAAATGTGGAAAAATTTGAAGATCCATGTCCTGTTGAATGTTGTCATGGAA 369
QY 165 AsnPhesArgLysTyrGlnHisPhesSerCysTyrSerAspProGluGlyAsnGlnLysSer 184
Db 370 AACTTTCAGGAGATATCAACACTTCTCTGCTATTCTGACCCAGAGAAACCAAGAGAT 429
QY 185 ValIleLeuThrLysLeuTyrSerSerAsnValLeuPheHisSerLeuPheTyrProThr 204
Db 430 GTTATCTCAACAACACTACAGTTCACAGTGCCTGTTCCATTCACCTCTTCTGSCCAACC 489
QY 205 CysMetMetAlaGlyGlyValAlaIleValAlaMetValLysLeuThrGlnTyrLeuSer 224
Db 490 TGTATGATGGCTGGGGGTGGCAATTTGTTCCCATGGTGAACCTTACACAGTACCTCTCC 549
QY 225 LeuLeuCysGlnArgGlnGlnArgIleAsnArg 235
Db 550 CTACTATGTGAGAGATCCACGGATCAATAGA 582

RESULT 13
RNO517198 487 bp mRNA linear ROD 15-DEC-2002
LOCUS Rattus norvegicus partial mRNA for calcium-activated potassium
DEFINITION channel beta 2 subunit (Kcnmb2 gene).
ACCESSION AJ517198
VERSION AJ517198.1 GI:26801163
KEYWORDS calcium-activated potassium channel beta 2 subunit; Kcnmb2 gene.
SOURCE Rattus norvegicus (Norway rat)
ORGANISM Rattus norvegicus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae;
Rattus.
REFERENCE 1
AUTHORS Langer, P., Grunder, S. and Rusch, A.
TITLE Expression of Ca2+-activated BK channel mRNA and its splice
JOURNAL variants in the rat cochlea
MEDLINE J. Comp. Neurol. 455 (2), 198-209 (2003)
PUBMED 22342043
REFERENCE 2 (bases 1 to 487)
AUTHORS Langer, P.
TITLE Direct Submission
JOURNAL Submitted (16-NOV-2002) Langer P., Institute of Physiology II,
University of Tuebingen, Gmelinstr. 5, Tuebingen, D-72076, GERMANY
FEATURES
source
Location/Qualifiers
1..487
/organism="Rattus norvegicus"
/mol_type="mRNA"
/strain="Wistar"
/db_xref="taxon:10116"
/tissue_type="brain"
1..487
/gene="Kcnmb2"
<1..>487
/gene="Kcnmb2"
/function="ion channel"
/codon_start=2
/product="calcium-activated potassium channel beta 2
subunit"
/protein_id="CAD56888.1"
/db_xref="GI:26801164"
/db_xref="GOA:Q8CF83"
/db_xref="TrEMBL:Q8CF83"
/translation="LKAGEDRAILLGLAMVCSIMYFLLLGITLLRSYMQSVMTERRAQ
CALLNVSITETFNCSFSGPCDWKLSQYPCIQVYVNLTSSEKLLVHTETWKINQK
CSYTPKGNFEESMSLVSVNFRHQHPFCISDPGKQSVILTKLYSSNVLFHS
LF"

ORIGIN
Alignment Scores: 1.04e-80 Length: 487
Pred. No.: 821.00 Matches: 153
Score:
```

```
Percent Similarity: 97.53% Conservative: 5
Best Local Similarity: 94.44% Mismatches: 4
Query Match: 66.16% Indels: 0
DB: 10 Gaps: 0
US-09-914-053a-5 (1-235) x RNO517198 (1-487)
QY 40 LeuLysAlaGlyGluAspArgAlaIleLeuLeuGlyLeuAlaMetMetValCysSerIle 59
Db 2 CTGAAGGCTGGAGAGACCGGGCCATCTGCTTGACTGGCCATGATGTTGCTCCATC 61
QY 60 MetMetTyrPheLeuLeuGlyIleThrLeuLeuArgSerTyrMetGlnSerValTyrThr 79
Db 62 ATGATGTACTTCTTACTGGGAATCACTGCTGCCCTGTTACATGCAGAGTGTGGACA 121
QY 80 GluGluSerGlnCysThrLeuLeuAsnAlaSerIleThrGluThrPheAsnCysSerPhe 99
Db 122 GAAGAAGCCCACTGTGCTGCTGAATGTGTCATCACAGAAACATTTAACTGTTCCCTC 181
QY 100 SerCysGlyProAspCysTyrLysLeuSerGlnTyrProCysLeuGlnValTyrValAsn 119
Db 182 AGCTGTGGCCCTGACTGTGGAACTCTCTCAGTACCTTGCCTGCAGGTATACGTGAAC 241
QY 120 LeuThrSerSerGlyGluLysLeuLeuTyrHisThrGluGluThrIleLysIleAsn 139
Db 242 CTGACATCTTCTGGGAGAGAGCTCTCTCTACACACAGAGAGACCATGAATCAAT 301
QY 140 GlnLysCysSerTyrIleProLysCysGlyLysAsnPhesGluGluSerMetSerLeuVal 159
Db 302 CAAAAGTGTCTCTATATCTTAAGTGTGAAACAACTTTGAGGAGTCCATGTCCTTGG 361
QY 160 AsnValValMetGluAsnPhesArgLysTyrGlnHisPhesSerCysTyrSerAspProGlu 179
Db 362 AGTGTGCTCATGGAAAACCTTCAGGAGACACCAACTTCCCTGCTATTCTGACCCAGAA 421
QY 180 GlyAsnGlnLysSerValIleLeuThrLysLeuTyrSerSerAsnValLeuPheHisSer 199
Db 422 GGGAAACCAAGAGGTGCTATCTCTGACCAACTCTATAGTCCCAATGTGCTGTTCATTC 481
QY 200 LeuPhe 201
Db 482 CTCCTC 487

RESULT 14
RNO517457 204899 bp DNA linear PRI 25-FEB-2003
LOCUS Homo sapiens 3 BAC RP11-385J1 (Rosewell Park Cancer Institute Human
DEFINITION BAC Library) complete sequence.
ACCESSION AC117457
VERSION AC117457.11 GI:28557825
KEYWORDS HTG.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1 (bases 1 to 204899)
Muzny, D.M., Adams, C., Adio-Oduola, B., Ali-Osman, F.R., Allen, C.,
Alsbrooks, S.L., Amaral, H.C., Are, J.R., Ayale, M., Banks, T.,
Barbaria, J., Benton, J., Bimaga, K., Blankenburg, K., Bonnin, D.,
Bouck, J., Bowie, S., Brieva, M., Brown, E., Brown, M., Bryant, N.P.,
Buhay, C., Burch, P., Burkett, C., Burrell, K.L., Byrd, N.C.,
Carroll, T.F., Carter, M., Cavazos, S.R., Chacko, J., Chavez, D.,
Chen, G., Chen, R., Chen, Z., Chowdhry, I., Christopoulos, C.,
Cleveland, C.D., Cox, C., Coyle, M.D., Dathorne, S.R., David, R.,
Davila, M.L., Davis, C., Davy-Carroll, L., Dederich, D.A.,
Delaney, K.R., Delgado, O., Denn, A.L., Ding, Y., Dinh, H.H.,
Douthwaite, K.J., Draper, H., Dugan-Rocha, S., Durbin, K.J.,
Earnhart, C., Edgar, D., Edwards, C.C., Elhaj, C., Escotto, M.,
Falls, T., Ferraguto, D., Flagg, N., Ford, J., Foster, P., Frantz, P.,
Gabisi, A., Gao, J., Garcia, A., Garner, T., Garza, N., Gill, R.,
Gorrell, J.H., Guevara, W., Gunaratne, P., Hale, S., Hamilton, K.,
Harris, C., Harris, K., Hart, M., Havlak, P., Hawes, A., He, X.,
Hernandez, J., Hernandez, O., Hodgson, A., Hogues, M., Holloway, C.,
```

Hollins, B., Honsi, F., Howard, S., Huber, J., Hulyk, S., Hume, J., Jackson, L. E., Jacobson, B., Jia, Y., Johnson, R., Jolivet, S., Joudah, S., Karlsson, E., Kelly, S., Khan, U., King, L., Korvan, J., Kovar, C., Kravovic, J., Kresh, A., Landry, N., Leal, B., Lewis, L. C., Lewis, L., Li, J., Li, Z., Lichtarge, O., Lieu, C., Liu, J., Liu, W., Louis, H., Lozano, R. J., Lu, X., Lucier, A., Lucier, R., Luna, R., Ma, J., Maheshwari, M., Mapus, P., Martin, R., Martindale, A., Martinez, E., Massey, B., Mawhney, E., McLeod, M. P., Meador, M., Mei, G., Metzger, M., Miner, G., Miner, Z., Mitchell, T., Mohabhat, K., Moore, S., Morgan, M., Moorish, T., Morris, S., Moser, M., Neal, D., Nelson, D., Newton, J., Newton, N., Nguyen, A., Nguyen, N., Nguyen, N., Nickerson, E., Nwokenkwo, S., Ogun, M., Okwuonu, G., Oragunye, N., Oviedo, R., Pace, A., Payton, B., Peery, J., Perez, L., Peters, L., Pickens, R., Primus, E., Fu, L. L., Quiles, M., Ren, Y., Rives, M., Rojas, A., Rojubokan, I., Rolfe, M., Ruiz, S., Savery, G., Scheter, S., Scott, G., Shen, H., Shoohtari, N., Sison, I., Sodergren, E., Sonaik, T., Sparks, A., Stanley, H., Stone, H., Sutton, A., Svatek, A., Tabor, P., Tamerisa, A., Tamerisa, K., Tang, H., Tansey, J., Taylor, C., Taylor, R., Telford, B., Thomas, N., Thomas, S., Umani, K., Vasquez, L., Vera, V., Villalón, D., Vinson, R., Wang, Q., Wang, S., Ward-Moore, S., Warren, R., Washington, C., Watlington, S., Williams, G., Williamson, A., Wleczky, R., Wooden, S., Worley, K., Wu, C., Wu, Y., Wu, Y. F., Zhou, J., Zorrilla, S., Naylor, S. L., Weinstein, G. and Gibbs, R.

Direct Submission  
Unpublished  
2 (bases 1 to 204899)  
Worley, K.C.

Direct Submission  
Submitted (10-APR-2002) Human Genome Sequencing Center, Department of Molecular and Human Genetics, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA  
3 (bases 1 to 204899)  
Worley, K.C.

Direct Submission  
Submitted (22-FEB-2003) Human Genome Sequencing Center, Department of Molecular and Human Genetics, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA  
4 (bases 1 to 204899)  
Worley, K.C.

Direct Submission  
Submitted (25-FEB-2003) Human Genome Sequencing Center, Department of Molecular and Human Genetics, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA  
On Feb 25 2003 this sequence version replaced gi:28467084.  
INFORMATION: <http://www.hgsc.bcm.tmc.edu/> or email [gc-help@bcm.tmc.edu](mailto:gc-help@bcm.tmc.edu)

CLONE LENGTH: This sequence does not necessarily represent the entire insert of this clone. Overlapping regions of clones are only sequenced and submitted once, so the sequence for the remainder of the insert may be found in the record for the adjacent clones. Overlapping clones are noted at the beginning and end of the Features listing.

#### ANNOTATION OF FEATURES:

STSs are identified using ePCR (Genome Res. 7:541-550) searches of a local database that includes entries from dbSTS, GDB, and local mapping efforts.

Repeats are identified using RepeatMasker (A. Smit and P. Green, unpublished.) for Human and Mouse sequences.

Genes and Region of sequence similarity are identified by BLAST (Nuc. Acids Res. 25:3389-3402) similarity (expect < 1e-34) to the EST and cDNA sequences. Genes demonstrate at least two exons flanked by consensus splice sites that maintained sequence continuity across the splice junctions. Sequences that are not identical matches are annotated as similar.

SEQUENCING READ COVERAGE: Sequencing is completed to a minimum standard of double strand coverage with a minimum of 2 clones and 2 reads with no ambiguities or 2 chemistries with a minimum of 2 clones and 3 reads with no ambiguities. If the sequence quality for a region does not meet this standard, it will be indicated in the

annotation as Low Coverage.

QUALITY OF INDIVIDUAL BASES: This sequence meets stringent quality standards - estimated error rate less than 1 per 10,000 bases. Reports of lowest quality individual bases and measures of base quality are listed below. Description of the metrics can be found at URL:

<http://www.hgsc.bcm.tmc.edu:8088/quality.info/genbank.annotation.ht>

FEATURES	Source	Location/Qualifiers
misc_feature	1..204899	/organism="Homo sapiens"
		/mol_type="genomic DNA"
		/db_xref="taxon:9606"
		/chromosomes="3"
		/clone="RP11-385J1"
		/complement(1..2000)
		/notes="overlaps bases 1..2000 of clone AC139661"
repeat_region		/function="clone overlap"
		/complement(501..659)
repeat_region		/rpt_family="L2"
		/complement(1481..1546)
repeat_region		/rpt_family="L2"
		1611..1689
repeat_region		/rpt_family="MLT1B"
		1694..1879
repeat_region		/rpt_family="MER2"
		1893..1922
repeat_region		/rpt_family="AT-rich"
		1964..2082
repeat_region		/rpt_family="MLT1B"
		2083..2421
repeat_region		/rpt_family="MLT1A1"
		2422..2587
repeat_region		/rpt_family="MLT1B"
		complement(2948..3005)
repeat_region		/rpt_family="L2"
		complement(4406..4536)
repeat_region		/rpt_family="L2"
		complement(5059..5175)
repeat_region		/rpt_family="MER20"
		complement(5428..5572)
repeat_region		/rpt_family="MIR"
		complement(5578..5707)
repeat_region		/rpt_family="MIR"
		complement(7008..7250)
repeat_region		/rpt_family="MIR"
		7575..7962
repeat_region		/rpt_family="L2"
		complement(10792..10921)
repeat_region		/rpt_family="MIR"
		complement(11688..11850)
repeat_region		/rpt_family="MIR"
		complement(12469..13201)
repeat_region		/rpt_family="MER49"
		13643..13814
repeat_region		/rpt_family="L2"
		13815..13840
repeat_region		/rpt_family="(TTG)n"
		13841..13878
repeat_region		/rpt_family="L2"
		complement(13891..13953)
repeat_region		/rpt_family="L1PA2"
		complement(14053..14222)
repeat_region		/rpt_family="FRAM"
		15886..15985
repeat_region		/rpt_family="MERSB"
		15990..16149
repeat_region		/rpt_family="MIR"
		complement(16360..16474)
repeat_region		/rpt_family="MIR"
		16570..16676
repeat_region		/rpt_family="L2"

```
repeat_region 16945..17166
/rpt_family="MIR"
repeat_region complement(17322..17473)
/rpt_family="MER33"
repeat_region 17474..18315
/rpt_family="L1PAl6"
repeat_region complement(18329..18510)
/rpt_family="MER33"
repeat_region 18610..19373
/rpt_family="L1MA8"
repeat_region 19374..19673
/rpt_family="AluSp"
repeat_region 19674..19760
/rpt_family="L1MA8"
repeat_region 20088..20127
/rpt_family="MER5B"
repeat_region 20874..20893
/rpt_family="(GA)n"
repeat_region complement(21009..21423)
/rpt_family="MER39"
repeat_region 22482..22503
/rpt_family="AT-rich"
repeat_region 24182..24476
/rpt_family="AluY"
repeat_region 24861..24881
/rpt_family="AT-rich"

Alignment Scores:
Pred. No.: 2.54e-43 Length: 204899
Score: 510.50 Matches: 120
Percent Similarity: 52.00% Conservative: 23
Best Local Similarity: 43.64% Mismatches: 31
Query Match: 41.14% Indels: 103
DE: 9 Gaps: 6

US-09-914-053A-5 (1-235) x AC117457 (1-204899)

Qy 44 GluAspArgAlaIleLeuLeuGlyLeuAlaMetMetValCysSerIleMetMetTyrPhe 63
Db 176994 AARGATAAGAGTATACCTACCTCTGAGAGAACTGGTAAGTTTATGTTATGAGAC- 177052
Qy 64 LeuLeuGlyleThr----- 68
Db 177053 AGATGTGAGACAGACAAATGATGCGAGAGTTGACATCTGATTCATTAAGAGATGTT 177112
Qy 69 -----LeuLeuAsnGlySerTyrMetGlnSerValThrThrGluGluSerGlnCysThr 85
Db 177113 CAATAGAAATATATTAACCTACCATACCTAGTATGCGAAAGAAATCC----- 177163
Qy 86 LeuLeuAsnAlaSerIleThrGluThrPheAsnGlySerPheSerCysGlyProAsp--- 104
Db 177164 -----TGGGAATCATTTAAATTTATTTTACGATCGAACATGGAATGA 177205
Qy 104 ----- 104
Db 177206 TTAATCAAGCTAATTAACATATCTATCATTTTATTTCAATCAATAATAATATATGGGT 177265
Qy 105 -----Cys--- 105
Db 177266 GAGCAATCAAGGACATCTTGGTCAGATACCTTAAACATTTGTTTAAATCAATGTTAT 177325
Qy 106 -----TrpLeuLeu 108
Db 177326 TTATTAGGGTTTCCAAAGGCCACAGTTTGAATATGAAAGAAATAACCAATGTTT-ATT 177384
Qy 109 SerGln-----TyrProCysLeuGlnValTyrValAsnLeu 120
Db 177385 TCACAGATCATTAATTGGACACAAATACCTCCACCCCTCTAGAGTCTCAACACACATA 177444
Qy 121 ThrSerSerGlyGluLeuLeuLeuLeuTyrHisThrGluGluThrIleLeuAsnGln 140
Db 177445 GTATCTTCTAGTAACAGTTTA-----TCTTATCTCCA 177477
```

